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Cachexia is a syndrome of progressive nutritional depletion that occurs in up to
one-half of all patients with cancer. In particular, cachexia involves a severe and
specific loss of skeletal muscle, which is associated with worsened patient
morbidity, reduced quality of life (QoL), and increased mortality. The aims of this
thesis were to investigate specific mediators, mechanisms and biomarkers of
muscle wasting and function in cancer cachexia. Models included human cancer
cell lines and tissue samples, and patients with different types of upper
gastrointestinal (GI) cancer. Upper GI cancer was chosen as the model for
investigation as such patients are known to have a high prevalence of cachexia.
Tumour-derived cachectic mediators were investigated initially (Chapters 3 to 5).
There has been much speculation about whether the murine tumour-derived
cachectic mediator known as proteolysis-inducing factor (PIF) has a human
homologue, and how this may be derived from a larger gene known to encode for
dermcidin, an anti-microbial peptide found in sweat. Messenger ribonucleic acid
(mRNA) expression levels of dermcidin were analysed in human tumour tissue and
human cancer cell lines. Expression of dermcidin was highly variable in human
tumours, but appeared to be largely absent or expressed at only very low levels in
oesophago-gastric cancer and prostate cancer (Chapter 3). Additionally, although
human cell lines did express dermcidin mRNA, sequence analysis of
complementary DNA (cDNA) derived from this mRNA demonstrated that
transcripts lacked a site for the glycosylation critical to the proteolysis-inducing
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activity of murine PIF, thus raising doubt about the existence of human PIF
(Chapter 4).
Attention was then focused on plasma concentrations of macrophage inhibitory
cytokine-1 (MIC-1), another potential tumour-derived mediator of cachexia in
humans (Chapter 5). In a cohort of patients with oesophago-gastric cancer (n=293),
although MIC-1 concentrations correlated with systemic inflammation (a key
component of the cachexia syndrome), there was no independent link between
plasma MIC-1 and nutritional status or survival. Thus, further investigations are
required before MIC-1 can be determined as a key mediator of cancer cachexia in
humans.
Next, the role of circulating neuroendocrine mediators, specifically sex steroids and
gonadotropins, were investigated in a cohort of patients with advanced pancreatic
cancer (n=175) (Chapter 6). Testosterone is known to be a significant determinant
of muscle mass. However, 73% of male cancer patients were hypogonadal (as
defined by calculated serum free testosterone). Hypogonadal males demonstrated
shortened survival compared with eugonadal males. Furthermore, male opioid use
(an iatrogenic cause of male hypogonadism) was associated with shortened survival.
In contrast, 18% of postmenopausal females exhibited premenopausal or
'hyperoestrogenic' serum oestradiol levels. Hyperoestrogenic females demonstrated
shortened survival compared with eugonadal females. Thus, clinical trials of
androgen replacement therapy (particularly in the presence of opioid analgesia)
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may be a potential route forwards in males with non-hormone sensitive types of
cancer.
Regulatory mechanisms of protein degradation within skeletal muscle were then
examined (Chapters 7 and 8). It has been suggested that there may be parallels in
the mechanisms of muscle wasting observed in genetic disorders, such as the
muscular dystrophies, and the mechanisms observed in acquired conditions such as
cancer cachexia. In rectus abdominis muscle samples from patients with
oesophago-gastric cancer (n=27), deregulation of the sarcolemma-bound, muscular
dystrophy-associated dystrophin glycoprotein complex (DGC) (involving reduced
expression of dystrophin and hyperglycosylation of key DGC proteins) was found
in 17/27 (63%) samples (Chapter 7). Moreover, the presence of DGC deregulation
was associated with worsened patient function and shortened patient survival.
These results suggest a possible common pathway between genetic and acquired
forms of muscle wasting.
The mass of a muscle is determined by the balance between protein synthesis and
degradation. Pathways that can both increase protein degradation and suppress
synthesis could have a profound influence on the rate of muscle wasting. Levels of
the activated (phosphorylated) forms of the dsRNA-dependent protein kinase (PKR)
and eukaryotic translation initiation factor 2a (eEF2a), intracellular mediators in
pathways leading to increased muscle protein degradation and reduced protein
synthesis, were determined in rectus abdominis samples from oesophago-gastric
cancer patients (n=15) (Chapter 8). Levels of both phospho PKR and phospho
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eIF2a were significantly enhanced in muscle from cachectic patients, and there was
a linear relationship between myosin expression and the extent of eIF2a
phosphorylation. These results suggest that phosphorylation of PKR may be an
important initiator of muscle wasting in cancer cachexia.
Next, the presence of urinary biomarkers of skeletal muscle wasting were analysed
using mass spectrometry in urine samples from cachectic oesophago-gastric cancer
patients (n=8), weight-stable cancer patients (n=8) and healthy controls (n=8)
(Chapter 9). The identification of early biomarkers of cachexia, the clinical
detection of which would allow the institution of prophylactic therapeutic measures,
is one of the key areas of need in cancer cachexia research. The number of protein
species identified in urine samples from cachectic cancer patients (n=199) was
significantly greater than that identified in samples from weight-stable cancer
patients (n=79) and controls (n=49). Proteins identified specifically in cachectic
samples, and thus potential biomarkers of muscle wasting that could be utilised in
future clinical trials, included muscle (myosin species), cytoskeletal, and
microtubule-associated proteins.
Lastly, the use of objective assessment of physical activity as a potential biomarker
of skeletal muscle function, and thus a novel outcome measure in the clinical
management of advanced cancer patients, was explored (Chapters 10 and 11).
Criterion-based validation of estimates of energy expenditure using an
accelerometer-based activity-monitoring system (activPAL™) was performed using
a combination of doubly labelled water and indirect calorimetry in cancer patients
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(n=6) and healthy controls (n=9) (Chapter 10). Although absolute errors for
activPAL™-derived estimates of mean energy expenditure of activity (1.4%) and
mean total energy expenditure (0.4%) were low, there was considerable variability
in individual patient results, suggesting that further prospective validation studies of
energy expenditure are required. (Step count and other PA measures have been
validated previously). The activPAL™ meter was also used to take sequential
measurements of objective PA in a cohort of patients with upper GI cancer
undergoing palliative chemotherapy (n=16) (Chapter 11). Recruited patients
demonstrated a complex "journey" of PA during treatment, with individuals
describing worsened, improved or unchanged PA. However, the overall trend was
one of deterioration in PA during chemotherapy. Importantly, objective measures of
PA correlated with subjective scores of QoL, fatigue and performance status,
supporting the use of objective PA as a patient-centred outcome.
In summary, certain circulating mediators (sex steroids) and intracellular
mechanisms (DGC deregulation and PKR phosphorylation) have been shown to be
important in the aetiology of cachexia/skeletal muscle wasting in cancer, and the
determination of patient outcome. Urinary biomarkers of muscle protein
degradation (myosin species) and biomarkers of muscle function (physical activity)
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Chapter 1 - Introduction
1.1 Overview
The present thesis integrates a range of different studies of mediators, mechanisms
and biomarkers of skeletal muscle wasting and function in cancer cachexia. The
following chapter offers an overview of cancer cachexia. In particular, this chapter
details the importance of skeletal muscle wasting within cachexia, and highlights
the relevance of muscle wasting within the context of human disease. When
discussing the aetiology of cancer cachexia, reference is made to potential
therapeutic strategies where relevant.
Cachexia is a feature of many chronic disease states including cancer, chronic
obstructive pulmonary disease (COPD), chronic heart failure (CHF), chronic renal
failure (CRF), rheumatoid arthritis and acquired immune deficiency syndrome
(AIDS). The etymological origins of the word cachexia are the Greek words kakos
and hexis meaning "poor condition". Cachexia is characterised by a chronic wasting
syndrome, involving loss of both lean body mass (LBM) and adipose tissue [1],
which is resistant to conventional nutritional support [2]. In particular, there is a
severe and specific loss of skeletal muscle [1]. Similar muscle wasting is also
encountered in patients who are not considered to have cachexia per se but other
pathological endocrine and musculoskeletal conditions, including Cushing's
syndrome, diabetes mellitus (DM), hyperthyroidism, muscular dystrophy, muscle
denervation, and physical inactivity (e.g. bed rest, fracture/joint immobilisation and
spaceflight microgravity). In old age, muscle wasting is usually referred to as
sarcopenia. The difference in nomenclature between cachexia and sarcopenia is a
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reflection of differences that exist in the regulation of skeletal muscle protein
degradation between various types of wasting. However, despite the large variety of
initiating events and the subtle differences in molecular regulation, many of the
underlying intracellular signalling pathways, target genes and effector mechanisms
remain the same [3].
Cachexia occurs in up to one half of all patients diagnosed with cancer [4], and
represents a significant physical and psychological burden for these individuals.
The typical patient with advanced cachexia demonstrates obvious changes in body
composition including severe weight loss and peripheral oedema [1], Furthermore,
he or she experiences numerous symptoms, including anorexia, early satiety,
weakness and fatigue (Figure 1.1) [1]. These subjective feelings of weakness and
fatigue may be the result of both physiological and psychological factors.
Physiological phenomena include anaemia, the central effects of cytokine release,
the side-effects of anti-cancer treatments, and phenomena within skeletal muscle
similar to those observed in the process of ageing (e.g. reductions in muscle cell
mass, glycogen content, and mitochondrial number [5, 6]). Psychological factors
include depression, anxiety and insomnia [7],
The cumulative effects of the numerous signs and symptoms of cachexia on patient
outcome are adverse and various: cachectic individuals report decreased quality of
life (QoL) scores [8] and decreased levels of physical performance, and they
experience increased risks of treatment failure [4] (be it chemotherapy,
radiotherapy or surgery), increased risks of treatment side-effects [4], and increased
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Figure 1.1 Clinical features of cancer cachexia.
Cancer cachexia causes a constellation of signs and symptoms within the affected
patient, including changes in body composition, anaemia, and subjective feelings of
fatigue.
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rates of mortality [4]. In fact, it has been estimated historically that cachexia
accounts for up to 20% of all cancer deaths (through immobility and
cardiorespiratory failure) [9]. In cancer types that are associated with a high
incidence of cachexia (e.g. advanced pancreatic cancer), the syndrome may account
for up to 80% of all deaths [10, 11], Cachexia is therefore an extremely important,
yet often under-appreciated, cause of morbidity and mortality in cancer patients.
In recent years, cancer cachexia has been recognised, both nationally and
internationally, as a condition that requires immediate investigation and the urgent
development of a strategy for progress. Within the UK, the National Cancer
Research Institute (NCRI) Strategic Planning Group on Supportive and Palliative
Care has identified cachexia as a gap area that is researched inadequately at present
[12], In addition, a joint Cancer Research UK (CRUK)/Medical Research Council
(MRC) workshop on cancer cachexia identified the syndrome as a key under¬
funded and under-researched area in cancer care [13]. Outwith the UK, the
Canadian Institute for Cancer Research (ICR) has also acknowledged the need for
further research. In particular, the ICR recognised that the assessment and
characterisation of cachectic patient populations and the investigation of
fundamental mechanisms underlying cancer cachexia are two of the most important
and pressing areas requiring attention [14],
Cancer cachexia has long been considered to be the result of a variety of
interactions between the host and the tumour, the full nature of which are not
understood fully (Figure 1.2) [15], The tumour's role in the aetiology of cachexia
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includes the local secretion of pro-inflammatory cytokines that initiate the host
systemic inflammatory response/acute phase protein response (APPR) [16], and the
production of pro-cachectic factors that have direct catabolic effects on host tissues
(e.g. proteolysis-inducing factor [PIF] [17] and lipid mobilising factor [LMF]) [18].
Host mechanisms involve an aberrant response to the tumour's presence, and
include activation of both the APPR [16] and the neuroendocrine stress response
[19, 20], The net result of such host-tumour interaction is an alteration in body
composition, a key feature of which is a severe and specific loss of skeletal muscle
mass with relative preservation of the visceral protein mass [1]. These gross
changes are a reflection of a complex array of metabolic changes in both the
skeletal muscle and the liver of the affected individual. The key inflammatory
(Chapter 1.4), neuroendocrine (Chapter 1.5) and tumour-derived mediators
(Chapter 1.6) involved in cancer cachexia are summarised later in this thesis, as are
the intracellular mechanisms involved in skeletal muscle protein degradation
(Chapter 1.9). However, the relative importance of each of the different
host/tumour mediators and mechanisms in the genesis of cachexia in individual
patients/tumour types remains unclear. Moreover, in recent years, it has become
apparent that host-tumour interaction may not be the sole factor driving cancer
cachexia. Patient demographics, including age and habitual levels of physical
activity (PA), may also play a role. Furthermore, specific patterns in the
metabolism and sequestration of ingested protein by the host may account for both
the irreversibility of catabolism and the sub-optimal response to nutritional support
observed in cachectic cancer patients [2], These alternative mechanisms of cancer
cachexia are discussed later in this thesis (Chapter 1.8).
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The previous section has afforded a general overview of cancer cachexia and has
described in simple terms the mechanisms that cause cachexia. In the following
section, ongoing difficulties in defining and diagnosing cancer cachexia are
explained with reference to the current operational definitions and diagnostic tools
available.
1.2 Definition and diagnosis of cancer cachexia
1.2.1 Definition
Cachexia is a clinical syndrome that is difficult to define as the complex,
multifactorial origin of the condition precludes a uniform pathophysiological
definition. Various authors have attempted to reach a concise definition for
cachexia. MacDonald et al, for example, proposed the following definition: 'a
wasting syndrome involving loss ofmuscle andfat directly caused by tumour
factors, or indirectly caused by an aberrant host response to tumour presence'''' [21],
This simple description, however, is disadvantaged, as it does not indicate the depth
of complexity of cachexia. In comparison, the Cachexia Consensus Conference
devised a more lengthy definition: "cachexia is a complex metabolic syndrome
associated with underlying illness and characterized by loss ofmuscle with or
without loss offat mass. The prominent clinical feature ofcachexia is weight loss in
adults (correctedforfluid retention) or growth failure in children (excluding
endocrine disorders). Anorexia, inflammation, insulin resistance and increased
muscle protein breakdown are frequently associated with cachexia. Cachexia is
distinct from starvation, age-related loss ofmuscle mass, primary depression,
malabsorption and hyperthyroidism and is associated with increased morbidity"
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[22]. This definition incorporates satisfactorily the complexity of cachexia but it
does not estimate the expected prognosis of the cachectic patient. Any appropriate
definition of cancer cachexia should attempt to identify those components of
cachexia that demonstrate prognostic power and impact on important domains of
QoL, physical functioning (PF) or survival. Previous attempts at tailoring the
definition of cachexia according to patient outcome have yielded interesting results.
In one study of weight-losing patients with unresectable pancreatic cancer (n=170),
weight loss alone was not a prognostic variable and did not identify patients that
differed in functional aspects of self-reported QoL or health status [8]. However,
the three-factor profile of systemic inflammation (C-reactive protein [CRP] >
10mg/l), reduced food intake (<1500kcal/day) and weight loss (>10%) defined
those with both adverse function and prognosis [8].
When devising a future definition of cancer cachexia, it should also be remembered
that cachexia is not a state that exists independent of time. It represents a
progressive condition that can pass through early, middle and late phases (Figure
1.3) and thus any definition of cachexia or diagnostic tool should reflect temporal
progression and syndrome severity. Two tools exist currently that, although not
devised specifically for cachexia studies, can be used to stratify cachectic
populations according to severity. The 'Constitutional Symptoms' section of the
National Cancer Institute (NCI) Common Toxicity Criteria uses stratification by
weight loss (Grade 0: <5%; Grade 1: 5-<10%; Grade 2: 10-<20%; Grade 3: > 20%;
Grade 4: undefined but life-threatening), whereas the Patient-Generated
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Figure 1.3 The cancer cachexia journey.
Cancer cachexia is a progressive condition that increases in severity over time until
patient death.
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Subjective Global Assessment (PG-SGA) combines questions on weight loss
(graded 0-5) with food intake, functional status and other relevant factors [23]. In
comparison, specific attempts to stratify cachectic cancer patients have also been
carried out, and include those performed by the SCRINIO Working Group. This
group employed a database of 1,307 cancer outpatients to generate a 4-stage cancer
cachexia classification system ranging from asymptomatic pre-cachexia to
symptomatic cachexia, based on weight loss (< or >10%) combined with the
presence or absence of at least 1 symptom of anorexia, fatigue, or early satiety [24].
The concept of pre-cachexia (i.e. patients at risk of cachexia) is gaining favour in
nutritional circles, as an adequate definition would allow the institution of
prophylactic therapeutic intervention prior to the development of significant weight
loss. Such a prophylactic approach to management is considered superior to
attempting to slow or reverse nutritional depletion once weight loss is clearly
evident, as such an approach is unlikely to be successful. The European Society for
Clinical Nutrition and Metabolism (ESPEN) Special Interest Groups (SIGs) on
"cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"
recently defined pre-cachexia as the presence of all of the following criteria: (i)
underlying chronic disease; (ii) unintentional weight loss <5% of usual body weight
during the last 6 months; (iii) chronic or recurrent systemic inflammatory response;
and (iv) anorexia or anorexia-related symptoms [25]. The European Palliative Care
Research Collaborative (EPCRC) is also presently performing literature reviews
and Delphi-process rounds with international cachexia experts to generate
definitions for pre-cachexia, cachexia and refractory cachexia [23]. In the future,
additional work should also be aimed at quantifying accurately the degree of
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activation of aetiological mechanisms within cachectic patients, as identification of
subgroups of cachectic patients with different dominant features might permit
targeted therapeutic strategies. For example, the efficacy of anti-inflammatory
agents may be influenced strongly by the level of activation of pro-inflammatory
pathways (as evidenced, for example, by plasma CRP concentration).
1.2.2 Diagnosis
In the absence of a user-friendly, formalised definition, the clinical diagnosis of
cancer cachexia is complicated (except when the patient has obvious severe or
refractory cachexia). Severe cachexia is easily diagnosed in patients with
significant non-volitional weight loss (e.g. body mass index [BMI] <18.5kg/m2 or
weight loss >10% of pre-morbid weight) and muscle wasting. The choice of weight
loss as a marker of cachexia is understandable as it is self-evident, simple to
measure and related clinically to patient outcome [4]. However, weight loss is non¬
specific. Not only is weight loss compromised as a direct index of wasting in those
patients who develop significant fluid retention/oedema, it may also be an
insensitive marker of the physiological dysfunction driving cachexia. Furthermore,
weight loss may not be helpful in identifying patients in the early stages of cachexia.
Moreover, by the time a patient does manifest significant weight loss, the cachectic
process is firmly established and is likely to be more difficult to slow or reverse.
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The assessment of LBM may be a more sensitive measure of cachexia, as a marked
loss of LBM (primarily skeletal muscle) is a specific characteristic of cachexia [26]
and distinguishes the syndrome from simple starvation. However, LBM is also
somewhat compromised as it includes the extracellular water (ECW) space and is
therefore expanded 'artificially' by fluid retention. Recently, cross-sectional
imaging of muscle mass and visceral fat (using computerised tomography [CT] or
magnetic resonance imaging [MRI]) has been used as a direct clinical measure to
assess cachexia [27, 28], Although this method allows highly accurate assessments
of body composition, it measures tissue volume rather than tissue content (e.g.
protein) and is therefore also open to misinterpretation. However, it does have the
advantage of being capable of identifying patients who, despite being over ideal
weight, still have underlying evidence of skeletal muscle wasting. In one
prospective CT study of a cohort of 441 patients with non-small cell lung cancer
(NSCLC), mean BMI was 24.9kg/m2, with 47.4% of patients being overweight
(BMI 25-30kg/m2) or obese (BMI >30kg/m2), and only 7.5% being underweight
(BMI <18.5kg/m2) [29]. However, analysis of CT images demonstrated that the
overall prevalence of severe muscle depletion was 46.8% and was present in
patients in all BMI categories [29]. Such so-called 'overweight/obese sarcopenia'
was also found in 16% of patients with pancreatic cancer, and was shown to be an
independent adverse prognostic factor [30].
Compared with objective changes in body composition, subjective patient
symptoms are equally compromised as diagnostic markers of cachexia. For
example, fatigue may be described by 70-100% of advanced cancer patients [7],
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including those who do not develop obvious wasting, and thus it retains limited
sensitivity as a cachectic marker. Furthermore, patient levels of fatigue are
influenced strongly by anti-cancer therapies (e.g. radiotherapy) [31]. To complicate
matters further, fatigue has not yet been the subject of a consensus definition review.
The lack of strict diagnostic criteria for cachexia hinders clinical studies and has led
to a multitude of inclusion criteria being used. For example, many Phase III studies
(e.g. the North Central Cancer Treatment Group [NCCTG] studies) have used
either involuntary weight loss (2% in 2 months or 5% in 6 months), anorexia
(assessed by visual analogue scale [VAS]) or reduced oral nutritional intake (<75%
of normal or <20 kcal/kg body weight) as inclusion criteria [23], whereas
observational mechanistic studies have utilised different cut-offs for weight loss
(e.g. >10%). Ultimately, the current status quo is detrimental to the progressive
introduction of effective anti-cachexia therapies via clinical trials. Whichever
diagnosis of cachexia is used, trial patients are only recruited once cachexia is
plainly evident, and at this stage, when the patient has become severely wasted, the
primary initiating events are compounded frequently by secondary factors (e.g.
prolonged bed rest). In this situation, the patient can be considered to have
refractory cachexia, as it is often impossible to make any realistic form of
therapeutic intervention, either practical or (given the patient's almost imminent
demise) ethically advisable. Thus, in a systematic approach to the management of
cachexia, there is an urgent need for validated, internationally agreed, early
biomarkers of cachexia (clinical or biochemical). Much of this thesis is targeted at
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the identification of mechanisms and markers that, in the future, may be used as
early biomarkers of cachexia.
In the previous section, the complexities of defining and diagnosing cancer
cachexia have been discussed, and current variations in definition use within
clinical trial design have been described. Moreover, the need for early markers of
cachexia has been highlighted as an unmet clinical priority. In the following section,
the epidemiology and incidence of cancer cachexia (within the existing limitations
of definition and diagnosis) are described.
1.3 Epidemiology and incidence of cancer cachexia
Accepting the problems associated with diagnosing cachexia, the incidence of the
syndrome in cancer patients is determined most readily by assessing the degree of
weight loss. It is estimated that half of all cancer patients experience weight loss
and one-third lose more than 5% of their original body weight [4], In 1980, Dewys
and the Eastern Co-operative Oncology Group (ECOG) performed one of the most
comprehensive clinical studies to examine the prevalence and prognostic potential
of weight loss in cancer patients who had not yet received chemotherapy [4], The
frequency and severity of weight loss during the previous 6 months was recorded in
a range of different tumour types (Table 1.1). Importantly, the prevalence of weight
loss in each tumour type also correlated with magnitude of weight loss. Upper GI
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Non-small cell lung cancer 61







Acute non-lymphocytic leukaemia 39
Breast cancer 36
Favourable non-Hodgkin's lymphoma 31
Table 1.1 Cancer types with the highest prevalence of cachexia.
Upper GI (gastric and pancreatic) cancer and lung cancer patients, in particular,
demonstrate a high prevalence of cachexia. Cachexia is defined as the presence of
weight loss over the preceding 6 months (2 months for patients with pancreatic
cancer). Adapted from Dewys et al, 1980 [4].
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(gastric and pancreatic) cancer patients in particular demonstrated high frequencies
of weight loss. It is worth noting that, unlike the rest of the data, weight loss in
pancreatic cancer patients was only analysed over the preceding 2 months,
indicating the severity of cachexia in this particular disease. In another study of 20
patients with unresectable pancreatic cancer, Wigmore et al demonstrated that 85%
of patients had lost a median of 14% of their premorbid stable weight at diagnosis
[32]. This increased to a median of 25% at or near the time of death (median inter-
assessment period of 27 weeks). Over this period, LBM fell from 43.4kg to 40.1kg
and adipose mass decreased from 12.5kg to 9.6kg.
Apart from patients with upper GI malignancy, lung cancer patients are the other
major group known to sustain significant weight loss. In a study by Ross and co¬
workers, weight loss at presentation was reported by 59%, 58% and 76% of patients
with small cell lung cancer (SCLC), unresectable NSCLC and mesothelioma
respectively [33].
At the commencement of radiotherapy, Lees et al found that 57% of head and neck
cancer patients had lost weight [34], A mean weight loss of 6.5kg, equating to
approximately 10% of body weight, was reported. Head and neck cancer patients
suffer significantly from dysphagia and thus weight loss could be secondary to
semi- starvation, rather than true cachexia. Therefore, these patients often respond
readily to enteral nutritional support. However, Richey et al found that, following
exclusion of those individuals with severe dysphagia, 46% of patients with head
and neck squamous cell carcinoma (HNSCC) still experienced weight loss
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exceeding 5% of premorbid body weight over the preceding 3-6 months [35].
In the previous section, the prevalence of weight loss (as a marker of cachexia)
within different cancer types has been described. Patients with upper GI cancer, in
particular, demonstrate high frequencies of weight loss, and for this reason, these
patients (or tissue sample samples from these patients) are used as the investigative
models of choice in the present thesis. In the following sections (Chapters 1.4 to
1.6), the circulating mediators that induce cachexia are discussed in more detail.
Furthermore, where appropriate, inhibition or activation of specific mediators are
discussed as potential therapeutic strategies against cancer cachexia. Firstly,
attention is focused on inflammatory mediators and the host APPR.
1.4 Inflammatory mediators of cancer cachexia
Inflammation is of paramount importance in the aetiology of cancer cachexia. The
tumour initiates a cytokine cascade that has multiple, direct, distant effects
including the central induction of anorexia and the peripheral initiation of skeletal
muscle protein degradation, whereas the host responds by activating the hepatic
APPR (Figure 1.4). The role of cytokines in the central induction of anorexia is
discussed in Chapter 1.7.
1.4.1 Pro-inflammatory and anti-inflammatory mediators
1.4.1.1 Pro-inflammatory cytokines
A variety of human cancer cell lines have been shown to produce both pro¬
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released by tumour cells in vivo are generally not detectable in the host's circulation,
and probably act only locally to promote inflammation and activate host
inflammatory cells passing through the tumour. In patients with cancer where
serum levels of cytokines (e.g. tumour necrosis factor [TNF]-a) are detectable,
these levels correlate poorly with patient weight loss or survival [38],
In cancer, host peripheral blood mononuclear cells (PBMCs) are recruited to
tumours by various signals, including hypoxia. Thus, a major inflammatory
component of tumour stroma is made up of so-called tumour-associated
macrophages (TAMs). It has been postulated that the interplay between tumour
cells, host lymphocytes and TAMs results in alternatively activated monocytes
giving rise to a predominantly Type 2 helper T cell (Th2) microenviroment that may
favour tumour progression via the promotion of angiogenesis, the remodelling of
the extracellular matrix (ECM) to allow invasion, and the suppression of adaptive
immunity [39-41]. By virtue of tumour cell phenotype (production of pro¬
inflammatory mediators) and local tissue effects/destruction, this Th2 type
microenvironment may paradoxically promote systemic inflammation. How TAMs
may be involved in the activation of host PBMCs is not yet known but macrophage-
associated cytokines (e.g. macrophage migratory inhibitory factor [MIF]) have been
shown to induce an APPR in isolated human hepatocytes [42], Furthermore, high
tumour chronic inflammatory cell content is associated with systemic inflammation
and poor patient prognosis [16]. However, little is known about the predominant
cytokine profile of tumour cells and macrophages within a cancer mass or the
surrounding "normal" tissue in relation to the induction of cachexia. In oesophago-
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gastric tumours, expression levels of several pro-inflammatory cytokines have been
found to be elevated (e.g. interleukin [IL]-1B) [16].
Other putative cytokine mediators of cachexia include IL-6, TNF-a, interferon
(IFN)-y, leukaemia inhibitory factor (LIF), transforming growth factor (TGF)-(i,
vascular endothelial growth factor (VEGF)-A and midkine. Chinese hamster ovary
(CHO) cells transfected with the human TNF-a gene produced cachexia when
implanted into nude mice [43]. A similar result was also found if the same mice
were transfected with CHO cells constitutively producing IFN-y [44]. An anti-IFN-
y monoclonal antibody was able to reverse the wasting syndrome associated with
the murine Lewis lung carcinoma [45]. TNF-a and IFN-y worked co-operatively to
down-regulate transcription of the myosin heavy chain (MyHC) gene in vitro an in
vivo, but not other core myofibrillar proteins [46]. Furthermore, MyHC protein
expression was decreased in a specific fashion in the colon-26 (C-26)
adenocarcinoma mouse [46], a largely IL-6 dependent model [47], In mice with a
mutation in the adenomatosis polyposis coli (APC) tumour suppressor gene,
elevated circulating IL-6 levels were associated with the presence of cachexia [48].
Knockout of IL-6 prevented loss of muscle weight and epididymal fat, and reduced
intestinal polyp number, implying the existence of an IL-6 cytokine amplification
loop between host and tumour cells. Lurthermore, recent human studies have
suggested that IL-6 overexpression in weight-losing pancreatic cancer patients was
related to the ability of certain IL-6-producing tumours to sensitise and induce
cytokine expression in PBMCs [49],
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Despite the primacy of pro-inflammatory cytokines in cancer cachexia, mediators
such as IL-6, one of the key inducers of the APPR, are incapable of inducing the
full cachexia syndrome alone in humans. Patients receiving treatment with IL-6 as
part of antineoplastic trials report side effects of fatigue and flu-like symptoms, but
only a proportion develop weight loss [50], Therefore, it seems likely that a
combination of pro-inflammatory mediators work together to induce cachexia.
1.4.1.2 Anti-inflammatory cytokines
Some cytokines may be potential repressors of cachexia. For example, IL-4, IL-10
and IL-13 all demonstrate anti-inflammatory, and hence presumably anti-cachectic,
activity [51]. In the C-26 mouse model, IL-10 gene transfer reduced cachexia and
prolonged survival [52]. Other cytokines (e.g. IL-15) may have potential
'antioxidant' properties that can counter the excess levels of reactive oxygen and
nitrogen species (ROS and RNS) (caused by the inefficiency of host antioxidant
enzymes) that have been proposed as mediators of muscle atrophy [53]. IL-15 was
capable of inhibiting skeletal muscle wasting in the Yoshida AH-130 rat ascites
hepatoma model by decreasing muscle protein degradation rates [54],
Overexpression of IL-15 in cultured myotubes induced a hypertrophic morphology
and increased myofibrillar protein accumulation in co-cultured cells [55]. The final
wasting status of the cachectic patient presumably depends on the balance between
pro-inflammatory and anti-inflammatory cytokines.
1.4.1.3 Host cytokine genotype
In recent years, host cytokine genotype has been proposed as one determinant of the
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development of cachexia by influencing the aetiology of systemic inflammation and
the APPR [56], In patients with oesophago-gastric cancer (OGC), specific IL-10
and IL-6 single nucleotide polymorphisms (SNPs) were related to systemic
inflammation and adverse prognosis, and a TNF-a polymorphism was associated
with adverse prognosis [57], Moreover, the TNF-a polymorphism rs800629 was
associated with anorexia in patients with NSCLC [58], Conversely, the IFN-y
'allele 2' polymorphism was related to improved survival in patients with non-
resectable pancreatic cancer [59]. Regarding cachexia specifically (as evidenced by
weight loss), certain IL-lfi polymorphisms were associated with the development of
cachexia and adverse prognosis in pancreatic and gastric cancer [60, 61], whereas
the IL-10 1082 GG genotype was associated with cachexia in patients with OGC
[62], Thus, inflammation may be an inevitable consequence of cancer but the effect
of this inflammation on the host may be directly related to the ability of the host to
regulate such inflammation. Presumably, other aspects of skeletal muscle wasting
may be influenced similarly by host genotype of other non-inflammatory cachectic
mediators.
1.4.1.4 Non-cytokine inflammatory mediators
Although cytokines may play a prominent role in the activation of the APPR, other
non-cytokine pro-inflammatory mediators may also exist. Elevated serum
parathyroid hormone-related peptide (PTHrP) levels have been found in patients
with OGC in the absence of hypercalcaemia, and were associated with the presence
of an APPR and worsened survival [63]. Furthermore, studies in mice have
demonstrated that the peripheral administration of PTHrP decreases food intake and
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gastric emptying via the activation of hypothalamic urocortins 2 and 3 through
vagal afferent pathways and the suppression of gastroduodenal motor activity [64],
1.4.1.5 Cytokine inhibitors in the treatment of cancer cachexia
Despite the pivotal role of pro-inflammatory cytokines in the aetiology of cancer
cachexia, human trials to date using cytokine antagonists have not been successful
at ameliorating weight loss. The use of infliximab, an anti-TNF-a monoclonal
antibody (mAb), in conjunction with docetaxel was shown to be associated with
increased fatigue and worsened QoL scores in NSCLC patients compared with
docetaxel with placebo, and therefore the trial was stopped [65]. Neither arm of the
study demonstrated palliation of weight loss. A further trial of infliximab with
gemcitabine in pancreatic cancer patients was unable to demonstrate a significant
improvement in LBM or survival [66], whereas a trial of etanercept, a TNF-a
inhibitor, in cachectic cancer patients was not associated with weight gain or
improved survival [67], Patients receiving etanercept did, however, experience
higher rates of neurotoxicity, but lower rates of anaemia and thrombocytopenia
compared with placebo [67], Trials of pentoxyfilline, a cytokine inhibitor, have also
shown little clinical benefit in the treatment of cachexia and anorexia in cancer
patients [68], Human trials of an anti-IL6 mAb, in conjunction with gemcitabine, in
pancreatic cancer patients are ongoing. It is anticipated that results may be superior
to previous trials of cytokine inhibitors due to the critical role that IL6 plays in the
initiation of the hepatic APPR (see below, p.51). Other cytokine inhibitors that have
been studied in pre-clinical models of cancer cachexia, such as suramin [47], have
not yet been reported in the clinical literature.
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1.4.2 Host Response Mechanisms
1.4.2.1 The Hepatic Acute Phase Protein Response
An organism responds to the presence of tumour, infection, immunological
disorders, tissue injury, trauma or surgery by eliciting the APPR, a response
designed to help limit tissue injury. However, in certain circumstances when the
APPR is prolonged or severe, it can lead to detrimental effects. The APPR is
identified frequently in weight-losing cancer patients and is now well recognised as
an independent adverse prognostic factor [69].
The APPR is a complex physiological event involving reprioritisation of hepatic
protein synthesis, resulting in increased production of the positive acute phase
proteins, such as CRP, fibrinogen, serum amyloid A, a 1-acid glycoprotein (AGP),
al-antichymotrypsin and haptoglobin. The APPR is probably initiated and
modulated by pro-inflammatory cytokines released from either the tumour and/or
the host monocyte/macrophage cell system. Target organ changes are then
mediated through secondary messengers (e.g. eicosanoids, arachidonic acid [AA],
platelet activating factor [PAF], nitric oxide [NO]). The main cytokine influencing
the APPR in humans is thought to be IL-6. The ability of human hepatocytes co-
cultured with PBMCs to produce acute phase protein was inhibited almost
completely by anti-IL-6 antibodies [70].
The mechanism by which the APPR is related to weight loss and survival is
unknown, but it has been suggested that acute phase protein production represents a
sink for amino acids that, in the face of inadequate dietary protein intake (due to
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anorexia), contributes to the overall loss of skeletal muscle. This protein loss is
further aggravated by a mismatch in the amino acid composition between proteins
synthesised in the liver and those broken down in muscle [71]. It has been
calculated that 2.6g of muscle protein must be catabolised to produce lg of
fibrinogen [72], This mismatch demonstrates how aggressively the APPR may
drive nutritional depletion. To complicate matters further, nutritional support, an
obvious required treatment for malnourished cancer patients, may accelerate
positive acute phase protein synthesis and thus exacerbate one of the basic
mechanisms that contributes to the loss of lean tissue. In weight-losing patients
with pancreatic cancer, synthesis rates of hepatic export proteins (fibrinogen) are
elevated in the fasted state, but rise even higher during enteral feeding (Figure 1.5)
[73], These findings emphasise the need for inclusion of anti-inflammatory/anti-
APPR strategies within any programme of high calorie/high protein nutritional
support in the treatment of cancer cachexia.
CRP is the prototypical positive acute phase reactant (Figure 1.5), the main function
of which is thought to relate to bacterial opsonisation [74], The factors contributing
to an elevated CRP may include tumour-induced systemic inflammation [16] and
gut-derived inflammatory mediators as a result of increased bacterial translocation
[75], although other initiatory mediators are proposed in this thesis. Elevated
plasma CRP levels (>10mg/L) have been identified in patients with lung [76],
breast [77], ovarian [78], renal [79], pancreatic [69], OGC [16], colorectal [80] and
malignant melanoma [81] tumours, as well as individuals with multiple myeloma
[82] and lymphoma [83], Within these disease conditions, plasma CRP
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Figure 1.5 Acute phase protein synthesis during systemic inflammation in
cancer cachexia.
Hepatic fibrinogen synthesis is increased in cachectic cancer patients and may be
exacerbated further by feeding. Thus, paradoxically, feeding may contribute to the
loss of lean tissue in cachexia. Although albumin levels may be decreased in
cachectic cancer patients, this is not due to decreased synthesis, as synthetic levels
are comparable to healthy controls.
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concentration has correlated positively with weight loss [84], the presence of
hypermetabolism and anorexia [85], disease recurrence [86], and reduced survival
[69]. Elevated CRP levels have even demonstrated prognostic value in colorectal
cancer [80], pancreatic cancer [87] and OGC patients [88] undergoing surgical
resection with curative intent. For these reasons, in the present thesis, circulating
CRP concentration is utilised as a measure of systemic inflammation. Regarding
other positive acute phase reactants, elevated fibrinogen levels have also been
associated with poor outcome in melanoma [89] and lung cancer patients [90].
In contrast to positive acute phase reactants, the plasma concentrations of other
liver export proteins (the so-called negative acute phase reactants) may decrease in
the cachectic patient. Albumin is one example of a negative acute phase reactant.
However, despite significant hypoalbuminaemia, the total albumin synthesis rate in
both the fasting and fed state is not different between patients with advanced cancer
and healthy controls (Figure 1.5) [73, 91]. Thus, the hypoalbuminaemia of cancer
cachexia cannot be explained by a reduced synthesis rate, but must reflect
alternative mechanisms of albumin loss e.g. increased transcapillary escape
secondary to an increase in microvascular permeability. When considering whole-
body protein kinetics, this means that, in the cachectic patient, the increased hepatic
synthesis of positive acute phase reactants is not compensated for by reduced
synthesis of negative acute phase reactants, resulting in net increased hepatic
protein production.
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1.4.2.2 Prognostic scoring systems
Although plasma levels of acute phase reactants may exhibit prognostic value when
considered singly, some authors have attempted to combine the results of different
acute phase reactants or add in clinico-pathological variables to generate prognostic
scoring systems for clinical decision-making. The Glasgow Prognostic Score (GPS)
and modified GPS (mGPS) are simple scores based on the presence or absence of
both elevated plasma CRP and hypoalbuminaemia. Both scores have demonstrated
prognostic power in a range of cancer types, particularly colorectal cancer in which
they have been able to predict survival even in patients undergoing surgery with
curative intent [92, 93]. In comparison, the Edinburgh Clinical Risk Score (ECRS)
combines CRP, weight loss, Karnofsky performance score (KPS) and clinical stage
of disease (cTNM) and has been shown to predict accurately death at 12 and 24
months in patients with OGC [94]. A recent study that compared the mGPS and
ECRS in OGC patients concluded that, of the 2 tests, only the mGPS was
associated with survival on multivariate analysis [95]. The mGPS is utilised in the
present thesis in Chapter 4.
In the previous section, the integral roles of inflammatory cytokines (particularly
IL-6) and the host APPR in the aetiology of cancer cachexia have been explored.
However, the present lack of efficacy of cytokine antagonists in human trials has
also been described. Host cytokine genotype as a determinant of inflammation
regulation has been discussed as a potential regulator of weight loss and prognosis
in cancer patients. Furthermore, the mechanism by which feeding, a basic anti-
cachexia therapy, can exacerbate the host APPR has been explained. In the
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following section, the subject of discussion moves away from inflammatory factors
to neuroendocrine mediators of cancer cachexia. Furthermore, the potential role of
autonomic dysregulation within cancer cachexia is also explored.
1.5 Neuroendocrine mediators of cancer cachexia
The precise roles of circulating neuroendocrine hormones/growth factors (GFs) and
the neuroendocrine stress response in the aetiology of cancer cachexia, and in
particular skeletal muscle atrophy, are understood poorly. However, when
considering their roles, one can regard muscle wasting as the result of an imbalance
between anabolic and catabolic mediators.
1.5.1 Anabolic hormones and growth factors
1.5.1.1 Androgens
A significant portion of the anabolic action of testosterone and the other androgens
occurs directly in skeletal muscle, predominantly through interactions with the
androgen receptor (AR). In this mechanism, free testosterone is transported into the
cytoplasm of target tissue cells, where it may bind directly to the AR, or first be
reduced to 5a-dihydrotestosterone (DHT) by cytoplasmic 5a-reductase prior to
receptor binding. The receptor complex then undergoes a conformational change
that allows it to translocate to the nucleus and bind directly to specific
deoxyribonucleic acid (DNA) nucleotide sequences, termed hormone response
elements (HREs), which influence the transcriptional activity of certain pro-
anabolic genes. Despite the predominance of this particular androgenic pathway,
growing evidence suggests that testosterone may also exert anabolic effects through
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actions mediated via the skeletal muscle a-actin promoter [96] and the oestrogen
receptor (following the aromatisation of testosterone to oestradiol) [97], and
through other indirect mechanisms. Such indirect pathways may include
modulation of the growth hormone (GH)/insulin-like growth factor (IGF)-l axis
(see below, p.58) [98], regulation of motor neurons [99], and genotype-dependent
changes in spontaneous PA and reactivity (animal locomotor activity in response to
a novel environment) [100],
A significant prevalence of male hypogonadism has been detected in patients with
metastatic cancer [101], old age [102] and human immunodeficiency virus (HIV)
[103]. However, despite these observations, many authors have expressed concern
regarding the lack of clear epidemiological data linking hypogonadism to the
clinical and biological sequelae of cancer cachexia [104], Furthermore, trials of
androgen therapy in pre-clinical and clinical models of cancer cachexia have not
been successful consistently. For example, nandrolone propionate therapy in a
murine model of cancer cachexia was only able to demonstrate weight gain via
fluid retention [105], whereas a trial of nandrolone decanoate in patients with
advanced NSCLC could demonstrate only a trend for decreased weight loss [106].
One potential obstacle to the success of androgen therapy in cancer cachexia is that
the ideal dose of androgen is currently unknown. Debate exists as to whether a
physiological or supra-physiological approach is superior. However, regardless of
the tempered findings in cancer cachexia, androgens, including testosterone,
nandrolone and oxandrolone, are now recognised therapies for patients with HIV-
associated wasting [107], sarcopenia [108], burns [109, 110], and muscle atrophy
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associated with orchidectomy [111]. However, even in these patients, despite
obvious gains in muscle mass, studies have not always been able to prove
conclusively an improvement in patient functional status [107],
Recently, selective androgen receptor modulators (SARMs) have received much
attention as potential muscle-targeted treatments for cancer cachexia. Already, such
drugs have demonstrated efficacy at restoring LBM and muscle strength [112], and
reducing bone loss [113] in orchidectomised male rats. In murine models, SARMs
blocked dexamethasone-induced dephosphorylation of proteins involved in protein
synthesis and reduced castration-induced up-regulation of E3 ligases and down-
regulation of IGF-1 [114]. In humans, Phase I and II clinical trials have shown that
SARMs increased LBM and enhanced functional status [115], but large,
randomised controlled trials in cachectic cancer patients are still awaited.
To investigate further the epidemiology of hypogonadism in cancer cachexia and
the role of androgens within the context of human muscle wasting, circulating
levels of free testosterone and other sex steroids/gonadotropins in cancer patients
are studied in detail later in this thesis (Chapter 6).
1.5.1.2 Growth Hormone
GH is of vital importance in promoting growth and protein synthesis in a wide
range of tissues (including skeletal muscle). For example, animal studies have
shown that muscles lacking GH receptors are smaller in mass due to a decrease in
myofibre size and number [116]. Furthermore, GH facilitates the fusion of
58
myoblasts to nascent myotubes in vitro [117]. GH appears to achieve its actions
through both IGF-1 -dependent and independent actions (GH is the most potent
stimulator of IGF-1 production by the liver [see below, p. 61]) [117].
Despite the importance of GH in muscle anabolism, evidence for alterations of the
somatotroph axis as a causative factor in human muscle atrophy is limited. Studies
in cachectic cancer patients have demonstrated high GH levels as one might expect
in a normal reactive response [118]. However, in certain tumour types there may be
emerging evidence of a GH-resistance syndrome [119].
Trials of GH therapy in catabolic patients have had mixed results, and, as with
androgens, the exact required dosage remains unclear. GH has been used
successfully to reduce muscle loss in patients with HIV-associated wasting [120]
and burns [121]. However, under such circumstances, patients often experience
symptoms similar to subacute acromegaly (e.g. stiff joints and carpal tunnel
syndrome). Furthermore, although preliminary, small-scale studies yielded
promising findings, large, randomised, placebo-controlled, multi-centre trials of GH
administration to critically ill intensive care unit (ICU) patients have demonstrated
an increase in morbidity and mortality [122], possibly related to GH-induced
reduction in glycaemic control. Moreover, recent studies have shown that GH
administration stimulates collagen synthesis in human tendon and skeletal muscle
without affecting myofibrillar protein synthesis, suggesting that GH is more
important in matrix strengthening than for actual muscle cell hypertrophy [123].
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Thus, the efficacy of GH treatment in humans as a method of increasing skeletal
muscle mass remains uncertain.
1.5.1.3 Insulin
Insulin provides an anabolic stimulus for muscle protein production. Therefore, in
'insulin deficient' states (i.e. Type I DM or insulin resistance) there is a reduction
of muscle protein synthesis. Insulin resistance and impaired glucose utilisation are
common findings in a wide range of diseases associated with muscle wasting,
including cancer cachexia [19, 124]. For example, in CHF patients, insulin
resistance is related directly to reduced muscle strength, exercise capacity and
patient survival [125].
There is now robust evidence that insulin resistance also results from systemic
inflammation. In weight-losing cancer patients, insulin resistance is associated with
increased plasma concentrations of IL-6 [19]. Furthermore, in healthy human
subjects, TNF-a has been shown to promote insulin resistance in skeletal muscle by
attenuating phosphorylation of the insulin receptor substrate (IRS)-l, thus altering
insulin signal transduction [126].
Low dose insulin therapy administered to weight-losing cancer patients in the
context of additional palliative support (anti-inflammatory treatment with
indomethacin; prevention of anaemia with recombinant erythropoietin [rhEPO];
and specialised nutritional care including oral supplements and home total
parenteral nutrition [TPN]) stimulated carbohydrate intake, decreased serum-free
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fatty acids, increased whole body fat, but did not affect LBM, maximum exercise
capacity or spontaneous PA [127].
1.5.1.4 Insulin-Like Growth Factor-1
IGF-1 is a polypeptide hormone produced by the liver (and target tissues) under the
positive regulatory control of GH. The anabolic action of IGF-1 is mediated
through the tyrosine kinase IGF-1 receptor interacting with members of the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway. The majority of IGF-1 present
in body fluids is bound to one of six structurally related high-affinity IGF binding
proteins (IGFBP). These proteins can thus modulate bioavailability either positively
or negatively. The catabolic response in patients is usually characterised by a
marked increase in IGFBP-1, frequent decrease in IGFBP-3, and a TNF-dependent
decrease in IGFBP-5 [128]. GH not only stimulates the production of IGF-1, but
may also modulate IGFBP levels [129], thus further influencing IGF-1 activity.
In the rat AH-130 hepatoma ascites model of cancer cachexia, muscle expression of
IGF-1 messenger ribonucleic acid (mRNA) decreased progressively whereas IGF-1
receptor and insulin receptor mRNA levels increased compared with controls [20].
Furthermore, circulating levels of IGF-1 and insulin were reduced. However, the
exact mechanism of IGF-1 down-regulation in this scenario is unclear, as
administration of exogenous IGF-1 to tumour-bearing rats did not prevent cachexia
[20],
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Despite the failure of exogenous IGF-1 in the above-mentioned study, IGF-1
upregulation may still represent a possible therapeutic mechanism for the treatment
of human muscle wasting. In rodent models, transgenic overexpression of IGF-1
inhibits muscle atrophy in both chronic left ventricular failure (LVF) and
angiotensin Il-induced wasting [130], Serum IGF-1 has been capable of predicting
body cell mass and weight loss in cancer patients [131]. Furthermore, higher
circulating levels of IGF-1 are associated with improved patient survival in
cardiovascular disease [132] and cancer [133].
In the field of cancer research, much work has focused on the inhibition of the
GH/IGF-1 axis as a means of decelerating tumour growth [134]. Although this
work might ultimately achieve its goal, it may occur at the expense of accelerated
muscle wasting.
1.5.1.5 (3-adrenergic system
Although used traditionally for bronchospasm, it has become evident that some [3-
adrenoceptor agonists also exhibit 'repartitioning effects' within the body, resulting
in an increase in muscle mass and a decrease in fat mass [135]. In animal tumour
models, P-agonists have decreased muscle protein breakdown [136], increased
muscle protein synthesis [137], diminished the increased rate of muscle apoptosis
[138], and also induced the expression of genes involved in lipid metabolism,
indicating a metabolic shift towards a more oxidative phenotype [139]. However,
the long-term results of P-agonist therapy in humans remain unclear, and could be
tempered by undesirable side effects [135]. Although p2-agonist administration in
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the perfused hind-limb model increased gastrocnemius-plantaris-soleus muscle
mass by 21% and stimulated protein expression of type lib MyHC, greater fatigue
occurred on contraction [140], Furthermore, chronic p2-agonist therapy resulted in
impaired maximal lipid oxidation capacity and reduced glutamate dehydrogenase
activity, implying that the shift in muscle phenotype may not always be a beneficial
one [140], Moreover, older generation P-agonists (such as clenbuterol and fenoterol)
are associated with significant cardiovascular side effects [135]. Results of Phase
I/II clinical trials of formoterol (a newer generation P-agonist with a more
acceptable cardiovascular side effect profile) and megestrol acetate (MA, an
appetite stimulant) are awaited.
1.5.2 Catabolic hormones and growth factors
1.5.2.1 Myostatin
Myostatin, a member of the TGF-P protein superfamily, is an autocrine/paracrine
inhibitory GF produced by skeletal muscle myocytes. It binds to the activin type 2
cell surface receptor to activate the SMAD (member of TGF-P superfamily of
modulators) intracellular signalling pathways leading to changes in gene regulation.
In particular, myostatin activity is able to repress myogenesis by inhibiting the
synthesis and activity of the myogenic regulatory factor, MyoD [141].
Myostatin overexpression has been detected in a wide variety of forms of muscle
wasting, including cancer cachexia [142], HIV-associated wasting, disuse atrophy
and sarcopenia [143], Furthermore, exogenous myostatin administration [144] or
forced muscle-specific myostatin overexpression [145] in mice leads to dramatic
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muscle wasting. Therefore, methods to inhibit myostatin expression have been
proposed as potential therapies to reduce muscle wasting and promote muscle
growth. Models of myostatin inhibition are known to occur both naturally and
artificially. In experimental murine models, deletion of the myostatin gene locus
resulted in a 200-250% increase in muscle mass [146]. Furthermore, loss of
myostatin has been shown to improve significantly muscle mass, strength and
function in the mdx mouse model of muscular dystrophy [147], Pharmacological
and genetic methods of myostatin inhibition have been shown to improve muscle
mass in a wide range of laboratory models, including cancer cachexia [148].
Inhibitory agents have included antisense RNA oligonucleotides [149], activin
receptor molecules [150] and follistatin, the natural inhibitor of myostatin [148,
151]. Recently, studies in several cancer cachexia models have shown that
pharmacological blockade of ActRIIB, a high affinity activin type 2 receptor that
mediates signalling by a subset of TGF-P family ligands including myostatin,
activin and growth differentiation factor 11 (GDF11), reversed completely prior
loss of skeletal muscle and cancer-induced cardiac atrophy [152], Moreover, this
treatment prolonged survival dramatically, even in those animals in which tumour
growth was not inhibited and fat loss was not reduced [152].
Spontaneous myostatin gene mutations have been described in humans [153],
whippets [154], and Belgian Blue and Piedmontese cattle [155], This gene is highly
conserved between species, but the evolutionary advantage of myostatin expression
is not immediately obvious: loss-of-function myostatin gene mutations appear to
confer significant strength upon the host without obvious associated survival
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disadvantage. Furthermore, in whippets, a significant advantage of heterozygous
myostatin mutation status on racing performance has also been demonstrated
(although dogs with homozygous mutations were less able runners) [156],
When considering myostatin inhibition as an anti-cachexia therapy in humans, one
potential complication of long-term treatment may be the depletion of muscle stem
cells [157], thus significantly worsening the syndrome were disease relapse to occur.
However, trials of myostatin inhibition are due to start in humans.
1.5.2.2 Glucocorticoids
In a human patient, glucocorticoids (GCs) may be endogenous (e.g. Cortisol) or
exogenous (i.e. medical therapy for chronic inflammatory disease) in origin. Any
type of GC can cause muscle wasting, but it is much more common with
fluorinated steroids, such as dexamethasone or triamcinolone, than with
nonfluorinated steroids, such as prednisolone or hydrocortisone [158],
The catabolic effects of GCs on skeletal muscle appear to be mediated by several
different mechanisms. Firstly, GC combines with the cytosolic GC receptor (GCR)
to enter the cell nucleus and regulate gene transcription. This leads to both
upregulation of protein degradation pathways and enhanced glutamine synthetase
activity, resulting in increased levels of intracellular glutamine, an important
substrate for gluconeogenesis and energy yielding pathways [159]. There is a
subsequent reduction in the amino acid pool, thus preventing muscle protein
synthesis [160], Secondly, GCs inhibit muscle differentiation through the
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upregulation of myostatin. The human myostatin gene contains a number of GC
response elements within its promoter region, allowing dose dependent activation
of myostatin production [161]. Myostatin gene deletion in mice reduced
glucocorticoid-induced muscle proteolysis [162],
Hypercortisolaemia is associated with muscle atrophy in Cushing's disease, severe
trauma (e.g. burns), disuse muscle atrophy [163], and cancer cachexia [164],
Weight-losing pancreatic cancer patients have been shown to exhibit elevated
serum Cortisol levels and Cortisol: insulin ratios [19]. The muscles most commonly
affected by GC-induced atrophy are the proximal limb muscles and, in particular,
the quadriceps and pelvic muscles. Fast-twitch fibres are especially susceptible
[158],
Several strategies for the treatment of GC-induced muscle atrophy have been
proposed including recombinant human GH [165], IGF-1 [166] and anabolic
steroids [112], There have also been suggestions that progression of wasting may
be slowed by exercise, as the mechanism of GC muscle wasting is similar to that of
disuse atrophy [167], Withdrawal or dose reduction of exogenous GC may give
symptomatic improvement; however this may obviously result in relapse of the
underlying inflammatory condition for which the steroids were prescribed.
1.5.2.3 Angiotensin II
Angiotensin II is a component hormone of the renin-angiotensin syndrome.
Angiotensinogen produced by the liver is converted to angiotensin I by the action
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of renin (secreted by the kidney), which is then converted to angiotensin II by the
removal of 2 carboxy-terminal residues by angiotensin-converting enzyme (ACE)
(found predominantly in lung capillaries). Angiotensin II may play a role in both
cardiac and cancer cachexia via upregulation of the ubiquitin-proteasome pathway
(UPP) (one of the key intracellular mechanisms of muscle protein degradation)
[168, 169], the direct inhibition of protein synthesis [170], the modulation of IGF-1
pathways [171, 172], and the formation of ROS [173]. In animals, angiotensin II
produces weight loss through a repressor-independent mechanism, accompanied by
decreased levels of circulating and skeletal muscle IGF-1 and increased skeletal
mRNA levels of specific E3 ubiquitin ligases [128], The induction of the UPP may
occur via a protein kinase C (PKC) and non-classical nuclear factor-icB (NF-kB)-
dependent pathway [174], Furthermore, plasma angiotensinogen levels are
increased by the actions of thyroxine and corticosteroids [175], thus affording
another mechanism through which these two hormones can induce muscle wasting.
Methods to reduce circulating angiotensin II levels represent possible therapeutic
options for cachexia, and it has been shown that ACE inhibitors are capable of
reducing the risk of weight loss in patients with CHF [176], No trials in cachectic
cancer patients have yet been published. However, in patients with newly
diagnosed GI cancer and NSCLC, genetic polymorphisms in the ACE gene have
been shown to be associated with LBM, fat mass and muscle strength [177].
Further data are required to determine the clinical impact of ACE polymorphisms in
cachectic cancer patients.
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1.5.3 Autonomic nervous system
Dysregulation of the autonomic nervous system (ANS) has been recognised in
association with advanced cancer. In one study of male patients with metastatic or
recurrent cancer, autonomic dysfunction was found in 81% of patients [178],
whereas another study found a significant association between autonomic
dysfunction and survival [179]. It has been proposed that autonomic dysfunction
might actually represent a tumour-related epiphenomenon, the role of which is to
promote tumour cell survival [180], The hypothesis states that, by inducing host
sympathetic activation and cytokine cascade, the tumour is capable of promoting its
own growth (via adrenergic-induced angiogenesis) and evading host immunity (via
cytokine and adrenergic-induced shift of local immune balance to a tumour-
favourable Th2 bias). Other researchers have also postulated that cytokine-induced
anorexia/reduction in food intake may modulate both the neurohormonal and
autonomic axes even further [181]. How ANS dysregulation might impact on
skeletal muscle wasting, however, is not currently known.
In the previous section, the role of circulating neuroendocrine mediators in the
aetiology of cachexia has been discussed, by considering skeletal muscle atrophy as
a result of either decreased anabolic factors and/or increased catabolic factors.
Various abnormalities in circulating neuroendocrine factors have been identified in
cachectic cancer patients, but the identities of the most influential are unclear
currently. Exogenous supplementation of androgens, GH and insulin, and inhibition
of myostatin have been discussed as potential anti-cachectic therapeutic strategies.
Furthermore, early studies exploring the significance of ANS dysregulation within
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cancer cachexia have been referenced. In the following section, the subject of
discussion changes once again to focus on the role of tumour-derived mediators of
cachexia.
1.6 Tumour-derived mediators of cancer cachexia
The induction of cancer cachexia in surgically conjoined tumour-bearing rats
provided early evidence that cachexia is mediated by circulating, tumour-derived
factors that can initiate catabolism of host tissues [182], A number of cachectic
mediators, including pro-inflammatory cytokines, could be considered tumour-
derived in origin. However, this section focuses predominantly on PIF and LMF.
1.6.1 Proteolysis-inducing factor
PIF was first identified as a glycosylated polypeptide using an antibody cloned
from splenocytes of mice transplanted with the murine adenocarcinoma 16
(MAC 16) tumour [17]. This antibody bound to a 24kDa sulphated glycoprotein,
which was also present in the urine of cachectic human cancer patients [17]. A
hybridoma was subsequently developed for the production of the antibody, for use
in purification of PIF by affinity chromatography and for assay of physiological
samples. Immunoreactivity with the murine anti-PIF antibody has since been
described in the urine of weight-losing patients with carcinoma of the pancreas,
breast, ovary, lung, colon, rectum and liver [17]. Patients with pancreatic cancer
demonstrating PIF immunoreactivity in urine had a significantly greater total
weight loss and rate of weight loss than patients whose urine did not [183],
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Furthermore, isolation of protein with PIF immunoreactivity from human urine
induced muscle wasting when injected into mice [184],
In murine and pre-clinical models, PIF appears to be capable of inducing skeletal
muscle wasting via a number of different mechanisms. Firstly, PIF may induce
muscle protein degradation via activation of the UPP. PIF-induced protein
degradation, both in gastrocnemius muscle in vivo and murine fibroblasts in vitro,
was associated with increased expression of mRNA and protein of the ubiquitin
conjugating protein and the proteasome a and (3 subunits [185]. Upregulated
expression of the UPP in murine myotubes was associated with PIF-induced
activation of the transcription factor NF-kB [186], possibly through activation of
PKC [187], ROS may be additional intermediates of murine PIF-induced
proteolysis in vitro [173], Secondly, not only does PIF induce muscle protein
degradation, but it also appears to inhibit muscle protein synthesis by reducing
translational efficiency via double-stranded RNA-dependent protein kinase (PKR)
and eukaryotic initiation factor (elF) 2a phosphorylation [188], Thirdly, PIF is also
capable of inducing skeletal muscle apoptosis via stimulation of caspase activity in
vitro [189, 190]. Lastly, PIF may also induce skeletal muscle wasting indirectly by
virtue of pro-inflammatory activity. Protein with PIF immunoreactivity extracted
from human urine has been shown to activate NF-kB and signal transducer and
activator of transcription 3 (STAT3) in isolated hepatocytes, certain endothelial cell
types, monocytes and Kupffer cells, resulting in increased production of IL-6, EL-8
and CRP, and decreased production of transferrin [191-193], Thus, PIF and 11-6
may be common activators of the APPR in cancer cachexia.
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PIF-like transcripts appear to be absent or minimally present in normal human
tissues, with the exception of sweat glands [194], the pons, and the paracentral
gyrus of the cerebral cortex [195]. In contrast, PIF-like mRNA has been
demonstrated in malignant human tumours, including upper GI cancer [196],
prostate cancer [197] and the human melanoma cell line, G361 [198], Further
expression studies of PIF mRNA are detailed later in this thesis (Chapters 3 and 4).
There remain, however, a number of unresolved issues concerning the biology of
PIF. Firstly, it appears to be transcribed from a gene that, depending on the extent
of transcription, may result in other functional proteins being produced (Figure 1.6).
In 1998, Incyte Pharmaceuticals first identified the human homologue of murine
PIF in a breast cancer library by using the known sequence of the 20-amino acid
PIF core peptide (PIF-CP) [199]. The discovered sequence shared 90% homology
with murine PIF and was named the human cachexia associated protein (HCAP).
HCAP mRNA was later detected in prostate cancer cell lines, whereas HCAP
protein was found in metastatic tissue and urine of cachectic patients with prostate
cancer using rabbit antisera raised to a peptide consisting of the 25 amino acids at
the N-terminus of the deduced HCAP protein that overlapped with the known
sequence of PIF [197], The gene sequence of HCAP is identical to that of another
gene known as DCD. This latter gene codes for a 110-amino acid, antimicrobial
protein called dermcidin, which was expressed specifically and constitutively in
sweat glands [194], Only the terminal 47 amino acids of the DCD sequence were
secreted into human sweat, and this peptide fragment was named DCD-1 (Figure
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was purified from medium conditioned by human retinoblastoma cells and a mouse
hippocampal cell line exposed to oxidative stress [200]. When the human
complementary DNA (cDNA) encoding Y-P30 was identified, the resultant native
12 kDa, 110-amino acid polypeptide (which included Y-P30 at amino acids 20-49)
was named diffusible survival evasion peptide (DSEP) (Figure 1.6) [201]. Like Y-
P30, DSEP was also found to increase resistance to oxidative stress. The gene
encoding DSEP was identified as the same gene that encodes dermcidin [195].
Since these earlier studies, dermcidin has also been identified in human placental
tissue and has been shown to have previously uncharacterised proteolytic activity
[202], Furthermore, recombinant DCD was capable of inducing an invasive
phenotype in a human choriocarcinoma cell line in vitro [202]. Due to the absence
of a reliable antibody for the detection of PIF protein in humans, in PIF studies
within this thesis (Chapters 3 and 4), dermcidin mRNA levels are used as a proxy
of PIF expression.
The various protein products of the DCD gene (Figure 1.6) are thought to depend
on cleavage of the primary transcript, with or without additional post-translational
modifications. However, currently there are no data regarding proteolytic
processing of the DCD polypeptide into its peptide subunits. Furthermore, although
many precursor polypeptides (e.g. pro-opiomelanocortin [POMC], glucagon-like
peptides) undergo post-translational cleavage to form molecules with related
biological activities, the discordant activities attributed to DCD gene products in
normal and malignant cells are difficult to reconcile. The investigation of PIF is
complicated even further when one considers that the murine DCD gene appears to
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be absent from the map of the mouse genome (although the homologous gene has
been described in the rat and chimpanzee).
The second PIF controversy concerns the glycosylation shell of this protein. The
murine PIF-CP was reported to be extensively glycosylated, with an /V-1 inked
sulphated oligosaccharide chain of approximately 10 kDa, and an O-linked
sulphated oligosaccharide chain of approximately 6 kDa [17, 203]. It is a
component of this carbohydrate shell that is recognised by the existing PIF mAb
upon which most PIF protein studies are reliant [17, 203], Furthermore, N- and O-
glycosylation is crucial to the muscle proteolysis induced by PIF in mice. Stable
forced expression of the human gene homologue of PIF in multiple murine and
human cell lines produces a non-glycosylated secreted protein that does not induce
murine cachexia in vivo [204], However, the absence of a site with a classical motif
for /V-glycosylation in the human PIF-CP/Y-P30 sequence remains an important
barrier to proving that human cancer cells can transform the DCD gene product into
a proteolysis-inducing factor. Sequence analysis suggests that there are 3 potential
O-glycosylation sites and 2 potential /V-glycosylation sites in the putative human
PIF-CP. An Asp-X-Ser/Cys sequon is required for /V-glycosylation, in which X
may be any amino acid other than proline. The putative /V-glycosylation site at
asparagine residue 32 has an Asp-Pro-Cys sequence, making it possible, but unclear,
if atypical N-glycosylation is likely to occur [205], Furthermore, bioinformatic
analysis indicates that the human PIF-CP is unlikely to be O-glycosylated at any of
the putative sites in the sequence (N- and O-glycosylation were modelled using Net
N-Glyc (http://www.cbs.dtu.dk/services/NetNGlyc/) and Net O-Glyc
74
(http://www.cbs.dtu.dk/services/NetOGlyc/), respectively) [206], The sequences of
DCD gene transcripts in human cell lines are analysed later in this thesis in order to
detect the potential existence of any sequence variants that might increase the
chances of glycosylation (Chapter 4).
The third problem surrounding PIF arises from the fact that investigations of
putative glycosylated PEF in humans have all relied on a single murine mAb. The
potential human homologue of PIF was reported originally to be associated
specifically with the weight loss of malignant disease (based on its absence from
the urine of healthy controls and weight-losing patients with trauma or sepsis) [17].
However, recent results neither confirm specificity of the presence of PIF
immunoreactivity with malignancy, nor associate PIF immunoreactivity with
weight loss, muscle catabolism [207, 208] or survival [183, 209]. Given these
findings, an exact understanding of the specificity of the antibody is crucial. A
number of recent studies have tried to use molecular tools based on the peptide
portion of PIF. Polyclonal antibodies have been raised against varying fragments of
the DCD protein [197, 204, 210], but none of these antibodies have been specific to
the putative PEF-CP, apart from those utilised in studies in collaboration with Astra-
Zeneca [191-193], Due to steric hindrance by the two large oligosaccharide chains
[203], it is not clear from the literature if an antibody to the PIF-CP would be able
to bind to glycosylated PIF. Thus, in studies where antibodies to the peptide portion
were used to identify and/or purify PIF from human samples, without confirmation
of the presence of the proteolysis-inducing carbohydrate shell, it may be regarded
that the presence of bioactive PIF was not confirmed.
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Future attempts at purifying PIF may be more specific and successful following the
recent characterisation of the murine PIF membrane receptor [211]. Murine PIF
was found to bind with strong affinity (Kj, 1-26 nM) to sarcolemma membranes
from mouse and pig skeletal muscle, murine myoblasts and a human muscle cell
line [211], Binding was competitively inhibited by chondroitin sulphate, suggesting
interaction between the receptor and the sulphated oligosaccharide chains of the
PIF glycoprotein. Antisera to the PIF receptor inhibited PIF-induced activation of
the UPP in murine myotubes, and prevented PIF-induced weight loss in the
MAC 16 murine model [211]. The PIF receptor was identified as a DING protein of
approximately 40kDa. Although DING proteins seem to play key roles in various
human diseases, (e.g. rheumatoid arthritis, atherosclerosis, HIY), no mammalian
cDNA or genomic DING sequences have been published. This is hypothesised to
be due to low transcript abundance, mRNA instability, rapid turnover or gaps in the
genome [212], It has been proposed previously that DING proteins do not exist in
eukaryotic cells and that any detected are due to contamination with prokaryotes, in
particular Pseudomonas species [213], However, the authors who characterised the
receptor ensured that their cell systems were free of Pseudomonas [211].
Lastly, any investigation of human PIF is complicated by the fact that there are no
readily available sources of glycosylated PIF. The original reports concluded that
human PIF is found in very low abundance in vivo. Estimates suggest that PIF
comprises only 5xl0"4% of the total urinary protein of humans with cancer cachexia
[17]. Furthermore, although the human melanoma cell line G361 has been proposed
as a potential source of glycosylated PIF [198], there are no human tumour cell
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lines proven to produce glycosylated PIF and thereby providing an alternative
source to urine for purification. Some previous studies have relied on using
recombinant, partially glycosylated PIF produced by the transfection of G361 cells
with the HCAP (DCD) gene [192], but in this scenario, it is unclear as to how much
such models might mimic accurately human biology.
1.6.2 Lipid mobilising factor
Zinc-a-2-glycoprotein (ZAG), otherwise known as LMF, is involved in the specific
mobilisation of adipose tissue, with increased oxidation of released fatty acids,
possibly via induction of uncoupling protein (UCP) expression [214], LMF isolated
from the MAC 16 murine tumour, or from the urine of patents with cancer cachexia,
stimulated lipolysis directly through interaction with adenylate cyclase in a
guanosine triphosphate (GTP)-dependent process [16]. This effect was also
produced by the interaction of LMF with the [^-adrenoceptor [215].
Mitochondrial UCPs transport protons across the inner mitochondrial membrane,
not linked to ATP synthesis. They constitute a potential energy sink and thus the
overexpression of UCPs could be an aetiological factor in cachexia (although there
is little evidence for this in humans). LMF has been shown to increase both mRNA
and protein levels of UCP-1, -2 and -3 in brown adipose tissue (BAT) and UCP-2 in
murine skeletal muscle and liver [214], LMF is also thought to be the cause of lipid
mobilisation and the decrease in plasma leptin observed in the MAC 16 model. In
these mice, UCP-1 mRNA levels were elevated in BAT, and UCP-2 and UCP-3
levels were increased in skeletal muscle [216]. Transgenic mice overexpressing
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UCP-3 in skeletal muscle were hyperphagic and weighed less than wild type
littermates, largely through a reduction in adipose tissue mass [217]. Increased
levels of UCP-2 and UCP-3 mRNA expression were also demonstrated in the
gastrocnemius and soleus muscles of cachectic rats bearing the Yoshida AH-130
ascites hepatoma [218]. This increase in mRNA content was associated with a two¬
fold increase in fatty acid, triglyceride and cholesterol levels. Reduction of
hyperlipaemia with nicotinic acid also reduced UCP-3 expression in soleus, but not
in gastrocnemius. This suggests that circulating fatty acids may be involved in the
regulation of UCP-3 gene expression in aerobic muscles during cancer cachexia.
Furthermore, a single intravenous (IV) injection of TNF-a administered to these
rats caused a significant increase in skeletal muscle UCP-2 and 3 [219], suggesting
that LMF and/or TNF-a may be responsible for the elevation of UCP mRNA seen
in cachectic rodent muscle, possibly through elevation of serum lipid levels.
The exact cellular source of LMF is unclear from the published literature.
Cachexia-inducing murine tumours (e.g. MAC 16 adenocarcinoma) express ZAG
mRNA at elevated levels [220], suggesting that tumour cells are the primary
producers. However, other studies have demonstrated overexpression of ZAG in the
white adipose tissue (WAT) of tumour-bearing mice [221], suggesting a secreted
paracrine role for adipocyte-derived ZAG in the reduction of adiposity. In obese
humans, expression of ZAG mRNA by adipocytes was correlated inversely with
BMI and fat mass [222], Thus, in cancer, LMF may not represent a tumour-derived
cachectic mediator, but may actually be a component of the aberrant host response.
The discovery of ZAG/LMF as a potential adipokine has also led to investigations
78
of body weight regulation in other disease conditions. Recombinant human ZAG
has already shown promise as a potential treatment for Type II DM in the ob/ob
mouse model [223].
Despite the apparent relationship between LMF and UCP in the regulation of body
composition in animal models, evidence of a role for UCPs in human cancer
cachexia is limited [224], Some studies have been unable to demonstrate increased
expression of UCPs in skeletal muscle samples from patients with cancer [225].
However, in one study, it was shown that the muscle of patients with gastric
adenocarcinoma and weight loss demonstrated a five-fold increase in mRNA levels
for mitochondrial UCP-3 compared with controls and cancer patients who had not
lost weight [226], If UCPs are involved in human cancer cachexia, they may offer a
potential route by which LMF, a factor that causes fat catabolism, could affect
indirectly skeletal muscle [227],
In the previous section, attention has focused on two specific tumour-derived
cachectic mediators, namely PIF and LMF, although it has been suggested that
further unidentified mediators may exist. Current controversies regarding the
existence of a putative homologue of human PEF have been described, and thus it
remains unclear as to whether or not PIF inhibition may be a useful anti-cachectic
strategy in cancer patients. The emerging evidence of a role for LMF/ZAG in the
regulation of human body composition has also been explored, but again, the
functional benefits of ZAG downregulation and gain in fat mass as an anti-
cachectic strategy are uncertain in cancer patients. This section represents the last
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of three sections focused specifically on circulating mediators of cancer cachexia
(inflammatory, neuroendocrine and tumour-derived mediators). Figure 1.7 is an
expanded version of Figure 1.2 and summarises the involvement of circulating
mediators within the host-tumour interaction. In the following two sections, the
overall focus remains on mechanisms of cancer cachexia. However, the specific
topic of discussion changes from circulating mediators of the syndrome to
alternative mechanisms of weight loss and muscle wasting in cancer patients,
including inadequate nutritional intake (Chapter 1.7) and mechanisms that lie
outwith the bounds of the oft-considered, classical host-tumour interaction (Chapter
1.8).
1.7 Inadequate nutritional intake in cancer cachexia
Nutritional depletion is exacerbated in cancer patients by inadequate nutritional
intake, which may be the result of either 'primary' anorexia and/or other secondary
mechanisms (Figure 1.8).
1.7.1 Anorexia
Anorexia is defined clinically as the reduction or loss of appetite. It is experienced
by approximately 15-40% of cancer patients at diagnosis, but by almost all
advanced cancer patients [228], Indeed, cancer cachexia is often termed the "cancer
anorexia-cachexia syndrome", thus highlighting the significant mechanistic overlap
that underlies the patient's nutritional depletion. Difficulties in clearly defining and
diagnosing anorexia still exist. A VAS can be used but is unreliable if small
changes in appetite are to be detected. Often, the diagnosis of anorexia is made on
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the basis of reduced energy intake, but this procedure can be misleading since the
reduction of ingested calories might be the consequence of secondary mechanisms
rather than a sign of anorexia. To assess reliably the presence of anorexia, several
symptoms that interfere with food intake and are likely to be related to changes in
the central control of energy intake have been identified: early satiety, taste
alterations, smell alterations, meat aversion, and nausea/vomiting [229]. Patients
reporting at least one of these symptoms may be defined as anorectic. However,
this diagnostic tool only provides a qualitative assessment of anorexia, so it may
still be advisable to quantify anorexia severity by VAS [230],
The mediators and neuronal peptide systems involved in the central regulation of
appetite are discussed below. Such mediators induce either an orectic or anorectic
state in the individual (Figure 1.8). However, most of the experimental work aimed
at identifying these mediators has been performed in animals, and little human data
are available, particularly in the context of cancer cachexia.
1.7.1.1 Neuropeptide Y and pro-opiomelanocortin systems
The pathogenesis of primary anorexia/early satiety and the control of human
appetite are understood incompletely. Cytokines, (including IL-1 p, IL-6 and TNF-
a), central neurotransmitters (e.g. serotonin), feeding-stimulating neuropeptides (e.g.
NPY), hormones (e.g. leptin and ghrelin) and tumour-derived factors have all been
implicated (Table 1.2) [230, 231]. However, two peptide systems in particular
appear to be strongly influential in the control of feeding behaviour: these are the
orexigenic NPY and the anorexigenic POMC systems [232], Many mediators of
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Table 1.2 Mediators of appetite control.
Orexigenic and anorexigenic mediators that act centrally on the hypothalamus to
stimulate or inhibit food intake, and are thus hypothesised to be involved in the
induction of primary anorexia in cancer patients. Anorexia may be the result of an
excess of anorexigenic mediators and/or a deficiency of orexigenic mediators.
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appetite control exert their effects through induced changes in these two systems.
Both originate in the hypothalamic arcuate nucleus (ARC) and extend projections
widely over the brain [232], They have been shown to be linked intricately with
each other and to operate in parallel. POMC neurons are the source of the potent
melanocortin neuropeptides, such as oc-melanocyte-stimulating hormone (a-MSH),
which, via interaction with the central melanocortin-3 and 4 receptors (MC3/4-R),
induce an anorectic state.
1.7.1.2 Cytokines
The role of cytokines in cancer anorexia may be effected through influence on both
the NPY and POMC systems. In particular, IL-1 has been associated with the
induction of anorexia by blocking NPY-induced feeding [233], NPY levels are
reduced in anorectic tumour-bearing rats, and a correlation between reduced food
intake and brain IL-1 was also demonstrated in the same animals [234], The
mechanism involved in the attenuation of NPY activity by cytokines may involve
inhibition of NPY synthesis, inhibition of neuronal firing rates or an attenuation of
its post-synaptic effects [235]. Studies in rats have also shown that the anorectic,
but not pyrogenic actions, of IL-1 [3 are modulated by central MC3/4-R [236], and
that the carboxyl terminal dipeptide of a-MSH, Lys-Pro, transiently antagonises
anorexia induced by IL-1 (3 [237]. Cytokines may further mediate anorexia via an
increase in corticotropin-releasing factor (CRF), a central neurotransmitter that
suppresses the function of glucose-sensitive neurons and food intake. The
neuroanatomical site of action of this pathway is likely to be the bed nucleus of the
stria terminalis [238], Surprisingly, in animal models, CRF-induced anorexia is not
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influenced by MC-4 R blockage [239], despite the fact that oc-MSH can antagonise
the anorexia induced by CRF [240], suggesting the existence of a feedback loop.
1.7.1.3 Leptin
Human leptin is a protein of 167 amino acids that is manufactured in and secreted
primarily by adipocytes within WAT, although a range of other tissues including
skeletal muscle and gastric chief and P/Dl cells have also been shown to produce it
[241], The level of circulating leptin is directly proportional to the total amount of
fat in the body [242], and in this way leptin acts as an adiposity signal. Leptin is
known to increase the frequency of action potentials in POMC neurons by two
different mechanisms: depolarisation through a non-specific cation channel; and
reduced inhibition by local orexigenic NPY/gamma aminobutyric acid (GABA)
neurons [243]. Downstream melanocortin peptides have an autoinhibitory effect on
this circuit [243].
In human cancer cachexia, leptin levels are markedly low [19] (presumably because
of weight loss, although other mechanisms may also be at play) and therefore
melanocortin signalling should be reduced. However, studies show that the POMC
system still appears to be important in the development of cancer-associated
anorexia. For example, when administered into the third cerebral ventricle of
Lobund-Wistar rats (an anorectic animal model of prostate cancer), the MC-R
antagonist SHU9119 completely reversed anorexia and produced weight gain
comparable to that observed in non-tumour bearing control animals [244], However,
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intracerebroventricular injections of NPY and ghrelin (see below, p.87) were unable
to elicit the same response.
1.7.1.4 Ghrelin
Ghrelin, a 28 amino acid peptide produced by the P/Dl cells of the stomach, acts as
the natural counterpart to leptin. Not only does ghrelin stimulate GH secretion (via
the GH secretagogue receptor [GHS-R]-la), but it also promotes food intake (via
the orexigenic NPY system) [245] and decreases sympathetic nerve activity [246].
Ghrelin has therefore been proposed as an alternative measure to GH therapy in
muscle wasting.
Patients with cancer cachexia demonstrate increased plasma concentrations of
active ghrelin, suggesting a compensatory response to weight loss [247],
Intravenous ghrelin has been shown to be safe and well tolerated in patients with
advanced cancer [248]. Furthermore, synthetic human ghrelin has been shown to
improve muscle wasting and functional capacity in patients with cardiopulmonary-
associated cachexia [249, 250], to improve energy intake in anorectic cancer
patients [251], and to improve appetite and reduce loss of body fat in weight-losing
cancer patients [252],
1.7.1.5 Macrophage inhibitory cytokine-1
Recently, much interest has focused on the anorectic action of macrophage
inhibitory cytokine-1 (MIC-1), a tumour-secreted cytokine [253]. Studies in murine
models of prostate cancer have suggested that the underlying mechanism is reduced
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NPY expression and increased POMC expression in the ARC [254], and thus MIC-
1 inhibition has been proposed as a potential anti-cachexia therapy in humans.
However, to date, the existence of a role for MIC-1 in human cancer cachexia
(either nutritional depletion or appetite suppression) has not been proven
conclusively. The existence of such an association is questioned in more detail later
in this thesis (Chapter 4).
1.7.1.6 Other mediators of appetite control
Other mediators of appetite control that may be over- or underexpressed during
cancer-associated anorexia include serotonin, prostaglandins, malonyl-coenzyme A,
endocannabinoids, and PTHrP. Changes in the circulating levels of free tryptophan
induce changes in brain serotonin concentration and, consequently, changes in food
intake [255]. Prostaglandins may act as mediators of anorexia in disease states
associated with systemic inflammation [256], Thus, anti-inflammatory therapies,
such as cyclooxygenase (COX)-2 inhibitors, may be beneficial in the management
of cancer cachexia. Malonyl-coenzyme A plays a key role in long-chain fatty acid
biosynthesis. An increased level of hypothalamic malonyl CoA is an indicator of
energy surplus, resulting in a decrease in food intake [257], Endocannabinoids,
lipid-derived signalling molecules (e.g. 2-arachidonoylglycerol and anandamide),
are involved in the control of eating motivation via effects in the hypothalamus and
nucleus accumbens [258], Overactivity of the endocannabinoid system has been
implicated in the aetiology of obesity [259], The use of exogenous cannabinoids as
an appetite stimulant for the treatment of cancer cachexia is discussed in Chapter
1.11.4.2. PTHrP has already been discussed as a pro-inflammatory mediator of
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cachexia in Chapter 1.4.1.4. However, in rats, peripherally administered PTHrP has
also been shown to decrease food intake and gastric emptying [64], The decreased
PA of cachectic cancer patients may also have the potential to reduce appetite by
improving the sensitivity of the physiological satiety signalling system, by
adjusting macronutrient preferences or food choices, and by altering the hedonic
response to food [260],
1.7.2 Secondary mechanisms
Secondary mechanisms of reduced nutritional intake include physiological and
psychological problems associated with the physical presence of tumour e.g.
mechanical gut obstruction, dysphagia, nausea, constipation, depression, Gl/oral
fungal infection and side effects of treatment. Such problems should be sought
actively by medical staff and appropriately managed. If not, the patient's physical
status will deteriorate further, and the inanition, depression and fatigue that
cachectic patients suffer will be further compounded by social isolation, as they are
unable to take part in normal social patterns of eating [261, 262].
In the previous section, the high prevalence of reduced nutritional intake in
advanced cancer patients has been asserted. Moreover, the underlying primary and
secondary mechanisms that cause inadequate nutritional intake have been described
(Figure 1.8 represents a summary diagram). The need for more research regarding
the role of MIC-1 in humans has been expressed, whereas ghrelin administration
has been suggested as a potential anti-cachexia therapy. In the following section,
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alternative mechanisms of cachexia that lie outwith the usually considered
components of the host-tumour interaction are discussed.
1.8 Beyond the host-tumour interaction
Up to this point, the present thesis has examined predominantly classical
components of the host-tumour interaction, including the APPR, the
neuroendocrine response and tumour-derived catabolic mediators, in the aetiology
of cancer cachexia. However, there is emerging evidence that other factors
including patient age, habitual levels of PA, and specifics of whole-body protein
metabolism may also contribute to the deterioration of nutritional status in the
cachectic cancer patient.
1.8.1 Patient age
Generally, most patients with cancer are elderly, with an average age over 70 years.
Moreover, the main reason for a persistent rise in the incidence of cancer in
Western society is the ever-increasing average age of the population. From the age
of 50 years onwards, aging is associated with the degenerative loss of skeletal
muscle, a condition known as sarcopenia [263], The mechanisms underlying this
condition are various and include reductions in circulating levels of anabolic
hormones e.g. testosterone. Furthermore, sarcopenia is exacerbated by chronic
illness, inadequate diet and inactivity [264], However, one of the chief mechanisms
underlying sarcopenia appears to be the anabolic resistance of elderly muscles to
post-prandial amino acid loading. Normally, in the physiological post-absorptive
state there is a negative balance between whole-body protein synthesis and
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degradation. Any protein loss is immediately made-up in the post-prandial state by
protein gain stimulated by nutrient intake [265]. In human studies, the post-prandial
increase in plasma amino acid concentration stimulates muscle and whole-body
protein synthesis by 50% and 40% respectively [266, 267], and whole-body protein
balance is reversed from negative to positive. Sarcopenia appears to be (at least
partly) the result of deficits in intracellular anabolic signalling pathways normally
involved in these processes [264], Although the basal (post-absorptive) rates of
muscle protein synthesis are similar between elderly and young human muscle,
elderly muscle demonstrates less anabolic sensitivity and responsiveness of protein
synthesis to essential amino acids. In particular, there is an associated reduction in
the expression and activation of several intramuscular mediators of protein
synthesis: mammalian target of rapamycin (mTOR), p70 s6 kinase (p70s6k), eIF4E
binding protein 1 (eIF4E-BPl) and eIF2B [264] (see Chapter 1.9, p.98, for a
detailed discussion of intracellular mechanisms of skeletal muscle wasting).
Furthermore, there is a marked increase in expression of the inflammation
associated transcription factor NF-kB [264], The effect of insulin on leg protein
breakdown is also diminished in older patients, possibly mediated by blunted Akt-
protein kinase B (PKB) activity [268]. Clearly, these phenomena may not only be
present in the skeletal muscle of elderly cancer patients, but may be exacerbated by
the presence of ongoing systemic inflammation during cancer cachexia.
Mitochondrial dysfunction has also been proposed as part of a 'vicious cycle'
theory of aging and muscle sarcopenia [269]. Enhanced ROS production, increased
mitochondrial apoptotic susceptibility and reduced transcriptional drive for
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mitochondrial biogenesis have all been described in sarcopenic animal models
[270]. Overexpression of the mitochondrial T3 receptor induced mitochondrial
activity, which resulted in sarcopenia [271]. In humans, impaired aerobic
metabolism at rest and during modest levels of activity has also been observed in
patients with sarcopenia [272],
1.8.2 Physical activity
In the present thesis, PF and PA are considered as different patient variables. PF is
the ability to conduct a variety of everyday activities, ranging from self-care to
more challenging activities requiring greater mobility, strength, or endurance,
whereas PA is considered as an objective measure of physical exercise, such as the
number of steps walked per day or the calorific energy expenditure spent on
activity. Cancer patients may lose weight despite a normal food intake, suggesting
that resting energy requirements are increased. However, in practice, measured
resting energy expenditure (REE) levels have been variable. Indeed, increased
[273], normal [274] and reduced REE [275] have all been described in cancer
patients. It has been suggested that different tumour types (and stage of disease)
may be associated with different effects on REE; lung and pancreatic cancer
induced an increased REE [276, 277], whilst gastric and colorectal cancer had little
effect [278]. Any increase in REE observed may be driven by an increase in mass
and relative proportion of high metabolic rate tissues (such as liver and tumour)
[279]. However, although REE may be increased in some hypermetabolic, wasted
cancer patients, total energy expenditure (TEE) may actually fall due to a reduction
in PA [277], PA is a significant and variable component of daily energy
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expenditure (EE) in free-living individuals and a reduction in PA can more than
compensate for any elevation in REE. Whether such a reduction in PA represents
an adaptive homeostatic response of energy regulation or a simple result of the
patient's primary disease process is unclear currently. However, it seems clear that,
without intervention, the cachectic cancer patient will enter a vicious circle: muscle
wasting causes physical inactivity that, in turn, aggravates muscle wasting.
In a study of hypermetabolic, cachectic pancreatic cancer patients, it was shown
that the measured mean physical activity level (PAL: ratio of TEE to REE) was
much lower (mean 1.24) (Figure 1.9) than that recorded in healthy adults of similar
age (mean 1.62) [277]. This level of PA is comparable to that observed in spinal
cord injury patients living at home [280], It is also entirely plausible that levels of
activity as low as this may exacerbate wasting [281], as it is well understood that, in
any individual, a lack of PA will cause deconditioning and deterioration in skeletal
muscle mass. Two weeks of bed rest in healthy volunteers resulted in losses
equivalent to 70g protein, or 350g wet weight of muscle [282]. Furthermore, 2
weeks of simulated microgravity (bed rest at minus-6 degrees tilt) in healthy
volunteers caused a decrease in leg and whole-body lean muscle mass by 3.9% and
1.7% respectively, and a 50% reduction in muscle protein synthesis [283]. This
reduction in whole-body protein with physical inactivity is a result of the loss of the
stimulatory effect of PA on amino acid-mediated promotion of muscle protein
synthesis [282], The ability of combined insulin and glucose infusions to decrease
whole-body proteolysis was unaffected by muscle inactivity [281], and therefore





1.2 barely out of bed
no activity
Figure 1.9 Physical activity level of cachectic pancreatic cancer patients
(n=24).
The PAL of cachectic pancreatic cancer patients (mean 1.24) is much lower than
that recorded in healthy adults of similar age. A degree of inactivity as severe as
this will exacerbate skeletal muscle wasting further. Adapted from Moses et al
[277],
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the loss of anabolic stimulation by PA only tends to affect bed-rested individuals
during the fed state; protein balance was similar to that observed in healthy controls
during the fasted state. When combined, these results suggest that a supra-normal
protein intake is required to achieve the same post-prandial anabolic effect during
muscle inactivity and cachexia. It also points to the importance of maintaining even
modest levels of PA in cancer.
It is worth noting that, in weight-losing pancreatic cancer patients that are not
bedridden, it is possible to increase TEE and PAL with a specialised nutritional
supplement containing eicospentaenoic acid (EPA) (an n-3 fatty acid with anti¬
inflammatory properties) administered over an 8-week period, but not with an
isocaloric, isonitrogenous control supplement [277], As PA is also an important
component of the physical and social domains of QoL, any restoration of PAL
towards a normal level may translate into an improvement in QoL for cachectic
patients.
The topic of PA in cancer patients recurs in this introductory chapter when it will
be considered as a useful outcome measure in cancer cachexia (Chapter 1.12).
Moreover, the objective assessment of PA as just such an outcome measure will be
investigated later in this thesis (Chapters 10 to 11).
1.8.3 Protein metabolism in the fed versus fasted state
In the past, most metabolic studies have tended to focus on patients studied in the
fasted state rather than the fed state. In those studies that have investigated the post-
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prandial state, feeding was associated with increased hepatic synthesis of acute
phase proteins (see Chapter 1.4.2.1, p.51, and Figures 1.4 and 1.5) [73], However,
more recent investigations into the whole-body protein metabolism of fed cachectic
patients have yielded intriguing results. Such studies have confirmed that whole-
body protein catabolism is markedly increased in the fasting state in patients with
advanced pancreatic cancer compared with healthy controls [284], However,
repeated half-hourly oral supplement feeding reduced whole-body protein
breakdown rates to levels approaching those of normal controls, and interestingly,
whole-body protein synthesis was increased [284], This work emphasises the role
of nutrition as a core element in the treatment of weight loss in cancer. Patients
should receive small, frequent meals to attenuate protein catabolism. However, to
date, no clinically applied feeding protocol has been completely successful at
reversing cancer-associated weight loss.
Anti-inflammatory nutriceuticals might be the key to combining high calorie/high
protein nutrition with modulation of hepatic acute phase protein synthesis. Such
modulation has been demonstrated in cachectic pancreatic cancer patients receiving
oral supplements enriched with EPA. After a 3-week course of treatment, not only
had the patients' weight stabilised, but the combined synthetic rate of albumin and
fibrinogen was reduced significantly in the fed state and demonstrated a tendency to
fall in the fasting state [285],
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1.8.4 Anti-neoplastic therapy
Many cancer interventions will exacerbate reduced energy and nutrient intake.
Surgical patients may be fasted for prolonged periods peri-operatively, and both
chemotherapy and radiotherapy can induce side effects such as anorexia, nausea,
vomiting, mucositis, taste change or lethargy [286], For example, in animal models,
cisplatin-induced anorexia was mediated through reduced hypothalamic ghrelin
secretion [287], whereas the ghrelin agonist, GH releasing peptide 2 (GHRP-2),
reduced anorexia associated with 5-fluorouracil treatment (5-FU) in C-26 mice
[288]. Symptoms will depend on the nature and course of the chemotherapeutic
drugs being utilised, and the location, volume and dose of radiotherapy.
Some cytotoxic drugs may even generate their own cachexia-like side effects. For
example, antitubulin taxanes induced greater loss of body weight in tumour-
bearing mice than in healthy mice, even when the agents significantly reduced
tumour growth [289]. Moreover, CT analysis of patients with metastatic renal cell
cancer resistant to standard therapy demonstrated that individuals receiving
sorafenib lost skeletal muscle progressively at 6 months (decrease of 4.9%) and 12
months (decrease of 8.0%), whereas patients receiving placebo were weight-stable
[290]. The complex interaction between nutrition, cachexia and chemotherapy still
requires further elucidation [291, 292],
In the previous section, mechanisms of skeletal muscle wasting outwith the usually
considered components of the host-tumour interaction, including elderly patient age,
physical inactivity, treatment-related side effects, and specific aberrations in protein
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metabolism demonstrated by cancer patients, have all been discussed (Figure 1.10
represents a summary diagram). The treating physician should appreciate such
'non- classical' mechanisms, as immediate recognition of these additive causes of
nutritional depletion may reduce the time to early prophylactic intervention. The
following section is the last addressed specifically to mechanisms of cancer
cachexia, and the thesis now focuses on intracellular mechanisms of skeletal muscle
proteolysis.
1.9 Intracellular mechanisms of skeletal muscle wasting
Muscle protein is continually synthesised and broken down each day with an
average turnover rate in humans of 1-2% [293]. Under normal circumstances,
synthesis equals breakdown and muscle bulk remains constant. Muscle wasting
occurs when synthesis is decreased, breakdown is increased, or a combination of
events leads to a net negative balance. In cancer cachexia, the initial loss of muscle
may appear subtle but, over prolonged periods of time, severe wasting with >75%
loss of skeletal muscle mass can occur [1].
Although the major focus of this thesis is skeletal muscle wasting in cancer
cachexia, much of the important work that has led to our understanding of the
underlying molecular mechanisms has been performed in other models of wasting,
and so these models are also discussed below. Indeed, the mechanistic similarities
between cancer cachexia and muscular dystrophy are studied in more detail later in
this thesis (Chapter 7). However, as with the data regarding anorexia, most of the
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experimental work has been performed in pre-clinical models, rather than human
patients.
1.9.1 Intracellular signalling pathways in skeletal muscle wasting
Several transcription factors and intracellular signalling pathways have been
implicated in the regulation of skeletal muscle wasting. These pathways may be
largely anabolic or catabolic in nature, but there is likely to be significant crosstalk
between the individual cascades. Muscle wasting results from a chronic imbalance
in the activation of these different pathways. The major catabolic pathways involve
cytokine-induced activation of NF-kB signalling, and the upregulation of members
of the proteolytic UPP via NF-kB or the Forkhead box, class O (FOXO)
transcription factors (Figure 1.11). Alternatively, myostatin, a major inhibitory
muscle GF, can prevent muscle differentiation and repair by inhibiting the synthesis
and activity of MyoD, an essential transcriptional regulator of these activities
(Figure 1.12). The major anabolic pathway is the IGF-1/PI3K/Akt pathway that
results in the phosphorylation of mTOR and p70s6k, and the subsequent increase in
protein synthesis (Figure 1.11).
1.9.1.1 Nuclear Factor-Kappa B
In recent years, a vital role has emerged for NF-kB signalling in the control of
muscle degradation. There are five known mammalian NF-kB transcription factors
(p65 [Rel A], Rel B, c-Rel, p52 and p50), and all are expressed in skeletal muscle.
Together they modulate a variety of processes, including apoptosis, inflammation






Figure 1.11 The major catabolic and anabolic signalling pathways involved
in skeletal muscle homeostasis.
The balance between protein synthesis and degradation determines whether
muscles hypertrophy or atrophy. In diseases states that induce muscle atrophy,
insulin/IGF-1 signalling is suppressed and the PI3K/Akt pathway is depressed,
leading to decreased protein synthesis and FOXO phosphorylation. This allows
FOXO to stimulate the expression of the E3 ubiquitin ligases MAFbx/atrogin-1 and
MuRF-1 (see later, p. 105), leading to protein degradation. Inflammatory cytokines,
such as TNF-a, also signal through the IKK complex, which causes IkBci
phosphorylation and degradation, and subsequent NF-kB nuclear translocation,




Figure 1.12 Emerging intracellular signalling pathways of muscle wasting in
cancer cachexia.
Myostatin in its cleaved and active form, signals through a type II receptor to
regulate muscle atrophy through the induction of Foxo-1 and MAFBx/atrogin-1, a
process that is independent of NF-kB. Also contributing to this signalling is the
newly implicated dystrophin glycoprotein complex, whose dysfunction by an
unknown mechanism regulates muscle wasting through the induction of MuRFl
and MAFBx/atrogin-1. Shown in the cytoplasm is the MyHC protein that is a
selective myofibrillar protein target of the proteasome system in cancer cachexia.
From Acharyya and Guttridge, 2007 [294],
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the classical activator of NF-kB in a variety of cell types, and NF-kB is necessary
for TNF-induced muscle atrophy [295]. TNF-a induces the biphasic cytosolic
release of NF-kB from its inhibitory IkB proteins to allow translocation of NF-kB
into the nucleus and subsequent transcription of proteolytic pathway components
[295], In both myocytes and murine models, the cytokine-induced activation of NF-
kB has been shown to inhibit muscle differentiation and function through the
suppression of MyoD mRNA and protein [296]. In fact, chronic muscle-specific
NF-kB activation in transgenic mice is associated with profound muscle wasting
due to accelerated ubiquitin-dependent proteolysis [297]. In contrast, NF-kB
knockout mice, specific to the p50 subunit, do not demonstrate the usual decrease
in muscle fibre size associated with a period of unloading [298]. However, even in
non-inflammatory models of muscle wasting that do not involve cytokine activation
(e.g. disuse atrophy), the activation of NF-kB through non-classical pathways has
been demonstrated. In animal models of disuse atrophy, Bcl-3, a transcriptional co-
activator and singular member of the IkB family, is upregulated [298]. Importantly,
mice null for Bcl-3 demonstrate complete inhibition of unloading-induced NF-kB
activity [298],
Regarding cachexia, daily treatment of rats bearing the Yoshida AH-130 ascites
hepatoma with a double inhibitor of NF-kB and activator protein-1 (AP-1) caused a
significant recovery of muscle weight [299], whereas skeletal muscle from




The PI3K pathway is an anabolic pathway that demonstrates robust experimental
evidence of chronic deactivation in muscle wasting [301]. During anabolism,
activation of PI3K pathway by upstream ligands, such as insulin and IGF-1, leads
to activation of Akt (a serine-threonine kinase), which in turn phosphorylates and
activates the mTOR kinase. The activation of mTOR then results in increased
protein synthesis via the phosphorylation and activation of p70s6k, and
phosphorylation of eEF4E-BPl, which relieves the repression of eIF4E. In several
different models of wasting, a marked decrease in the phosphorylation of Akt,
mTOR and p70s6k has been demonstrated [302, 303]. Furthermore, transgenic mice
with disruption of the Aktl gene demonstrate growth retardation, whereas mice with
knockout of both the Aktl and Akt2 genes exhibit significant muscle atrophy [304].
Interestingly, both the NF-kB and PI3K pathways are capable of influencing each
other. For example, Akt stimulates NF-KB-dependent transcription by stimulating
the transactivation domain 1 of the p65 subunit (in an IkB kinase [IKK]-dependent
pathway) [305]. In contrast, oncogenic Ras, an upstream activator of Akt, requires
NF-kB to initiate transformation [306],
In muscle samples from cachectic patients with pancreatic cancer, Akt protein level
was decreased by 55%, and the phosphorylated forms of mTOR and p70s6k were
decreased by 82% and 39%, respectively, compared with non-cachectic individuals
[307],
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Alterations in the expression levels of intracellular pathways involved in human
muscle protein translation and synthesis during cancer cachexia are studied in more
detail later in this thesis (Chapter 8). In particular, the roles of PKR, an enzyme
activated by double-stranded RNA (dsRNA) produced in response to viral infection,
and its substrate, eEF2a, are explored in muscle samples from cachectic patients.
1.9.1.3 Forkhead Box, Class O transcription factors
The FOXO family of gene transcription factors has been shown to regulate
expression of vital components of the proteolytic UPP, namely the E3 ligases
muscle-specific F-box (MAFbx) (also known as atrogin-1) and muscle-specific
RING ('Really Interesting New Gene') finger-1 (MURF-1) [308] (see Chapter
1.9.2.4, p.l 16), in various models of skeletal muscle wasting, including cancer
cachexia, DM, fasting, aging, angiotensin Il-induced, and dexamethasone-induced
[309]. These transcription factors are under inhibitory control by the IGF/Akt/PI3K
pathway [310]. When Akt is activated, FOXO is phosphorylated and bound by 14-
3-3 proteins that mediate its movement from the cell nucleus to the cytoplasm.
Inactivation of Akt leads to dephosphorylation and nuclear localisation of FOXO,
with subsequent activation of genes involved with cell death, cell cycle inhibition
and metabolism. In particular, FOXO-3 upregulates atrogin-1, resulting in
decreased muscle fibre size, while FOXO-1 is induced specifically in atrophying
muscle [309].
Reduced levels of phosphorylated (inactive) F0X03a have been observed in the
skeletal muscle of cachectic pancreatic cancer patients compared with non-
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cachectic individuals, but an unexplained twofold reduction in the total amount of
FOXOl and F0X03a was also seen [307],
19.1.4 Dystrophin glycoprotein complex
Cancer cachexia represents an acquired syndrome of skeletal muscle wasting, but a
separate group of muscle disorders also characterised by severe muscle wasting are
the muscular dystrophies. Duchenne muscular dystrophy (DMD), Becker muscular
dystrophy (BMD) and several forms of limb-girdle muscular dystrophy (LGMD)
have been linked to mutations in different genes that encode components of the
dystrophin glycoprotein complex (DGC), a multi-protein structure associated with
myofibre membranes (Figure 1.13) [311-313]. At the core of the DGC is dystrophin,
a large 427kDa protein that associates with the cytoskeleton through its interactions
with F-actin at its amino terminus and connects to the sarcolemma by binding to p-
dystroglycan (p-DG) at its carboxyl end [314-316], Dystroglycan is made of a and
P forms, which are derived from a single protein precursor through post-
translational processing. P-DG is tightly bound to a-DG, which itself is linked to
the ECM by its interactions with laminin-2. The DGC therefore forms a strong
mechanical link between the cytoskeleton and the ECM, protecting cells from
contraction-induced injuries [317]. In addition, the DGC maintains an active signal
transduction pathway by interacting with growth factor receptor-bound protein 2
(Grb2) and neuronal nitric oxide synthase (nNOS) [318], Mutations in dystrophin
or other members of the DGC disrupt the mechanical linkage and/or signalling
















Figure 1.13 The dystrophin-glycoprotein complex and aetiology of the
muscular dystrophies.
The DGC provides a strong mechanical link between the cytoskeleton and the
extracellular matrix protecting cells from contraction-induced injuries. Mutations in
dystrophin and other DGC members cause a variety of muscular dystrophies.
Adapted from Khurana and Davies, 2003 [319],
BMD, Becker muscular dystrophy; CMD, congenital muscular dystrophy; CYS,
cysteine; DG, dystroglycan; DMD, Duchenne muscular dystrophy; LGMD, Limb
girdle muscular dystrophy; NOS, nitric oxide synthase.
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In recent years, it has been demonstrated that alterations in the muscular dystrophy-
associated DGC also represent a key initiating event in skeletal muscle wasting in
animal models of cancer cachexia (Figure 1.12) [321], Using both the C-26 and
Lewis lung carcinoma (LLC) murine cancer models, it was shown that muscles
from tumour-bearing mice exhibited membrane abnormalities, accompanied by
reduced dystrophin (core DGC member) expression and increased glycosylation of
DGC proteins [321]. However, the existence of a role for DGC deregulation in
skeletal muscle wasting within human cancer cachexia has not been proven. This
question is addressed in detail later in this thesis (Chapter 7).
1.9.2 Intracellular effector mechanisms of skeletal muscle wasting
Several different intracellular effector mechanisms of muscle proteolysis exist. The
system believed to degrade the major contractile skeletal muscle proteins
(monomeric actin and myosin) is the UPP. However, the UPP cannot break down
actomyosin complexes or myofibrils, and therefore other proteolytic enzymes are
required to act upstream (m-calpain, cathepsin-L and/or caspase-3) and downstream
(tripeptidyl peptidase II and aminopeptidases) of the UPP for the complete
degradation of myofibrillar proteins into free amino acids.
1.9.2.1 Caspases
Caspases (cysteine-aspartic acid proteases) are a group of enzymes usually
associated with the induction of cellular apoptosis in response to death signals.
There are two types of caspases: initiator caspases and effector caspases. Initiator
caspases (e.g. caspase-8, caspase-9) cleave inactive pro-forms of effector caspases,
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thereby activating them; effector caspases (e.g. caspase-3, caspase-7) then cleave
other protein substrates within the cell, resulting in apoptosis. This process may be
important in muscle wasting during the apoptotic response to calcium pathways and
TNF-a (which can activate caspase-8 and -10) [322], However, perhaps the most
significant action of caspases in muscle wasting is during the initial steps of
myofibrillar degradation. Increased caspase-3 activity associated with increased
actin fragmentation has been shown in experimental muscle wasting associated
with both DM and angiotensin II [323],
Caspases, along with PWl/Peg3 and bax, are usually considered as downstream
effectors of the p53 cell death pathway. TNF-a has been shown to inhibit myogenic
differentiation and skeletal muscle regeneration in vitro via PWl/Peg3, bax, and
caspases [324], Furthermore, the p53 pathway was implicated in muscle wasting
experienced by mice inoculated with the C26 tumour [325], Gene transfer of a
dominant-negative form of PW1 into murine muscle tissue in vivo also blocked
myofibre atrophy in response to tumour load [325]. Taken together, these results
may point to a novel role for p53 in mediating muscle wasting during cancer
cachexia.
There is some evidence of a role for apoptosis in muscle wasting experienced by
cachectic human patients. Muscle biopsies from weight-losing patients with upper
GI cancer showed a three-fold increase in muscle DNA fragmentation compared
with control subjects [326], Furthermore, the increase in DNA fragmentation was
associated with a four-fold increase in poly (adenosine diphosphate-ribose)
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polymerase (PARP) cleavage, indicating the presence of apoptosis [326], Apoptosis
has also been identified in the muscles of patients with CHF and is associated with
impaired exercise tolerance [327]. However, these apoptotic changes were not
specific to patients with cachexia. Also, circulating levels of soluble Fas ligand, one
of the key initiators of the death pathway, are higher in cachectic COPD patients
compared with non-cachectic patients, but levels are lower than those observed in
healthy controls [328], implying that the overall regulation of muscle apoptosis in
human disease states requires further elucidation.
1.9.2.2 Calcium-dependent enzyme systems
Several different calcium-dependent enzyme systems exist, including the calpains
and the Ca2+/calmodulin-dependent protein kinases (CaMK). The calpains are a
family of intracellular, non-lysosomal, calcium-regulated cysteine proteases that
mediate cleavage of specific substrates in a large number of regulatory cell
processes [329]. The calpain family includes three ubiquitous enzymes and several
tissue-specific forms.
In excessive amounts, calpains are capable of degrading cytoskeletal elements, ion
channels, other enzymes, cellular adhesion molecules and cell surface receptors.
Furthermore, calpains cleave the enzyme xanthine dehydrogenase to xanthine
oxidase (XOA), thus indirectly creating the formation of superoxide radicals. This
pathway is upregulated in CHF, and radical-induced impairment of NO-dependent
vasodilator capacity is a characteristic feature of CHF pathology [330].
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Hyperuricaemia is thus a strong and independent marker of impaired prognosis in
CHF [331],
Muscle tissue expresses three different calpains: 1, 2 and 3. The ubiquitous calpains
1 and 2 (also called p and m) have been heavily implicated in both the initial
degradation of myofibrillar proteins during muscle wasting [332] and the necrosis
associated with muscular dystrophy [333], Ubiquitous calpain activity is under the
control of the endogenous inhibitor calpastatin, and downregulation of calpastatin
expression has been suggested as one potential mechanism of muscle atrophy. In
contrast, overexpression of calpastatin may have potential therapeutic benefits
against muscle atrophy. In animal models, transgenic overexpression of calpastatin
can reduce both the atrophy caused by unloading and the necrosis associated with
muscular dystrophy [334],
The role of muscle-specific calpain 3 is less well understood, but experimental
results would suggest that calpain 3 inhibition is required for atrophy to occur. For
example, calpain 3 expression is often downregulated in wasting models [335],
whereas inactivating mutations in the calpain 3 gene are responsible for limb-girdle
muscular dystrophy type 2A [333], Studies performed on muscle biopsies from
patients with this latter condition have led to the postulation that the normal
function of calpain 3 is to intervene in the regulation of expression of NF-kB-
dependent survival genes to prevent skeletal muscle apoptosis [336]. Thus,
calpainopathies lead to deregulation of NF-kB activity and resultant muscle
wasting.
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Although calpain 3 expression has not been analysed in muscle samples form
cachectic cancer patients, increased muscle mRNA levels for calpain 2 and
cathepsin D (see Chapter 1.9.2.3, p.l 13) have been detected in critically ill ICU
patients with severe head trauma [337].
Recent mRNA and protein studies have demonstrated that expression of CaMKIIB,
a serine/threonine-specific protein kinase regulated primarily by the
Ca2+/calmodulin complex, is elevated in muscle samples from cachectic patients
with upper GI cancer [338]. CaMKIlp protein levels and activity normally increase
after exercise training [339], implying that cancer cachexia does not simply reflect
a profile of physical inactivity. It has also been suggested recently that Ca2+-CaM-
eukaryotic elongation factor-2 kinase (eEF2K) signalling may be responsible for
acute exercise-induced inhibition of muscle protein synthesis [340], and it is thus
conceivable that chronic inappropriate activation of this 'endurance training'-related
signalling molecule [341] subdues normal maintenance of skeletal muscle mass.
Additional factors that could modulate CaMKII activity in cachectic cancer patients
include alterations in lipid metabolism [342] and generation of ROS. CaMKII has
also been implicated in muscle adaptation through phosphorylation of histone
deacetylase 5 (HDAC5) leading to MyoD/myocyte enhancer factor-2 (MEF2)-
driven differentiation of muscle cells [343]. Therefore, it is plausible that CaMKII
activation within cachectic muscle is a compensatory strategy in the face of failing
protein synthesis. Alternatively, the CaMKIip response may simply indicate failure
of calcium homeostasis, a factor that would also activate proteolytic calpain and
caspase activity [344, 345].
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1.9.2.3 Lysosomal enzymes and autophagy
Intracellular lysosomes contain a number of enzymes required for the digestion of
macromolecules, including proteases, carbohydrases, lipases and nucleases.
Cathepsins L, B, D and H are the major lysosomal proteases and determine
primarily the proteolytic capacity of lysosomes. Although represented poorly in
adult skeletal muscle compared to foetal, lysosomal proteases are upregulated in
pathological conditions [346], Cathepsin-L, in particular, is induced early in
catabolic states, and levels correlate with increased protein breakdown. Increased
cathepsin activity has been demonstrated in various models of muscle wasting,
including cancer cachexia, DM, dexamethasone-induced, disuse, fasting and
muscular dystrophy [347, 348].
Lysosomes may also induce muscle wasting by taking part in autophagy, the
absorption and digestion of cytoplasm and intracellular organelles, which is
required for cellular survival and for the clearance of damaged proteins and altered
organelles. Autophagy of skeletal muscle is observed commonly in response to
starvation, denervation, ageing and oxidative stress [349].
In most mechanistic studies, induction of autophagy has been associated with
increased activation of F0X03A-dependent transcription of autophagy-related
genes such as LC3B and BNIP3 [350]. In particular, BNIP3 induces autophagosome
formation and is responsible primarily for the induction of autophagy by F0X03A.
Rapamycin is not able to induce autophagy in skeletal muscle in vivo, thus
indicating that it is the Akt-FOXO axis that is involved in autophagy, rather than
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the Akt-mTOR pathway [350]. Alternative mediators/mechanisms of autophagy
may also include increased activation of FOXOl [351], increased activation of p38
mitogen-activated protein kinase (MAPK) [352], and reduced levels of superoxide
dismutase (SOD) [353],
Autophagy has been proposed as a potential link between electrical activity (in the
form of excitation-contraction coupling) and muscle wasting. It has been suggested
that the T-tubule (deep invagination of the sarcolemma which transmits
depolarisation to the interior of the cell) is the membrane donor that forms
2+
sequestering autophagic vesicles [353]. Furthermore, L-type Ca channels have
also been offered as voltage-gated sensors that are linked to transcriptional activity
controlling muscle differentiation [354], Downregulation of the dihydropyridine
receptor (DHPR) a IS subunit (which forms the L-type Ca2+ channel in T-tubules
and is also the voltage sensor of excitation-contraction coupling at the level of
triads) caused severe muscle atrophy in animal models [354], Moreover, decreased
levels of Runxl (AML1), a DNA-binding protein that has critical roles in
haematopoiesis and leukaemogenesis (AML represents 'Acute Myeloid
Leukaemia'), and that regulates transcription of genes encoding ion channels,
signalling molecules and muscle structural proteins, have been implicated as
another potential causative factor in autophagy-associated wasting [355].
In humans, data indicating a role for autophagy in muscle wasting are limited
currently. However, a couple of supportive studies do exist. In patients receiving
controlled mechanical ventilation, autophagy of the diaphragmatic muscle has been
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detected [356]. In latissimus dorsi samples from resectional lung cancer patients,
cathepsin B mRNA levels were elevated compared with controls, and correlated
with fat-free mass (FFM) index and tumour stage [357]. Furthermore, in patients
with cancer cachexia, modestly increased transcription of the autophagy-related
genes GABRAPL1 (GABA receptor-associated protein-like 1) and BN1P3 was
demonstrated in rectus abdominis compared with weight-stable cancer patients and
controls [338]. However, as autophagy also plays a normal role in muscle cell
homeostasis and survival, repression of autophagy as a potential therapeutic
strategy in cancer cachexia may not represent a viable tactic. Inducible, muscle-
specific knockout of the genc, ATG7 (which is critical for autophagy) in mice
revealed an unexpected phenotype characterised by muscle atrophy, weakness and
features of myofibre degeneration, including presence of protein aggregates,
abnormal mitochondria, accumulation of membrane bodies, sarcoplasmic reticulum
distension, vacuolisation, oxidative stress and apoptosis [358], Moreover,
autophagy inhibition did not protect skeletal muscles from wasting during
denervation and fasting, but instead promoted greater muscle atrophy. Furthermore,
in humans, X-linked myopathy with excessive autophagy (XMEA) is a childhood-
onset disease characterised by progressive atrophy of skeletal muscle, which
appears to be the result of reduced lysosomal degradative ability [359]. XMEA is
caused by hypomorphic alleles of the VMA21 gene, which encodes for an essential
assembly chaperone of the major mammalian proton pump complex, vacuolar-type
H+-ATPase (V-ATPase; ATP is adenosine-5'-triphosphate) [359]. Decreased
VMA21 raises lysosomal pH, which leads ultimately to macroautophagic
overcompensation and cell vacuolisation.
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1.9.2.4 Ubiquitin-proteasome pathway and E3 ligases
Most models of muscle wasting have suggested that the dominant mechanism of
proteolysis is increased activity of the UPP (Figure 1.14). In addition to degrading
misfolded proteins, the UPP is involved normally in the destruction of proteins that
are under temporal (e.g. cell cycle regulators) or environmental (e.g. several
transcription factors) control. The UPP is therefore essential for the regulation of
cell cycling, signal transduction and gene expression [164],
In the UPP, target proteins are identified for degradation by being covalently
bonded with a polyubiquitin chain (Figure 1.14). This process of ubiquitination is
under the control of an E3 ubiquitin ligase, which operates in conjunction with an
El ubiquitin-activating enzyme and an E2 ubiquitin-conjugating enzyme [164], The
E3, which may be a multi-protein complex, is generally responsible for the
selection and specific timing of targeting ubiquitination to specific substrate
proteins. There are several families of E3 ubiquitin ligases that are characterised by
particular protein domains. Following polyubiquitination, target proteins are
recognised by the 26S proteasome, a large ATP-dependent multicatalytic protease,
which removes the ubiquitin chain and degrades the proteins into 8-11 amino acid
oligopeptides. The 26S proteasome spans the cell's nuclear membrane and consists
of a 20S core protease particle and two 19S regulatory particles.
Increased mRNA and protein expression of components of the UPP have been
demonstrated in several models of muscle atrophy, including those induced by
cancer cachexia [360], glucocorticoids, and angiotensin II [164], Recently, two
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The Ubiquitiri - Proteasome Pathway
Figure 1.14 The ubiquitin-proteasome pathway of protein degradation.
The ubiquitin-proteasome pathway is a complex multi-step, ATP-dependent
process, which requires 3 enzymes and which results in the tagging of specific
proteins with ubiquitin for degradation in the proteasome. A chain of 5 ubiquitin
molecules attached to the protein substrate is sufficient for the complex to be
recognised by the 26S proteasome. In addition to ATP-dependent reactions,
ubiquitin is removed and the protein is linearised and injected into the central core
of the proteasome, where it is digested to peptides. The peptides are then degraded
to free amino acids by peptidases in the cytoplasm or used in antigen presentation.
From Lecker et al, 2006 [ 164).
El = ubiquitin-activating enzyme; E2 = ubiquitin-conjugating enzyme; E3 =
ubiquitin ligase.
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muscle-specific E3 ligases, MAFbx and MURF-1, have been identified that seem to
be of profound importance in a wide range of atrophies. MAFbx and MURF-1
knockout mice demonstrated 56% and 36% attenuation in gastrocnemius wasting,
respectively, following 14 days of denervation [308],
Other ubiquitin ligases may also be important in skeletal muscle protein
degradation via regulation of the 'N-end rule' pathway, a mechanism that relates
the in vivo half-life of a protein to the identity of its N-terminal residue [361], E3a-
II, a novel N-end rule ubiquitin ligase, has shown to be highly expressed in the
skeletal muscle of both the Yoshida hepatoma rat cachexia model and the C-26
mouse model, accompanied by a dramatic increase in protein ubiquitination [362].
Furthermore, expression of E3a-II is induced by IL-6 and TNF-a, thus suggesting
another link between systemic inflammation and muscle wasting [362].
The E3 ligases may also play roles in the development of cancer, by functioning as
either oncogenes or oncosuppressor genes. Examples of oncogenic ubiquitin ligases
include HectH9, which regulates transcriptional activation by Myc [363] and is
essential for tumour cell proliferation, and MDM2, which regulates p53 inactivation
[364], An example of oncosuppressor activity is that of the vHL (von Hippel-
Lindau) gene on the short arm of chromosome 3 [365]. The main function of the
encoded protein is an E3 ubiquitin ligase which targets (amongst others) hypoxia
inducible factor (HIF) la, a transcription factor that controls the expression of a
number of angiogenic proteins. Loss of VHL protein activity results in an increased
amount of HIF la, increased levels of angiogenic factors, and the development of
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VHL syndrome, a condition characterised by multiple benign and malignant
vascular tumours [365],
Increased activity and expression of the UPP has been demonstrated in several
human disease states associated with muscle wasting, including sepsis with
multiple organ failure, and cancer [164, 225, 366]. Specifically, ubiquitin mRNA
levels and proteasome proteolytic activities (chymotrypsin-like, trypsin-like, and
peptidyl-glutamyl-peptidase) were increased in muscle samples from gastric cancer
patients [367, 368], whereas levels of ubiquitin mRNA, proteasome subunit (C2
and C5) mRNA and ubiquitin conjugating enzyme E2(14k) protein were correlated
with weight loss in pancreatic cancer patients [225, 360].
When considering the efficacy of an upstream approach to preventing muscle
catabolism, it should be remembered that the consequences of chronic impairment
of the systemic inflammatory (and immune response) in patients with underlying
cancer are currently unknown. Trials of IL-1 receptor antagonists (e.g. anakinra)
and TNF inhibitors (e.g. infliximab, etanercept) in rheumatoid arthritis have been
complicated by increased rates of opportunistic infections (particularly reactivation
of tuberculosis in the case of infliximab) [369]. Therefore, a more selective
downstream approach would be safer and more effective at attenuating muscle loss.
In this respect, direct proteasome inhibition could prove an effective strategy.
Experimental pharmacological agents that could achieve this aim include peptide
aldehydes, lactacystin/(3-lactone, vinyl sulphones and dipeptide boronic acid
analogues [370], Bortezomib is an example of the latter type of agent and a
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selective inhibitor of the 20S proteasome [370]. Marketed as Velcade, it is now a
recognised anti-tumour treatment for patients with relapsed, treatment-refractory
multiple myeloma [371]. The main modes of action of bortezomib in inducing
tumour cell death appear to be the regulation of NF-kB activity [372], the induction
of apoptotic pathways [373], and the induction of autophagy [374], Unfortunately,
the current evidence for proteasome inhibitors as a means of reducing human
muscle wasting is less encouraging. Despite rat studies demonstrating a significant
reduction in denervation-induced muscle atrophy following bortezomib
administration [375], preliminary studies in human patients with metastatic
pancreatic cancer have demonstrated an insignificant impact on weight loss [376].
Moreover, despite being a selective downstream approach, bortezomib may still be
too non-specific to be a successful intervention in cancer cachexia. Global
inhibition of proteasome activity will impact on a wide range of regulatory,
proteolytic systems (other than just muscle atrophy), and therefore the side effect
profile is likely to be prohibitively toxic. At doses used for the treatment of multiple
myeloma, asthenia and anorexia, two undesirable symptoms of cachexia, are two of
the commonest side effects associated with bortezomib administration [371]. Thus,
a targeted approach to UPP inhibition (e.g. enzyme inhibitor of MAFbx or MURF-1)
would be superior.
1.9.2.5 Tripeptidyl peptidase
Tripeptidyl peptidase (TPP) is a high molecular weight peptidase that sequentially
removes tripeptides from free N-termini of oligopeptides generated by the
proteasome. It may also have a low-grade endopeptidase action and play a role in
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the degradation of specific cellular substrates. TPP activity was upregulated in
sepsis-induced muscle wasting [377], In the MAC 16 mouse tumour model, both
proteasome activity and TPPII activity increased with increasing weight loss,
reaching a maximum at 16% weight loss, after which there was a progressive
decrease in activity of both proteases [378].
In summary, over the previous six sections, it has been shown that numerous
processes may contribute to weight loss in cancer. With regard to the key target of
skeletal muscle, inflammatory, neuroendocrine and tumour-derived mediators
appear to act through a variety of intracellular proteolytic processes that have been
summarised in this chapter. In particular, the IGF-1/PI3K/Akt pathway has been
identified as a key anabolic signalling mechanism, whereas the NF-kB and FOXO
transcription factors have been acknowledged as crucial mediators in the
transcriptional regulation of atrogenes. The need for confirmation of whether or not
DGC deregulation is involved in human cancer cachexia has been recognised.
When considering intracellular effector mechanisms of muscle wasting, the UPP
has been identified as a key apparatus of protein degradation, and the emerging
roles of caspases and autophagy/lysosomal machinery have been described (Figure
1.15). At present, no studies have been performed in cachectic cancer patients to
assess the final outcome of degraded myofibrillar proteins. However, this thesis
explores the fate of degraded proteins that enter the systemic circulation and are
excreted in urine, in order to assess their usefulness as biomarkers of skeletal
muscle wasting (Chapter 9). This section represents the last to detail the aetiology
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of cancer cachexia. The following section considers the clinical consequences of
cancer cachexia.
1.10 Clinical consequences of cancer cachexia
The objective clinical consequences of cachexia are profound including shortened
survival [4], impaired response to anti-cancer therapy [4], impaired immunity [379],
reduced performance status (PS) [380], reduced PA [380] and worsened QoL
(Figure 1.16). Specific examples of studies that support these assertions are detailed
below. There is a prima facie case that depletion of skeletal muscle is the key
component of weight loss that underpins many of the symptoms experienced by
cachectic cancer patients. Muscle wasting leads to reduced exercise capacity and
increased fatigue [381], which results in the lower PS scores, reduced PA and
worsened QoL scores observed. Furthermore, there does not appear to be an
alternative explanation by which loss of fat mass could account for such findings.
Thus, skeletal muscle wasting is the critical driver behind patient symptomatology
in cancer cachexia. This supposition is supported by studies that have demonstrated
that sarcopenic obesity (i.e. skeletal muscle wasting in the ongoing maintenance of
fat mass) in cancer patients was associated with poorer functional status compared
with obese patients who did not have sarcopenia [382],
The mechanism by which skeletal muscle wasting is linked to the actual mode of
death of the cachectic patient is not proven. However, the most common cause of
death in cancer patients is infection and respiratory failure [383], presumably as a
result of wasting of the respiratory muscles. Furthermore, patients with nutritional
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Figure 1.16 Clinical consequences of cancer cachexia.
Reduced survival, impaired response to anti-cancer therapy, impaired immunity,
lower performance status scores, increased symptomatology, reduced PA and
worsened QoL scores have all been demonstrated in association with cancer
cachexia. Prima facie evidence would state that skeletal muscle wasting is an
important determinant of outcome within cachexia that results in the reduced PS
scores, decreased PA, worsened QoL scores, and, presumably, shortened survival
experienced by cachectic cancer patients.
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depletion and less physiological reserve are known to be more susceptible to
complications [4], which will deplete nutritional status further, and ultimately may
have fatal consequences (Figure 1.17).
1.10.1 Effect on functional status and quality of life
The functional consequences of cancer cachexia have been discussed briefly in
Chapter 1.8.2, in which the level of PA of patients with cancer cachexia was seen to
be as low as that observed in patients with spinal cord injury [280]. In addition,
there exist many other studies in the literature that demonstrate the impact of
cachexia on PF and QoL.
In a study of patients with inoperable NSCLC, approximately 40% had lost at least
5% of pre-morbid weight, and almost 80% exhibited an elevated CRP [384],
Weight-losing patients suffered greater fatigue and pain and demonstrated
significantly lower KPS and overall QoL scores than weight-stable counterparts
[384], An elevated CRP was also associated independently with increased fatigue.
In another 1-month study of 24 patients with lung cancer, KPS and self-reported
tools were used to show that PF deteriorated in those not receiving chemotherapy
[385], Thirty three percent of patients experienced difficulty walking one block or
more, 79% complained of serious fatigue and 44% had difficulty with household
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In another population of 100 ambulant patients with advanced NSCLC, PF was
assessed both subjectively (KPS) and objectively (Simmonds Functional
Assessment tool [SFA] and six-minute walk) [386]. The authors concluded that
measurable differences in daily tasks were identifiable when compared with a
normative population. There was only low to moderate correlation between these
abnormalities and subjective fatigue tests, suggesting that objective measures of PF
provide important and independent endpoints for clinical trials and therapeutic
interventions in this population [386], This notion is discussed in detail in Chapter
1.12.
In a series of studies on patients with advanced GI cancer, patients with more than
5% weight loss had a higher CRP, lower albumin, lower anthropometry measures,
poorer appetite and reduced QoL scores [387-389]. The authors calculated that a
loss or gain of >2.5kg over 6-8 weeks was required to produce a significant change
in PS in weight-losing patients [388]. Both reduced PS and elevated CRP were also
associated independently with survival [389].
In patients with advanced GI cancer receiving palliative chemotherapy, weight loss
was associated with reduced global QoL [390], In addition, weight loss and poor PS
were related independently to lower probability of treatment response and
decreased survival on multivariate analysis [390].
1.10.2 Effect on response to palliative therapy
A retrospective review of 1555 patients receiving chemotherapy for GI malignancy
determined that patients with weight loss received lower initial drug doses but
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developed more frequent and severe dose-limiting toxicity: on average, they
received 1 month less treatment [391], Furthermore, weight loss correlated with
reduced failure-free and overall survival. Patients who stopped losing weight had an
improved overall survival. The authors concluded that these results provided a
rationale for randomised nutritional intervention studies in this population [391],
Comparable results have been found in studies of lung cancer. NSCLC or
mesothelioma patients with weight loss failed more frequently to complete at least
3 cycles of chemotherapy, and experienced anaemia more frequently as a drug-
associated toxicity [33]. In similar patients, the Voorrips Physical Activity
Questionnaire (PAQ) was also shown to be predictive of World Health
Organisation (WHO) grade 3 or higher toxicity, but not 90-day disease progression
[392],
In women with metastatic breast cancer resistant to anthracycline and/or taxane
treatment, CT body composition analysis demonstrated that capecitabine-associated
toxicity was present in 50% of sarcopenic patients, compared with only 20% of
non-sarcopenic patients [393]. Furthermore, time to tumour progression was shorter
in the sarcopenic patients [393],
1.10.3 Effect on survival
Weight loss and KPS have long been known to be predictive of survival. In the
ECOG's paper of 1980 [4], weight loss prior to chemotherapy was noted be a
significant prognostic factor in a wide range of malignancies. Within each of the 12
cancer types investigated, survival was shorter in the patients who had experienced
weight loss compared with patients who had not. For sarcoma, unfavourable non-
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Hodgkin's lymphoma, colon and prostate cancer, the median survival was
approximately twice as long in the weight-stable patients compared with weight-
losing patients [4]. When the data were analysed by weight loss categories, the
greatest difference in survival was noted between the 0% weight loss and the 0-5 %
weight loss categories, suggesting that the presence of cachexia is more important
as a marker of survival than the severity of the cachexia at presentation. Weight loss
also correlated with deterioration in PS in 11 of 12 cancer types [4],
The importance of the APPR as a prognostic variable in cancer patients has been
discussed previously in Chapter 1.4.2.1. However, the exact magnitude of the
impact on survival was not described, and potentially this effect can be very
clinically significant. For example, in patients with gastric cancer, those with an
APPR exhibited a severely shortened median survival duration compared with
patients without evidence of systemic inflammation (9 weeks versus 53 weeks)
[394],
In this section, the clinical consequences of cancer cachexia, including decreased
QoL scores, poorer functional status and impaired physical activity, and shortened
survival, have all been summarised. In the following section, general approaches
for the management of the cachectic cancer patient are outlined, including other
potential nutritional and therapeutic interventions not yet discussed.
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1.11 Management of cancer cachexia
The management of cancer cachexia requires a multimodal approach involving a
dedicated multidisciplinary team consisting of physician/oncologist, surgeon,
general practitioner, nurse specialist and dietician. This team should follow patients
regularly as cachexia is a progressive condition that requires repeated evaluation
over time (Figure 1.3). At present, there is no single therapeutic intervention of
proven benefit in all cachectic cancer patients. Instead, in the future, it is likely that
a combination of different treatments will be required simultaneously to reverse
wasting successfully (Figure 1.18).
1.11.1 Symptom control and supportive care
Cancer and cachexia can be associated with a wide range of distressing, yet
reversible, symptoms. Efforts should be taken to ameliorate these symptoms
wherever possible, in order to maximise patient QoL and create an ideal
background for the optimisation of appetite and the reversal of the underlying
metabolic disorder. Nausea and vomiting should be controlled with regular anti¬
emetics (or surgery for mechanical obstruction); early satiety can be improved with
gastric prokinetic agents (e.g. metoclopramide); malabsorption is treated with
pancreatic enzyme supplements; and constipation is relieved by laxatives.
Whenever pain is a significant issue, attempts should be made to control it with the
minimum of sedation. The diagnosis of major depression in cachectic cancer
patients is often clouded by neurovegetative symptoms that may be secondary to
either cancer or depression. However, in those cases where depression is


















Figure 1.18 Combination therapy for patients with cancer cachexia.
A constellation of different pharmaceutical, nutritional, psychological and exercise-
related treatments, all under the regulation of a dedicated multidisciplinary team,
are required if cachexia is to be managed successfully. However, as there is




It is now more than 25 years since Nixon and co-workers observed a suboptimal
response to nutritional support in cancer patients [2, 396]. In this study, weight-
losing cancer patients who were treated with enteral nutritional support
demonstrated significantly less improvement in body weight, serum albumin level,
creatinine/height ratio, and mid-arm muscle area, compared with weight-losing
non-cancer controls [2], Thus, there appeared to be a partial anabolic blockade to
the accretion of lean tissue in advanced cancer patients. In contrast, gain in fat mass
was the same in the wasted cancer and non-cancer patients [2], These findings
demonstrate that although the negative energy balance in cancer cachexia can be
overcome by artificial nutritional support, it appears to be much more difficult to
prevent or reverse the loss of LBM. However, despite the fact that nutritional
support cannot represent the whole solution to cancer cachexia, ensuring that the
cachectic patient receives adequate nutritional intake is of paramount importance.
One interesting study examined the features of cachexia that correlated with
survival following a 4-month follow-up of cancer patients undergoing outpatient
palliative care (n=297) [397]. In this patient group, weight loss and persistent
hypermetabolism were found to be associated significantly with a shorter duration
of survival. The baseline nutritional intake of the patients at the start of the study
was 26kcal/kg/day or approximately 1560kcal/day [397], Dietary intake did not
differ between normo- and hypermetabolic patients, nor was tumour type or gender
related to energy and protein intake. Patients able to increase their energy intake
demonstrated a significant prolongation of survival [397], This study therefore
identified a daily food intake >1500kcal as a favourable prognostic variable. The
underlying reason for this observation is apparent from recent investigations of the
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individual components of TEE. In patients with advanced pancreatic cancer and
weight loss, average TEE was 1700kcal/day, average REE was 1400kcal/day, and
average food intake was 1500kcal/day [277]. Thus, the net result was a persistent
negative energy balance of approximately 200kcal/day per patient. In this scenario,
it seems that any increase in PA towards normal levels, in the absence of nutritional
supplementation, would simply worsen the established negative energy balance. In
contrast, any increase in food intake from approximately 1500kcal/day towards at
least 1700kcal/day would result in the restoration of positive energy balance, which
might prolong the patient's ultimate survival.
The Society for Sarcopenia, Cachexia, and Wasting Disease recently convened an
expert panel to develop nutritional recommendations for the prevention and
management of skeletal muscle wasting [398]. They identified that exercise (both
resistance and aerobic) in combination with adequate protein and energy intake
were the key components to any successful strategy. In particular, it was stressed
that adequate protein intake (including leucine-enriched balanced amino acids and
possibly creatine) may enhance muscle strength [398], They also recommended
vitamin D replacement where measured levels were low. However, in practice,
improvement of nutritional intake within the cachectic patient is difficult to
achieve. Early and formal nutritional advice should be sought from a dietician, and
if necessary, intensive nutritional counselling. Nutritional intake can be improved
by providing small, frequent meals that are energy-dense and easy to consume (e.g.
dairy products). The patient should avoid extremes of taste and smell, and meals
with high fat content (fat delays gastric emptying). Moderate alcohol consumption
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before and during a meal can help. Provision of energy and protein-dense oral
supplements can be beneficial if taken regularly, but patient compliance is often a
problem. Patients should aim to take 200-400mls of supplements daily (300-
600kcal) accepting that this may suppress some normal food intake but provide an
overall gain of 200-400kcal/d. In some advanced cancer patients, the decision may
be taken to pursue artificial nutritional support (either enteral or parenteral). Recent
studies of an integrated artificial nutrition approach to cancer patient care, involving
COX inhibitor treatment, rhEPO and either oral nutritional support or home total
TPN, have had success at improving patient energy balance and higher maximum
exercise capacity [399]. However, during such an approach, it is important to
consider the ethical balance between benefit in QoL and the potential problems
associated with artificial nutritional support (e.g. time spent in hospital, potential
complications of central venous access for TPN).
The above two paragraphs describe general recommendations for nutritional
support in the cachectic patients. However, two nutritional supplements have
received particular attention in the treatment of cancer cachexia and these are
discussed below.
1.11.2.1 Eicosapentaenoic acid
EPA is an omega-3 polyunsaturated fatty acid (PUFA), the main role of which is
exercised during inflammation [400]. Membrane-bound EPA and AA (i.e. 20
carbon fatty acids) are used as precursors by COX and lipoxygenase (LOX) to
generate physiologically active eicosanoids. COX activity produces prostaglandins
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and thromboxanes whereas LOX activity produces leukotrienes [400]. The majority
of eicosanoids are generated from AA, as it exists in much greater amounts than
EPA within the phospholipid cell bilayer. AA-derived eicosanoids (2-series
prostaglandins) are also more potent inducers of inflammation than their EPA-
derived counterparts (3-series prostaglandins). Thus, EPA-derived prostaglandins
are less favourable for the development of cachexia. EPA is also known to have a
number of specific anti-cachexia effects, including impacts on tumour
differentiation, lipid metabolism, tumour-derived mediator function, pro¬
inflammatory gene transcription and cytokine expression [400]. Furthermore, in
pre-clinical models, it has demonstrated synergistic anti-cancer effects with
conventional chemotherapeutic treatments. In the MAC 16 murine cachexia model,
EPA treatment resulted in an 88% decrease in muscle protein degradation (but had
no effect on protein synthesis) [401], The presumed mechanism behind these
observations is EPA-induced inhibition of the UPP, possibly via prevention of
formation of 15-hydroxyeicosatetraenoicacid (15-HETE). In rats bearing the
methylcholanthrene (MCA) fibrosarcoma, it has been shown that EPA
supplementation can decrease UPP components in both skeletal muscle and liver
[402], Specifically, skeletal muscle demonstrated decreased E2(14k) and E3a
expression, whereas hepatic tissue demonstrated decreased C2 mRNA expression
[402], The observed differences in the hepatic and muscle gene expressions of UPP
components suggested an organ-specific effect for omega-3 fatty acid activity.
Initial clinical studies of EPA in cachectic cancer patients were encouraging. When
administered either as fish oil capsules (12g EPA/day) or as a purified fatty acid (6g
EPA/day), EPA was shown to arrest the development of cachexia in weight-losing
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patients with pancreatic cancer [403]. Furthermore, a multimodal approach
combining oral nutritional supplementation and EPA (2.2g/day) in patients with
pancreatic cancer resulted in net gain of weight (median weight gain of 1 kg at 3
weeks) and LBM, along with an improvement in appetite and performance status
[404], The same combination was also shown to increase patients' PAL (although
this effect did not require a significant increase in LBM) [277] (see Chapter 1.8.2,
p.92) and decrease the stimulatory effect of feeding on the hepatic APPR (see
Chapter 1.8.3, p.95) [285]. A further study of 27 pancreatic cancer patients
undertaking a daily administration of 6g of EPA observed a reversal of weight loss
associated with decreases in serum levels of CRP, IL-6 and TNF-a [405], However,
despite these early positive results, larger randomised clinical trials have been less
successful. One such trial in cachectic pancreatic cancer patients (n=200) was
compromised by issues of non-compliance (although post-hoc dose-response
analysis did demonstrate a linear relationship between plasma EPA and gain in
LBM) [406], whereas in another trial of patients with advanced GI or lung cancer
(n=518), both intention-to-treat analysis and per protocol analysis revealed no
significant improvements in survival or weight [407]. In a further study of patients
with non-hormone-dependent types of cancer (n=421) treated with a combination of
MA and EPA, no significant improvement in weight gain, appetite or QoL was
observed over MA alone [408]. Ultimately, a recent Cochrane Database System
Review has concluded that there are currently insufficient data to establish whether
or not oral EPA is superior to placebo [409], However, once again, the failure of
efficacy of EPA may be due to a lack of patient targeting, a poor understanding of
dose-response relationships, and a need for combination strategies. For example,
certain combination strategies using EPA have been more efficacious. In one study
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of solid tumour patients (n=60) assigned randomly to receive a daily fish oil
supplement that contained EPA (18g of omega-3 PUFAs) with vitamin E (to
compensate for the oxidative effect of the fish oil), there was a doubling of median
survival in the EPA-supplemented arm compared with placebo [410], Furthermore,
in another trial of patients with advanced lung cancer (n=22), patients receiving fish
oil in combination with celecoxib (a COX-2 inhibitor) demonstrated lower CRP
levels, greater muscle strength and body weight compared with patients receiving
fish oil and placebo [411].
1.11.2.2 p -hydroxy-fi-methylbutyra te
Another nutritional agent that has been investigated in patients with cancer
cachexia is p-hydroxy-(3-methylbutyrate (HMB), a derivative of the branched-chain
amino acid (BCAA) leucine. It has long been known that TPN supplemented with
BCAA causes improved protein utilisation and synthesis in cancer patients [412]. In
experimental murine models, HMB was capable of increasing muscle protein
synthesis via increased phosphorylation of mTOR, p70s6k and eIF4E-BPl [413],
reduced expression of UPP components [414], and reduced proteolysis [414], Early
clinical trials of HMB administered with arginine and glutamine increased FFM,
improved emotional profile, and decreased subjective feelings of weakness in
wasted cancer patients [415, 416], However, the largest trial to date of weight-
losing cancer patients (n=472) was unable to prove conclusively an increase in
LBM, possibly due to the fact that the majority of patients dropped out of the study
prior to completion, leaving only 37% of participants to finish the 8-week protocol
[417],
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1.11.3 Exercise regimens and modulators of fatigue
Fatigued patients with significantly reduced energy reserves should be advised to
make efficient use of the energy they do have by focusing on meal times and social
interaction. Increasing psychosocial support and limiting patient stress levels may
further reduce fatigue, whereas input from occupational therapists and the provision
of physical aids in the home may also improve mobility. Regarding therapeutic
interventions aimed at improving exercise capacity in advanced cancer patients,
prescribed regimens of physical exercise and/or drugs that increase haemoglobin
concentrations or modulate fatigue centrally have all been trialled.
1.11.3.1 Exercise regimens
Exercise regimens have been shown to improve QoL, PF, LBM, mood, emotional
well-being and social well-being in palliative cancer patients [418], Moreover, in
the absence of such programmes, advanced cancer patients have expressed interest
in exercise regimens and have stated that they would feel able to participate in them
[419]. In particular, such patients have exhibited strong preferences for home-based
PA programmes that could be completed alone, including neuromuscular electrical
stimulation (NMES) [420], walking and resistance training being the most popular
types of activity [419]. However, despite such stated interest, an invitation to
undertake a regimen of therapeutic exercise is only accepted by approximately two-
thirds of cancer patients, and only completed by approximately one half [418].
At present, a number of different exercise regimens have been trialled, including
resistance training [421], aerobic training [422], yoga [423] and NMES [418], Yet
the superior type of exercise, the form it should take, the intensity, and the timing of
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said exercise remain unclear. Furthermore, despite patient enthusiasm, the
feasibility of commencing successful exercise regimens, particularly resistance
training, in elderly, frail patients is uncertain.
1.11.3.2 Fatigue modulators
If fatigue occurs in the presence of anaemia, rhEPO treatment may be effective at
restoring haemoglobin concentration and improving exercise capacity, although the
benefit derived may not solely arise from its haematopoietic effects. There is
increasing evidence for a protective role of EPO in experimental models of both
myocardial infarction and ischaemia/reperfusion injury through anti-apoptotic
effects within the myocardium [424, 425]. However, there remain concerns
regarding the effect of chronic EPO treatment on the progression of neoplastic
disease [426]. In studies of head and neck cancer patients with anaemia, long-term
rhEPO therapy significantly impaired loco-regional disease control and shortened
survival [427]. For this reason, a Cochrane Database System review on the
management of cancer-related fatigue does not recommend the use of rhEPO in
these patients [428]. However, the authors did suggest that psychostimulants, such
as methylphenidate, represent alternative pharmaceuticals that may be used to
decrease fatigue, which avoid the potential dangers associated with EPO [428].
1.11.4 Pharmaceutical intervention
In the previous sections dealing with the aetiology of cancer cachexia, a number of
therapeutic interventions that have been or are being trialled for cancer cachexia
have been described, including cytokine antagonists, SARMs, ACE inhibitors, P-
agonists, myostatin antagonists, GH, ghrelin analogues, and proteasome inhibitors.
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In the present section, pharmaceutical interventions that have been trialled in cancer
patients but not described previously in this thesis are discussed. Such therapies
interrupt the wasting process by either reducing anorexia/stimulating appetite or by
attenuating skeletal muscle catabolism.
1.11.4.1 Progestational agents and hormonal appetite stimulants
In patients complaining of severe anorexia or early satiety, an appetite stimulant
may provide symptomatic improvement. Progestational agents (e.g. MA or
medroxyprogesterone) at high doses can improve appetite in approximately 70% of
patients [429, 430] by downregulating pro-inflammatory cytokines [431]. However,
despite subjective improvements in appetite, increased food intake and weight gain
may only be observed in approximately 20% of patients [432-434]. The
dissociation between subjective appetite scores and objective improvement in
nutritional status may be the product of three particular problems associated with
progestational agents. Firstly, any observed weight gain is often due to oedema or
increased fat deposition, rather than skeletal muscle [435, 436]. Furthermore, by
reducing circulating androgen levels, progestagens might actually decrease skeletal
muscle mass [437]. Secondly, the exact dose of progestagens required is unknown,
and trial doses have ranged from 160 to 1600mg/day [438]. Thirdly, there are a
significant number of potential side effects that arise from these treatments,
including thromboembolism [439], hyperglycaemia, hypertension, peripheral
oedema, alopecia and adrenal insufficiency. A recent Cochrane review concluded
that MA can increase appetite and weight gain in cancer patients, but that there is
not yet sufficient evidence to reach a conclusion about the optimal dose or the
effect on QoL [440]. Other hormonal appetite stimulants available include
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corticosteroids (e.g. prednisolone, dexamethasone) and ghrelin (see Chapter 1.7.1.4,
p.87). Corticosteroids can induce a transient effect on appetite, PS and subjective
physical well-being, but these sensations are limited usually to a few weeks
duration [441, 442],
1.11.4.2 Cannabinoids
Cannabinoids represent an alternative group of pharmaceutical agents known to
increase appetite through their interaction with CBi cannabinoid receptors within
the hypothalamic ARC [443], However, two published trials regarding the use of
cannabinoids in cancer-associated anorexia were largely unsuccessful. The first
study, which compared the use of cannabis extract, 5-9-tetrahydrocannabinol
(THC), and placebo on appetite and QOL in advanced cancer patients (n=243), was
terminated because of insufficient differences between study arms [444], The
second study, which compared dronabinol alone, MA alone, and a combination
therapy of the two drugs on appetite, nutritional status and QoL in cachectic
advanced cancer patients (n=469), concluded that MA provided superior palliation
of anorexia compared with dronabinol alone, and that combination therapy
conferred no additional benefit [445],
1.11.4.3 Non-steroidal anti-inflammatory drugs and COX-2 inhibitors
Early attempts at COX inhibition in cachectic cancer patients using non-steroidal
anti-inflammatory drugs (NSAIDS) were encouraging. In one study, indomethacin
(50mg twice daily) was capable of doubling mean survival duration in
malnourished patients with solid tumours (n=135) [446]. Furthermore, subsequent
studies demonstrated reductions in systemic inflammation and REE [447, 448].
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However, a positive impact on survival has not yet been replicated, possibly due to
the fact that NSAIDs appear able to add or maintain fat mass but not LBM [447],
Recently, researchers have favoured selective COX-2 inhibitors [449], rather than
NSAIDs, as they avoid the unwanted risk of peptic ulceration. (Fears still surround
the potential for cardiac-associated toxicities following chronic COX-2 inhibition
[450], but these latter side effects are likely to be less significant in palliative cancer
patients with short life expectancies). For reasons that are not yet clear, these
second-generation medications may be capable of improving LBM, whereas
NSAIDs were not. A 4-month treatment course of celecoxib (300 mg/day) in
patients with advanced cancer was well tolerated and resulted in significant
increases of LBM, grip strength, QoL, and PS [449]. COX-2 inhibitors are already
being employed within multimodal anti-cachexia treatment stategies [451].
1.11.4.4 Thalidomide
Thalidomide is well known for its teratogenic effects but it is licensed currently for
the treatment of multiple myeloma [452]. The treatment effects of thalidomide are
not explained fully, but appear to be the result of its immunomodulatory and anti-
angiogenic properties [453]. The proposed anti-cachectic mechanism of
thalidomide is an inhibition of TNF-a synthesis [454], although reduction in serum
IL-6 and CRP levels have also been demonstrated [455]. In a cachectic rat
cholangiocarcinoma model, thalidomide treatment preserved fast-twitch skeletal
muscle fibres and was associated with decreased expression of TNF-a and TGF-0
[456],
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Both thalidomide and the thalidomide analogue, lenalidomide [457], have been
trialled for use in patients with advanced solid tumours. In advanced pancreatic
cancer patients (n=50), thalidomide was able to prevent loss of arm muscle mass
and patient weight after both 4 and 8 weeks of therapy [458]. In a further study of
patients with non-obstructing but inoperable oesophageal cancer (n= 11), a 2-week
treatment course of thalidomide (200mg daily) was capable of reversing the loss of
weight and LBM experienced by patients established on an isocaloric diet for 2
weeks previously [459].
1.11.4.5 Adenosine-5'-triphosphate
Extracellular ATP is involved in the regulation of a variety of energetic biological
processes, including muscle contraction, neurotransmission and liver glucose
metabolism via purinergic receptors [460], It has therefore been hypothesised that
ATP infusion may reverse the negative energy balance found within cachectic
cancer patients [461]. In clinical trials, ATP infusion inhibited the depletion of body
composition and the loss of QoL in patients with advanced NSCLC [462], but did
not alter REE [461]. Interestingly, ATP infusion appeared to be especially
beneficial to those patients who were identified as cachectic (defined as weight loss
>5%), perhaps because the energy imbalance in these patients is at its most
profound [462, 463]. In these individuals, ATP infusion was shown to be most
effective at restoring liver energy balance [463], Furthermore, ATP was able to
prolong the survival of weight-losing patients with stage Illb NSCLC, but not
weight-stable patients or patients with stage IV NSLC [464, 465].
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In the previous section, the multimodal approach to any cancer cachexia therapeutic
intervention has been stressed. Furthermore, examples of clinical trials that have
investigated anti-cachexia interventions have been cited. Many of these trials have
been largely unsuccessful, probably because most of the interventions have been
unimodal in nature. However, several other problems that confound the current
design of anti-cachexia clinical trials will also have contributed to the generation of
negative findings, not least the difficulties in defining and diagnosing cachexia and
the lack of agreed biomarkers (see Chapter 1.2, p.34). In the next section, the
complexities of cancer cachexia trial design are discussed, and, in particular, the
use of outcome measures.
1.12 Outcome measures in cancer cachexia
The challenge in clinical trials of cancer cachexia is to develop an intervention of
sufficient efficacy that, not only does the measured nutritional status of patients
improve significantly, but that the effect of this improved nutritional status on
adverse clinical outcomes can also be demonstrated. Cachexia becomes even more
complex when we attempt to judge the success or failure of any proposed therapy
for its amelioration. The United States Food and Drug Administration (FDA) has
decreed that, in order for a treatment to be licensed for the management of cachexia,
there must be a documented improvement in both the nutritional and functional
status of a patient so treated [466]. To achieve this aim, any primary outcome
measure used in clinical trials should ideally be a biomarker of both nutritional and
functional status. This section details a critical evaluation of the use of outcome
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measures in cancer cachexia. In particular, the objective assessment of PA is
proposed as a clinical biomarker of nutritional status, functional status and QoL.
1.12.1 Reaching a consensus on primary outcome measures
Outcome measures are " the results ofhealth care processes" [467], They are a
measure of change and represent the difference from one point in time (usually
before an intervention) to another point in time (usually following an intervention)
[468], Outcome measures should be standardised, with explicit instructions for
administration and scoring [469].
When developing a primary outcome measure for studies in cachexia, it is crucial
to remember that it should represent the outcome of prime importance. As such, it
should be a significant and relevant end-point, which is clearly stated and defined.
It should also have a reasonable chance of being proven (c.f. power analysis) by the
proposed intervention trial. In contrast, a surrogate outcome measure is an
observational marker that is believed to relate to the primary end-point. It can be
clinical, physiological, chemical or biological. Surrogate outcomes should be easy
to identify and should be a good proxy or true predictor of the primary outcome.
The primary clinical outcome measures that have been used in clinical nutrition
trials include variables that are either patient-, doctor- or service-focused. Patient-
focused outcomes may include QoL variables [470] or measures of patient
independence [430]. Doctor-focused outcomes include measures of patient survival
[432], the incidence of complications [438] and the length of hospital stay [471].
Service-focused outcomes include assessments of the cost effectiveness of any new
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treatment and the financial viability of the introduction of such a treatment to
medical practice [472], Unfortunately, the direct measurement of any of these
variables is often a difficult and costly exercise. This problem, compounded by the
multiple potential confounding influences on such outcomes, renders a trial of
appropriate statistical power dauntingly large, complex and expensive. This has
often led investigators and pharmaceutical companies to abandon the direct
measurement of adverse clinical outcomes in favour of simpler, cheaper studies.
For example, if assessing the efficacy of a new nutritional intervention, the
temptation has been to aim at improving nutritional status, all the while assuming a
direct relationship between depleted nutritional status and adverse clinical
outcomes, independent of the disease process. This model, although less complex
and therefore less costly, is flawed as it leans towards the examination of surrogate
endpoints rather than important primary outcomes. It also relies on an assumption
that is potentially debatable. The failure to address clinical endpoints as primary
outcomes in cachexia trials has lead to the current status quo in which intervention
studies have had little impact on clinical practice.
1.12.2 Measures of nutritional status, functional status and quality of
life
In the development of primary outcome variables for future cachexia intervention
studies, it is useful to consider the relative advantages and disadvantages of the
outcomes currently being used.
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1.12.2.1 Weight loss and body composition
Nutritional outcomes that have been assessed in cachexia intervention trials have
included a variety of anthropometric, biochemical and physiological variables [406,
408, 473-476], Changes in body composition can be assessed with methods of
varying complexity. Simple and inexpensive measures include body weight, BMI
and bedside anthropometry using age-adjusted reference values (e.g. mid-arm
muscle circumference [MAMC], triceps skinfold thickness [TSF]). Bio-impedance
analysis (BIA) is a safe, quick and practical field-methodology that allows
estimation of total body water (TBW), ECW, intracellular water (ICW), LBM and
fat mass. However, the limitations of BIA mean that it is probably best for
comparison of groups of patients rather than individuals. Dual-energy X-ray
absorptiometry (DEXA), in-vitro neutron activation and tritiated water analysis,
total body potassium and underwater weighing are all more specialised techniques.
Weight loss, as a simple measure of nutritional depletion, has been used with
success as an entry criterion for various studies. Indeed, it is used in this respect
throughout the Results section of this thesis. However, it can be argued that weight
loss is inadequate to address fully the subtleties of cachexia. Despite being the most
intuitive of all the outcomes currently employed, and perhaps the simplest to
measure in a sensitive, objective manner, it remains difficult to determine exactly
how much weight gain is required in the individual patient to be clinically
significant, rather than statistically significant. Equally, total body weight
represents the sum of a variety of different body compartments, and therefore
documentation of a change in weight does not identify the specific nature of tissue
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lost or gained. In other words, has the patient with weight loss actually experienced
a depletion of skeletal muscle mass, or simply a loss of fat mass? Also, it is
important to note that how weight loss is defined may influence the conclusions
reached by clinical studies of cachexia. One such trial studied prospectively 8
weight-loss-related variables in patients with NSCLC [477], The authors found that
total weight loss was the best predictor of prognosis and that it was a superior
measure to rate of weight loss [477].
The use of LBM as a primary end-point is perhaps superior to body weight alone as
it reflects, at least to some degree, the functional protein mass in the body. It can be
estimated either directly or indirectly by a variety of techniques, including
anthropometry, BIA, isotope dilution or DEXA [478, 479]. However, as has been
discussed previously in Chapter 1.2.2, as LBM is not a measure of a specific tissue
mass, and also includes the mass of the ECW space, it is subject to some of the
same criticisms as total body weight. As a patient becomes more oedematous, a
change in LBM may be independent of the protein content of that mass.
Furthermore, the functional significance of a change in lean tissue mass is still not
established clearly.
Recently, cross-sectional imaging using MRI or CT has been utilised as a method
of assessing patient muscularity. Usually, a single body compartment is assessed
(e.g. mid-thigh muscle cross-sectional area; single-slice abdominal cross-sectional
muscle area) as a surrogate measure of whole-body muscularity. In particular, L3
single-slice abdominal CT has been used with success in cancer patients, and has
been capable of identifying obese patients with obvious muscle wasting (see
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Chapter 1.2.2, p.38) [28], Such 'sarcopenic obesity' was associated with poorer
functional status compared with obese patients who did not have sarcopenia, and
was an independent predictor of survival [30, 382],
There are a number of objective nutritional assessment tools available that can also
be used to guide nutritional therapy [480]. The Mini-Nutritional Assessment (MNA)
was developed initially as an inexpensive assessment tool to identify elderly
persons (> 65 years) at risk of malnutrition. It consists of 18 questions in 4
categories relating to simple anthropometry, general assessment, dietary assessment
and subjective assessment. It has been shown to correlate with weight loss and
CRP in patients with advanced cancer receiving palliative chemotherapy [481]. The
Subjective Global Assessment (SGA) is a clinical tool that combines subjective and
objective information from patient history and examination and then categorises
patients according to nutritional status. It is effective in detecting cancer patients at
risk of malnutrition [482], The Prognostic Inflammatory Nutritional Index (PINI)
was originally developed for the assessment of nutritional status and prognosis in
critically ill patients [483]. In developing the tool, discrimant analysis of blood
markers, including those pertaining to nutritional status, was used to select acute
phase reactants (AGP, CRP) and visceral proteins (albumin, prealbumin). These
were then combined in a formula to yield a score that was able to stratify critically
ill patients according to their risk of complication and mortality. The authors
suggested that it could be used to assess most pathological conditions, and it has
been shown that the PINI is indeed highly abnormal in cancer patients [484, 485].
In such patients, high PINI scores correlated with elevated serum IL-6 levels [485],
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1.12.2.2 Functional status
Poor PF in cachexia may relate to many factors including loss of body mass,
reduced substrate supply (food intake) and reduced volitional effort (fatigue and
depression), all of which can been related, at least in part, to the effects of systemic
inflammation. The loss of physical reserve can lead to a devastating loss of
independence. Furthermore, it may also exacerbate functional decline as inactivity
is linked to muscle atrophy (see Chapter 1.8.2, p.92).
Clinically useful endpoints to assay changes in functional status have proved
controversial. Functional status can be assessed subjectively or objectively. One
basic subjective method that relies simply on questioning patients regarding their
independence and ability to work and be active is physician-assessed PS (e.g. the
KPS, WHO PS scores). These scores may be subject to bias but general agreement
has been demonstrated between oncologist and patient-assessed WHO scores [486],
Palliative therapy (i.e. chemotherapy and radiotherapy) is influenced heavily by
estimates of patient PS. PS tools have proven value as prognostic indicators in
cancer patients [487] and as clinical trial inclusion criteria [488]. Attempts have
also been made to validate accurately the scores as global markers of functional
status [489]. However, despite growing interest in the functional assessment of
cancer patients [490], it remains unclear exactly what PS scores measure and how
they relate to true levels of patient activity. It has been suggested that PS suffers
from being too narrow a tool [491], and that conventional PS scores may be less
informative in older patients.
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Objective assessment of a patient's PF can be performed using either simple
techniques or more involved technologies that accurately measure a patient's PAL.
Simple techniques involve direct measurement of muscle power (e.g. grip strength,
treadmill testing and dynamic evaluation of leg extensor power). Leg strength
correlates well with self-reported functional status in elderly women [492], and
improvements in lower extremity strength are associated with gains in chair rise
performance, gait speed, mobility and 'mobility confidence' in the elderly [493].
Hand-grip dynamometry is a readily measured tool, which is an accurate prognostic
indicator in surgical patients [494], The SFA combines a self-reported
questionnaire, which collects information on symptoms and function, and a panel of
nine physical tasks, including tying a belt, putting on a sock and walking tests [386],
However, all of these objective measures of PF simply measure one or a few facets
of the patient's entire spectrum of activity. None capture the entire range of PF.
Recently, objective assessment of spontaneous PA has been proposed as a more
complete measure of PF and a more useful index of patient-orientated QoL [495].
This proposition is discussed later in the present section.
1.12.2.3 Quality of life
The palliative therapy of advanced cancer patients is often administered to improve
symptoms, functional status and QoL. This is because objective tumour responses
vary between only 20-70%, and often there is no survival advantage. For these
reasons, research into QoL assessment has undergone a significant expansion in
clinical oncology over recent years [490], QoL is a multi-domain phenomenon and
subject to observer variation; physician, patient and partner perception of a patient's
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QoL can differ [496], When asked what factors are important to QoL, patients
group their responses into five distinct domains - their own state, the quality of
their palliative care, their physical environment, relationships and outlook [497].
No commonly used single instrument at this time addresses all these issues. Instead,
most tools use researcher-defined domains such as physical, functional, social and
emotional well-being [498], and there is a concern that in so doing they may reflect
the views of health professionals rather than patients. Indeed, the emphasis placed
on health by many QoL tools may be questionable in patients with advanced cancer
[499],
The measurement, analysis and interpretation of QoL data is challenging [500], and
the complexity of the tools has resulted in selection bias secondary to patient drop
out in some QoL studies [501]. Currently, the commonest tools for specific use in
cancer patients include the European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire and the Functional Assessment of
Chronic Illness Therapy [FACIT] questionnaires. The latter group of questionnaires
have a wide range of tools for use in different forms of cancer and cancer therapy,
including ones for the specific assessment of anorexia and cachexia therapy
(Functional Assessment of Anorexia/Cachexia Therapy [FAACT]) and fatigue
(FACIT-F). Unfortunately, different cancer QoL tools are not interchangeable and
are unlikely to be directly comparable [502], There have therefore been recent calls
for an international consensus on how best to assess quality of life in oncology
[503], The EORTC QLQ-30, FACIT-F and FAACT questionnaires are employed
later in this thesis (Chapter 11).
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1.12.3 Current use of outcome measures
In the past ten years, there has been considerable interest in the potential therapeutic
value of EPA for the treatment of cancer cachexia. A series of clinical trials have
been conducted to assess the efficacy of EPA, and this body of literature provides a
useful resource from which the current outcome measures reported in cachexia
trials can be reviewed. Table 1.3 documents the main outcome variables measured
in six of these studies [406-408, 473, 474, 504], Immediately, it can be seen that
there is no consensus as to which outcomes should actually be included in a trial of
anti-cachexia therapy. Neither is there a standard methodology for assessing these
outcomes. As can be seen in Table 1.3, although change in body weight was
documented in all six studies, LBM was only measured in three. Food intake was
measured in only three trials, and was assessed using either a 3-day diet diary or a
linear analogue scale to document self-reported appetite. PF was assessed using
either a self-reported tool as part of a QoL questionnaire, or physician-reported PS,
using the KPS or WHO PS scales. It was documented variably by three of the trials,
and it was not addressed at all by two major studies. Again, global QoL and
survival duration from the initiation of treatment were documented by most of the
studies, but not all. The obvious conclusions are that uncertainty surrounds both the
methodology of assessing seemingly simple outcomes and the question of which
variables should be examined in the first instance. The situation is equally
confusing when we consider the use of primary outcome measures in these six
studies. Weight was used as the primary outcome in two of the trials [407, 408]; the
primary outcome measure was not stated explicitly in three of the trials (but
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was appetite score in the last study [474]. Thus, clearly there is no agreement
concerning the identity of the primary outcome measure in cachexia intervention
trials either.
1.12.4 Importance of patient-centred outcome measures
The real value of any cachexia intervention can only be measured truly by assessing
the day-to-day impact on the individual patient, whether that is an impact on QoL
or patient independence. Over the past twenty years, the importance of such patient-
centred outcomes has become evident. Studies have shown that cancer patients
receiving palliative care are interested not only in the quantity of their remaining
life, but also the quality. For example, in a survey of patients with advanced lung
cancer, only 22% of patients chose palliative chemotherapy, in preference to
supportive care alone, to benefit from the associated 3-month survival advantage
[505]. In contrast, 68% of patients chose chemotherapy when it substantially
reduced adverse symptoms without prolonging life. However, QoL is a very
complex issue to address. It is a multidimensional construct that includes clinical,
psychological, physical, cognitive, emotional, spiritual and social domains. It is
therefore best-measured using tools that assess multiple domains of patient well-
being [506-508], as well as common symptoms of cancer and its treatment (e.g.
pain, nausea, fatigue). It is generally accepted that QoL is a subjective phenomenon,
which is best assessed by the individual patient. Indeed, studies have shown that
considerable disparities exist between concurrent ratings of QoL made by patients
and their physicians [509, 510]. Various attempts have been made to develop a
crude assessment of overall QoL, and these are generally known as global QoL
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measurements [511]. However, when determining the impact of a nutritional
intervention on QoL, rather than measuring global QoL (which is likely to be
influenced by many other factors independent of nutritional status), it might be
more relevant to assay the intensity of a specific symptom that is readily influenced
by nutritional status. The FAACT and FACIT-F tools, which target anorexia-
cachexia and fatigue respectively, are appropriate examples of this strategy.
However, in particular, the PF of a patient is one such proximal index of QoL that
might be useful in application to cachexia intervention trials [495].
1.12.5 Timing of the primary outcome measure
In general, cachexia intervention trials study patients over a period of weeks,
looking for a change in either body composition, functional status or a combination
of both. However, there is no agreement regarding how long any interventional
study should be. To detect a measurable change in body composition usually
requires a trial lasting 6-8 weeks. In the six EPA trials examined above, the
duration of the intervention ranged from 2 weeks to 6 months [406-408, 473, 474,
504], Assessment of functional status may have an advantage over nutritional
status, as it tends to improve ahead of changes in body composition and therefore
may be demonstrable over a shorter timescale (e.g. days). However, no matter
which variable is selected as primary outcome measure, cachectic cancer patients
are generally so unwell when entered into intervention trials that less than 50% are
still assessable at 8 weeks from treatment initiation [406]. This fact suggests that
there is a probable selective attrition of the patient population, a problem that has
not been adequately addressed by refinement of trial methodology.
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1.12.6 Physical activity as a patient-centred outcome measure
When we consider all of the potential difficulties in the measurement of current
outcomes in cachexia trials, the objective assessment of patient PA (as a global
measure of complete PF) offers a viable and advantageous alternative. PF is an
important domain of QoL that may be strongly influenced by nutritional status.
Furthermore, it is a direct product of skeletal muscle action, the major tissue type
depleted by cancer cachexia. Thus, objective PA is a clinical biomarker of both
nutritional and functional status, and could be utilised as a primary outcome
measure.
To improve PA in cancer cachexia, there are a number of areas that may be targeted
(Figure 1.19). LBM (the patient's "engine") may be optimised either by size and/or
by the efficiency of its function. Food intake (the patient's "fuel") may be optimised
by increasing the total supply of macronutrients (more calories) and/or improving
the energy quality or density of the food. Finally, medical, nursing or physiotherapy
staff may attempt to motivate the cachectic patient (the "driver") to mobilise, or
instruct the patient on how to utilise their limited energy reserves more efficiently.
Crucially, it has been proven that PA can be improved by anti-cachexia
interventions (see Chapter 1.8.2, p.92) [406], Moses and co-workers demonstrated
that the baseline PAL (ratio of TEE/REE) of cachectic pancreatic cancer patients
was very low (with patients spending prolonged periods at rest or in bed) [406].
Patients were randomised to receive either an energy and protein dense oral
nutritional supplement, or the same supplement enriched with a pharmacological









Figure 1.19 Improving physical activity in cancer cachexia.
In order to improve PA in cachectic cancer patients, LBM (the patient's "engine")
may be maximised either by size and/or by the efficiency of its function; food
intake (the patient's ' fuel") may be maximised by increasing the total supply of
macronutrients (more calories) and/or improving the energy quality or density of
the food; and the cachectic patient (the "driver") may be encouraged to mobilise, or
instructed on how best to utilise their limited energy reserves more efficiently.
LBM = lean body mass; PAL = physical activity level
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food intake but also to address some of the underlying metabolic abnormalities that
contribute to the syndrome of cachexia (e.g. systemic inflammation). Patients
receiving the conventional supplement did not demonstrate increased PAL.
However, PAL increased significantly in those patients receiving the combined
regimen, to values commensurate for sedentary office workers [512]. This is one of
the few randomised studies that has used objective methodology and shown that a
nutritional intervention can improve PF in advanced cancer patients. Furthermore,
there is evidence emerging that PA does indeed reflect and correlate with QoL
scores in cancer patients [380, 513].
However, despite the primacy of patient PA as an outcome measure, the gold-
standard methodologies for objectively assessing PA are expensive, time-
consuming, work-intensive and not patient-friendly. The classical methodology for
determining PAL involves combined measurement of TEE by the doubly labelled
water (DLW) stable isotope technique and REE by indirect calorimetry (Figure
1.20). PAL represents estimated energy requirements as a multiple of the basal
metabolic rate (BMR) and is derived from the ratio of TEE to REE. PA is a
significant and variable component of TEE in free-living individuals. Although
REE may be increased in some wasted cancer patients, TEE may actually fall
suggesting that they modulate energy demand by reducing PA [406].
In recent years, the development of accelerometer-based PA meters now means that
there are viable, cost-effective, patient-friendly and reusable technologies to assess
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meter (Figure 1.21) has been used to objectively measure PA in a range of patient
cohorts, including cachectic cancer patients (median weight loss 9%) undergoing
palliative chemotherapy [380] (Figure 1.22). This latter study demonstrated that
estimated TEE was 8% lower, time spent upright was approximately 2 hours/day
less, and step count was 43% lower than that of age-matched, healthy controls
[380]. The activPAL™ meter is studied later in this thesis (Chapters 10 and 11).
Firstly, its ability to measure EE is validated against the DLW technique. Secondly,
it is employed in a cohort of patients undergoing palliative chemotherapy in order
to develop further objective PA as a clinical biomarker of nutritional status,
functional status and QoL in advanced cancer and cachexia.
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Figure 1.21 Techniques of objective measurement of physical activity II:
activPAL™ meter.
The activPAL™ meter is a lightweight, accelerometer-based device that is secured
to the patient's anterior thigh, and which measures objectively a number of PA-
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meter (Figure 1.21) has been used to objectively measure PA in a range of patient
cohorts, including cachectic cancer patients (median weight loss 9%) undergoing
palliative chemotherapy [380] (Figure 1.22). This latter study demonstrated that
estimated TEE was 8% lower, time spent upright was approximately 2 hours/day
less, and step count was 43% lower than that of age-matched, healthy controls
[380], The activPAL™ meter is studied later in this thesis (Chapters 10 and 11).
Firstly, its ability to measure EE is validated against the DLW technique. Secondly,
it is employed in a cohort of patients undergoing palliative chemotherapy in order
to develop further objective PA as a clinical biomarker of nutritional status,
functional status and QoL in advanced cancer and cachexia.
In this section, following a critical appraisal of the current status quo of clinical
trial methodology, the objective assessment of PA has been proposed as a novel
outcome measure for use in studies of anti-cachexia therapeutic interventions. This
section represents the last of the introductory sections that summarise cancer
cachexia. The following section details the objectives for the present thesis.
1.13 Thesis objectives
This chapter has attempted to provide a full summary of the current knowledge
base of cancer cachexia, including some of the remaining unanswered questions
and controversies. In particular, this chapter has stressed that skeletal muscle is the
key tissue type affected by cancer cachexia, and that wasting of this tissue is the
most significant determinant of patient function and outcome. Furthermore, it has
highlighted that there is a pressing need for biomarkers of cachexia (either
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biological or clinical) for effective clinical trial design. These biomarkers could act
as inclusion criteria, outcome measures or both. Lastly, it has been emphasised that
the majority of mechanistic studies have been carried out in animal models and in
vitro systems, and that there remains a paucity of human data. Therefore, this thesis
is aimed at the study of mediators, mechanisms and biomarkers of skeletal muscle
wasting and function in cancer cachexia, using human cell lines, human samples
and cancer patients as the investigative models of choice. A number of diverse
studies in this field have been carried out, with the main objectives appearing below:
1. Quantify the expression of dermcidin mRNA (as a proxy of PIF expression)
in primary upper GI cancer and prostate cancer tissue (see Chapter 1.6.1,
P-69);
2. determine the expression of dermcidin mRNA (as a proxy of PIF expression)
in a range of human cancer cell lines (see Chapter 1.6.1, p.69);
3. analyse the sequence of dermcidin cDNA from human cancer cell lines in
order to investigate the potential for PIF glycosylation (see Chapter 1.6.1,
P-69);
4. analyse the effect of serum sex steroids and gonadotropins on nutritional
status, systemic inflammation and survival in cancer patients (see Chapter
1.5.1.1, p.56);
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5. analyse the effect of plasma MIC-1 on nutritional status, food intake,
systemic inflammation and survival in cancer patients (see Chapter 1.7.1.5,
p.87);
6. determine the presence of DGC abnormalities in muscle from cancer
patients and relate such abnormalities to nutritional status, systemic
inflammation, and survival (see Chapter 1.9.1.4, p. 106);
7. determine the expression of phosphorylated and non-phosphorylated forms
of PKR and eIF2a in muscle from cancer patients and relate such expression
to nutritional status and survival (see Chapter 1.9.1.2, p. 104);
8. investigate the presence of biomarkers of skeletal muscle wasting in urine
from cancer patients (see Chapter 1.9.2, p. 108);
9. validate estimates of EE measured by the activPAL™ PA meter using a
DLW stable isotope technique (see Chapter 1.12.6, p. 157);
10. measure objective PA in palliative cancer patients undergoing
chemotherapy, and relate such measurements to nutritional status, mood and
QoL.
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Chapter 2 - Patients, Materials and Methods
2.1 Patients and healthy controls
For all studies, patients with upper GI cancer (OGC and pancreatic cancer) were
recruited from the Surgical Department of the Royal Infirmary of Edinburgh and
the Oncology Department of the Western General Hospital, Edinburgh. Staging was
carried out according to the American Joint Committee on Cancer (AJCC)/Union
Internationale Contre le Cancer (UICC) systems [514], Blood, tissue and urine
samples were collected from these individuals. If patients were undergoing cancer
surgery with or without curative intent, samples of skeletal muscle and tumour
tissue were also collected (see Chapters 2.4, p. 173). Local ethics committees
approved the protocols, and written informed consent was obtained from all patients.
Procedures were in accordance with the International Committee for Harmonization,
Good Clinical Practice, and the Helsinki Declaration.
Samples of blood, urine and/or skeletal muscle were also obtained from patients
undergoing minor surgical procedures for benign, non-inflammatory conditions (e.g.
hernia repair), or laboratory/hospital staff, for use as healthy controls. Samples of
oesophago-gastric control tissue were taken from patients having normal upper GI
endoscopies (see Chapter 2.4.2, p. 174).
Specific circumstances and inclusion/exclusion criteria of certain patient and
control cohorts are described in detail in the Results chapters.
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2.2 Nutritional Assessment
2.2.1 Weight and height
At recruitment, pre-illness stable weight and duration of weight loss were self-
reported by cancer patients, in order to calculate percentage weight loss [515],
Patients were weighed on spring balance scales without shoes and wearing light
clothing. With the exception of the sex steroid/gonadotropin study (Chapter 3) for
which weight loss >5% of pre-illness stable weight over the previous 6 months was
one of the initial inclusion criteria for the original randomised trial, cachexia was
defined as >10% weight loss. Height was measured using a wall-mounted
stadiometer with the patient standing erect without shoes.
2.2.2 Lean body mass
Body composition, including LBM (as an estimate of skeletal muscle mass) and
body water, was assessed using BIA. In the sex steroid/gonadotropin study
(Chapter 3), a Xitron Hydra multiple-frequency bio-impedance analyser (Xitron
Technologies, San Diego, USA) was used, whereas in the activPAL™ studies
(Chapters 10 to 12), a Bodystat Quadscan 4000 multiple-frequency bio-impedance
analyser (Bodystat Ltd, Isle of Man, UK) was used. Such techniques have been
validated previously in similar patients [516, 517], and have been used in
comparative studies of large patient groups [406, 407],
2.2.3 Anthropometry
Mid-arm circumference (MAC) was measured (in cms) at the mid-point between
the acromion and olecranon processes in the non-dominant arm. TSF, as a measure
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of adiposity, was measured (in mms) with Harpenden skin callipers (Holtain,
Crymych, UK). MAMC, as a measure of muscularity, was calculated according to
the formula: MAMC = MAC-[tt x TSF/10].
2.2.4 Grip strength
Maximal grip strength was assessed by a hand-held spring-loaded dynamometer
(Takei, Nigata, Japan). The maximum reading from 3 attempts using the dominant
hand was recorded.
2.2.5 Performance status
KPS and WHO PS scores (see Appendix II, p.484) were documented by the
recruiting physician.
2.2.6 Assessment of dysphagia and dietary intake
Dysphagia score (normal swallowing = 0; dysphagia to solids = 1; dysphagia to
softened foods = 2; dysphagia to liquids = 3; and total dysphagia = 4) and
subjective diet score (normal dietary intake = 1; reduced dietary intake = 2; and
poor dietary intake = 3) were used as surrogate measures of food intake.
2.3 Blood tests
2.3.1 Plasma and serum separation
For plasma separation, venous blood collected in lithium heparin tubes was
centrifuged at l,500rpm at 4°C for 5min. For serum separation, clotted blood was
centrifuged at l,500rpm for 30min. Both plasma and serum samples were stored as
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ImL aliquots at -80°C until analysis.
2.3.2 Analysis of circulating CRP concentration
For the sex steroid/gonadotropin study, serum CRP concentration was measured by
enzyme-linked immunosorbent assay (ELISA) (Dako, High Wycombe, UK),
according to the manufacturer's instructions [518], The limit of detection was
lmg/L. Coefficient of variation (CV) was <9% across the concentration range
studied. For all other studies, plasma CRP was assayed using automated methods
on an Olympus AU2700 analyser (Olympus Diagnostica GmbH [Irish Branch],
Lismeehan, Ireland), in the Department of Clinical Chemistry, Royal Infirmary of
Edinburgh (fully accredited by Clinical Pathology Accreditation [UK] Ltd).1
Appropriate internal quality controls (IQC) were included, with CVs typically 3.4%
at concentrations <15mg/L and 1.6% at 80mg/L. Presence of systemic
inflammation/APPR was defined by a plasma/serum CRP >10mg/L.
2.3.3 Analysis of circulating albumin concentration
Plasma/serum albumin concentration was assayed using automated methods on an
Olympus AU640 analyser (Olympus Diagnostica GmbH [Irish Branch],
Lismeehan, Ireland), in the Department of Clinical Chemistry, Royal Infirmary of
Edinburgh. Appropriate IQC were included, with CVs typically <3.0% at all
concentrations'. By combining the results of both plasma CRP and albumin
concentrations (Chapter 4), the mGPS could be calculated as follows: patients with
plasma CRP >10mg/L were allocated a mGPS of 1 or 2 depending on the absence
'i acknowledge Dr. Catharine Sturgeon of the Department of Clinical Chemistry, Royal Infirmary of
Edinburgh, who performed these analyses.
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or presence of hypoalbuminaemia (<35g/L), whereas patients with plasma CRP
<10mg/L were allocated a mGPS of 0.
2.3.4 Analysis of serum gonadotropin, sex steroid and CA19.9
concentrations
A single blood sample was drawn in the morning between the hours of 0930 and
1200. Total testosterone (TT), oestradiol, luteinising hormone (LH), follicle
stimulating hormone (FSH), sex hormone binding globulin (SHBG), albumin and
carbohydrate antigen 19-9 (CA19-9) were assayed using automated methods (Bayer
Immuno-1 for all analytes except SHBG [DPC Immulite]) on an Olympus AU640
analyser in the Department of Clinical Chemistry, Royal Infirmary of Edinburgh1.
Appropriate IQC were included, with between-run CVs typically <8%. Male
oestradiol concentrations and female control TT concentrations were not available.
Control albumin concentrations were not measured but were assumed to be 42.5g/L,
the median of the reference range. Calculated free testosterone (cFT) was derived
from TT, albumin and SHBG using the Vermeulen formula [519]:
cFT = TT-n-S+V 1 (n+S-TT)2 x 4nTTl
2n
where TT= total testosterone
n = (0.5217 x A) + 1
S = SHBG in nmol/L
A = albumin in g/L
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Male hypogonadism was defined either as TT <10nmol/L or normal TT (10-
30nmol/L) with raised LH (>9.0U/L), known henceforth as 'TT definition', or as
cFT <0.245nmol/L, known henceforth as 'cFT definition' [519]. In female subjects,
elevated oestradiol was defined as >150pmol/L, the upper limit of normal for
postmenopausal women.
2.3.5 Analysis of serum IL-6 and sTNFR75 concentrations
Serum IL-6 and soluble TNF receptor 75 (sTNFR75) concentrations were measured
by EL1SA (Quantikine, R&D Systems, Abingdon, UK), according to the
manufacturer's instructions2. Limits of detection were 0.5 pg/mL, and CVs were
<9% across the concentration ranges studied.
2.3.6 Analysis of plasma MIC-1 concentration
Samples were examined in duplicate using a well-established sandwich ELISA as
previously described [520]3. Briefly, 96-well Maxisorp ELISA plates were coated
with mAb 26G6H6 supernatant diluted 1:5 (final immunoglobulin [Ig]
concentration was approximately 20ng/mL) in coating buffer at 4°C for 24h. ELISA
plates were then washed three times with 30()uL/well of wash buffer. Non-specific
binding was blocked with 250pL/well of 1% (wt/vol) bovine serum albumin (BSA)
in phosphate buffered saline (PBS) for 2h at 37°C. Recombinant human MIC-1
(rhMIC-1) standards and plasma samples in Ab Dil were then added to the plates
(lOOpL/well) and incubated for lh at 37°C. The plates were washed three times,
2I acknowledge Mr. Alastair Moses who performed these analyses.
3I acknowledge Dr. David Brown, Mr. Mark Hunter and Prof. Sam Breit of the Centre for
Immunology, St. Vincent's Hospital and University of New South Wales, Sydney, Australia, who
perfomed these analyses.
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followed by the addition of lOOpL/well of the sheep polyclonal antibody (pAb)
233B3-P diluted 1:5000 in Ab Dil and incubated for lh at 37°C. ELISA plates were
then washed three times, and lOOpL/well of biotinylated donkey antisheep IgG
diluted to 1:5000 in Ab dil was added and incubated for lh at 37°C. The plates were
then developed and the MIC-1 plasma concentration was determined by reference
to a standard curve constructed using rhMIC-1 as the standard. All samples had
duplicate values with a CV <10%. Assay performance was monitored additionally
using standard diagnostic laboratory procedures.
2.3.7 Analysis of plasma creatinine and creatine kinase
concentrations
Plasma creatinine concentration was measured using a kinetic Jaffe technique on an
Olympus AU2700 analyser (Olympus UK Ltd, Watford, UK) (normal defined as
<120pmol/L)'. Plasma creatine kinase (CK) concentration was measured using a
CK- N-acetyl-L-cysteine (NAC) (International Federation of Clinical Chemistry
and Laboratory Medicine: IFCC) technique, also on an Olympus AU2700 analyser
(normal defined as <170U/L in males and <135U/L in females)1. Within and
between-run CVs were <2.0% at all concentrations for both tests.
2.4 Tissue biopsies
2.4.1 Skeletal muscle biopsies
Samples of rectus abdominis muscle were obtained without the use of diathermy
from the edge of the abdominal wounds of patients undergoing cancer surgery with
or without curative intent or controls undergoing minor surgical procedures for
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benign, non-inflammatory conditions e.g. hernia repair. Samples were taken within
20 minutes of induction of general anaesthesia. Samples were frozen immediately
in liquid nitrogen using liquid nitrogen-resistant tubes (Corning BV, Netherlands),
and then stored at -80°C until analysis.
2.4.2 Oesophageal and pancreatic tissue biopsies
Samples of tumour tissue were dissected from the resected cancer specimens by a
Consultant Pathologist within 20 minutes of the staple guns being fired and the
blood supply of the resection specimen being interrupted. Samples were frozen
immediately in liquid nitrogen using liquid nitrogen-resistant tubes (Corning BV,
Netherlands), and then stored at -80°C until analysis. A Consultant Pathologist
analysed representative tissue sections to confirm the presence of malignant cells in
tumour samples and the absence of malignant cells within the benign samples.
Control gastric and oesophageal biopsies were collected from healthy volunteers
undergoing negative endoscopic investigation of GI symptoms4. For patients
undergoing pancreatectomy, samples of tumour and normal tissue were removed
from fresh surgical specimens by a Consultant Pathologist. For patients undergoing
palliative bypasses for pancreatic cancer, core biopsies of tumour tissue were taken
intraoperatively5.
2.4.3 Prostatic tissue biopsies
Samples of malignant and benign human prostate tissue were obtained from the
Partners in Cancer Research Tissue Bank, held in the Department of
4I acknowledge Mr. Christopher Deans who collected these control biopsies.
5I acknowledge Mr. Alastair Lowrie who collected the pancreatic tumour biopsies.
174
Histopathology at the Norfolk & Norwich University Hospital. Detailed procedures
for obtaining informed patient consent, tissue acquisition, and histopathological and
molecular quality control and validation have been described [521]6. Samples of
malignant prostate tissue were collected from patients undergoing radical
prostatectomy or channel transurethral resection of the prostate (TURP), and non-
malignant samples were obtained from patients undergoing radical
cystoprostatectomy for transitional cell carcinoma of the bladder or TURP for
benign prostatic hypertrophy (BPH).
2.5 Urine samples
2.5.1 Urine collection
Morning urine samples were taken and stored at -20°C until analysis. First urine
samples of the day were not used in order to avoid urine that may have remained in
the bladder overnight.
2.5.2 Urinary protein precipitation
Following centrifugation to remove debris, proteins were precipitated from 20mL
urine by incubation at -20°C for 2h with 40mL cold acetone containing 20mM
dithiothreitol (DTT). Samples were centrifuged and the protein pellet was re-
dissolved in 3mL PBS/3mL rehydration buffer (8mol/L urea, 2% 3-[(3-
cholamidopropyl)dimethylammonio]-l-propanesulphonate (CHAPS), 20mM DTT).
A 200|iL aliquot was centrifuged and the supernatant assayed for protein
concentration using the Bradford technique (BioRad Protein Assay kit, USA).
6I acknowledge Mr. Anthony Riddick and Mr. Grant Stewart who forged this collaboration and
collected several of these samples.
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Absorbance was read at 630nm (MRX II spectrophotometer, Dynex Technologies)
compared to a standard reference curve created using a 1:1:1 dilution of bovine-y-
globulin protein standard with PBS and re-hydration buffer.
2.6 Cell culture
2.6.1 Cell lines
The following immortalised human cancer cell lines were obtained from the
European Collection of Cell Cultures (ECACC), Porton Down, UK: hormone-
sensitive prostate cancer cell line LNCaP; hormone-insensitive prostate cancer cell
lines PC-3 and DU145; human hepatocellular carcinoma cell lines Huh-7 and Hep
G2; and human pancreatic adenocarcinoma cell lines PANC-1, CFPAC and MIA-
Pa-Ca-2 (Table 2.1). Hormone-sensitive prostate cell line PC-3M was kindly
donated by Dr C Pettaway, University of Texas, M.D. Anderson Cancer Center,
Houston, TX, USA, whereas human malignant melanoma cell line G-361 was
kindly donated by Professor Michael Tisdale, Aston University, UK. Prostate cell
lines were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium
(Invitrogen, Paisley, UK). Melanoma G-361 cells were cultured in McCoy's 5A
medium (Invitrogen). Hepatocellular carcinoma and pancreatic cancer cell lines
were cultured in Dulbecco's Modified Eagle Medium (Invitrogen). Media were
supplemented with 10% foetal calf serum (FCS), 50u/mL penicillin, 50pg/mL
streptomycin and 2mM glutamine (all from Invitrogen, Paisley, UK). Cells were
grown in 75cm2 flasks (Corning BY, Schipol-Rijk, The Netherlands).
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Tissue Type of Origin Cell Lines
Hormone-sensitive prostate cancer LNCaP
PC-3M








Table 2.1 Cell lines used in experimental work.
The above listed cell lines were utilised in the investigations pertaining to PEF
within this thesis. These cell lines were chosen as they either represent the tissue
type in which dermcidin expression was first described (i.e. prostate cancer - see
Chapter 1.6.1, p.69) or they represent the tissue type most commonly associated
with cancer cachexia (i.e. upper gastrointestinal cancer types - see Chapter 1.3,
P-41).
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2.6.2 Transfection of cells with DCD cDNA for use as a positive
control
Wang et al demonstrated that the PC-3M cell line does not express DCD mRNA
[197] and it was thus chosen as a suitable cell line to be transfected stably with a
pcDNA3.1+DCD vector, in order to create a robust positive control for DCD real¬
time PCR. The pcDNA3.1+ mammalian expression vector (Invitrogen, Paisley, UK)
had full length DCD cDNA directionally cloned into the multiple cloning site using
the EcoRI and BamHI restriction enzymes (Promega, Southampton, UK).
pcDNA3.1+DCD vector was transfected stably into PC-3M cells using FuGENE-6
n
(Roche Applied Science, Lewes, UK) . Geneticin selection antibiotic (Invitrogen,
Paisley, UK) (600pg/mL) was used to select transfected cells and eventually create
stable transfectants. Sham transfected PC-3M cells were created using an empty
pcDNA3.1 vector as a control. Geneticin (300pg/mL) was used to supplement
medium to maintain the transfected cells.
2.7 Polymerase chain reaction
2.7A RNA isolation
For RNA preparation from intact upper GI and pancreatic tissue samples, a rotor-
stator homogeniser was used for homogenisation. RNA was then extracted using an
RNAeasy kit (Qiagen, Crawley, West Susses, UK) according to the manufacturer's
instructions. Certified ribonuclease (RNAse)-free pipette tips and microcentrifuge
tubes were used at all times. RNA was resuspended in nuclease free water and
7I acknowledge Mr. Grant Stewart who performed this transfection.
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concentrations determined by spectrophotometry using a GeneQuant pro
RNA/DNA calculator (Amersham Pharmacia Biotech, Bucks, UK). For RNA
preparation from cell lines, RNA was extracted using the TRizol method according
to the manufacturer's instructions (Invitrogen, Paisley, UK). Following
resuspension, RNA concentrations were determined by spectrophotometry using an
Ultraspec 2000 spectrophotometer (Pharmacia Biotech, Cambridge, UK).
2.7,2 Reverse transcription polymerase chain reaction (RT-PCR)
One mg of total RNA was used for reverse transcription (RT). RNA was first
deoxyribonuclease (DNAse)-I-treated using RQ1 DNAse (Promega, Southampton,
UK) to ensure no contamination. Reverse transcription was performed using avian
myeloblastosis virus (AMV) reverse transcriptase (Promega, Southampton, UK)
according to the manufacturer's instructions. cDNA was stored at -20°C until used.
Two different sets of primers (named PIF and HCAP) were used with
individualised polymerase chain reaction (PCR) programmes to identify DCD
cDNA. PIF primers were designed using the Primer3 primer design programme
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and used with P actin
housekeeping primers. All primers were manufactured by Sigma, Irvine, UK.
PIF forward primer: CCTCTTCCTGACAGCTCTGG
PIF reverse primer: CTGGATCTCTGCTTCCTTGG
p actin forward primer: ACTGACTACCTCATGAAGAT
P actin reverse primer: CGTCATACTCCTGCTTGCTGAT
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HCAP forward primer: ACTCTCCTCTTCCTGACAGCTCTGG
HCAP reverse primer: CTGCTGCTCCTGGGTATCATTTCTC
MIC forward primer: CACGTCATCCAGCAGAGAATGGAAAGTC
MIC reverse primer: TGACCAAGATGTTGATGTTGGATAAGAG
Figure 2.1 shows the primer targets on the DCD nucleotide sequence.
Each reaction was performed in 25pL and contained the equivalent of lpL of
reverse transcribed RNA, lpM each of the forward and reverse primer, 0.2mM
deoxyribonucleotide triphosphate (dNTP) (Invitrogen, Paisley, UK), 2.5mM MgCl2
and 1 unit of Taq DNA polymerase (Promega, Southampton, UK). Conditions for
both the PIF and /? actin PCR reactions were: 94°C for 5min, then 35 cycles,
consisting of 94°C for lmin, 56°C for lmin and 72°C for lmin, followed by 72°C
for lOmin. HCAP primers designed by Wang et al (which encompass the PIF
nucleotide sequence) [197], were used with [32-microglobulin (MIC) PCR control
for RNA quality and RT performance. Conditions for both the HCAP and MIC PCR
reactions were: 80°C for 3min, then 35 cycles, consisting of 95°C for 5s and 69°C
for lmin, followed by 72°C for 7min. HCAP (361 base pairs [bp]) and MIC (555bp)
PCR products separated on a 1.6% agarose gels (agarose (Flowgen Bioscience,
Nottingham, UK) dissolved in IX Tris-acetate-EDTA (TAE; Appendix I, p.483)
with 5pl ethidium bromide run in 1XTAE. PIF (174bp) and (3 actin (535bp) PCR
products were separted on 6% acrylamide gels run in IX Tris-borate-EDTA (TBE;
Appendix I, p.483), for enhanced resolution. A 50-1000bp PCR Marker (Promega,









Figure 2.1 DCD gene nucleotide sequence with marked targets for PIF and
HCAP PCR primers.
PIF-core peptide nucleotide sequence in bold, f denotes site of an intron. PIF
primer targets singly underlined. HCAP primer targets in italics. Putative O-
glycosylation sites doubly underlined, whereas putative N-glycosylation sites
dotted underlined. Start and stop codons are shown in upper case.
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2.7.3 Real-time polymerase chain reaction
cDNA preparation and real-time PCR were performed as previously described [522,
523] . Briefly, lpg of total RNA was reverse transcribed using 2pg random
hexamers (Amersham, Bucks, UK) and Superscript II reverse transcriptase (Life
Technologies, Paisley, UK) according to the manufacturer's instructions. cDNA
was stored at -20°C until used.
For PCR reactions, specific primers and fluorogenic probes for DCD were designed
using Primer Express 1.0 software (Applied Biosystems, Warrington, UK) and
synthesised by Applied Biosystems. Figure 2.2 shows the primer and probe targets
on the DCD nucleotide sequence, which partially overlaps with the nucleotide
sequence for the PIF-CP.
DCD real-time forward primer: CAAAAGGAAAATGCAGGTGAAGA
DCD real-time reverse primer: TGGAAAAAGGCCTAGACGGAG
DCD real-time probe: FAM-ACAGGCACCAAAGCCAAGGAAGCA-TAMRA
To control against amplification of genomic DNA, primers were designed to span
exon boundaries. The 18S ribosomal RNA (rRNA) gene was used as an
endogenous control to normalise for differences in the amount of total RNA in each
sample. 18S rRNA primers and probe were purchased from Applied Biosystems.
PCR reactions were performed using the ABI Prism 7500 fast Sequence Detection
System (Applied Biosystems, Warrington, UK), according to the manufacturer's
8I acknowledge Dr. Caroline Pennington and Prof. Dylan Edwards, School of Biological Sciences,









Figure 2.2 DCD gene nucleotide sequence with marked targets for the real¬
time PCR primers and probe.
f denotes site of an intron. DCD real-time PCR primer target singly underlined and
probe target doubly underlined. PIF-CP nucleotide sequence in bold. Start and stop
codons are shown in upper case.
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instructions. Each reaction was performed in 25pL and contained the equivalent of
5ng of reverse transcribed RNA (lng RNA for the 18S analyses), 50% TaqMan 2X
PCR Master Mix (Applied Biosystems), 200nM each of the forward and reverse
primer, and lOOnM of probe. Conditions for the PCR reaction were: 2min at 50°C,
10 min at 95°C and then 40 cycles, each consisting of 15s at 95°C and 1 min at
60°C. The ABI Prism 7500 measured the cycle-cycle changes in fluorescence in
each sample and generated a kinetic profile of DNA amplification over the 40-cycle
PCR reaction. The cycle number (termed cycle threshold, or Ct) at which
amplification entered the exponential phase was determined and this number was
used as an indicator of the amount of target RNA in each tissue; that is, a lower Ct
indicated a higher quantity of starting RNA. Relative and/or absolute standard
curves for CT versus input RNA were prepared, and relative and/or absolute levels
of starting RNA in each sample were determined. Only DNA samples with an 18S
CT value within 1.5 CTs of the median CT for 18S were used for analysis as this
value suggested that the RNA was of sufficient quality for analysis of DCD
expression. The CT value of DCD was used to classify its expression as: very high
(Ct<25.5), high (>25.5 Ct<30.5), moderate (>30.5 Ct <35.5), low/absent (>35.5
CT <40), or not detected/below the limits of detection (Ct = 40) [522], Because of a
drop off in sensitivity of the instrument, CT values >35.5 are unreliable in terms of
exact levels of mRNA expression or assessing changes in Ct values. The PC-3M
cells transfected with the pcDNA3.1+DCD plasmid gave a Ct value of 23.1. Thus,
the positive control was in the very high range of DCD mRNA expression. All in
vitro experiments were performed in sextuplet and repeated three times.
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2.7.4 Nucleotide sequencing
Nucleotide sequencing of PCR products was performed as a commercial service
(MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK) using the
PIF and HCAP primers.
2.8 Western blotting and co-immunoprecipitation
2.8.1 DGC study (Chapter 7)9
For immunoprecipitation reactions, muscles were homogenised in lmL of
immunoprecipitation lysis buffer (1% Triton X-100, 150mM NaCl, 50mM Tris-
HC1 [pH 7.5], ImM ethylenediaminetetraacetic acid [EDTA], ImM
phenylmethanesulphonylfluoride [PMSF], with standard protease and phosphatase
inhibitors), and 500pg of protein was used for each reaction. Extracts were
precleared of non-specific immunoprecipitates with lpg IgG for lh at 4°C.
Supernatants were transferred to a fresh tube, and 1 pg of antibody was added to the
tube and incubated by rocking overnight at 4°C. After immunoprecipitation,
complexes were collected, washed, and resuspended in 30pL in standard loading
buffer. Western blots were performed to probe for myofibrillar proteins as
previously described [46], with the exception that a-dystroglycan (a-DG)
incubations were done with 150mM NaCl, 20mM Tris (pH 7.4). Antibodies used
were dystrophin (dys-2, carboxy specific; 1:50), B-DG (1:100), a-sarcoglycan (a-
SG) (1:200), B-SG (1:200), and dysferlin (1:100) (all from Novocastra, Newcastle
Upon Tyne, UK), MyHC I and II, and skeletal actin (all from Sigma-Aldrich, St.
9I acknowledge Dr. Swarnali Acharyya and Prof. Denis Guttridge, Division of Cancer Genetics, The
Ohio State University, Columbus, OH, USA, who performed these analyses.
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Louis, MO, USA), and the 18.4 dystrophin rabbit pAb (carboxy specific; 1:50,000)
(Cox et al., 1994). For enzymatic deglycosylation and dephosphorylation analysis,
20pg of tissue lysate was treated with either N-glycosidase F (PNGase F) or y-
phosphatase (New England Biolabs, Ipswich, MA, USA) respectively, according to
the manufacturers' instructions.
2.8.2 PKR/ elF2cc study (Chapter 8)10
Muscle samples (approximately lOmg) were homogenised in 500ml of
PhosphoSafe™ Extraction Reagent (Merck Biosciences, Nottingham, UK), and
centrifuged at 15,000g for 15min. Samples of cytosolic protein (lOmg) were
resolved using 10% sodium dodecylsulphate polyacrylamide gel electrophoresis
(SDS-PAGE) (6% for eIF2a), and transferred to 0.45mm Hybond A nitrocellulose
membranes (Amersham Biosciences Ltd, Bucks, UK), which had been blocked
with 5% Marvel in Tris-buffered saline (pH 7.5) at 4°C for l-2h. Membranes were
then washed for 15min in 0.5% Tween-buffered saline or Tris-buffered saline
(TBS)-Tween. Antibodies were rabbit pAbs to phospho PKR (pThr 446; 1:1000)
(Insight Biotechnology, Wembley, UK) and total PKR (carboxy specific; 1:1000)
(New England Biolabs, Herts, UK), rabbit polyclonal antisera to total eIF2a
(1:1000) (Santa Cruz Biotechnology, CA, USA), rabbit polyclonal antisera to
phospho eIF2a (1:1000) (Abeam, Cambridge, UK), mouse mAb to MyHC II
(1:100) (Novocastra, Newcastle, UK), rabbit polyclonal antisera to actin (1:250)
(Sigma Aldridge, Dorset, UK), peroxidase-conjugated goat anti-rabbit Ab (1:1000)
10I acknowledge Dr. Helen Eley, Dr. Steven Russell and Prof. Michael, Tisdale, School of Life and
Health Sciences, Aston University, UK, who performed these analyses.
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and peroxidase-conjugated rabbit anti-mouse Ab (1:1000) (Dako Ltd, Cambridge,
UK). Incubation with primary antibodies was at 4°C overnight, except for total
eEF2a (l-2h at room temperature). Primary antibodies were washed off the
membranes for 15min (changing the wash every 5min), except for actin, which was
washed for 45min (changing the wash every 15 min). TBS-Tween (0.1%) was used
for washing phospho antibodies and total antibodies. Secondary antibodies were
used at a dilution of 1:1000, and were washed off after 45min. Development was by
enhanced chemiluminescence (ECL) (development kits from Amersham
Biosciences Ltd, Bucks, UK), and films were developed for 3-6min. Densitometry
was used to quantify differences in protein levels.
2.9 Mass spectrometry of urinary proteins
2.9.1 1D SDS-PAGE gel electrophoresis
Preliminary work with 2D gels of urinary proteins demonstrated a low level of
complexity compared to previous experience with plasma, serum and saliva; thus,
ID SDS-PAGE was used for initial separation (NuPAGE Novex 4-12% Bis-Tris
gradient gels, Invitrogen, Paisley, UK). In order to avoid potential 'masking' of
normal urinary proteins by novel species that may be highly prevalent in cancer
patient urine, equal volumes (rather than equal amounts) of precipitated protein
supernatant were loaded onto gels. Thirteen pL of protein sample were prepared
with 5pL of 4X SDS sample buffer and 2pL of 10X reducing agent. Gels were
loaded with low and high molecular weight markers (GE Healthcare UK Ltd, Little
Chalfont, UK) and stained with GelCode Blue (Pierce, Loughborough, UK). Using
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a clean scalpel, bands were excised in an identical fashion from each gel lane in
seven separate blocks (see Figure 9.1, p.326).
2.9.2 In-gel tryptic digestion
Gel blocks were incubated 3 times in 200mM NH4HCO3 in 50% acetonitrile (ACN)
at 30°C for 30min. Each block was incubated in 20mM DTT/200mM NH4HCO3 in
50% ACN at 30°C for lh to reduce the protein, followed by three washes in
200mM NH4HCO3 in 50% ACN. Cysteines were alkylated by incubation in 50mM
iodoacetamide/200mM NH4HCO3 in 50% ACN at room temperature for 20min in
the dark, followed by 3 further washes. Gel blocks were cut into pieces and
incubated with 100% ACN until white. Gel pieces were then air-dried before
incubation with 0.5pg trypsin (Promega, Southampton, UK) in 50mM NH4HCO3
for 16h.
2.9.3 Matrix-assisted laser desorption/ionisation mass spectrometry
Tryptic digests were sonicated for lOmin. Samples were passed through zip-tip
pipette tips (CI8 Zip-Tip, Millipore, Watford, UK) to reduce salt contamination.
Aliquots of the tryptic digests (0.5pL) were mixed with 0.5pL of lOmg/mL a-
cyano-4-hydroxycinnamic acid (CHCA) matrix, and analysed using a Voyager DE-
STR matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass
spectrometer (MS) (Applied Biosystems, Warrington, UK). Processed spectra were
searched against the Swissprot and National Center for Biotechnology Information
(NCBI) non-redundant databases using Protein Prospector MSFit and Mascot PMF
(Matrix Science, London, UK). Search parameters included a maximum of 1
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missed cleavage per peptide and a mass tolerance of 100 parts per million (ppm).
Proteins with a significant Molecular Weight Search (MOWSE) score (p<0.05) are
reported.
2.9.4 Liquid chromatography tandem mass spectrometry
Tryptic digests were sonicated for lOmin. Samples were passed through zip-tip
pipette tips (CI8 Zip-Tip, Millipore, Watford, UK) to reduce salt contamination.
For liquid chromatography tandem MS (LC-MS/MS), tryptic digests from gel
blocks were pooled into two groups by molecular weight (MW): MW <30kD and
MW >30kD. Pooled samples were spun through a 0.22pm filter (Millipore,
Watford, UK). One hundred pL of each pooled sample were loaded onto a PepMap
C18 column (3pm particle size, 75pm x 15cm) on a Famos/Swichos/Ultimate high
performance liquid chromatography (HPLC) system (Dionex, Camberley, Surrey,
UK) at a flow rate of 200nL/min. The column was equilibrated with solvent A
(0.1% formic acid) and eluted with a linear gradient from 0 to 70% solvent B (0.1%
formic acid in 100% ACN) over 45min. Flow was controlled by Chromeleon
software and interfaced to the LCQ deca MS (Thermo Electron, Auchtermuchty,
Fife, UK) with a PicoTip (FS-360-20-10-N-20-C12 DOM, New Objective,
Basingstoke, UK). Output was monitored at 214nm. Data dependent acquisition
was controlled by Xcalibur software, and database searching was achieved using
TurboSequest software and Mascot. Redundancy was avoided within the protein
counts by identifying the gene of origin of hypothetical and KIAA proteins
wherever possible.
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2.10 Assessment of physical activity
2.10.1 Accelerometer-based activity monitoring
Objective assessment of PA was performed using the activPAL™ PA meter
(dimensions: 35x53x7mm; mass: 20g; PAL Technologies Ltd, Glasgow, UK),
which uses a uni-axial accelerometer sampling at 10 hertz (Hz) to produce signals
reflecting thigh inclination and movement with offline algorithms to generate an
activity record on a second-by-second basis. A Universal Serial Bus (USB)
interface docking station connects the monitor to a Windows-based computer and
software package that classifies positions and activities into three categories: lying
or sitting, standing and stepping (Figure 2.3). Acceleration signals exceeding
particular peak acceleration amplitudes are registered as steps. Cadence and number
of steps taken describe the intensity and volume of activity. The software assigns
each activity an estimated energy cost in metabolic equivalents (METs) [524],
representing the ratio of the active to resting metabolic rate, which are then
summated over the assessment period to derive a value in MET.hrs that reflects
overall free-living EE. One MET is equivalent to lkcal/kg of body weight/hour
(BMR). Lying or sitting is assigned an energy cost of 1.25METs, quiet standing
1.4METs and walking at 120steps/min 4METs. EE of stepping is scaled linearly
according to the equation:
EE (in MET.hrs) = (1.4d) + (4-1.4) x (c/120) x d
where c = cadence (steps/min)
d = activity duration (hrs)
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By recording the duration and intensity of activity categories, the activPAL™
system summates estimated EE over the assessment period. Data extracted were
averaged over the length of a recording period to obtain average values per day. In
the case of step cadence, data were analysed by comparing median step cadence
during a recording period. To derive energy expenditure of activity (EEA), in the
validation study of Chapter 10 (EEAacUvpal), the number of METs awarded to
represent REE (i.e. 1.0 x 24 = 24METs/day) was subtracted from the total number
of METs/day, This definition of EEA includes dietary-induced thermogenesis and
non-exercise activity thermogenesis [525]. In Chapter 11 (in which 'EEA' is simply
used as a measure of global PA), the number of METs recorded for non-activity (i.e.
1.25 x 24 = 30METs/day) was subtracted from the total number of METs/day. In
all studies, an activPAL™ was attached to the subject's anterior mid-thigh with
adhesive dressings (Figure 2.4). Subjects were allowed to remove activPAL™
during water-related activities.
2.10.2 Indirect calorimetry assessment of resting energy expenditure
Following an overnight fast, subjects attended at 0800. Subjects rested in a supine
position for at least 30min before undergoing indirect calorimetry for 30min using a
ventilated hood technique (GEM; NutrEn Technology Ltd, Lanes, UK). This
system provides measurements of V02 and VC02 (L/min) with errors of less than
2.3% [526]. Measurements performed in the last 20 min were averaged to calculate
REE using the Weir equation [527]:
REE=[V02 (3.94)+ VC02 (1.11)] x 1440
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Figure 2.4 ActivPAL™ meter attached to a patient's anterior thigh.
The meter was attached in a sandwich of waterproof dressings. Firstly, a dressing
was applied to the thigh to protect the skin. A further dressing was then applied
over the meter to affix it in place. The patient was instructed how to remove and re¬
attach the meter, so that they could remove it for bathing, if desired. However, they
were also instructed to re-attach the meter as soon as the thigh had been towelled
dry.
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2.10.3 Doubly labelled water assessment of total energy expenditure
2.10.3.1 Preparation of doubly labelled water
2 18
H-H2O and 0-H20 doses were made from a common stock for the study which
was optimised for a body weight of 70kg and assuming 40kg TBW1'. Doses were
prepared from 10% l80-H20 and 100% 2H-H20 to give an initial enrichment of
125ppm excess in body water. Each dose was aliquotted into 125mL leakproof
wide neck polypropylene bottles (#2105-0004, Nalgene, Rochester, NY, USA) and
weighed to 4 decimal places (dp). All were within 1% of a target weight of 48g.
Doses were stored at -20°C until required. No weight loss on freezer storage was
observed. The final aliquot (or incomplete dose) was used to prepare a 500-fold
gravimetric dilution (O.lg in 50g, weighed to 4dp) with tap water. Aliquots of this
'diluted dose' and the local tap water were retained for analysis.
2.10.3.2 Doubly labelled water protocol
On day 0, subjects collected an aliquot of the second urine sample of the day in a
30mL universal container and recorded the time. The DLW was then consumed and
the bottle rinsed with tap water and the contents re-drunk to ensure that all DLW
had been ingested. The time, date and unique code of the ingested dose were
recorded. On days l, 2, 3, 7, 12, 13 and 14, aliquots of the second urine samples of
the day were collected and frozen at -20°C prior to analysis.
"i acknowledge Ms. Alexandra Small and Prof. Tom Preston, Scottish Universities Environmental
Research Center, The University of Glasgow, East Kilbride, UK, who prepared the DLW doses and
perfomed the MS analysis of the DLW urine samples.
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2.10.3.3 Deuterium and oxygen-18 analysis of urine samples
2H analysis was performed according to the method of Scrimgeour et al [528], as
described in Moses et al [277], with certain improvements". Each sample tube was
automatically overgassed with a lOOmL/min flow of 20% hydrogen in helium for
40s (Air Products Special Gases, Crewe, UK) on a 220-place manifold. 2H
abundance was measured by continuous flow isotope ratio MS (CF-IRMS) with
reference to working water standards, which had been calibrated against
international standards. To ensure temperature stability, tubes were equilibrated
beside this instrument within an air-conditioned instrument laboratory. After 2H
analysis, 180 analysis was performed according to the method of Prosser et al [529].
Samples were overgassed with a lOOmL/min flow of 3% CCb in nitrogen for 40s
(Air Products Special Gases, Crewe) on the 220-place manifold. Reference samples
(0 and 150ppm excess lsO) were prepared and analysed with each batch. Samples
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were left to equilibrate for 24h at ambient temperature. The abundance of O in
CO2 was measured by CF-IRMS and calculated according to the known abundance
of reference waters. For both 2H and l80 analyses, additional water samples were
2 18
included in each sample batch for quality control purposes. H and O adundances
of the independent quality control samples were typically within lppm and 0.5ppm,
respectively, of the accepted values.
2.10.3.4 Calculation of total energy expenditure
'Multipoint' calculations were used to derive turnover rates and initial enrichments
of each isotope, to estimate CO2 production and TBW, respectively". Schoeller's
equation for estimating TEE was used in the form given by Goran et al [530], A
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resampling procedure was used to estimate errors in TBW and TEE measurement
[531]. The precision of TBW analysis was 0.11kg (standard deviation [SD]). TEE
errors estimated by the resampling procedure averaged 3.1% (76.43kcal/d [SD
28.66]). Tracer elimination rate was normal (k0/ku =1.289, SD 0.051) and the
average 2H:180 distribution volume or pool space ratio was 1.0294 (SD 0.0123).
Predicted values for TEE were derived from predicted REE values [532] multiplied
by 1.5. This prediction derives from the lifestyle category defined as 'Seated work
with no option of moving around and little or no strenuous activity' given a PAL
range of 1.4-1.5 by Black et al [512], LBM was calculated from TBW data by
assuming a hydration factor of 0.732 [533]. Body fat was calculated by difference
(body weight - LBM). EEA was calculated from the formula:
EEA = TEE - REE
This definition of EEA also includes dietary-induced thermogenesis and non-
exercise activity thermogenesis [525], PAL was calculated from the formula:
PAL = TEE/REE
2.11 Questionnaires
2.11.1 Quality of life and physical functioning
During each activPAL™ recording period, subjects completed health-related QoL
and mood questionnaires (see Appendix III, p.485). The EORTC QLQ-C30
(version 3.0) questionnaire was used to assess functional, symptomatic and global
196
QoL scores [534-536]. The FAACT (version 4) and FACIT-Fatigue (FACIT-F)
(version 4) questionnaires were used to report anorexia/cachexia and fatigue scores
using the appropriate 'Trial Outcome Index' (TOI), which summates the scores for
physical well-being, functional well-being and the domain of interest (i.e.
anorexia/cachexia or fatigue) [537],
2.11.2 Mood
During each activPAL™ recording period, mood was assessed using the Hospital
Anxiety and Depression Scale (HADS) questionnaire (see Appendix III, p.485),
which provides symptom scores for both anxiety (HADS-A) and depression
(HADS-D) [538].
2.12 Statistical analysis
All statistical analyses were performed using Statistical Package for Social Services
(SPSS) version 13.0 or version 15.0 (Chicago, IL, USA). Specific details on
methods of data analysis for each study are found in the Results chapters. Statistical
significance was set at the p<0.05 level for all tests. Quoted p-values are two-tailed.
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Part B - Mediators of Muscle Wasting
in Cancer Cachexia
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Chapter 3 - Tumour-Derived Mediators I: Variation in
dermcidin expression (as a surrogate for PIF
expression) in a range of primary human tumours
and human cell lines
3.1 Introduction
Cachexia is considered the result of an interaction between tumour-derived and
host-derived mediators (Chapter 1.4). Part B focuses on the investigation of
tumour-derived mediators of muscle wasting, including PIF and MIC-1, and host-
derived mediators, including sex steroids. In Chapters 3 and 4, the expression of
DCD mRNA, as a proxy of PIF expression, is studied in human cell lines and
tumour samples.
DCD and its protein products have been investigated from a number of different
scientific angles and, consequently, they have received several different but
synonymous names. The DCD gene was identified on chromosome 12ql3.1 and
encodes different proteins with divergent biological functions (see Figure 1.6, p.72)
[194], The 110-amino acid DCD polypeptide [194] is identical to HCAP [197] and
DSEP [201], The protein products of the DCD peptide include the 47-amino acid
DCD-1 peptide (a skin antimicrobial) [194] and the 30-amino acid PIF-CP [206],
the latter of which is identical to Y-P30 [200], When glycosylated, PIF-CP is
reported to behave as a pro-cachectic factor in cancer [17], capable of inducing
skeletal muscle proteolysis in animal models [539] and cultured myotubes [540].
However, control of expression and post-translational processing of DCD into its
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various subunits (including PIF) has not yet been fully elucidated (see Figure 1.6,
p.72).
DCD acts as a survival factor in prostate cancer cells exposed to either hypoxia or
oxidative stress [541], and hepatoma cell lines subject to oxidative stress [206].
Porter et al determined that DCD expression in breast cancer cell lines was
associated with cancer cell growth and survival [195], As such, DCD has been
suggested as a candidate oncogene in breast cancer [195]. Cunningham et al studied
the role of oxidative stress in neuronal degeneration and identified a 30 amino acid
survival-promoting peptide, which they named Y-P30 [200]. The Y-P30 peptide
was present in medium conditioned by human retinoblastoma cells and a mouse
hippocampal cell line exposed to hydrogen peroxide. Y-P30 was subsequently
identified as comprising part of the 110-amino acid DSEP polypeptide (identical to
DCD) [201], DSEP-overexpressing neuronal cells were also found to have an
increased resistance to oxidative stress [201]. Thus, Y-P30 and PIF-CP represent
different names (and functions) for the same peptide. When non-glycosylated, the
peptide appears to behave as a tumour survival factor (Y-P30) [200], and when
glycosylated, it has been proposed as a pro-cachectic factor (PIF) [17]. However,
the existence of a functional human PIF has been called into question recently. The
previous studies focused on cancer cachexia have all employed a mAb that may not
be specific to PIF, and might also bind albumin and immunoglobulins [208].
Furthermore, using this mAb, PIF immunoreactivity was not associated specifically
with cancer, skeletal muscle wasting or survival [208]. Thus, there are no validated
or specific methods with which to prove conclusively the existence of a human PIF.
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As DCD appears to encode for both putative cachectic and tumour survival factors
(see Figure 1.6, p.72), it represents an important potential therapeutic target in
cancer patients. The expression of DCD mRNA has been used previously as a
proxy for PEF expression in studies of prostate cancer (DCD mRNA was detected in
most prostate cancer cell lines, primary prostate tumours and bony metastases)
[197]. Thus, the present study aimed to evaluate the expression of DCD mRNA (as
a surrogate of PIF-CP expression) using quantitative real-time PCR in a range of
malignant human tumours (specifically OGC, pancreatic, bile duct and prostate
cancer) and human cell lines (pancreatic cancer and prostate cancer cell lines).
Upper GI cancer types are associated significantly with the development of cancer
cachexia [4], whereas prostate cancer represents the first tumour type in which
DCD expression was analysed (although the prevalence of cachexia in prostate
cancer is lower than that seen in upper GI cancer) [197].
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3.2 Hypothesis
DCD mRNA is expressed at high levels in tissue samples from malignant human
tumours (including oesophageal, gastric, pancreatic/bile duct and prostate tumours)
and human cell lines (including pancreatic cell lines and some prostate cell lines),
but is not expressed by benign human tissue.
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3.3 Patients, healthy controls and cell lines
Upper GI cancer patients and healthy controls were recruited (see Methods Chapter
2.1, p. 167). Tissue samples were obtained from patients with oesophageal cancer
(n=28); gastric cancer (n=20); benign oesophago-gastric tissue (n=10); a range of
benign and malignant pancreatic/bile duct masses (n=5 pancreatic adenocarcinoma,
n=2 chronic pancreatitis, n=l cholangiocarcinoma, n=l liposarcoma, n=l adenoma,
and n=l cystadenoma); prostate cancer (n=8 Gleason six, n=31 Gleason seven, n=3
Gleason eight, n=6 Gleason nine, and n=4 Gleason ten); and BPH (n=16) (see
Methods Chapter 2.4.2 and 2.4.3, p. 174). Pancreatic (MIA-Pa-Ca-2 and CFPAC)
and prostate cancer cell lines (hormone-sensitive PC-3M and LNCaP; hormone-
insensitive PC-3 and DU145) were also included (see Methods Chapter 2.6.1,
p. 176). Quantitative DCD mRNA expression was analysed in tissue samples and
cell lines using real-time PCR (see Methods Chapter 2.7.3, p. 182). The Cj value of
DCD was used to classify its expression as: very high (Ct<25.5), high (>25.5 Cj
<30.5), moderate (>30.5 CT <35.5), low/absent (>35.5 Ct <40), or not
detected/below the limits of detection (CT = 40) [522]. PC-3M cells transfected
with the pcDNA3.1+DCD plasmid were used as a positive control (see Methods
Chapter 2.6.2, p. 178), and gave a Ct value of 23.1. Thus, the positive control was in
the very high range of DCD mRNA expression. All in vitro experiments were
performed in sextuplet and repeated three times.
3.4 Statistical analysis
Where appropriate, results were expressed as means.
203
3.5 Results
3.5.1 DCD expression levels in oesophageal and gastric tissue
samples
Table 3.1 details the DCD expression levels of all of the clinical tissue samples.
Nine (19%) of the 48 OGC samples displayed detectable levels of DCD expression
(Ct<40), including 4/28 (14%) oesophageal and 5/20 (25%) gastric tumours.
However, only 2/48 (4%) of the tumour samples produced a DCD CT value <35.5,
representing reliable moderate levels of DCD expression (2 gastric
adenocarcinomas with Ct values of 30.5 and 31.7, respectively). None of the 10
benign control samples demonstrated detectable levels of DCD mRNA.
3.5.2 DCD expression levels in pancreatic cell lines and tissue
samples
3.5.2.1 DCD mRNA expression in pancreatic cell lines
Both pancreatic cancer cell lines used in this study demonstrated DCD mRNA
expression. MIA-Pa-Ca-2 and CFPAC cell lines had Ct values of 35.1 and 37.6 (i.e.
moderate and low/absent levels of DCD mRNA expression), respectively.
3.5.2.2 DCD mRNA expression in pancreatic tissue samples
Of the pancreatic/bile duct tissue samples, 5/11 (45.5%) expressed DCD mRNA, 3
of which had Ct values 25.5-30.5, defined as high levels of expression (2 metastatic
pancreatic adenocarcinomas and 1 poorly differentiated cholangiocarcinoma).
Overall, 3/5 (60%) pancreatic adenocarcinoma samples had moderate or high levels
of DCD expression. The histopathology and CT values of pancreatic/bile duct tissue
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samples that expressed DCD mRNA are shown in Table 3.2.
3.5.3 DCD expression levels in prostate cancer cell lines and tissue
samples
3.5.3.1 DCD mRNA expression in prostate cancer cell lines
The prostate cancer cell lines that were investigated demonstrated only low or
absent levels of DCD expression. PC-3 had a Ct value of 36.7, LNCaP a Cj of 39.2
and DU145 a Ct of 39.6. PC-3M had a Cj value of 40.
3.5.3.2 DCD mRNA expression in prostate cancer tissue samples
None of the 68 prostate tissue samples, either benign or malignant, expressed DCD
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3.6 Discussion
The present study demonstrated a wide range of levels of DCD mRNA expression
across different cancer types, namely prostate, gastric, oesophageal, pancreatic and
bile duct cancer. DCD mRNA expression was undetectable in the primary prostate
cancer samples. In contrast, 60% of pancreatic cancer samples expressed significant
quantities of DCD mRNA. Additionally, the MLA-Pa-Ca-2 pancreatic cancer cell
line was the only cell line that reliably expressed borderline moderate levels of
DCD mRNA.
Assessment of 58 gastric and oesophageal biopsy samples showed that DCD
mRNA expression occurred in a small percentage of OGC and that expression
levels were minimal. (Only 2 (4%) OGC samples expressed moderate levels of
DCD mRNA). Thirty-three of the 48 (68.8%) gastric and oesophageal cancer
patients were weight-losing (median weight loss of the whole group = 3.5%; range
0.0-23.2), and are described in detail later in this thesis. However, the 9 OGC
patients with tumours that demonstrated any level of DCD expression did not have
significantly greater weight loss, lower BMI or higher CRP than those patients not
expressing DCD (data not shown). However, with such low numbers of DCD-
expressing tumours, it is difficult to make robust conclusions regarding differences
in patient characteristics between groups.
Some of the OGC samples utilised in this study have been included in previous
work published from the author's laboratory [542], Deans et al found a higher
percentage of PIF-CP mRNA-expressing OGC samples than in the present work.
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The previous analysis used the MIA-Pa-Ca-2 cell line as a positive control from
which to compare relative expression of DCD mRNA [542], In the present study,
MIA-Pa-Ca-2 was found to have a Ct value of 35.1, equating to borderline
moderate DCD expression. Due to the limited expression of this cell line, MIA-Pa-
Ca-2 was not chosen as a positive control in the present study. Thus, PIF-CP
expression may have been overestimated in the previous study due to comparison
with a control that has only a limited level of DCD mRNA expression. In the
current study, mRNA from PC-3M cells stably transfected with DCD was used to
confirm DCD mRNA expression for real time PCR. However, as DCD had been
artificially overexpressed in the PC-3M cell line, this was not an acceptable positive
control for use in a relative gene expression method of real-time data expression, as
it does not bear any relationship to the in vivo situation. Thus, Ct values and
DCD/18S rRNA ratios were used in this study to assess DCD mRNA expression.
Results from prostate tissue samples suggest that DCD was not expressed by
primary prostate cancer. Moreover, the immortalised prostate cell lines that did
express DCD, only did so at a very low/absent level. Other sources have suggested
previously that DCD is expressed by prostate cancer. In agreement with the data
presented above, Wang et al demonstrated DCD/HCAP mRNA expression in
prostate cancer cell lines other than PC-3M [197], However, Wang and co-workers
also identified DCD/HCAP mRNA in primary prostate cancer tumours and
secondary bone metastases, results that differ from those presented here. One
possible explanation for these differences is that Wang et al used RT-PCR rather
than real-time PCR, and thus Wang was only able to qualify DCD mRNA
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expression but was unable to quantify this as being of only negligible amount.
Another possible explanation is that, although the present study included a large
number of patient samples from five tumour types, plus benign tissue from some of
the affected organs, there were no samples taken from distant metastatic deposits,
which have been shown to express high levels of DCD in previous studies [197].
A further hypothesis underlying the lack of DCD mRNA expression in the prostate
cancer samples analysed in the present study is selective degradation of DCD
mRNA. A major control step in gene expression is the turnover of mRNA, a tightly
regulated process. Important cfv-acting elements controlling the half-life of mRNA
are adenylate- and uridylate-rich (AU-rich) elements (AREs) found in the 3'
untranslated regions (UTRs) of many unstable mRNAs [543]. AREs usually
contain repeats of AUUUA, and inclusion of AUUUA motifs within 3'UTRs of
mRNA may accelerate their decay. Dermcidin has one AUUUA pentamer within its
3'UTR (http://www.genomatix.de), which may make DCD mRNA more
susceptible to degradation. However, for destabilising proteins to form stable
complexes with ARE-containing mRNAs, many AUUUA pentamers are usually
required [543].
In this study, absolute Ct values were used to assess DCD mRNA expression. Due
to a drop off in the sensitivity of the instrument, CT values >35.5 are unreliable in
terms of the amount of mRNA expressed. Furthermore, the comparison of CT
values >35.5 is not reliable, as differences in Ct are unlikely to represent real or
meaningful differences in the amount of mRNA present. In primary tumour
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samples, which have a large degree of cellular heterogeneity, Cx values >35.5
mRNA represent low expression. Such CT values may reflect generally low
expression or there may be a subset of cells expressing an appreciable level of the
mRNA. However, in cell lines, where heterogeneity is not such an issue, a CT value
>35.5 means that mRNA may be absent or expressed at only a very low level on a
per cell basis.
For the current study, the presence of DCD was assessed using mRNA rather than
protein levels. A DCD mAb called G-81 is available. However, G-81 recognises the
carboxy-terminus of DCD-1 rather than full length DCD or PIF-CP/Y-P30 [544].
Polyclonal antibodies to DCD also exist, but, in the past, it has not been possible to
use these to identify successfully DCD or PIF-CP. PIF is also reported to exist in a
glycosylated form and is a putative factor in the increased muscle
proteolysis/decreased protein synthesis of cancer cachexia [545]. As the existing
mAb directed against PIF is not specific to glycosylated PIF alone but may also
recognise carbohydrate epitopes on other molecules [208], it was not used in the
present study. The rationale for using DCD mRNA expression as a proxy of PEF
expression is based on the facts that DCD/HCAP shares homology with murine PIF,
and that such a technique has been utilised previously. Further supportive evidence
for a role for DCD in cachexia comes from the observation that DCD has been
shown to induce lipolysis in normal mice via TNF-a-induced downregulation of
perilipin in adipose tissue [546]. However, at present, there is no conclusive
evidence that human PIF-CP is indeed a downstream proteolytic product of DCD.
If PIF-CP protein expression was to be confirmed in humans, it seems likely that
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differential proteolysis of DCD would be the underlying regulatory mechanism, as
the downstream sweat peptide products of DCD all appear to be proteolytic in
origin [547]. However, the subsequent glycosylation of PEF-CP to create a human
PIF with functional proteolytic action would still be in question.
In summary, the results presented here demonstrate that DCD mRNA expression
varied between tumour types and within primary tumours of the same type. The
substantial variability of DCD expression in primary tumours and cell lines
demands development of accurate and novel detection methods for the DCD/PIF
protein itself. The lack of such methods makes the evaluation of the role of
DCD/PIF in human tumour biology elusive. However, it would appear, based on
mRNA data that, the expression of DCD/PEF is very infrequent in OGC and
prostate cancer, but may be more prevalent in pancreaticobiliary tumours. Thus, if
PIF is a downstream product of DCD, PIF might account for some of the skeletal
muscle wasting associated with the latter tumours. It remains possible that even low
levels of DCD expression by a subset of cancer cells may be sufficient to promote
clonal cancer cell survival in an adverse environment and the subsequent induction
of a severe cachectic phenotype. As such, further studies of DCD expression in
human pancreatic cancer and the relationship with patient phenotype and outcome
may be the optimum way of taking the biology of human DCD forward, in the
absence of an accurate methodology for PIF detection.
This chapter utilised real-time PCR as the investigative method of choice for DCD
mRNA detection. In Chapter 4, RT-PCR is utilised instead, in order to generate
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cDNA that can be sequence analysed to investigate the potential for PIF
glycosylation.
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Chapter 4 - Tumour-Derived Mediators II: Sequence
analysis of the dermcidin gene for PIF glycosylation
sites in human cancer cell lines
4.1 Introduction
Using the PEF mAb, urinary PIF immunoreactivity has been reported in 80% of
patients with advanced pancreatic cancer [183] and in 56% of patients with
advanced OGC [208]. However, PIF immunoreactivity was not specific to cancer
patients and was not necessarily associated with clinical outcomes (e.g. weight loss,
skeletal muscle wasting or survival) [208], Furthermore, the PIF mAb has
demonstrated non-specific binding activity with other proteins [208], Thus,
controversy surrounds the role of PIF in human cancer cachexia.
Purified murine PIF is resistant to trypsin, has a mass of ~24kDa, and consists of a
short polypeptide core (3kDa), an A-linked sulphated oligosaccharide chain (-10
kDa), and an 0-linked sulphated oligosaccharide chain (-6 kDa) [203]. However,
the exact nature of the carbohydrate structures that confer the proteolysis-inducing
activity to this unusual molecule remain unresolved [203], The sites at which
glycosylation occurs to form the functional glycoprotein have not been established.
Furthermore, there are a number of outstanding questions related to the peptide core.
A peptide sequence and two patents describing the HCAP gene encoding PIF and
its putative peptide products have been published previously (Genebank accession
number AR053250) [197]. Whilst the sequence of the PIF-CP was novel at the time,
there have been several reports of other molecules encoded by the same gene (see
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Figure 1.6, p.72) [194, 201]. The organisation of the dermcidin gene should allow
discrete expression of molecules with various functions. However, the absence of
the A-glycosylation site seen in murine PIF (amino acids 13-15, Asn-Pro-Ser)
within the human sequence (Asn-Pro-Cys) has raised doubt as to whether the
human homologue can be glycosylated. It is worth noting that a serine/cysteine
substitution mutant of PIF protein transfected into and expressed in human
immortalised cell lines was not glycosylated [204],
It has been hypothesised that the presence of polymorphic or mutant species of
DCD/PIF mRNA may make glycosylation, and hence proteolytic activity, of the
resultant PIF possible within human tumours. In order to assess the likelihood that
the PIF-CP contained within DCD can be glycosylated in humans, the present study
aimed to use RT-PCR, followed by nucleotide sequencing of the resultant PCR
products, to investigate the presence or absence of DCD gene sequence variants in
human cancer cell lines, including pancreatic (CFPAC, PANC-1 and MLA-Pa-Ca-2),
hepatocellular (Hep G2 and Huh-7), prostatic (PC-3M, LNCaP, PC-3, DU145) and
malignant melanoma (G361) cell lines. Upper GI cancer cell lines were chosen as
these types of cancer are associated significantly with the development of cancer
cachexia [4], whereas prostate cancer represents the first tumour type in which
DCD mRNA expression was analysed [197], The malignant melanoma line G361
was chosen for investigation as it has been reported to produce a glycosylated
human homologue of PIF (based on PIF mAb immunoreactivity), which induces
skeletal muscle wasting in nude mice [198],
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4.2 Hypothesis
Human cancer cell lines express polymorphic or mutant species of DCD mRNA
that make glycosylation of the resultant PIF-CP possible.
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4.3 Cell lines
DCD mRNA expression was analysed in human cancer cell lines using RT-PCR
(see Methods Chapter 2.7.2, p. 179). Cell lines included were pancreatic (CFPAC,
PANC-1 and MIA-Pa-Ca-2), hepatocellular (Hep G2 and Huh-7), prostatic
(hormone-sensitive PC-3M and LNCaP; hormone-insensitive PC-3 and DU145),
and malignant melanoma (G361) cell lines (see Methods Chapter 2.6.1, p.176). PC-
3M cells transfected with the pcDNA3.1+DCD plasmid were used as a positive





4.5.1 Expression of DCD mRNA by human cancer cell lines
Compared with the positive control created by stably transfecting PC-3M cells with
a DCD-expressing vector, DCD mRNA expression was detected consistently in
multiple human cancer cell lines by RT-PCR. All of the results reported are from
cDNA specimens with confirmed expression of an appropriate housekeeping gene,
and two different sets of PCR primers (PIF and HCAP) used to identify DCD
mRNA. Subsequent PCR product nucleotide sequencing confirmed the identity of
the amplified products.
The PIF primers amplified a band of the appropriate size (174bp) in 8 of the 10
human cancer cell lines assessed, including PC-3, PC-3M, DU145, G-361, Hep G2,
CFPAC, PANC-1 and MLA-Pa-Ca-2 (Table 4.1 and Figure 4.1). A 174bp product
was not detected in LNCaP and Huh-7 cell lines using the PIF primers. HCAP
primers amplified a band of appropriate size (361bp) in 6 of the 10 cell lines,
including PC-3, PC-3M, DU145, Hep G2, CFPAC, and MIA-Pa-Ca-2 (very weak
band) (Table 4.1 and Figure 4.2). A 361bp product was not detected in G-361,
PANC-1, LNCaP and Huh-7 cell lines using the HCAP primers. Thus, in G-361 and
PANC-1 cell lines, an appropriately sized product could only be demonstrated by
the PIF primers and could not be confirmed by the HCAP primers. This finding
was consistent over 5 replications of the corresponding PCR reactions.
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Amplification of DCD nucleotide sequence
Cell line PIF primers HCAP primers




LNCaP X X X X
PC-3 v'
PC-3M S X
DU145 V V S X
G-361 V V X X
Hep G2 s V V X
Huh-7 X X X X









Table 4.1 Results of RT-PCR of immortalised human cell lines using PIF
and HCAP primers.
Three of the cell lines have been reported to be cachexia-inducing in
immunocompromised mice, namely G-361 (34), PC-3M (25), and DU145 (37).
Only LNCaP and Huh-7 cell lines demonstrated no evidence of DCD mRNA









Figure 4.1 RT-PCR of immortalised human cancer cell lines using PIF
(upper gel) and /? actin (lower gel) primers.
DCD cDNA product at 174bp. Bands were demonstrated for PC-3, PC-3M, DU145,
G-361, Hep G2, CFPAC, PANC-1 and MIA-Pa-Ca-2 at the same level as DCD
positive control. All products were identified as DCD cDNA on nucleotide
sequencing. P actin cDNA product at 535bp present for all cell lines.
220
Figure 4.2 RT-PCR of immortalised human cancer cell lines using HCAP
(upper gel) and MIC (lower gel) primers.
DCD cDNA product at 361 bp. Bands were demonstrated for PC-3, DU145, Hep G2,
PANC-1, MIA-Pa-Ca-2, PC-3M (not shown) and CFPAC (not shown) at the same
level as DCD positive control. P2-microglobulin cDNA product at 555bp present
for all cell lines.
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4.5.2 Nucleotide sequencing of PCR products
The 174bp and 361bp PCR products generated from the PIF and HCAP primers,
respectively, were sent for nucleotide sequencing to confirm their identity. DCD
cDNA was confirmed in products amplified by the PIF primers from PC-3, PC-3M,
DU145, G-361, Hep G2, CFPAC, and MIA-Pa-Ca-2 cells, as well as from the
prostate cell line PC-3 amplified with the HCAP primers. In all cases, the sequences
obtained were those of the appropriate sections of the DCD cDNA nucleotide
sequence that the primers were designed to amplify. Furthermore, in all cases, the
nucleotide sequences were identical, and they exactly matched that of DCD cDNA
(see Figure 2.1, p. 181, and Figure 2.2, p. 183). Moreover, the sequences all matched
exactly with the sequence obtained from RT-PCR of the DCD-PC-3M positive
control. The region of the DCD cDNA which corresponds to the PIF-CP cDNA
also had an identical sequence in all of the positive cell lines and positive control,
and it exactly matched the published sequence of the putative human homologue of
PIF [204], There were no polymorphic forms with mutations at the sites of the
putative PIF N- and 0-glycosylation sites, which would have made glycosylation
more likely to occur.
PANC-1 cells produced only a weak band using the PIF primers and it was not
possible to obtain a nucleotide sequence from the corresponding PCR product.
Similarly, the DCD nucleotide sequence was confirmed positively in only 1 of the 6
cell lines (namely, PC-3) in which the HCAP primers amplified a product. Reasons
for failure of sequencing might have included low cDNA concentration or
inappropriateness of the PCR primers for sequencing. The fact that the amplified
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products were of the correct size, and the fact that no other recognisable cDNA
sequences were identified in these products means that it is highly likely that they
did indeed represent DCD cDNA.
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4.6 Discussion
DCD mRNA was expressed by multiple immortalised human cancer cells, but there
were some minor differences from the previous results in Chapter 3, possibly due to
clonal variation within cell lines. For example, LNCaP, which demonstrated
marginal DCD mRNA expression on real-time PCR (CT of 39.2), did not
demonstrate expression with either the PIF or HCAP primers on RT-PCR, whereas
PC3-M, which did not demonstrate expression on real-time PCR (Cj of 40),
demonstrated expression with both the PIF and HCAP primers on RT-PCR.
However, in most cell lines, DCD cDNA was identified by both sets of primers
utilised. Sequencing of the PCR products was consistently possible only from the
PIF primers. However, all sequenced PCR products revealed a sequence identical
to that described as the potential human homologue of PIF [204], Importantly, both
primers encompassed the 90-nucleotide sequence of PEF-CP. These PCR results
indicate that production of both the 110 amino acid DCD polypeptide and the 30-
amino acid PIF-CP is possible from these cell lines. However, despite the
theoretical production of PDF mRNA by human cancer cells, there is no evidence
that the transcribed product is translated or that any ultimate protein is capable of
inducing muscle proteolysis. Furthermore, the results of Chapter 3 would imply that
any expression that does occur is at only a very low or unreliable level.
Glycosylation of the PIF-CP has been shown to be crucial for the increased muscle
proteolysis induced by PIF in mice [203] (i.e. the non-glycosylated peptide alone is
devoid of proteolytic activity). To date, there have not been any studies
demonstrating that a homologue of glycosylated PIF can be produced in human
224
cells. Indeed, Monitto et al were only able to detect an unglycosylated secreted
protein on stable forced expression of human PIF in multiple murine and human
cell lines [204], This group also found that tumour xenografts engineered to
overexpress human PIF protein did not induce cachexia in vivo [204],
Bioinformatic analysis has suggested that the human PIF-CP is unlikely to be found
in a glycosylated form, based on the predicted amino acid sequence [206],
Furthermore, in the present study, the lack of mutant or polymorphic species of
DCD cDNA with a higher chance of successful glycosylation means that the
existence of a functional human PIF remains doubtful.
In summary, based on the cumulative data from both Chapters 3 and 4, although
DCD may be expressed by a subset of pancreatic tumours, analysis of pancreatic
human cell lines suggests that the possibility of PIF glycosylation is unlikely. In
OGC and prostate cancer, expression of DCD mRNA (and, hence, presumably PIF)
is very low or, in most cases, absent. Thus, within upper GI cancer, a disease
commonly associated with cancer cachexia in humans, the role of PIF as a mediator
of skeletal muscle wasting should be viewed with caution.
In the next chapter, the area of investigation moves away from PIF to another
potential tumour-derived mediator of skeletal muscle wasting, MIC-1.
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Chapter 5 - Tumour-Derived Mediators III: Plasma
MIC-1 correlates with systemic inflammation but is
not an independent determinant of nutritional status
or survival in oesophago-gastric cancer
5.1 Introduction
Systemic inflammation has been linked with adverse survival in a variety of cancer
types [69, 78, 84], This association could be explained by a variety of tumour-
related phenomena including enhanced tumour progression [78], angiogenesis
[548], and metastasis [549]. However, the presence of systemic inflammation has
also been linked with both hypermetabolism [550] and reduced food intake [8], two
key components of the cachexia syndrome known to result in shortened survival in
patients with advanced malignancy [8],
The mechanisms whereby systemic inflammation arises in cancer patients are not
established clearly. One hypothesis is that interaction between host and tumour
cells within the tumour mass results in activation of TAMs [70] (see Chapter
1.4.1.1, p.44). The latter circulate to distant target organs where enhanced
cytokine/mediator production results in the generation of a systemic inflammatory
response. Target organs include the liver (production of acute phase proteins e.g.
CRP) [70], the brain (induction of anorexia) [551] and skeletal muscle (induction of
protein degradation and net amino-acid mobilisation) [225, 321], Increased pro¬
inflammatory cytokine release by PBMCs from patients with elevated plasma CRP
concentrations has been demonstrated previously [70]. The ability of such PBMCs
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to induce acute-phase protein production from co-cultured human hepatocytes
appeared to be IL-6-dependent [70]. In patients with OGC (where systemic
inflammation is associated with weight loss and shortened survival), it has been
shown previously that tumour IL-1 (3 overexpression and chronic inflammatory cell
infiltrate are independent factors influencing systemic inflammation [16]. However,
the precise role of various pro-inflammatory cytokines within human tumours in the
generation of a systemic response is still understood incompletely.
MIC-1 is a divergent member of the TGF-|3 superfamily that is produced by
macrophages in response to activation (see Chapter 1.7.1.5, p.87) [552]. MIC-1 is
not expressed in most human tissues at basal conditions (except the placenta) but is
expressed at high concentrations during inflammation and injury [553, 554], MIC-1
is overexpressed by malignant melanoma cells and is associated with
tumourigenicity [555]. High serum concentrations of MIC-1 have been observed in
patients with pancreatic [556, 557], gastric [558] and breast cancer [559], and have
been associated with adverse survival in colorectal cancer [560] and glioblastoma
[561]. In prostate cancer, high patient serum levels of MIC-1 have been associated
with increased disease stage [562], docetaxel resistance [563] and adverse survival
[564], In prostate cancer bone metastases, MIC-1 induced osteoclast activation
[565], In mice bearing human prostate cancer xenografts, elevated MIC-1
concentrations were associated with marked weight, fat and lean tissue loss that
was mediated by decreased food intake and was reversed by an antibody to MIC-1
[254], Additionally, normal mice administered systemic MIC-1, and transgenic
mice overexpressing MIC-1, demonstrated hypophagia and reduced body weight
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[254], In a small group of cachectic prostate cancer patients (n=26), serum MIC-1
concentrations were significantly associated with weight loss and weakly correlated
with serum IL-6 [254], Thus, a synthesis of the current data would suggest that
MIC-1 might play a role in the aetiology of systemic inflammation, whereas animal
data would imply a role in the induction of anorexia. The two roles are consistent,
as many pro-inflammatory cytokines are known to induce centrally an anorectic
state.
To determine whether MIC-1 is associated with human cachexia, this study aimed
to measure circulating concentrations of MIC-1 in a large cohort (n>250) of
patients with OGC, a disease strongly associated with cachexia, and to analyse the
relationships between MIC-1, systemic inflammation, nutritional status, food intake
and survival. MIC-1 was chosen as a mediator of interest, as it was believed
initially that MIC-1 might provide a crossover link between host-derived and
tumour-derived mediators within the host-tumour interaction (see Chapter 1.4.2,
p.51). This is because the published data, to date, would suggest that the cellular
source of MIC-1 might be either tumour cells and/or TAMs within the




Figure 5.1 The possible cellular origins of macrophage inhibitory cytokine-
1 within the tumour mass.
Within the tumour mass, macrophage inhibitory cytokine-1 (MIC-1) could be
secreted by either the tumour cells and/or host tumour-associated macrophages
(TAMs) activated as part of the host-tumour interaction.
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5.2 Hypothesis
Plasma MIC-1 levels are elevated in patients with OGC and are associated with
systemic inflammation, nutritional depletion, decreased food intake, and worsened
survival.
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5.3 Patients and healthy controls
Patients with a new histological diagnosis of OGC were recruited (n=293; 198
males and 95 females) (see Methods Chapter 2.1, p.167)12. Whole blood was taken
at diagnosis for plasma analysis of MIC-1 (see Methods Chapter 2.3.6, p.172) and
CRP concentration (see Methods Chapter 2.3.2, p. 170). In a subset of patients
(n=197), plasma albumin concentration was determined (see Methods Chapter 2.3.3,
p. 170) as well as CRP, and thus calculation of the systemic inflammation-based
score, the mGPS [566], was performed. Nutritional assessment was also performed
(see Methods Chapter 2.2, p. 168). In a subset of patients (n=188), dysphagia score
and subjective diet score were assessed (see Methods Chapter 2.2.6, p. 169) as
surrogate measures of food intake. The majority of patients (n=186) were followed
up until death.
Thirty-five (25 males, 10 females) control subjects, including laboratory and
hospital staff (n=28) and patients undergoing minor operative procedures for benign,
non-inflammatory conditions (n=7), were recruited for comparative MIC-1 analysis
(see Methods Chapter 2.1, p. 167). Median age was 29yrs (range 24-85).
5.4 Statistical analysis
Plasma MIC-1 data are presented as box plots. Mild outliers (MIC-1 concentration
more than 1.5 times the interquartile range [IQR] above the 3rd quartile/below the
1st quartile) are represented as circles and extreme outliers (MIC-1 concentration
more than 3 times the IQR above the 3rd quartile/below the 1st quartile) are
121 acknowledge Mr. Christopher Deans who recruited some of these patients.
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presented as stars. For visual clarity, the y-axes are limited to a maximum MIC-1
concentration of 5000 or 8000pg/ml. Differences between the distribution functions
of data for 3 or more subject groups were determined by Kruskal-Wallis test (KWT)
(displayed in text and figure legends). Subsequent analysis to determine differences
between any 2 groups was determined by Mann-Whitney test (MWT) (displayed on
figures). Correlation analysis was performed using non-parametric Spearman's
Rank Correlation Coefficient. Linear regression was used to investigate the
relationship between CRP and MIC-1. Significance levels for the explanatory
variables of interest were 0.10 to enter stepwise into the model. Survival analyses
were performed on those patients followed until death using univariate Kaplan-
Meier (KM) plots and a multivariate Cox Proportional Hazards Model. For
construction of the latter model, treatment regimen was defined as either surgery
with curative intent, radical chemo/radiotherapy with curative intent,




Demographics, nutritional status and plasma concentrations of inflammatory
mediators of the OGC patients (n=293) are shown in Table 5.1. OGC patients
exhibited a median weight loss of 6.4% (range 0.0-33.4%) (Table 5.1), and 34% of
patients had lost >10% body weight, consistent with significant cachexia.
Furthermore, median BMI, MAMC and TSF measures were lower than those
reported in healthy elderly populations [567], Forty two percent of patients (n=123)
exhibited plasma CRP concentrations >10mg/L consistent with the presence of an
APPR. Of those patients assessed, 29.9% (59/197) had a mGPS of 1 and 13.7%
(27/197) had a mGPS of 2.
5.5.2 Plasma MIC-1 concentrations are elevated in oesophago-gastric
cancer
Plasma MIC-1 was elevated in OGC patients (median 1371pg/mL; range 141-
39053) compared with controls (median 377pg/mL; range 141-3786) (p<0.001)
(Figure 5.2). Patients with gastric tumours (median 1592pg/mL; range 141-12643)
demonstrated higher MIC-1 concentrations than patients with gastro-oesophageal
junction (GOJ) (median 1337pg/mL; range 383-39053) and oesophageal tumours
(median 1180pg/mL; range 258-31184) (p=0.015) (Figure 5.3). Patients with
poorly-differentiated tumours (median 1480pg/mL; range 245-9000) demonstrated
higher MIC-1 concentrations than patients with moderately-differentiated (median
1103pg/mL; range 378-6646) and well-differentiated tumours (median 875pg/mL;






















Body Mass Index 24.6
(kg/m2) (13.9-46.7)
Weight Loss 6.4
(% loss of pre-morbid weight) (0.0-33.4)
Mid-Arm Muscle Circumference 23.8
(cm) (15.6-32.10)
Triceps Skinfold Thickness 12.0
(mm) (3.0-52.0)






Table 5.1 Demographics and plasma concentrations of inflammatory
mediators of the oesophago-gastric cancer patients.
Although the median body mass index lay within the normal range, 34% of patients



























Figure 5.2 Box plot demonstrating increased plasma MIC-1 concentration
in cancer patients compared with controls (p<0.001).






















Oesophageal Tumours GOJ Tumours Gastric Tumours
Figure 5.3 Box plot demonstrating increasing plasma MIC-1 concentration
with more distal situation of the primary tumour (p=0.015).
Circles and stars represent mild and extreme outliers, respectively.





























Figure 5.4 Box plot demonstrating increasing plasma MIC-1 concentration
with worsening tumour grade (p=0.010).
Circles represent mild outliers.
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increased with worsening disease stage (Figure 5.5) and increasing mGPS (Figure
5.6).
5.5.3 Relationship of MIC-1 with systemic inflammation and
nutritional status
Plasma MIC-1 concentration correlated positively with disease stage (r=0.217;
p<0.001), patient age (r=0.332; p<0.001), CRP (r=0.314; p<0.001) and mGPS
(r=0.336; p<0.001), and correlated inversely with KPS (r=-0.269; p<0.001) (Table
5.2). Plasma MIC-1 also correlated weakly with diet score (r=0.157; p=0.031), but
did not correlate with dysphagia score or any of the nutritional and anthropometric
parameters measured. However, there was a small but significant increase (18.9%)
in plasma MIC-1 between those patients who had lost >10% weight (median
1493pg/mL; range 258-31184) compared with those who had not (median
1256pg/mL; range 141-39053) (p=0.036). In contrast, CRP (r=0.247; p<0.001) and
mGPS (r=0.280; p<0.001) both correlated with weight loss, and mGPS also
correlated inversely with MAMC (r=-0.318; p<0.001), a measure of muscularity
(Table 5.2). Furthermore, there was a highly significant increase in CRP and mGPS
between those patients who had lost >10% weight compared with those who had
not (median CRP 16.5mg/L vs 6.0mg/L; median mGPS 1 vs 0) (p=0.001 for both
tests).
The relationship between MIC-1 and CRP was not linear, as a dot-plot




























Stage III Stage IV
Figure 5.5 Box plot demonstrating increasing plasma MIC-1 concentration
with worsening disease stage (p=0.002).
Circles represent mild outliers.
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Figure 5.6 Box plot demonstrating increasing plasma MIC-1 concentration
with increasing mGPS (pcO.OOl).
Circles and stars represent mild and extreme outliers, respectively.
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Figure 5.7 Dot plot of MIC-1 versus CRP (linear r2 = 0.059).
There was wide variance of plasma CRP in relation to increasing plasma MIC-1.
Assuming linearity, regression analysis demonstrated that plasma MIC-1 accounted
for only 5.9% of the variation in plasma MIC-1.
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assuming linearity, regression analysis demonstrated that MIC-1 accounted for
5.9% of the variation in plasma CRP (p<0.001). In a regression model of CRP
(incorporating MIC-1, disease stage, tumour grade, percentage weight loss, diet
score and KPS i.e. those factors found to correlate with CRP), plasma MIC-1
concentration (p=0.003), diet score (p=0.001), and tumour grade (p=0.033) were
significant determinants (r2=0.179) (Table 5.3). In a regression model of
percentage weight loss (incorporating disease stage, mGPS, diet score and
dysphagia score), all four factors were significant determinants (r =0.259) (Table
5.3). Plasma MIC-1 concentration did not qualify to enter the model.
5.5.4 Relationship of MIC-1 with survival
Patients with plasma MIC-1 concentrations in the upper quartile (>2270pg/mL)
demonstrated worsened survival (median 204d; 95%CI: 157-251) compared with
patients with MIC-1 concentrations in the lower 3 quartiles (median 316d; 95%CI:
259-373) (p=0.036; log rank test) (Figure 5.8). In a Cox Proportional Hazards
model (incorporating MIC-1, CRP, percentage weight loss, disease stage, tumour
grade, patient age, dysphagia score, diet score, and treatment regimen), disease
stage (p<0.001), treatment regimen (p=0.003), CRP (p=0.034), and percentage
weight loss (p=0.002), but not plasma MIC-1 concentration, were significant
determinants of survival (Table 5.4). Substitution of mGPS for CRP within the
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Figure 5.8 Kaplan-Meier curve of survival of oesophago-gastric cancer
patients according to plasma MIC-1 concentration.
Patients with MIC-1 concentrations in the upper quartile exhibited worsened
survival (median 204d; 95%CI: 157-251) compared with patients with MIC-1
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5.6 Discussion
The present study demonstrates that plasma MIC-1 concentrations are elevated in
OGC patients compared with controls. Furthermore, increasing plasma MIC-1
concentrations are associated with indicators of poor patient prognosis, including
tumour grade and stage. Elevated circulating concentrations of MIC-1 have also
been associated with poor prognostic indicators in other cancer types, including
prostate cancer [562, 564], colorectal cancer [560] and glioblastoma [561],
In the present study, plasma MIC-1 also correlated significantly with mGPS and
plasma CRP concentration suggesting that MIC-1 might play a role in the aetiology
of systemic inflammation in OGC (although linear regression implies that this may
be a minor effect). In previous studies of advanced prostate cancer patients and
same-sex twins, MIC-1 has been correlated with serum IL-6 concentration. IL-6 is a
key regulator of the hepatic APPR during cancer cachexia [70], and therefore MIC-
1-induced stimulation of IL-6 may be the underlying mechanism linking MIC-1 to
elevation in CRP levels.
Plasma MIC-1 concentrations did not correlate with any measured nutritional or
anthropometric parameters, including patient weight loss or measures of
muscularity, such as MAMC. In a recent cohort of 220 patients with OGC, it was
demonstrated by multiple regression analysis that plasma CRP, stage of disease and
dietary intake were independent variables in determining degree of weight loss
[515]. These results are confirmed by the present study. Given such importance of
systemic inflammation, disease stage and dietary intake in the genesis of weight
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loss in OGC patients, it is somewhat surprising that although MIC-1 concentrations
correlated with all three of these variables in the current study, there was no
correlation with weight loss. However, MIC-1 levels were slightly elevated in
patients with >10% weight loss compared with patients without, suggesting that
MIC-1 may play a role in the maintenance, rather than the initiation, of weight loss.
Studies in mice with xenografted prostate tumours have suggested that the
mechanism underlying MIC-1-induced weight loss is hypophagia caused by
reduced NPY expression and increased POMC expression in the hypothalamic
ARC [254], In patients with OGC, a number of primary and secondary causes of
reduced dietary intake are at work simultaneously, including dysphagia [568], early
satiety [569], chronic nausea [568], alterations in circulating neuroendocrine
hormones (e.g. ghrelin [570] and leptin [571, 572]), hypogeusia/hyposmia [232],
and cytokine-induced central anorexia [232, 573]. Assuming that MIC-1 may be a
modulator of appetite in humans (there was a weak correlation between plasma
MIC-1 with subjective diet score), the complex constellation of additional factors
also controlling food intake may explain why plasma MIC-1 concentrations did not
correlate with nutritional status in the present study. Future studies of MIC-1 that
record accurately calorific intake in OGC patients are required to elucidate the
anorectic effect of different factors.
Another proposed mechanism of MIC-1 induced weight loss is via paracrine effects
on adipocytes [574], Recombinant MIC-1 stimulates adiponectin secretion by
human adipocytes, thus potentially negatively regulating body fat mass [574],
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However, in the present study, MIC-1 did not correlate with a measure of adiposity,
namely TSF. Furthermore, previous studies have proven that the relationship
between MIC-1 and fat mass is clearly not understood fully, as both obesity and
Type II DM are associated with increased circulating levels of MIC-1 [575],
However, the latter observation might be consistent with a role for MIC-1 in the
aetiology of systemic inflammation.
An alternative hypothesis to explain the lack of association between plasma MIC-1
and nutritional status in OGC is that circulating MIC-1 concentrations are simply
not elevated sufficiently to overcome regulatory mechanisms and induce cachexia.
In patients with prostate cancer and cachexia, serum MIC-1 concentrations were
significantly higher (mean 12416 ± SD 10235pg/mL) [254] than those measured in
the present cohort of OGC patients. Furthermore, in mice xenografted with prostate
tumours overexpressing human MIC-1, only animals with serum concentrations
>8500pg/mL demonstrated clinically significant levels of weight loss [254]. Of the
OGC patients in the present study, only 5 (1.7%) demonstrated plasma
concentrations of MIC-1 >8500pg/mL. In these individuals, plasma CRP was also
elevated (median 58mg/L; range 16-92) but there was no significant reduction in
BMI (median 30.1kg/m2; range 21.7-32.0) or increase in weight loss (median 6.5%;
range 0.0-12.5) compared with the rest of the group. Reasons for low circulating
MIC-1 concentrations in OGC patients may include low levels of activation of
MIC-1 through p53-dependent mechanisms [576-578], as many oesophago-gastric
tumours demonstrate p53 deletion, mutation and loss of heterozygosity [579, 580],
In the present study, elevated plasma MIC-1 was associated with worsened survival
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on univariate but not multivariate analysis. This is in contrast to a recent study of
876 male subjects aged 35-80 years (selected from the Swedish Population
Registry) and a cohort of 324 same-sex twins (69% female) (selected from the
Swedish Twin Registry) that suggested that serum MIC-1 concentration can be
used as a marker of all-cause mortality, even when data were adjusted for age, BM1
and smoking history [581], However, importantly, even though cancer accounted
for 64 (23%) of the 276 deaths seen in these two cohorts, serum MIC-1
concentration did not correlate with BMI. Such findings may vary depending on the
definition of normal MIC-1 concentration employed. Other studies which have
analysed relatively large cohorts of healthy controls have suggested that the upper
limit of normal plasma MIC-1 concentration lies between 1070-1600pg/mL [556,
557, 560] i.e. lower than the definition employed in the present study. However, the
present data also suggest that plasma MIC-1 concentration may increase with
patient age, thus implying that the normal range is not static. A lack of age-matched
healthy controls could be considered a disadvantage of both previous studies and
the present.
The present study did not investigate the exact cellular source of MIC-1 within the
tumour mass. However, the variation in plasma MIC-1 concentrations
observed between different tumour types, grades and stages implicates a tumour
cell-specific mechanism in the induction of MIC-1 expression. Furthermore,
previous researchers have found that MIC-1 is produced by tumour cells, rather
than TAMs [253]. MIC-1 is often secreted in an unprocessed propeptide form
(proMIC-1) that regulates the balance between ECM stores and circulating mature
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MIC-1 [253]. The absence of propeptide in xenograft animal tumour models is
associated with a 20-fold increase in serum MIC-1 [253], In low-grade localised
prostate cancer, the level of proMIC-1 stromal stores was the best predictor of
future disease relapse compared with other clinicopathological variables [253].
Mechanisms surrounding the processing and extracellular storage of MIC-1 may
represent one explanation for the observed differences in plasma MIC-1 between
different tumour variables. Therefore, it seems likely that MIC-1 is secreted
predominantly by tumour cells. Further work targeted specifically at host
mononuclear cells is required if evidence of TAM production of MIC-1 is to be
proven. The distinct role of macrophages in tumor progression and suppression is
influenced by tumour microenvironment [41]. Thus, dependent on the nature of the
trigger, macrophage-secreted MIC-1 might play an important role in the host-
tumour microenvironment to decide the fate of the cancer.
In conclusion, although plasma MIC-1 correlates with tumour grade, disease stage,
dietary intake and systemic inflammation, it does not appear to mediate weight loss,
nutritional depletion or muscle wasting significantly in OGC. Thus, MIC-1 is
unlikely to be a useful biomarker of skeletal muscle wasting in clinical trials.
In Chapters 3 to 5, this thesis has concentrated on the investigation of possible
tumour-derived mediators of cachexia. MIC-1 was proposed initially, although not
proven, as a mediator that may cross the boundary between tumour-derived and
host-derived circulating mediators. In Chapter 6, attention turns away from tumour-
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derived mediators and focuses solely on the study of other host-derived circulating
mediators, namely sex steroids and gonadotropins.
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Chapter 6 Neuroendocrine Mediators: Interaction of
gonadal status with systemic inflammation and
opioid use in determining nutritional status and
prognosis in advanced pancreatic cancer
6.1 Introduction
Patients with advanced pancreatic cancer survive only 3-6 months and have a high
incidence of cachexia [582]. Epidemiological studies suggest that prognosis may be
worse for older men and younger women [582], Mechanisms underlying these
observations are unclear but may reflect interactions between pro-inflammatory
cytokines, sex hormones and nutritional status, all of which might be subject to
intervention, thus improving prognosis.
A key determinant of prognosis in pancreatic cancer is systemic inflammation [69],
a core component of the complex syndrome of cachexia [8]. Patients with
pancreatic cancer exhibit elevated circulating IL-6, TNF-a and sTNFR75 [518], and
pancreatic tumours demonstrate upregulation of IL-6 in association with systemic
inflammation [583].
Hypogonadism is common in elderly men (i.e. the age group most at risk of
pancreatic cancer), with an incidence of approximately 20% in males aged 60 to
80yrs old [584], Androgens are key anabolic regulators of skeletal muscle mass and
the relative lack of androgens in hypogonadal patients has been hypothesised as one
253
cause of age-related skeletal muscle atrophy [585]. Thus, within cancer cachexia,
hypogonadism is a possible contributor to muscle wasting [585], weight loss and,
potentially, accelerated demise. Male patients with metastatic malignancy,
including pancreatic cancer, demonstrate low circulating testosterone [101, 586].
Furthermore, such patients often receive opioid analgesia, an iatrogenic cause of
secondary hypogonadism [587]. One study of male cancer patients demonstrated
that plasma levels of free testosterone and bioavailable testosterone correlated
inversely with plasma IL-6 [586], suggesting a potential interplay between pro¬
inflammatory cytokines and the hypothalamic-pituitary-gonadal axis.
In female pancreatic cancer patients, elevated oestradiol concentrations have been
observed [588]. There exists a complex relationship between oestrogens and
systemic inflammation. For example, the exogenous use of oestrogens by healthy
post-menopausal women increases systemic inflammation [589]. Furthermore, pro¬
inflammatory cytokines stimulate aromatase activity in peripheral tissues (e.g. fat)
in post-menopausal women [590]. However, the association between oestradiol and
cytokines in female cancer patients has not been studied.
The aim of the present study was to investigate the interaction of circulating sex
steroid and gonadotropin levels with nutritional status, systemic inflammation and
survival in males and females with advanced pancreatic cancer. Furthermore, as a




Serum testosterone levels are reduced in male pancreatic cancer patients and are
reduced further by opioid use, whereas serum oestradiol levels are elevated in
female pancreatic cancer patients. Alterations in the levels of circulating sex
steroids are associated with nutritional depletion, systemic inflammation, and
worsened survival.
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6.3 Patients and healthy controls
Two hundred patients with histologically proven or a firm radiological or operative
diagnosis of unresectable pancreatic cancer (see Methods Chapter 2.1, p. 167), of
whom 176 had blood drawn for hormonal status (see Methods Chapter 2.3.4, p.171),
serum CRP concentration (see Methods Chapter 2.3.2, p. 170), serum albumin
concentration (see Methods Chapter 2.3.3, p. 170), and serum IL-6 and TNF-oc
concentrations (see Methods Chapter 2.3.5, p. 172), were recruited originally to a
multicentre, randomised trial comparing a protein and energy-dense nutritional
supplement enriched with n-3 fatty acids (EPA) and antioxidants with an isocaloric
isonitrogenous control supplement [406]13. Patients were included if they had lost
weight over the previous 6 months, had a KPS >60, and had a life expectancy
greater than 2 months. Patients were excluded if they had undergone surgery,
endoscopic stenting, radiotherapy, or chemotherapy during the previous 4 weeks, or
had other active medical conditions (e.g. major GI disease, CRF, uncontrolled DM,
HIV). At the time of study, no patient had gross ascites or oedema, jaundice,
pyrexia, severe anaemia, or clinical or radiological evidence of infection.
Nutritional assessment was performed (see Methods Chapter 2.2, p. 168) and LBM
was measured using BIA (see Methods Chapter 2.2.2, p. 168). Body composition
results have been published previously [406]. Median survival from enrolment was
130 days, with no significant difference between groups (experimental 142d vs
control 128d). Thus, for the purposes of survival analysis, treatment of patients
during follow-up can be considered uniform.
131 acknowledge Abbott Laboratories, Chicago, IL, USA, and the numerous investigators of the
Cancer Cachexia Study Group, who recruited these patients to the original randomised trial.
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In the present study, blood and nutritional parameters were measured prior to
nutritional supplementation. Premenopausal women (age <50yrs with serum
oestradiol >150pmol/L or FSH <30U/L) were excluded retrospectively (n=l).
Patients receiving glucocorticoids (n=7 patients receiving dexamethasone) or sex
hormones (n=l patient receiving medroxyprogesterone) were excluded. The final
study cohort therefore consisted of 167 patients (90 males and 77 post-menopausal
females). Four (2.3%) patients were taking thyroxine for hypothyroidism, and 26
(14.9%) were taking hypoglycaemics for the management of DM, of whom 17
(9.7%) were self-administering insulin. Most patients (n=147; 84.0%) were
followed until death. The remainder were followed until study completion (8 weeks)
or dropout [406].
Opioid use was defined as 'regular' or 'as required' controlled opioids, including
oral morphine sulphate, oxycodone, hydromorphone, or transdermal fentanyl patch.
Dihydrocodeine, a weak opioid, and tramadol, an atypical opioid that has limited
activity through the opioid receptor, were not analysed. Oral morphine-equivalence
per 24hrs was calculated according to standard conversion tables published in the
British National Formulary [591]. Twenty-two (88%) of the 25 opioid-using males
with pancreatic cancer received a regular daily dose plus an additional undefined,
'as required' dosage for breakthrough pain. The remaining 3 patients only took 'as
required' opioids. Thus, it was not possible to assess average total daily dosage due
to the variability in 'as required' opioid use. For the purposes of statistical analysis,
regular daily oral morphine-equivalent dose was used as the tested variable.
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Nineteen (10 males, 9 females) elderly, non-cancer control subjects were recruited
to support and verify hormonal analyses14 (see Methods Chapter 2.1, p. 167).
Median age (69yrs; range 56-86) was not different from the cancer patients
(p=0.697).
6.4 Statistical analysis
Data are presented as medians with ranges. MWT and Fisher's Exact test (FET)
were used to compare variables between different subject groups. Correlation
analysis was performed using non-parametric Spearman's Rank Correlation
Coefficient in an exploratory fashion and correction was not made for multiple
comparisons. When investigating any potential correlation between opioid use and
serum sex steroid/gonadotropin concentrations, regular daily oral morphine-
equivalent dose was used as the tested variable. Univariate analysis of variance
(ANOVA) was used to investigate the effect of covariates on dependent variables
and to establish effect size using partial eta-squared test (Levene's test for equality
of variance p>0.05). Survival analyses were performed using univariate KM plots
and multivariate Cox Proportional Hazards models.
141 acknowledge Mr. Alastair Moses who recruited these healthy controls.
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6.5 Results
6.5.1 Patient sex steroid and gonadotropin status
Demographics, disease characteristics and nutritional status of the cancer patients
(n=167) are shown in Table 6.1. All patients reported weight loss. Sex steroid,
gonadotropin, CRP and pro-inflammatory cytokine levels of cancer patients and
elderly controls are shown in Table 6.2. TT was reduced in male patients (median
12.4nmol/L; range 0.3-33.5) compared with male controls (median 16.9nmol/L;
range 8.3-27.2) (p=0.045). Using TT definition, 48% of male patients were
eugonadal, whereas 9% had early primary hypogonadism (normal TT and raised
LH), 2% had frank primary hypogonadism (low TT and raised LH), and 37% had
secondary hypogonadism (low TT and low/normal LH). Thus, 48% of male
patients were hypogonadal, compared with 30% of controls (NS). Using cFT
definition, 73% of male patients were hypogonadal compared with 40% of controls
(p=0.029).
SHBG was elevated in male patients (median 65.7nmol/L; range 11.7-335.0)
compared with controls (median 41.5nmol/L; range 23.0-93.0) (p=0.030). Similarly,
SHBG was elevated in female patients (median 89.5nmol/L; range 35.0-232.0)
compared with controls (median 49.0nmol/L; range 28.0-98.0) (p=0.001).
Oestradiol also demonstrated a trend towards elevation in female patients (median
75.0pmol/L; range 28.0-2070.0) compared with controls (median 58.0pmol/L;
range 36.0-133.0) (p=0.069). Eighteen percent of female patients exhibited




Age 67 69 0.080
(yrs) (43-94) (50-91)
Disease Stage





Weight 66.1 55.0 <0.001
(kg) (41.5-94.6) (32.7-86.0)
Body Mass Index 21.8 22.0 0.890
(kg/m2) (13.6-30.0) (13.6-33.2)
Lean Body Mass 49.5 36.6 <0.001
(kg) (35.6-64.1) (28.8-49.5)
% Weight Loss 15.1 16.5 0.269
(% loss of pre-morbid weight) (1.6-35.0) (4.7-40.1)
Grip Strength 33.0 19.0 <0.001
(kg) (10.0-50.0) (6.0-35.0)
CA19.9 734.0 655.0 0.601
(kU/L) (0.7-168100.0) (0.5-716000.0)
Table 6.1 Demographics, disease stage, nutritional status and tumour
marker status of the pancreatic cancer patients.
Although the median body mass index lay within the normal range for both sexes,
all patients reported weight loss compared with pre-illness weight. Data are
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Median LH and FSH levels did not differ significantly between cancer patients and
controls for either sex.
6.5.2 Systemic inflammation
In both sexes, CRP, IL-6 and sTNFR75 concentrations were higher in cancer
patients compared with controls (p<0.01) (Table 6.2). Forty nine percent (n=81) of
cancer patients exhibited an APPR (CRP >10mg/L) compared with none of the
controls (pcO.OOl).
6.5.3 Interactions between gonadal status, systemic inflammation
and nutritional status
In male patients, cFT correlated positively with BMI (r=0.349, pcO.OOl) and grip
strength (r=0.229, p=0.034), and correlated inversely with percentage weight loss
(r=-0.287, p=0.007), CRP (r=-0.426, pcO.OOl) and IL-6 (r=-0.303, p=0.004). Using
cFT definition, hypogonadal male patients demonstrated greater percentage weight
loss (16.7% vs 11.3%; p=0.007) and higher CRP (12.2mg/L vs 3.9mg/L; p=0.001),
IL-6 (8.2pg/mL vs 4.5pg/mL; p=0.015) and sTNFR75 (14.2pg/mL vs 11.6pg/mL;
p=0.034) compared with eugonadal patients, but did not differ significantly in age
(67yrs vs 66yrs; p=0.917) or disease stage (p=0.298). In univariate ANOVA
models of TT (r2=0.273) and cFT (r2=0.309) (incorporating CRP, opioid dosage,
BMI, LH, FSH, age and disease stage as covariates), CRP (TT: p=0.004, effect size
10.2%; cFT: p=0.007, effect size 9.0%), opioid dosage (TT: p=0.007, effect size
8.7%; cFT: p=0.009, effect size 8.6%) and BMI (cFT: p=0.005, effect size 9.7%)
were significant determinants.
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In female patients, the relationship between sex steroid and inflammatory mediator
levels was reversed. Oestradiol correlated positively with sTNFR75 (r=0.299,
p=0.008) and demonstrated a trend towards a positive correlation with CRP
(r=0.210, p=0.066) and IL-6 (r=0.193, p=0.091). Female patients with
high/premenopausal levels of oestradiol demonstrated higher CRP (28.9mg/L vs
9.0mg/L; p=0.010), IL-6 (lO.Opg/mL vs 4.6pg/mL; p=0.025) and sTNFR75
(18.6pg/mL vs 13.1pg/mL; p=0.040) compared with eugonadal patients, but did not
differ significantly in age (71yrs vs 69yrs; p=0.687) or disease stage (p=0.659). In a
univariate ANOVA model of oestradiol (r2=0.941), CRP was the only significant
determinant (p<0.001, effect size 67.9%).
SHBG correlated inversely with nutritional status in both sexes, and positively with
systemic inflammation in male patients. In this latter group, SHBG correlated
inversely with weight (r=-0.326, p=0.002), BMI (r=-0.261, p=0.013), LBM (r=-
0.220, p=0.047) and albumin (r=-0.309, p=0.004), and positively with IL-6
(r=0.285, p=0.007) and sTNFR75 (r=0.227, p=0.033). In female patients, SHBG
correlated inversely with weight (r=-0.233, p=0.042) and BMI (r=-0.234, p=0.041),
and positively with percentage weight loss (r=0.265, p=0.020) and IL-6 (r=0.231,
p=0.043).
6.5.4 Relationship between male hypogonadism or female
"hyperoestrogenism" and survival
Using KM analysis and TT definition, hypogonadal male patients demonstrated
worsened survival (median 75.Od; 95% confidence interval [CI] 57.3-92.8)
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compared with eugonadal male patients (median 140.0d; 95%CI 95.9-184.1)
(p<0.001, log rank test) (Figure 6.1). Similarly, using cFT definition, hypogonadal
male patients demonstrated worsened survival (median 83.Od; 95%CI 66.9-99.1)
compared with eugonadal male patients (median 153.0d; 95%CI 60.5-245.5)
(p=0.005) (Figure 6.2).
As expected, presence of an APPR was also associated with worsened survival
(p=0.013). When hypogonadism, presence of an APPR, percentage weight loss,
disease stage and patient age were used as variables in a Cox proportional hazards
model, the hazards ratio (FIR) of death associated with male hypogonadism using
TT definition was 2.87 (95%CI 1.73-4.75; p<0.001), and using cFT definition was
2.26 (95%CI 1.21-4.24; p=0.011).
Female patients with elevated/premenopausal serum levels of oestradiol
demonstrated worsened survival (median 52.0d; 95%CI 29.9-74.1) compared with
female patients who had normal post-menopausal levels of oestradiol (median
163.Od; 95%CI 114.8-211.2) (p=0.020) (Figure 6.3). When hyperoestrogenism,
presence of an APPR, percentage weight loss, disease stage and patient age were
used as variables in a Cox proportional hazards model, the HR of death associated
with elevated oestradiol was 2.43 (95%CI 1.21-4.88; p=0.013).
6.5.5 Effect of medication use on gonadal status and male patient
survival
Sex hormone and inflammatory mediator levels of patients according to opioid use
264
•Hypogonadal males (TT definition)












Figure 6.1 Kaplan-Meier curve of survival of hypogonadal (TT definition)
male pancreatic cancer patients.
Male pancreatic cancer patients with hypogonadism by TT definition demonstrated
worsened survival (median 75.Od; 95%CI 57.3-92.8) compared with eugonadal
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Figure 6.2 Kaplan-Meier curve of survival of hypogonadal (cFT definition)
male pancreatic cancer patients.
Male pancreatic cancer patients with hypogonadism by cFT definition
demonstrated worsened survival (median 83.Od; 95%CI 66.9-99.1) compared with
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Figure 6.3 Kaplan-Meier curve of survival of hyperoestrogenal female
pancreatic cancer patients.
Female pancreatic cancer patients with high/premenopausal serum levels of
oestradiol (>150pmol/L) demonstrated worsened survival (median 52.Od; 95%CI
29.9 -74.1) compared with female patients who had postmenopausal levels of
oestradiol (<150pmol/L) (median 163.0d; 95%CI 114.8-211.2) (p=0.020, log rank
test).
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are shown in Table 6.3. Twenty-five male (28%) and 18 female (23%) patients used
opioids with regular median morphine-equivalence dosages of 80mg (range 0-700)
in males and 40mg (range 10-360) in females. Opioid-using males did not differ
from non opioid-using males in regard to disease stage or age, whereas opioid-
using females exhibited higher disease stage (median stage 4 vs 2; p=0.009) and
were younger (median age 63yrs vs 70yrs; p=0.014). Nutritional variables did not
differ between opioid-using and non opioid-using patients of either sex.
In both sexes, opioid use was associated with reduced LH (p<0.05) and FSH
(p<0.05), and elevated CRP (p<0.05). Furthermore, in males, opioids were
associated with a significant reduction in TT (p<0.001) and cFT (p<0.001). Daily
opioid dosage correlated inversely with TT (r=-0.494; p<0.001), cFT (r=-0.510;
p<0.001) and LH (r=-0.259; p=0.014), and positively with CRP (r=0.216; p=0.041)
and IL-6 (r=0.220; p=0.037). On KM analysis, survival was shorter in opioid-using
male patients (median 78.Od; 95%CI 59.7-96.3) compared with non-opioid-users
(median 132.Od; 95%CI 112.8-151.2) (p=0.009) (Figure 6.4). When opioid use,
presence of an APPR, percentage weight loss, disease stage and patient age were
used as variables in a Cox proportional hazards model, the HR of death associated
with opioid use in male patients was 1.96 (95%CI 1.16-3.31; p=0.012).
Regarding hormonal medications, insulin and thyroxine use did not affect




































































































Figure 6.4 Kaplan-Meier curve of survival of male pancreatic cancer
patients according to opioid use.
Male pancreatic cancer patients using opioids demonstrated worsened survival
(median 78.Od; 95%CI 59.7-96.3) compared with male patients who did not
(median 132.0d; 95%CI 112.8-151.2) (p=0.009, log rank test).
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6.6 Discussion
The present study represents one of the first descriptions of the interaction between
hormonal status and systemic inflammation in patients with advanced cancer (non-
prostate), and, importantly, the first description of the effects of this interaction on
survival. The majority of male patients with unresectable pancreatic cancer were
hypogonadal (cFT definition). In contrast, 18% of postmenopausal female patients
demonstrated elevated serum oestradiol. Male hypogonadism and female
'hyperoestrogenism' were associated with shortened survival.
Although elevated oestradiol has been documented previously in females with
pancreatic cancer [588], the role of androgens in male cancer patients has been
studied more widely [101, 178, 586]. Studies of testosterone in this latter group
have yielded variable results. Some reports have found both low TT and low cFT
[101], whereas others have demonstrated TT similar to controls, and have required
measures of cFT and bioavailable testosterone to demonstrate hypogonadism,
prompting the conclusion that measures of testosterone bioavailability should
always be used [586], In another study, TT was reduced but cFT was similar to
controls [592]. However, many investigations have considered heterogeneous
populations of different cancer types [101, 178, 586], whereas the present study has
the advantage of a single type.
The present data indicate an interaction between sex steroids and systemic
inflammation such that, in males, TT and cFT correlated inversely with
inflammatory mediators (particularly CRP and IL-6) whereas, in females, oestradiol
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correlated positively with inflammatory mediators (particularly sTNFR75) (Figure
3.5). Furthermore, CRP remained an independent determinant of TT, cFT and
oestradiol levels. These interactions appeared to occur outwith the influence of
disease stage, as neither circulating levels of inflammatory mediators nor sex
steroids correlated with stage. It has been hypothesised that, in men, pro¬
inflammatory cytokines act directly on the testicles to suppress testosterone [586],
Studies of IL-6 [593] and TNF-a [594] administration to healthy men have
demonstrated similar suppression. In postmenopausal women, most oestradiol
production is extragonadal. Pro-inflammatory cytokines stimulate aromatase
activity in women, thus increasing oestradiol production [590]. Therefore, in the
present study, the effects of cytokines are seen independent of ovarian function.
Elevated SHBG has been noted previously in male pancreatic cancer patients [586],
SHBG has an increased affinity for androgens and an elevation in serum level will
reduce male cFT, but have minimal impact on female bioavailable oestradiol. It has
been hypothesised that SHBG may be a positive acute phase reactant [586]. The
present study would support this hypothesis in males as almost half of male patients
exhibited an APPR, and SHBG correlated with circulating levels of inflammatory
mediators. However, the elevation of SHBG in the presence of systemic
inflammation may represent a cancer-specific phenomenon, as neither IL-6 nor
TNF-a administered to healthy males affected SHBG levels, even though TT was
decreased [593, 594], In females, SHBG, although elevated, did not correlate with
pro-inflammatory mediators. Mechanisms of SHBG elevation in females may
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involve indirect effects of altered body mass [595] or a direct effect of oestradiol
[590],
Mechanisms by which disturbances in sex steroid levels translate into accelerated
demise are not known. Such disturbances might simply represent markers of
systemic inflammation [596]. Alternatively, in hypogonadal males, the reduced
anabolic stimulus to skeletal muscle by testosterone might drive wasting, thus
reducing patient nutritional reserve and performance. The positive association of
cFT with both BMI and grip strength in the present study would support this
hypothesis. Initially, the observed correlation between BMI and cFT may appear at
odds with previous studies that have found an inverse relationship between BMI
and testosterone levels. However, many of the previous studies have focused on
patients within the overweight or obese BMI ranges [597], whereas the present
study features a weight-losing male cohort with a median BMI within the healthy
range. The present study is in accordance with other reports that have documented
low testosterone levels in anorectic males [598], and high testosterone levels in
obese patients with prostate cancer [599]. Thus, hypogonadism could represent an
important mechanism of weight loss. However, the iatrogenic induction of
hypogonadism in males with prostate cancer only results in loss of LBM at a rate of
2% per 6 months [600]. The short survival duration of pancreatic cancer patients
(average 6 months) makes it unlikely that the muscle-wasting effects of
hypogonadism alone would be the primary contributor to accelerated demise.
Rather, it is likely that hypogonadism is an overall frailty index and that the former
interacts with other factors to result in cachexia. These data support the
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development of a trial of testosterone treatment in hypogonadal men with advanced
pancreatic cancer. However, pancreas is a sex steroid-dependent tissue [601-603]
and therefore it is unclear how the primary cancer may respond to supplemental
testosterone. Initial studies using flutamide, an anti-androgen, for the treatment of
pancreatic cancer were encouraging [604], However, follow-on studies [605] and
trials of gonadotropin-releasing hormone (GnRH) analogues [606] demonstrated no
impact on survival. Trials yielding tamoxifen, an oestrogen receptor modulator,
either as a single agent therapy or in conjunction with other agents, have also
yielded variable results [607-610],
Compared with the proposed mechanisms underlying male hypogonadism and poor
prognosis, it is even less clear how elevated oestradiol might adversely affect
female nutrition and survival. Post-menopausal loss of oestradiol is considered to
be one of the main causes of sarcopenia in women [611]. In the present study,
hyperoestrogenal females did not differ from eugonadal females with regard to
weight loss, BMI or LBM. Presumably, the interaction between oestradiol and pro¬
inflammatory mediators remains the key mechanism of worsened survival.
Opioid use is known to induce secondary hypogonadism [587]. Twenty-seven
percent of patients in the present study were using opioids, and in males, opioid use
was associated with reductions in gonadotropins, TT and cFT in a dose-dependent
fashion. Furthermore, opioid use was an independent determinant of testosterone
levels and an adverse prognostic factor in male patients, a finding that has perhaps
not been fully appreciated in the literature previously [612]. Although LH and FSH
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were also reduced in post-menopausal females using opioids, oestradiol synthesis
appeared unaffected, presumably reflecting the high extragonadal contribution to
oestradiol production. Opioid-using females were younger than their non-using
counterparts but the reason why this should be remains unclear.
It is difficult to tease apart cause and effect when considering opioid requirement,
uncontrolled pain and patient prognosis. Previous studies have shown pain at
diagnosis to be an independent poor prognostic factor in pancreatic cancer [582],
suggesting that the host inflammatory response [613], pain-induced stress response
or the pattern of tumour invasion might underlie any detrimental response to
opioids. In the present study, opioids were associated with an elevated CRP but not
necessarily increased disease stage, an observation that could be consistent with
either pain-induced stress or an indirect effect of disturbed sex steroids. Thus, the
question remains as to whether shortened male survival associated with opioid use
is a direct result of the medication or simply a reflection of the fact that opioids are
often administered to frailer, hypogonadal patients with stronger systemic
inflammatory responses. Previous studies of end-of-life hospice patients have found
that increased opioid dosage was associated with reduced time until death, but that
this factor explained only very little of the variation in survival [614], However, the
mean survival duration of these hospice patients was only 12 days (compared with
135 days in the present study), and thus study time may have been insufficiently
long to assess the inflammatory and muscle wasting effects of opioids over
extended time periods. Certainly, the prognostic implications of opioid use would
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appear to warrant further investigation, and confirmation of these findings in larger
patient groups is needed.
Opioids are clearly of symptomatic benefit to patients with advanced cancer, and so
it would be inadvisable to omit them. However, based on the current results, it
might be useful to monitor serum gonadotropin levels during opioid use and
consider testosterone replacement. Furthermore, non-steroidal anti-inflammatory
medications, in combination with androgen replacement therapy, could be used as
important co-analgesics with opioid-sparing and life-prolonging effects in
hypogonadal males with advanced pancreatic cancer. Clinical trials of such
treatment approaches are required.
Limitations of the present study include the fact that gonadal and inflammatory
status were assessed on only a single blood test, and that only a small number of
controls were recruited. However, it is unlikely that a larger number of controls
would have altered the conclusions significantly as median control results lay
within the normal range.
In summary, elderly hypogonadal males and "hyperoestrogenic" females with
advanced pancreatic cancer appear to be at particular risk of accelerated demise.
Although systemic inflammation may contribute to gonadal dysfunction, it remains
an independent prognostic indicator. Systemic inflammation in both sexes and
hypogonadism in males are likely contributors to the cachexia that affects most
patients with progressive disease. Within the context of multimodal supportive care,
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this study supports trials of anti-inflammatory/androgen replacement therapy
(particularly when combined with opioid analgesia) in males, but a different
strategy involving anti-inflammatory therapy in females. Furthermore, this study
also supports the use of serum sex steroids as biomarkers of cachexia in pancreatic
cancer patients (namely, cFT/TT in males and oestradiol in females), and the use of
sex steroid abnormalities as targeting strategies for treatment.
In Part B, possible mediators of muscle wasting and cancer cachexia, including PIF,
MIC-1 and sex steroids, have been investigated. Of all of these mediator candidates,
only sex steroids have demonstrated robust evidence of a role in cancer-associated
wasting. In Part C, rather than human cell lines, tumour samples and patient blood
being the tissues of investigation, attention turns to the investigation of skeletal
muscle samples from weight-losing cancer patients, in order to elucidate
intracellular mechanisms of muscle wasting.
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Part C - Mechanisms of Muscle Wasting
in Cancer Cachexia
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Chapter 7 - Dystrophin glycoprotein complex
dysfunction: a regulatory link between muscular
dystrophy and cancer cachexia
7.1 Introduction
Part C focuses on the investigation of molecular mechanisms of skeletal muscle
wasting in cancer cachexia. In this chapter, the results of an international
collaborative study of DGC deregulation in murine and human cancer cachexia are
described. This is the first occasion in which DGC deregulation has been
investigated in cancer-associated muscle wasting. The results of murine DGC
studies are summarised in the Introduction, followed by an analysis of human
cachectic muscle samples in the Results section.
In muscle biopsies from cancer patients, wasting is thought to occur from the
selective atrophy of type II fibres [321]. Acharyya el al demonstrated that muscles
from C-26 mice recapitulated faithfully the clinical features of human cancer-
induced muscle wasting [321]. Muscles from such mice were severely atrophic,
exhibiting 45% reduction in mean fibre diameter. In addition, atrophic fibres were
selectively type II in origin. Upon close histological examination, alterations in
membrane structure were also apparent. As compared to the smooth and well-
defined membranes bordering each myofibre in control muscles, membranes in
cachectic murine muscles appeared wrinkled and irregular. This phenotype was
confirmed by electron microscopy and laminin staining, giving an early indication
that sarcolemma and the associated basal lamina from cachectic muscles were
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abnormal. Evans blue dye (EBD) uptake was then used to measure membrane
integrity. EBD is normally membrane impermeable, but in damaged myofibres this
dye penetrates the sarcolemma and accumulates in the cytoplasm [615]. Tumour-
bearing mice injected with EBD revealed visibly higher muscle uptake of the dye
compared with control mice. Serum CK can also be used as an indicator of
weakened membranes [312]. However, in C-26 mice, CK levels were only elevated
moderately over that of controls [321], indicating that although tumour burden
causes alterations to muscle membranes or associated basal lamina, the severity of
damage is not sufficient to cause a complete permeation of EBD or release of
intracellular proteins.
The DGC is a large, membrane-bound, multi-protein structure that forms a strong
mechanical link between the cytoskeleton and the ECM, and which plays a major
role in regulating membrane integrity [317]. In light of the abnormal membrane
morphology seen in the muscles of tumour-bearing mice, it was hypothesised that
the DGC might also be involved in the regulation of cancer cachexia. Acharyya et
al therefore examined the expression and potential regulation of the DGC core
member, dystrophin [321]. Western analysis revealed that dystrophin was reduced
in muscles from tumour-bearing mice at a time that preceded reductions in mean
fibre diameter. In DMD, loss of dystrophin is often associated with compensatory
upregulation of its autosomal homologue utrophin [616], Muscles from tumour-
bearing mice also showed similar induction of utrophin. Conditions where
dystrophin expression is lost, such as muscular dystrophies or enterovirus-mediated
cardiomyopathy, result typically in the concurrent downregulation of other DGC
280
members [312, 617]. Acharrya et al demonstrated that this was not the case in
murine cancer cachexia, as expression of other DGC members, including a-DG, P-
DG, a-sarcoglycan (a-SG), P-SG, 5-SG and dysferlin, was unaltered [321],
However, detected prominently was the presence of a higher migrating band for
both P-DG and P-SG proteins. Aberrant post-translational glycosylation of
dystroglycan proteins is known to occur in various disease states [618-620].
Treatment of cachectic muscle lysate with PNGase F not only caused decreases in
the MW of the basally glycosylated forms of P-DG and P-SG, but also resulted in
almost a complete disappearance of the higher migrating bands, with concomitant
increases in endogenous protein [321]. These results suggested that the higher
bands represented hyperglycosylated forms of these DGC proteins. No alterations
were detected in other glycosylated DGC members (namely, a-SG and 8-SG) or
non-DGC glycosylated proteins, such as pi subunit of ATPase and neural cell
adhesion molecule (NCAM). In summary, muscles from C-26 mice demonstrated
reduced dystrophin expression, hyperglycosylation of P-DG, and
hyperglycosylation of P-SG, a triad of alterations that has been termed 'DGC
deregulation'. Subsequent laser capture microdissection (LCM) confirmed a higher
intensity of DGC deregulation in cachectic fibres (diameter <30|im) and type II
fibres [321]. Furthermore, DGC deregulation was also demonstrated in mice
bearing LLC tumours.
To understand the functional relevance of DGC regulation, Acharyya et al assessed
binding interactions between DGC proteins [321]. In the DGC, a-DG serves as a
receptor binding laminin-2 in the ECM [317]. Using ligand overlay assays, a
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significant reduction in laminin-a-DG binding was observed in C-26 cachectic
muscles. Furthermore, co-immunoprecipitation analysis revealed pronounced
decreases in interactions between a-DG and P-DG, and between P-DG and
dystrophin.
To establish firmly the contribution of DGC deregulation to murine cancer cachexia,
C-26 and LLC tumours were administered to mdx mice, which have a mutation that
codes for a premature stop codon in the X-linked dystrophin gene [621], resulting
in the loss of dystrophin and associated DGC proteins [622]. Although the mdx
pathology resembles the early phases of DMD, relatively little muscle loss actually
occurs in these mice due to the high rate of muscle regeneration and hypertrophy in
response to the ongoing cycles of degeneration [312], Muscle loss was accentuated
in tumour-bearing mdx mice compared to tumour-bearing wild type littermates
[321], Importantly, fibre membranes from mdx mice alone were visibly irregular,
and DGC proteins were also glycosylated aberrantly, suggesting that loss of
dystrophin leads to P-DG and P-SG alterations. In contrast, transgenic mice
expressing a dystrophin minigene in skeletal muscle (A17-48) [623] demonstrated
little to no decrease in muscle mass or fibre diameter following tumour inoculation.
Muscles from A17-48 tumour mice were also spared of membrane abnormalities,
and showed restored DGC interactions. Furthermore, tumour-bearing wild type
mice exhibited a 30% reduction in hindlimb grip strength, while no differences
were observed between control and dystrophin transgenic mice [321], Taken
together, these results argued that DGC restoration could both structurally and
functionally block tumour-induced muscle changes.
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In order to determine whether DGC deregulation also occurs in human cancer
cachexia, the present study aimed to examine the expression levels and
glycosylation status of DGC members (namely, dystrophin, 0-DG and p-SG) in
skeletal muscle of patients with OGC and varying degrees of weight loss, in
comparison with healthy, weight-stable subjects undergoing minor elective surgery.
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7.2 Hypothesis
Skeletal muscle from weight-losing cancer patients demonstrates DGC deregulation
(namely, reduction in dystrophin expression, hyperglycosylation of (3-DG, and
hyperglycosylation of (3-SG) compared with weight-stable patients and healthy
controls. The presence of DGC deregulation is associated with nutritional depletion,
systemic inflammation and worsened survival.
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7.3 Patients and healthy controls
Patients with newly diagnosed OGC and varying degrees of weight loss undergoing
surgical resection with curative intent (n=27) were recruited (see Methods Chapter
2.1, p. 167). Rectus abdominis muscle samples were obtained (see Methods Chapter
2.4.1, p. 173) and plasma CRP concentration was measured (see Methods Chapter
2.3.2, p. 173). Patients were followed up and underwent sequential nutritional
assessment (see Methods Chapter 2.2, p. 168). Ten patients (37.0%) died during
follow-up. Patients undergoing minor operative procedures for benign, non¬
inflammatory conditions (n=7) were recruited as controls for comparative analysis
(see Methods Chapter 2.1, p. 167). Western blots and co-immunoprecipitations for
the core DGC members were performed (see Methods Chapter 2.8.1, p. 185). A
further 7 healthy controls were recruited from the institution performing the
molecular biology analyses.
7.4 Statistical analysis
Demographics of the cancer patients and healthy controls are presented as medians
with ranges. Differences between groups were determined by MWT or FET.
Survival analysis was performed using univariate KM plots.
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7.5 Results
The demographics of the weight-losing cancer patients (n=27) and the weight-
stable, healthy controls recruited from the author's institution (n=7) are shown in
Table 7.1. (A further 7 controls were also recruited for whom nutritional assessment
is unavailable). Following post-operative histopathological examination of the
tumour specimen, five of the patients had stage 4 disease. Age and sex ratio did not
differ significantly between the cancer and control groups. However, cancer
patients had lower MAC (p=0.0026) and TSF (p=0.048), and demonstrated a trend
towards lower BMI (p=0.059) and MAMC (p=0.054), compared with controls.
Moreover, 19/27 (70.4%) of the cancer patients had lost weight prior to resection
(median weight loss of all cancer patients = 3.2%; range 0.0-23.2).
Compared to weight-stable healthy controls, weight-losing cancer patients had a
dramatic reduction in dystrophin expression (Figure 7.1). Ponceau S staining
confirmed that loss of dystrophin was not due to a general reduction of total protein
(Figure 7.1). Similar to the changes observed in murine models of cancer cachexia,
in carcinoma patients, dystrophin downregulation was tightly linked with
hyperglycosylation of P-DG and p-SG, to the extent that a direct correlation could
be distinguished clearly between dystrophin reduction and increased P-DG and p-
SG glycosylation (Figure 7.1). In total, DGC deregulation was found in 17/27
(63.0%) of cancer samples, but was completely absent from controls (n=14).
Moreover, analogous to the C-26 murine cachexia model, ligand overlay assays
with muscle extracts from cancer patients revealed decreases in DGC complex
association (Figure 7.2A). Results also highlighted that wasting was not selective to
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Healthy Controls Cancer Patients
(Weight-Stable)


















Body Mass Index 29.0 25.5
(kg/m2) (19.6-35.2) (17.8-40.6)
Mid-Arm Circumference 32.6 27.5°
(cm) (25.5-36.2) (22.0-36.0)
Triceps Skinfold Thickness 16.0 11.0a
(mm) (5.4-35.4) (5.0-31.0)




Karnofsky Performance Score 100 100
(100-100) (70-100)
% Weight Loss 0 3.2°
(% loss of pre-morbid weight) (0.0-0.0) (0.0-23.2)
Table 7.1 Demographics of the weight-losing oesophago-gastric cancer
patients and weight-stable, healthy controls.
Mid-arm circumference and triceps skinfold thickness were significantly lower in
cancer patients compared with controls, whereas body mass index and mid-arm
muscle circumference demonstrated a trend towards being reduced. Cancer patients
exhibited a median weight loss of 3.2%. Data arc presented as medians with ranges








lanes: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 7.1 Dystrophin glycoprotein complex deregulation in rectus
abdominis samples from weight-losing cancer patients.
Rectus abdominis biopsies from controls (cont.) and cancer patients were
homogenised and analysed by Western blots probing for dystrophin (Dys), P-
dystroglycan (P-DG), and P-sarcoglycan (P-SG). Upper bands denote
hyperglycosylated products. Muscle samples from cancer patients demonstrated
reduced dystrophin expression, hyperglycosylated P-DG, and hyperglycosylated P~
SG.
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Figure 7.2 A) Ligand overlay assays performed with muscles from cancer
patients and controls.
Weight-losing cancer patients demonstrated decreases in DGC complex association.
B) Co-immunoprecipitations performed with samples from 7.2A
with a skeletal muscle actin antibody and immunobiotted subsequently for
myosin heavy chain.
The wasting phenomenon was not specific to the DGC as cancer patients also
demonstrated decreases in actin-myosin complex association. Corresponding actin
Western is also shown.
IB: immunoblot; IP: immunoprecipitation; MyHC: myosin heavy chain.
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the DGC, since similar deregulation occurred in actin-myosin complexes (Figure
7.2B).
The demographics of the cancer patients with deregulated DGC (n=17) and patients
with normal DGC (n=10) are shown in Table 7.2. Patients expressing deregulated
DGC demonstrated higher plasma levels of CRP (p=0.0046, MWT) compared with
patients with normal DGC, and demonstrated a trend towards lower KPS (p=0.052,
MWT). Furthermore, weight loss was increased in patients with deregulated DGC
compared with patients with normal DGC (median 6.6% vs 0.2%), although this
result did not reach statistical significance (p=0.14).
In order to investigate if deregulated DGC might be used as an early marker of
cachexia and therefore capable of predicting the future development of cachexia
and overall survival, data were analysed with regards to sequential nutritional
assessments. When cachexia was defined strictly as the simultaneous presence of
weight loss >10% and CRP >10mg/L [624], 10/11 (91%) patients who progressed
to demonstrate these findings exhibited prominent DGC deregulation (p=0.018,
FET). Furthermore, survival analysis demonstrated that all 10 (100%) non-
surviving cases were positive for DGC deregulation. Furthermore, KM analysis
demonstrated that patients with deregulated DGC demonstrated significantly
shortened survival (median 479d) compared with patients with normal DGC
(p=0.013, log rank test) (Figure 7.3).
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Cancer Patients Cancer Patients
Normal DGC Deregulated DGC


















Body Mass Index 24.8 25.5
(kg/m2) (19.5-28.7) (17.8-40.6)
Mid-Arm Circumference 27.3 28.0
(cm) (22.0-32.0) (22.5-36.0)
Triceps Skinfold Thickness 11.3 11.0
(mm) (8.5-14.0) (5.0-31.0)




Karnofsky Performance Score 100 90
(80-100) (70-100)
% Weight Loss 0.2 6.6
(% loss of pre-morbid weight) (0.0-13.9) (0.0-23.2)
Table 7.2 Demographics of the cancer patients with deregulated DGC
compared with patients with normal DGC.
Plasma CRP was significantly elevated in cancer patients with deregulated DGC
compared with patients with normal DGC. Data are presented as medians with
ranges in parentheses. Differences from cancer patients with normal DGC are
























Figure 7.3 Kaplan-Meier curve of survival of oesophago-gastric cancer
patients according to the presence of DGC deregulation within skeletal muscle.
All patients who died during follow-up (n=10) exhibited DGC deregulation.
Furthermore, patients with DGC deregulation (median survival 479d) demonstrated
worsened survival compared with patients with normal DGC (p=0.013, log rank
test).
DGC: dystrophin glycoprotein complex.
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7.6 Discussion
Although the underlying mechanisms of cancer cachexia are considered distinct
from those seen in muscular dystrophy, the present findings suggest that a
dysfunctional DGC might be a common link between these two disease states. This
conclusion was based initially on histological and ultrastructural analysis of muscle
from tumour-bearing mice, which revealed distinct morphological changes in
myofibre membranes [321]. These changes were associated with a reduction in
dystrophin expression and the appearance of glycosylated modifications on
selective members of the DGC. Tumour-induced alterations in the DGC also
correlated with reduced protein interactions within the complex. Indeed, muscle
wasting was exacerbated in tumour-bearing mdx mice that lacked dystrophin and a
functional DGC, but this wasting was abrogated in dystrophin transgenic mice
bearing similar tumour burden. Lastly, DGC deregulation (namely, reduced
expression of dystrophin, hyperglycosylation of [3-DG and hyperglycosylation of [3-
SG) was identified in 63% of weight-losing cancer patients, and was associated
with worsened survival on univariate analysis.
Although cancer cachexia and muscular dystrophy involve chronic muscle wasting,
from an aetiological and molecular standpoint, the causative mechanisms of these
disorders have been considered to be largely non-overlapping [320, 625, 626]. This
is because muscular dystrophies are genetic in origin, with numerous mutations
mapping to dystrophin and other members of the DGC. Moreover, features of
dystrophy include the recruitment of infiltrating T-lymphocytes and macrophages;
necrosis; muscle regeneration; apoptosis; and accumulation of fibrotic material and
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fatty deposits, that together culminate in a degenerative state [311, 317]. Biopsies
from cancer patients [627], and the C-26 murine model revealed little if any
evidence of infiltrating cells, necrosis, regeneration, or fibrosis [321], Rather,
muscle loss due to malignancy exhibited pronounced fibre atrophy and increased
vascularisation, which may serve to facilitate circulation of tumour factors and host
cytokines in the muscle microenvironment. Despite the differences between
cachexia and muscular dystrophy, the present findings indicate that one important
commonality is the abnormality of fibre membranes resulting from a deregulated
DGC. Interestingly, disruptions and irregularities of the membrane have also been
reported in DMD patients as secondary consequences of the loss of the DGC [628,
629]. In muscular dystrophy, mutations in DGC proteins are thought to weaken
muscle membranes, which can be measured by EBD permeability or the efflux of
cytoplasmic muscle proteins such as CK [630]. In muscles from mice bearing C-26
tumours, enhanced EBD association to membranes was clearly visible, but only on
rare occasions was cytoplasmic localisation of the dye observed, and significant CK
release was not noted [321], This would indicate that alterations in fibre membranes
occur in cachectic fibres, but to a lesser degree than in dystrophic muscles. It is
speculated that this difference in membrane damage correlates with the degree of
dysfunction exhibited by the DGC. For example, in DMD, the loss in dystrophin
leads to a reduction of DG and SG proteins, resulting in the functional breakdown
of the DGC [631], In the human cancer patients and the C-26 model of cancer
cachexia, dystrophin expression may be reduced, but the loss of other DGC proteins
was not observed [321], Nevertheless, evidence from the mdx and dystrophin
transgenic mice indicates that the alterations in the DGC elicited by a developing
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tumour are sufficient to induce membrane damage that may function as a cause and
not simply a consequence of muscle wasting.
In conjunction with the downregulation of dystrophin and a compensatory response
in utrophin expression, two other key members of the DGC, (3-DG and P-SG, were
glycosylated aberrantly in mouse tumour models and cachectic patients [321], The
extent of this glycosylation appeared to be linked closely with the level of
dystrophin reduction. P-DG and P-SG glycosylation occurred in multiple mouse
muscles and by LCM was found to be specific to atrophic type II fibres. The
observation that these glycosylated forms appear in mdx muscle lends genetic
support to the supposition that loss of dystrophin expression leads to aberrant
glycosylation in DGC proteins. Deregulation of these DGC proteins correlated with
a strong loss of binding between p-DG and dystrophin, a-DG and P-DG, and a-DG
and laminin [321]. It is hypothesised that the decrease in dystrophin contributes to
the reduction in these interactions, but further studies are warranted to determine
the significance of the increase in glycosylation pattern with respect to the
breakdown of the DGC and promotion of muscle wasting. In certain congenital
dystrophies, mutations arise in glycosyltransferases, which decrease rather than
increase glycosylation of DGC proteins, such as a-DG [619, 620], However,
overexpression of a glycosyltransferase specifically in muscle has also been shown
to lead to a decrease in fibre diameter [632]. Thus, it is possible that increases in
glycosyltransferase activity in tumour-bearing mice may be a contributing factor in
cachexia.
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It is not known whether the tumour-induced deregulation of the DGC leads to
muscle wasting via a breakdown in the mechanical link between the ECM and the
cytoskeletal network that interacts with the contractile proteins, or through a
disruption in the signalling link between the DGC and MAPK or the PI3K/Akt
pathways [633]. Data showing that P~DG/Grb2 interaction, as well as extracellular
signal-regulated kinase (ERK) and Akt activities, is maintained in cachectic
muscles would support the hypothesised connection between a disrupted
mechanical link and muscle wasting. However, it is equally likely that tumour-
induced alterations in the DGC may abrogate a separate, yet to be identified
pathway that is critical to the promotion of wasting. Such a pathway could be the
UPP. The accentuated reduction of MyHC in tumour-bearing mdx mice, and the
blockage of muscle wasting and E3 ubiquitin ligase (MuRFl and atrogin-l/MAFbx)
induction that were observed in dystrophin transgenic mice [321], both argue for a
role of deregulated DGC in proteasome regulation. Taken together, the results
support a model that during tumour progression circulating tumour factors function
to downregulate dystrophin expression leading to aberrant glycosylation of P-DG
and P-SG proteins. These regulatory events subsequently promote DGC breakdown
followed by membrane abnormalities. A dysfunctional DGC, either alone or in
combination with other deregulated factors associated with an altered membrane or
basal lamina, in turn stimulates the induction of E3 ligase genes and possibly other
components of the UPP required for protein degradation, culminating in a cachectic
state.
In weight-losing cancer patients, DGC deregulation was associated significantly
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with a higher plasma level of CRP, suggesting that DGC deregulation may be the
result of systemic inflammation. This finding in humans would be consistent with
the observations from murine studies, as the C-26 cachexia model is purported to be
IL-6-dependent. Certainly, within the present collaborative study, C-26 mice did
exhibit higher serum levels of IL-6 [321], DGC deregulation in cancer patients was
also associated with a greater degree of weight loss, although this result did not
reach statistical significance. Although these studies suggest heavily that DGC
deregulation is potentially a key mechanism of muscle wasting in human cancer
cachexia, future studies of larger patient numbers or specific assessments of skeletal
muscle mass/LBM may be required to prove this conclusively and avoid the
potential risk of type I errors. Moreover, in studies of larger patient numbers,
receiver operating characteristic (ROC) curves could be utilised to assess the
relationship between DGC deregulation and different clinical definitions of
cachexia. The observation that reduced dystrophin expression was seen prior to
decreases in muscle fibre diameter in tumour-bearing mice implies that DGC
deregulation may hold promise as an early marker of cancer cachexia.
Interestingly, in the present study, DGC deregulation also demonstrated a trend
towards association with lower patient KPS, suggesting that DGC deregulation may
not only represent a potential marker of muscle wasting, but also a marker of
impaired muscle function. This concept is supported by the maintenance of muscle
function observed in dystrophin transgenic mice bearing tumours. The notion of an
invasive biomarker of muscle function is an intriguing one, which could be
combined with other clinical biomarkers (e.g. PA - see Chapter 10, p.339, and
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Chapter 11, p.359) to obtain a global picture of patient PF.
Importantly, DGC deregulation was associated with shortened survival of cancer
patients on univariate analysis. Thus, despite the fact that all patients within the
study were planned for surgical resection with "curative intent", DGC deregulation
was capable of predicting survival before the implementation of surgery. Again,
larger patient numbers would allow multivariate survival analyses to ascertain the
independent prognostic significance of DGC deregulation, and the ability of DGC
dergulation to function as a marker of survival.
Collectively, evidence presented in this chapter suggests that DGC dysfunction is
an important step in the initiation of cancer cachexia in both murine cancer models
and human cancer patients. Since effective therapies are currently lacking, results
from this study also imply that approaches targeted to restore the DGC in muscular
dystrophies could also be considered as a viable option in designing anti-cancer
cachexia therapies. In Chapter 8, attention remains on intra-muscular mechanisms
of wasting, and focuses more specifically on molecular pathways involved in
protein synthesis and degradation.
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Chapter 8 - Increased expression of phosphorylated
forms of RNA-dependent protein kinase and
eukaryotic initiation factor 2a may signal skeletal
muscle wasting in weight-losing cancer patients
8.1 Introduction
Skeletal muscle atrophy is characterised by decreased protein content, fibre
diameter, force production and fatigue resistance. Muscle wasting is due to a
combination of depressed protein synthesis [634], and elevated endogenous protein
breakdown, with oxidation of the resultant amino acids [635]. In cancer patients,
the mechanism for the depression in protein synthesis is not known, while the
increased protein degradation has been attributed to an increased expression of the
UPP [360],
Several potential mediators of the cachectic process, including murine PIF and
angiotensin II, have been proposed to inhibit protein synthesis in murine skeletal
muscle [170, 545], and also stimulate protein degradation, through increased
activity and expression of the UPP [169, 185]. In murine myotubes [188], a link
between the ability of murine PEF and angiotensin II to inhibit protein synthesis and
increase protein degradation via PKR has been demonstrated. PKR is a
serine/threonine specific protein kinase, which undergoes autophosphorylation at
multiple serine and threonine residues, causing activation, in the presence of
interferon, in response to viral attack [636], In pre-clinical models, both murine PEF
and angiotensin II were shown to induce autophosphorylation of PKR. Activated
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PKR can phosphorylate several protein substrates including the a-subunit of eIF2
[637], The eIF2 complex initiates methionyl-transfer RNA (tRNA) binding to the
40S ribosomal subunit. However, phosphorylation of eIF2a inhibits continued
initiation of protein synthesis by this complex. During this process, GTP associated
with eIF2 is hydrolysed to guanosine diphosphate (GDP), and recycling of eIF2-
GDP to eIF2-GTP requires a guanine nucleotide exchange factor, eIF2B [638].
Phosphorylation of eIF2 on the a-subunit causes it to act as an inhibitor of eIF2B,
and the resultant reduction in eLF2-GTP levels reduces general translation (Figure
8.1) [639]. Activation of PKR by murine PEF and angiotensin II was responsible for
the observed depression in protein synthesis, since transfection of myotubes with a
mutant PKR incapable of autophosphorylation and induction of phosphorylation of
eIF2q attenuated completely the depression in protein synthesis by both agents
[188]. Mutation of PKR also attenuated completely the induction of protein
degradation and upregulation of the UPP. Induction of the UPP by both murine PIF
[640] and angiotensin II [174] requires activation of NF-kB. PKR has been shown
to activate upstream IKK, leading to degradation of the inhibitor IkB protein and
the release of NF-kB, which migrates to the nucleus and induces transcriptional
activation of specific genes [641], leading to activation of the UPP (Figure 8.1).
Thus, activation of PKR leads potentially to both a depression of protein synthesis
and an increase in protein degradation in skeletal muscle. These studies in vitro
were also reflected by changes in vivo in gastrocnemius muscle of mice bearing a
cachexia-inducing tumour, where levels of phosphorylated PKR and eIF2a were




Figure 8.1 Summary of pathways leading to a depression in protein
synthesis and an increase in protein degradation in skeletal muscle through
phosphorylation of PKR.
During skeletal muscle wasting, phosphorylation (denoted by a P in a circle) of
PKR not only leads to phosphorylation of eIF2a and an inhibition of protein
synthesis, but also to phosphorylation of IKK, leading to NF-icB-mediated protein
degradation. In vitro, phosphorylation of PKR has been induced by murine PIF and
angiotensin II.
eIF2a = eukaryotic initiation factor 2a; GDP = guanosine diphosphate; GTP =
guanosine triphosphate; IKK = IkB kinase; Met-tRNA = methionyl transfer-RNA;
NF-kB = nuclear factor-ic(3; PKR = double-stranded RNA-dependent protein kinase.
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In order to determine whether changes similar to those induced by murine PIF and
angiotensin II in vitro also occur in human cancer cachexia, the present study aimed
to examine the expression levels of phosphorylated PKR and eIF2a in skeletal
muscle of patients with OGC and varying degrees of weight loss, in comparison
with healthy, weight-stable subjects undergoing minor elective surgery.
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8.2 Hypothesis
Skeletal muscle from weight-losing cancer patients demonstrates increased levels
of phosphorylated PKR and phosphorylated eIF2a expression compared with
weight-stable patients and healthy controls.
303
8.3 Patients and healthy controls
Patients with newly diagnosed OGC and varying degrees of weight loss undergoing
surgical resection with curative intent (n=14) or without curative intent (n=l) were
recruited (see Methods Chapter 2.1, p. 167) and rectus abdominis muscle samples
were obtained (see Methods Chapter 2.4.1, p. 173). Nutritional assessment was
performed (see Methods Chapter 2.2, p. 168). Patients undergoing minor operative
procedures for benign, non-inflammatory conditions (n=9) were recruited as
controls for comparative analysis (see Methods Chapter 2.1, p. 167). Western blots
for the phospho and total forms of PKR and eIF2a, MyHC and actin in skeletal
muscle were performed in triplicate (see Methods Chapter 2.8.2, p. 186).
8.4 Statistical analysis
Demographics of the cancer patients and healthy controls are presented as medians
with ranges. Differences between the two groups were determined by MWT.
Western blot densitometry results are presented as means ± standard error of the
mean (SEM) for at least three replicate experiments. Differences in means between
groups were determined by one-way ANOVA, followed by the Tukey-Kramer




The demographics of the weight-losing cancer patients (n=15) and the weight-
stable, healthy controls (n=9) are shown in Table 8.1. Following post-operative
histopathological examination of the tumour specimen, three of the patients had
stage 4 disease. Age and sex ratio did not differ significantly between the cancer
and control groups. Thirteen (86.6%) of the cancer patients had lost weight prior to
resection (median weight loss of all cancer patients = 7.8%; range 0.0-27.5).
However, no cancer patient had a BMI less than 20 kg/m2, and median BMI of the
patients was not significantly lower than the control group (26.1 kg/m2 vs 28.5
kg/m2; p=0.311).
Western blots for the phospho and total forms of PKR and eIF2a in rectus
abdominus muscle as a function of weight loss are shown in Figures 8.2 and 8.3.
Levels of phospho PKR were elevated significantly compared with healthy controls
in 13 (86.6%; p<0.05) of the muscle samples from cancer patients, whereas
phospho eIF2a levels were enhanced significantly in 9 (60.0%; p<0.05). There did
not appear to be a significant relationship between the degree of patient weight loss
and the level of mediator phosphorylation. Moreover, one weight-stable cancer
patient demonstrated significantly elevated levels of intramuscular phospho PKR
(pcO.Ol). However, there was a linear correlation between phosphorylation of PKR
and phosphorylation of eIF2a (r=0.76, p=0.005), suggesting that phosphorylation of
PKR was associated with, and may have led to, phosphorylation of efF2a (Figure
8.4). Muscle myosin (MyHC II) levels decreased significantly as patient weight
loss increased beyond 5% (Figure 8.5A), whereas actin levels remained stable.
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Healthy Controls Cancer Patients
(Weight-Stable)

















Body Mass Index 28.5 26.1
(kg/m2) (19.6-35.2) (20.1-34.4)
Mid-Arm Circumference 32.6 28.9
(cm) (25.5-35.2) (23.0-40.0)
Triceps Skinfold Thickness 15.5 14.4
(mm) (5.0-29.4) (7.8-37.4)
Mid-Arm Muscle Circumference 25.8 25.3
(cm) (23.8-30.5) (18.3-30.0)
Karnofsky Performance Score 100 90a
(100-100) (60-100)
% Weight Loss 0 7.8d
(% loss of pre-morbid weight) (0.0-27.5)
Table 8.1 Demographics of the weight-losing oesophago-gastric cancer
patients and weight-stable, healthy controls.
Although median BMI was not significantly different between cancer patients and
controls, the cancer patients did exhibit a median weight loss of 7.8%. Data are
presented as medians with ranges in parentheses. Differences from healthy controls
are shown as as a, p<0.05; b, p<0.001.
306
Total PKR





Weigrs ices (%) HC HC HC HC 0 39 52 7.6 11.4 12.9 139
HC HC HC HC 0 0 33 52 7.6 11.4 12.9 139
weigrtt loss (*)
Figure 8.2 Western blots of phospho PKR (A) and eIF2a (B) compared
with total PKR and eIF2a in rectus abdominus muscle as a function of weight
loss.
The ratio of phospho to total PKR and eIF2a was greater in weight-losing cancer
patients. Actin was used as a loading control. Each lane represents muscle from an
individual patient. Densitometric analysis of the ratio of phospho to total forms
represents the average of 3 separate blots. Differences from healthy controls are
shown as as a, p<0.05, b, p<0.0l ore, p<0.001.
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Weigr* I06S (%) HC HC HC HC HC 2.4 5 6 7J 10.1 10.3 15 4 27.5
Weight loss HC HC HC HC HC 2.4 5.6 7.0 10.1 10.3 15.4 27.5
HC HC HC HC HC 2.4 5 6 7.0 10.1 10.3 15.4 27.5
Weight loss <%)
Figure 8.3 Western blots of phospho PKR (A) and eIF2a (B) compared
with total PKR and eIF2a in rectus abdominus muscle as a function of weight
loss. The ratio of phospho to total PKR and eIF2a was greater in weight-losing
cancer patients. Actin was used as a loading control. Each lane represents muscle
from an individual patient. Densitometric analysis of the ratio of phospho to total
forms represents the average of 3 separate blots. Differences from healthy controls
are shown as as a, p<0.05, b, p<0.01 or c, pcO.OOl.
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A
Figure 8.4 Relationship between the level of autophosphorylation of PKR
and eIF2a in skeletal muscle samples from: A) patients shown in Figure 8.2;
and B) patients shown in Figure 8.3.
There was a positive linear correlation between phosphorylation of PKR and
phosphorylation of eIF2a (r=0.76, p=0.005 for both graphs), suggesting that









Figure 8.5 (A) Western blot of myosin expression in rectus abdominis
muscle of the patients shown in Figure 8.3 as a function of weight loss.
Myosin (MyHC II) expression was reduced in weight-losing cancer patients. Actin
was used as a loading control. Each lane represents muscle from an individual
patient. Densitometric analysis represents the average of three separate blots.
Differences from healthy controls are shown as a, p<0.05.
(B) Relationship between the level of myosin and phospho eIF2a
in skeletal muscle samples from patients shown in Figure 8.5A.
There was a negative linear correlation between the expression levels of myosin
(MyHC II) and phospho eIF2a (r=-0.77, p=0.004).
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There was an inverse linear relationship between myosin expression and the extent
of phosphorylation of eIF2a (r=-0.77, p=0.004) (Figure 8.5B), suggesting that
phosphorylation of eIF2a was associated with reductions in myosin expression.
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8.6 Discussion
This is the first study to show an increased expression of phosphorylated PKR and
eIF2a in the skeletal muscle of weight-losing cancer patients, compared with
healthy weight-stable controls. As found in the gastrocnemius muscle of weight-
losing mice bearing the MAC 16 tumour [188], expression of both phospho PKR
and eIF2a was increased in cancer patients with weight loss. This suggests that the
same signalling mechanism is operative in the skeletal muscle of both cachectic
cancer patients and mice with experimental cancer cachexia. Similar findings have
been observed in murine myotubes in the presence of murine PIF or angiotensin II
and are thought to be responsible for the depression in protein synthesis and
increase in degradation [188].
PKR is normally activated in response to viral attack, and the depression of protein
synthesis resulting from phosphorylation of eEF2a constitutes one of the major
ways in which viral replication is impaired [642], However, PKR can also exert
effects in uninfected cells and can be a potent growth inhibitory protein when
activated [643], PKR is also linked to the induction of pro-apoptotic genes by
dsRNA, and may trigger cell death in response to viral infection and possible
tumourigenesis [644], Activation of PKR by murine PIF may also be involved in its
ability to induce apoptosis in murine myotubes [189]. Certainly, it has been
suggested that activation of PKR by PIF and angiotensin II is mediated through
Ca2+ induced activation of caspases-3 and -8 [190]. Furthermore, PKR has been
linked to ROS production via p38MAPK in response to bacterial
lipopolysaccharide [645], Increased apoptosis has been observed in the skeletal
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muscle of rats bearing the cachexia-inducing Yoshida AH-130 ascites hepatoma
[646] and in the early stage of weight loss in rabbits bearing the VX2 carcinoma
[647]. Thus, activation of PKR might be expected to contribute to wasting of the
skeletal muscle of cachectic cancer patients by leading to increased rates of
apoptosis. Phosphorylation of PKR would also be expected to lead to an increased
breakdown of myofibrillar proteins in skeletal muscle by induction of the UPP [174,
640] through activation of NF-kB [641], analogous to the effect of murine PIF and
angiotensin II [188].
The increased phosphorylation of eIF2a is likely to contribute to the depression of
protein synthesis in the skeletal muscle of cancer patients, through the inhibition of
eEF2B and subsequent translational repression [639], as was observed previously in
murine myotubes treated with murine PIF and angiotensin II [188].
Phosphorylation of eEF2a has also been shown to be responsible for the inhibition
of protein synthesis in rat liver by vasopressin [648] and rat skeletal muscle by IL-1
[649]. The observed inverse linear correlation between intramuscular myosin
protein levels and phospho eIF2a would support the concept of a direct role for
eIF2a phosphorylation in the suppression of myofibrillar protein synthesis in cancer.
Furthermore, the linear relationship between activation (autophosphorylation) of
PKR and phosphorylation of eEF2a suggests that PKR is responsible for this effect
rather than general control non-repressed 2 (GCN2 - the protein kinase usually
considered to be in control of eIF2a phosphorylation), which one might expect to
be activated [650] by the reduction in plasma levels of amino acids in cachectic
subjects [651],
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In the absence of conclusive evidence for the existence of human PIF (see Chapter
3, p. 199, and Chapter 4, p.218), the identity of the key initiator of PKR
phosphorylation in human muscle wasting is unclear. Angiotensin II remains a
possible candidate, but at present, there is also a paucity of human data linking this
potential mediator to cancer cachexia. Genetic studies have shown alterations in
body composition in advanced cancer patients in relation to ACE gene
polymorphism status [177], but further human data are required to ascertain the
clinical implications of ACE in cancer cachexia.
In the current study, although expression of both phospho PKR and phospho eIF2a
was increased in cancer patients with weight loss, there was no consistent trend
towards increased expression with increasing weight loss. In contrast, in studies
using murine MAC 16 cachexia model, these changes appeared to be progressive
[188]. However, most of the recruited patients were at a relatively early stage of
disease where resectional surgery was still considered possible. Moreover, although
some patients had lost a considerable amount of weight, no patients were below the
normal BMI range (20-25 kg/m ). (This reflects, in part, the general trend towards
obesity in the current general population and the fact that obesity is a risk factor for
oesophago-gastric adenocarcinoma). Thus, it remains to be determined whether in
patients with more advanced cachexia a similar pattern would be observed as seen
in mice bearing the MAC-16 tumour.
In the MAC-16 model, treatment with a PKR inhibitor, at a concentration that
reduced levels of phospho PKR down to that found in non tumour-bearing animals,
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effectively attenuated the depression of body weight, through an increase in LBM
[652]. This was achieved through attenuation of both the depression in protein
synthesis and the increase in protein degradation observed in murine myotubes
exposed to either PfF or angiotensin II [188]. Thus, pathological human muscle
wasting may also be responsive to inhibitors of PKR. Such wasting might include
that experienced by cachectic cancer patients, but also patients with other
pathological disorders. For example, angiotensin II has been linked with muscle
wasting in CHF [653], TNF-a, which may be linked to muscle wasting in sepsis,
AIDS and parasitic infections, as well as cancer, has also been shown to activate
PKR [654], Furthermore, burn injury is associated with increased phosphorylation
of eEF2a as a result of a 274% increase in phosphorylation of PKR [655].
This chapter has demonstrated that phosphorylation of PKR and eEF2a are key
events seen in human muscle wasting, and that these events are proposed as
mechanisms leading to a repression of protein synthesis and an increase in protein
degradation. Thus, intramuscular levels of phospho PKR and phospho eIF2a could,
in the future, be investigated as potential biomarkers of cachexia in human trials.
This chapter concludes Part C concerning molecular mechanisms of muscle wasting,
but the supposition regarding biomarkers leads appropriately into the focus of the
next chapter (Part D), which explores specifically the use of urinary proteins as
biomarkers of skeletal muscle wasting in human cancer cachexia.
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Part D - Biomarkers of Muscle Wasting
in Cancer Cachexia
316
Chapter 9 - Mass spectrometric detection of
candidate protein biomarkers of cancer cachexia in
human urine
9.1 Introduction
In Chapters 7 and 8, molecular mechanisms leading to protein degradation and
skeletal muscle wasting in human cancer cachexia have been described. During this
catabolic response in skeletal muscle, release of myofilaments from the sarcomere
by calcium/calpain-dependent pathways may be an early, and perhaps rate-limiting,
step [656], Activation of the UPP is then believed to degrade the released
myofibrillar proteins [225], In murine tumour models, cancer cachexia involves the
selective reduction of MyHC protein expression within skeletal muscle [294], This
reduction in MyHC levels is associated with increased activity of the UPP,
suggesting that cachexia is the result of targeted depletion of specific myofibrillar
proteins. Studies in cytokine-dependent animal tumour models have also identified
specific changes in skeletal muscle membrane structure and function during
cachexia [321], In particular, the DGC appears deregulated and the sarcolemma
becomes permeable to vital dyes. In Chapter 7, similar deregulation of the DGC
was identified in cachectic human muscle. The severity of membrane damage
would appear, at first glance, to be insufficient to cause a free permeation of
intracellular proteins, particularly as circulating levels of CK, a marker of muscle
damage, are not elevated [321, 657]. However, it was hypothesised that highly
permeable cachectic muscle fibres might excrete some products of muscle protein
degradation, which then enter the circulation, are filtered by the kidneys, and are
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expelled in patient urine. The multifactorial catabolic and inflammatory
mechanisms at work in cancer cachexia are already known to result in an increase
in circulating proteins, leading to significant proteinuria and urinary nitrogen loss
[658], Such proteinuria has been shown to be associated with worsened patient
prognosis [659], However, the exact identity of protein species within urine has not
been elucidated.
The systematic approach to the management of cachexia requires early
identification of patients at risk and institution of prophylactic measures to
attenuate its progression. However, there are currently no agreed early biomarkers
(clinical or biochemical). It was hypothesised that the identification of proteins
within the systemic compartment of cachectic patients may identify proteins that
have been degraded selectively and expelled by "leaky" cachectic muscle, and that
may thus act as biomarkers of muscle wasting. The identification of proteins within
patient plasma (as a representative matrix of the systemic compartment) is highly
complex due to the multiplicity of species involved in non-cachectic processes
found therein [660], However, MS has been successful at species identification
within urine [661]. Thus, in a preliminary attempt to identify urinary proteins that
might be used in future biomarker studies to target patients for therapeutic
intervention, the aim of the present study was to use MS to identify and compare
the protein contents of urine from cachectic cancer patients, weight-stable cancer
patients and healthy controls.
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9.2 Hypothesis
Using MALDI-TOF MS and/or LC-MS/MS, degraded skeletal muscle protein
products can be detected in the urine of weight-losing patients with OGC, whereas
such products are absent from the urine of weight-stable patients and healthy
controls.
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9.3 Patients and healthy controls
Patients with OGC and varying degrees of weight loss (n=16) were recruited (see
Methods Chapter 2.1, p. 167). Patients were defined as either cachectic (n=8) or
weight-stable (n=8), depending on the presence or absence of cachexia (defined as
weight loss >10%). Laboratory staff were recruited as healthy controls (n=8) for
comparative analysis. Nutritional assessment was performed (see Methods Chapter
2.2, p. 168). Urine samples were obtained and the urinary proteins were precipitated
(see Methods Chapter 2.5, p. 175). Proteins were then separated using ID SDS-
PAGE (see Methods Chapter 2.9.1, p. 187). Following electrophoresis, gel blocks
were excised and trypsinised (see Methods Chapter 2.9.2, p. 188). Tryptic digests
were then analysed by MALDI-TOF MS and LC-MS/MS (see Methods Chapter
2.9.3 and 2.9.4, p. 188-189). Blood samples were also obtained and analysed for
plasma CRP concentration (see Methods Chapter 2.3.3, p. 170), creatinine
concentration and CK concentration (see Methods Chapter 2.3.7, p. 173). Exclusion
criteria included known renal failure (defined as creatinine > 120pmol/L in males or
>11 Opmol/L in females or estimated glomerular filtration rate <60ml/min/1.73m2).
9.4 Statistical analysis
Concentrations of the precipitated protein supernatants were used to derive protein
concentrations of the initial urine samples in mg/L. Differences between
distribution functions of data for the 3 patient groups was determined by KWT.
Subsequent analysis to determine differences between any 2 groups was determined
by MWT and FET. Asymptotic p-values are quoted for KW test whereas two-sided




Tumour site, histology, and stage of disease did not differ between the weight-
stable and cachectic cancer groups (Table 9.1). The control group was younger than
both the weight-stable cancer group (p=0.001) and cachectic cancer group (p=0.002)
(Table 9.2). However, there was no difference in age or sex ratio between the
weight stable and cachectic cancer groups. The cachectic group had lost a median
of 17.9% of pre-illness weight (range 12.7-25.6) compared with both the weight-
stable cancer and control groups, which had not lost weight (p<0.001). Other
nutritional parameters (BMI, MAC, MAMC) were also reduced in the cachectic
group compared with the weight-stable cancer group, consistent with a specific loss
of skeletal muscle mass in the cachectic patients. The weight-stable cancer group
exhibited an elevated BMI compared with controls, reflecting the role of obesity in
the pathogenesis of oesophago-gastric adenocarcinoma.
9.5.2 Plasma levels of CRP, creatinine and CK
Plasma creatinine was elevated in one patient in the weight-stable cancer group
suggesting mild renal impairment, but there was no overall difference between the
weight-stable and cachectic cancer patients (p=0.234). Six (37.5%) cancer patients
exhibited evidence of an acute phase response (plasma CRP>10mg/L), but there
was no difference in CRP between the weight-stable and cachectic groups
(p=0.613). Plasma CK was not elevated in any of the cancer patients and did not
differ between the weight-stable and cachectic groups (p=0.083).
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Weight-stable Cancer Cancer Cachexia Overall
(n=8) (n=8) (n=16)
Tumour Site
Oesophageal 3 5 8
Gastric 5 3 8
Histology
Adenocarcinoma 7 5 12
Squamous 1 3 4
Disease Stage
1 4 3 7
II 1 0 1
III 1 4 5
IV 2 1 3
Table 9.1 Tumour details of the oesophago-gastric cancer patients (n=16)
in the urinary biomarker study.
There were no significant differences in tumour site, histology and disease stage
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9.5.3 Cachectic cancer urine contains more protein species than
weight-stable cancer and control urine
There was no significant difference in the urinary protein concentration of the three
groups (p=0.149) (Table 9.2). Thus, the finite amounts of protein loaded onto gels
were comparable statistically. Using both MS approaches, the number of proteins
identified in each cachectic urine sample (median 42, range 26-61) was greater than
that identified in each weight-stable cancer sample (median 15; range 9-28) and
control sample (median 12.5; range 5-18) (p<0.001) (Table 9.3). Furthermore, the
total number of different protein species identified in all samples of the cachectic
group combined (n=199) was higher than that identified in the weight-stable cancer
(n=79) and control (n=49) groups (Table 9.3). There was no difference between the
numbers of proteins identified in the weight-stable samples compared with controls
(p=0.234). In all 3 groups, the number of proteins identified by MALDI-TOF MS
was higher than that identified by LC-MS/MS.
9.5.4 Candidate biomarkers of cachexia
The distribution of gel bands did not differ observably between the 3 patient groups
(Figure 9.1). Thirty-five protein species were identified that appeared in at least 3
urine samples within any patient group of 8 (i.e. at least 37.5%). Of these 35
species, 21 were not specific to the cachectic group. These non-cachexia-specific
protein species included common urinary proteins such as albumin, cytokeratins 1
and 10, and uromodulin, plus many proteins not previously reported in the urine of
cancer patients (Tables 9.4 and 9.5). Immunoglobulin (Ig) K-light chain was











Total 37 23 49
Median 8.5 7 12.5





Total 64 21 79
Median 11.5a 6 15




Total 187 18 199
Median 41.5D'c'a 6.5 42c,a
Range (26-59) (4-9) (26-61)
Table 9.3 Number of urinary proteins identified within each patient group
by each mass spectrometric technique.
The number of proteins identified in each cachectic cancer urine sample was
greater than that identified in each weight-stable cancer sample and healthy control
sample (p<0.001). Furthermore, the total number of different protein species
identified in all samples of the cachectic cancer group combined (n=199) was
higher than that identified in the weight-stable cancer (n=79) and healthy control
(n=49) groups. Total number of proteins identified within a patient group are shown
in bold. Median number of proteins identified within a single urine sample are
shown in normal type with range in parentheses.
1
= difference between the 3 patient groups on KW test p<0.001.
a'h
= difference from LC technique within same patient group on MW test p<0.05 a;
p<0.001 b.
c= difference from healthy control group on MW test p<0.001.
d
= difference from weight-stable group on MW test pcO.OOl.
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Figure 9.1 Representative 4-12% Bis-Tris gradient gel lanes of urinary
proteins from a healthy control (HC), weight-stable cancer patient (WS) and
cachectic cancer patient (CC) with high (HMW) and low (LMW) molecular
weight markers.
The sites of gel block excision (blocks 1-7) for LC-MS/MS analysis and the
locations of the abundant urinary proteins are demonstrated. Locations of the
abundant urinary proteins: Block 1 - c-myc intron binding protein 1 (MIBP1),
JmjC domain-containing histone demethylation protein 2A, maltase glucoamylase,
microtubule associated protein IB (MAPIB), myosins, spectrins, talin-2; Block 2 -
chromosome 14 open reading frame 78; Block 3 - a-fetoprotein, uromodulin;
Block 4 - albumin; Block 5 - kininogen, zinc-a-2 glycoprotein; Block 6 - a-1-
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a =differencefromhealthycontrolgroupFEt stp<0.05
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compared with 1 (12.5%) control sample (cachectic vs control p=0.041), whereas
zinc alpha-2 glycoprotein (ZAG) (either precursor chains A-D or the whole
molecule) was identified in 5 (62.5%) cachectic samples and 5 (62.5%) weight-
stable cancer samples compared with 1 (12.5%) control sample. These two proteins
may therefore represent markers of cancer or ill health.
All of the cachectic samples exhibited at least one species of myosin, including
sarcomeric myosin heavy chain 2, and myosins 3A, 4, 5A, 5C, 7A, 8, 9A, 9B, 10,
13 andl8B. In comparison, none of the weight-stable cancer samples expressed
myosin species whereas only one (12.5%) control sample expressed myosin 18b.
Furthermore, all of the cachectic samples expressed species of spectrin. Fourteen
proteins were found exclusively in at least 3 out of 8 (37.5%) cachectic samples and
may therefore represent specific markers of cachexia. All 14 of these proteins were
detected by MALDI-MS, and not LC-MS/MS. The identities and functions of these
proteins are shown in Tables 9.6 and 9.7. Retrospective analysis of ID gels
suggests that some markers (e.g. myosins and a-spectrin) were excreted in complete
or near-complete form, whereas other biomarkers (e.g. MACF1) appear to have
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Autoantigen of bullous pemphigoid (autoimmune subepithelial
skin blistering disease). Member of spectraplakin family of
cytoskeletal linker proteins. Highly expressed in skeletal







Transcription factor. Belongs to the MHC binding protein
family. May repress c-myc transcription from major promoter,




Determines small intestinal starch digestion into glucose.
Alternate pathway for when luminal alpha-amylase activity is
reduced due to immaturity or malnutrition [660], May play role





Member of plakin family of cytoskeletal linker proteins [661].
Functions in microtubule dynamics to facilitate actin-
microtubule interactions at cell periphery and to couple




Binds to tubulin to regulate microtubule function. Commonly
found in dendrites and axons. Promotes axon formation
through regulation of microtubule dynamics and cytoskeletal
organisation. Muscle expression is increased in lean men by
fat overfeeding [662].
Myosin 5C Powers actin-based membrane trafficking, particularly of
transferrin [663]. Expressed in many secretory and glandular
tissues.
Myosin 7A Expressed in testis, kidney, lung, inner ear, retina and the
ciliated epithelium of nasal mucosa. Gene mutations are
responsible for Usher syndrome type 1B [664], an autosomal




cardiac muscle, (3 variant
Gene defects cause familial hypertrophic cardiomyopathy
type 1 [665], myosin storage myopathy (involves type I fibre
predominance and increased interstitial fat/connective tissue)
[666], and Laing early-onset distal myopathy [667].
Myosin 9A Expressed in all mammalian tissues. Involved in control of
actin cytoskeleton by negatively regulating the small G-protein
Rho [668]. Gene mutations implicated in Bardet-Biedl
syndrome (autosomal recessive disorder characterized by
cognitive impairment, obesity, retinitis pigmentosa,
syndactyly/polydactyly, short stature, and hypogenitalism)
[669].
Myosin 10 Involved in mitotic spindle function and filopodia formation
[670], Tail contains multiple pleckstrin homology domains
[671],
Nischarin Binds to cytoplasmic domain of integrin a5 subunit, inhibiting
cell motility and altering actin filament organisation [672],
Inhibits Rac-induced migration and invasion of epithelial cells
by affecting PAK signalling cascades [673].
a-Spectrin 1 (non-
erythrocytic)
Cleavage of a-spectrin by calpain/caspase leads to
membrane disruption and cellular death [674]. Overexpressed
in some gastric tumours [675].
Zinc finger protein 106
homolog
Unknown
Table 9.7 Functions o;
'
the candidate biomarkers of cachexia [662-680].
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9.6 Discussion
MS has been utilised successfully for the identification of urinary proteins [661],
oligosaccharides [681] and nucleosides [682], Furthermore, MALDI-MS has been
employed in the detection of biomarkers in kidney disease [683], genitourinary
tumours, including bladder [684] and prostate cancer [685], and tumours outwith
the genitourinary tract, including pancreatic [686] and colon cancer [687], In this
preliminary study, MS was used to demonstrate that urine from cachectic OGC
patients contained significantly more protein species than urine from weight-stable
OGC patients and healthy controls, in the absence of an elevated CK level. Cancer
patients were older than healthy controls, but ages of the cachectic and weight-
stable cancer groups were comparable, and thus age alone is unlikely to explain the
different numbers of protein species between groups.
MALDI-MS was capable of identifying more protein species than LC-MS/MS.
Furthermore, all cachexia-specific protein species were detected exclusively by
MALDI-MS. These results probably reflect the increased sensitivity of MALDI-MS,
and the fact that, during LC-MS/MS analysis, highly abundant proteins will mask
less abundant species [688], Masking may have taken place during LC-MS/MS
analysis within the present study as, for example, uromodulin was detected by LC-
MS/MS in all members of the control group, but was found in only 2 of the weight-
stable cancer group and 1 of the cachectic patients.
The protein species identified specifically in the cachectic urine samples could be
considered to share a common structural function, and thus their urinary excretion
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might point to a prima facie deterioration in muscle structure during cachexia. The
myofibrillar proteins detected in cachectic urine were predominantly myosin
species. Titin and cytoplasmic actin 1 were found in individual cachectic patients
but none of the other core myofibrillar proteins, such as troponin T and
tropomyosin, were detected. Myosins can be subdivided into 18 different classes
based on homologous myosin head domain sequences [689]. Conventional myosins,
such as those found in muscle tissue, are composed of two MyHC subunits, each
associated with two light-chain subunits that bind at the neck region and play a
regulatory role. Unconventional myosins, believed to function in intracellular
motion and signal transduction [690], may contain one or two heavy chains, and
associated light chains. The seven MyHC isoforms that predominate in mammalian
skeletal muscles include two developmental isoforms (MyHC-embryonic and
MyHC-perinatal); three adult skeletal muscle isoforms (MyHC-IIa, MyHC-IIb,
MyHC-IIx/d); and MyHC-|3/slow, which represents the main MyHC component in
slow, oxidative, type I skeletal muscle fibres and cardiac muscle (24). This last
isoform (specifically MyHC 7/cardiac muscle/p variant) was identified specifically
in cachectic urine within the present study. At first glance, this result might appear
contradictory to previous studies (including Chapters 7 and 8), which have
predominantly found a reduction in type II fast fibres in cachectic murine and
human muscle [321] (although expression levels of MyHC I were not tested
specifically in Chapter 8). However, Acharyya et al also found slight reductions in
type I MyHC within cachectic muscle [321], whereas other studies have
demonstrated switching of fibre type from I to Ha in animal tumour models [691].
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The remaining four myosins (5C, 7A, 9A and 10) detected exclusively in cachectic
patients were all unconventional myosins. Myosin 18B was detected in 3 cachectic
patients, but was not cachexia-specific as it was also found in one healthy control.
Myosin 18B is detected predominantly in all types of striated muscle but at much
lower levels compared to class II sarcomeric myosins. It moves into the myonuclei
on differentiation to possibly regulate muscle-specific genes [692].
The cytoskeletal proteins detected in cachectic urine included a-spectrin 1 (non-
erythrocytic) and nischarin. The (3 spectrins I and IV were also found in several
cachectic samples but were not specific. The spectrins are a family of widely
distributed filamentous cytoskeletal protein heterodimers that consist of a constant
alpha-chain and variable, tissue-specific beta-chains, which associate with short
actin filaments to form a hexagonal mesh. They play an important role in the
maintenance of plasma membrane integrity [679]. In pathological processes such as
diffuse axonal injury, cleavage of a-spectrin by calpain/casapse activity (an enzyme
system hypothesised to be involved in the early stages of myofibrillar degradation)
leads to membrane disruption and, ultimately, cellular death [679], suggesting that
the cachectic process does indeed involve membrane disruption. a-Spectrin has
been found to be overexpressed in intestinal-type gastric tumours [680], but in the
present cohort was found primarily in samples from patients with oesophageal
cancer. Nischarin binds to the cytoplasmic domain of the integrin a5 subunit, thus
inhibiting cell motility, and altering actin filament organisation [677].
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Another high-molecular weight cytoskeletal protein involved in integrin function
and found in a high proportion, albeit non-specifically, within the cachectic samples
was talin-2. Talin is concentrated at regions of cell-substratum contact and is
capable of activating integrins enabling linkage to the actin cytoskeleton [693]. It is
also a substrate for the calpain system [694].
The microtubule-associated proteins found specifically in the cachectic samples
included microtubule associated protein IB (MAPIB) and microtubule actin
crosslinking factor 1 (MACF1). Microtubule-associated proteins (MAPs), including
MAP IB, are thought to regulate the formation and stability of microtubules via
their interaction with tubulin [695], MACF1 is a member of the plakin family of
cytoskeletal linker proteins and is a structural hybrid of dystrophin (at the C-
terminal) and bullous pemphigoid antigen 1 (BPAG1) (at the N-terminal) [666],
BPAG-1 is another member of the plakin family which is highly expressed in
skeletal muscle [662] and which was also identified specifically in the cachectic
cancer group.
Two-thirds of the cancer samples expressed Ig K-light chain and/or ZAG. Ig light
chains have been detected in the urine of ill patients since 1848 (so-called Bence-
Jones protein). Recently, Ig K-light chains have been demonstrated in the urine of
patients with CHF and various malignancies [208]. ZAG has been found previously
in increased quantities in the urine of patients with bladder cancer [696],
Furthermore, ZAG has been postulated as the lipid mobilising factor in cachexia
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[221], However, a putative human homologue of PIF [17] was not detected in any
of the urine samples.
One disadvantage of the present study is that it has utilised probability-based
database searching. Thus, the identified urinary proteins represent statistical
predictions based on smaller peptide fragments. Such a methodology also gives rise
to the risk of redundancy within the identified biomarkers. Some MS studies have
suggested that the urinary proteome may contain as many as 1500 species [697],
Only a third of proteins identified are described as classical circulatory plasma
proteins, which are known to be relatively abundant in urine despite their retention
to a large extent during the glomerular filtration process. However, other studies
have demonstrated that sequential preparation of urine samples by gel filtration and
protein precipitation results in low amounts of detectable protein on 2D gels [698].
These latter results are consistent with the present findings. Improvements in
methodology, such as the use of storage agents [699]; alternative strategies of
protein precipitation [700]; a return to 2D PAGE [701]; or the use of bioinformatics
[701] may all increase the accuracy and yield of potential biomarkers.
In the present study, weight loss alone was used as the definition of cachexia. It has
been shown previously that a 3-factor profile of cancer cachexia, incorporating
weight loss, dietary intake and systemic inflammation, better defines groups with
worsened prognostic outcome [8]. Future biomarker studies that incorporate more
detailed definitions of cachexia will help to elucidate changes caused independently
by systemic inflammation and hyponutrition.
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In summary, it would appear that degraded skeletal muscle protein products can be
detected in cachectic cancer patient urine using MS techniques. These molecules
are candidates for potential targeting as novel biomarkers of skeletal muscle
wasting and cachexia in OGC patients. Biomarker strategies targeting myofibrillar,
cytoskeletal and microtubule-associated proteins within the context of future
longitudinal studies of large patient numbers will be required to assess fully the
changing prevalence of biomarkers within different cachectic populations.
In the next chapter (Part E), the study of biomarkers for use in clinical trials
continues. However, rather than focus on molecular markers of skeletal muscle
wasting, the use of objective assessment of PA as both a biomarker of skeletal
muscle function and an outcome measure of cancer cachexia is explored.
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Part E - Biomarkers of Muscle Function
in Cancer Cachexia
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Chapter 10 - Criterion-based validation of
accelerometer-based activity-monitoring using a
stable isotope dilution technique
10.1 Introduction
Patients with advanced cancer often report a significant decline in PF that has a
major impact on QoL [702], Such loss of QoL may be more pronounced in patients
with cancer cachexia [703]. When developing palliative therapies focused either on
the tumour or its systemic effects, one challenge is to use patient-centered outcomes
that are 'fit for purpose' and relate clinically to PF and QoL during everyday
situations [704],
In routine practice or clinical trials, PF is measured by healthcare provider
instruments [489, 535], which are of diagnostic value, but lack responsiveness to
change following disease progression and interventions. PA, as an indicator of PF,
is assessed traditionally by self-report. However, such tools are subjective,
correspond only loosely with objectively measured activity [705], and may fail to
recognise activity characteristic of frail populations [706]. Recently, objective
measurement of daily PA has been proposed as an important patient-centered
outcome in advanced cancer [495], Crucially, it has been shown that PA variables
correlate with some QoL scores in advanced cancer patients [380], and that PA can
be improved by nutriceutical intervention in cachectic pancreatic cancer patients
[277]. However, gold-standard PA assessments (e.g. stable isotope studies) can be
complex, patient-intense, and expensive, and often provide limited detail regarding
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different PA behaviours. In contrast, modern accelerometer-based activity-
monitoring systems potentially offer a patient-friendly methodology of long-term
PA assessment, which can be used easily in both the clinical and free-living
environments. Activity-monitoring systems can estimate EE based on the amplitude
and frequency of acceleration signals or on recognised activities [707]. Accurate
identification of postures and transfers in healthy young adults [708], older adults
[709], and persons with minor functional limitations [710, 711] by activity-
monitoring systems has been demonstrated previously. Activity monitoring systems
have also been trialled for the objective assessment of PA in cancer patients
undergoing palliative chemotherapy [380]. However, recognition of PA from
acceleration signals may be potentially more challenging in frail patients who walk
slowly and have a cautious movement pattern [712],
The aim of the present study was to assess whether a small, lightweight activity-
monitoring system (activPAL™) could be used as an objective measure of daily PA
and EE in both advanced cancer outpatients and healthy adults. More specifically,
the criterion-based validity of activPAL™ was tested with regard to TEE and EEA
against DLW and indirect calorimetry. Although activPAL™ offers a range of
potential PA outcome measures, TEE and EEA were chosen as the outcomes of
choice for validation as only these represent global and complete assessments of PA.




The activPAL™ meter records accurate measures of EE in advanced cancer
patients and healthy controls, which can be validated by the combination of DLW
and indirect calorimetry.
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10.3 Patients and healthy controls
Patients with advanced OGC (n=7), and healthy subjects (n=10 assessments in 9
subjects) with a wide spectrum of PA (ranging from sedentary office workers to
competitive athletes) were recruited (see Methods Chapter 2.1, p. 167), in order to
validate the activPAL™ meter across the full range of PA. Exclusion criteria
included physical handicap, severe co-morbidity/metastases that grossly impaired
mobility, or inability to complete the study protocol or
surgery/radiotherapy/chemotherapy during the previous 4 weeks. Recruits wore the
activPAL™ meter (see Methods Chapter 2.10.1, p.190) during a 2-week DLW
protocol (see Methods Chapter 2.10.3, p. 194). Urine samples were collected for
CF-IRMS analysis of stable isotope elimination rates (see Methods Chapter
2.10.3.3, p. 195) and calculation of TEE (see Methods Chapter 2.10.3.4, p. 195).
Recruits were required to collect and complete at least 7 days of activPAL™ data
[713]. Indirect calorimetry was performed to assess REE (see Methods Chapter
2.10.2, p.192).
10.4 Statistical analysis
'TEEmet was defined as the average MET.hrs/day over a recording period. To
derive 'EEAMet\ the number of MET.hrs awarded for non-activity
(24MET.hrs/day) was subtracted from TEEmet- METs are measured in kcal/kg/hr
and thus, to allow comparison between DLW and activPAL™, data were reduced
to kcal/kg/hr by dividing DLW and indirect calorimetry data (expressed as kcal/day)
by 24xbody weight, whereas activPAL™ data (expressed in MET.hrs/day) was
simply divided by 24. Variables expressed in kcal/kg/hr are denoted with by \
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Demographics are presented as means, SD and ranges, and dichotomous variables
are presented as absolute numbers and percentages. Differences between groups
were determined using Student's Independent Sample t-test using exact, two-sided
p-values. Bland-Altman plots with 95% limits of agreement (LOA) and percentage
absolute errors were used to assess agreement between methods expressed in
absolute units. Bi-variate relationships were assessed by Pearson's product moment
correlation and linear regression. Linear regression was also used to determine the
contribution of the two independent variables predicted REE and EEA by
ActivPAL™ (EEAacuvpal), on the dependent variable TEE by DLW (TEEDLW).
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10.5 Results
10.5.1 Patients and healthy subjects
Two recruited subjects did not complete 7 days of activPAL™ data during the 2-
week DLW protocol and were therefore excluded retrospectively. Fifteen
assessments were included (in 6 cancer patients and 9 healthy subjects). Cancer
patients did not differ from healthy subjects in LBM or fat mass (Table 10.1). As
expected, when assessed by DLW, cancer patients exhibited lower mean TEE
(2321kcal/day vs. 3202kcal/day; p=0.044) and EEA (742kcal/day vs. 1609kcal/day;
p=0.036) compared with healthy subjects (Table 10.2).
10.5.2 Resting energy expenditure
When expressed in relation to body weight, average measured REE1 for the entire
study cohort was 0.84kcal/kg/hr (SD=0.12, range=0.63-1.14). This value equates to
the EE of 1MET and differs from the hypothesised value of lkcal/kg/hr. Predicted
REE was derived by multiplication of 0.84kcal/kg/hr by 24xbody weight (Table
10.2). A Bland-Altman plot of the agreement between predicted REE (mean=1587
kcal/day, SD=259, range=l 160-2054) and measured REE (mean=1614 kcal/day,
SD=168, range= 1280-1885) demonstrated a mean difference of 27kcal/day
(SD=218; 95%LOA=-400, 454) or absolute percentage error of 1.7% (Figure 10.1).
10.5.3 Energy expenditure of activity
Median length of activPAL™ monitoring was 14 days (range=7-14). On regression
analysis, step count accounted for 80.0% of the variation in EEA'dlw (in kcal/kg/hr)







































































































































3140 (888, 2129- 5045)
2.09 (0.67, 1.50-3.43)
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Figure 10.1 Bland-Altman plot of agreement between REEacUvpal and
REEdlw-
Y axis defined by calculation: REEActivPAL - REEDlw- Dotted lines represent 95%
limits of agreement (bias +/- 2SD). Black circles represent cancer patients whereas
white circles represent healthy controls.
DLW = doubly labelled water; REE = resting energy expenditure.
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Step Count (steps per day)
Figure 10.2 Scatter plot of step count versus EEA by DLW (r =0.80).
Black circles represent cancer patients whereas white circles represent healthy
controls.
DLW = doubly labelled water; EEA = energy expenditure of activity.
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EEA'dlw was less strong (r2=0.52).
Values of EEA'dlw were higher than values of EEA'met (Figure 10.3). These two
variables expressed a non-linear relationship with equation:
EEA'niy^=15.08EEAlMET3'6' (r2=0.80) (Figure 10.3). Thus, a validated estimate of
EEA (in kcal/day) was derived using the equation:
EEAactjVPAL=24 x weight x 15.08EEA1met3'6'
This equation was transposed further to use the primary EE output of activPAL™,
namely TEEMet:
EEAactjVpAL=362 x weight x ((TEEmet-24)/24) 3 61
A Bland-Altman plot of the agreement between EEAactivpAL (mean=1244kcal/day,
SD=825, range=486-3334) and EEAdlw (mean=1262kcal/day, SD=807,
range=374-3424) demonstrated a mean difference of -18kcal/day (SD=347;
95%LOA=-699, 663) or absolute percentage error of 1.4% (Figure 10.4).
Furthermore, as TEE^REE'+EEA1, a validated estimate of TEE (in kcal/day) was
derived using the equation:
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Figure 10.3 Scatter plot of EEA'met versus EEA'dlw (r2=0.80).
Black circles represent cancer patients whereas white circles represent healthy
controls.
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Figure 10.4 Bland-Altman plot of agreement between EEAacUvpal and
EEAdlw-
Y axis defined by calculation: EEAacuvpal - EEAdlw- Dotted lines represent 95%
limits of agreement (bias +/- 2SD). Black circles represent cancer patients whereas
white circles represent healthy controls.
DLW = doubly labelled water; EEA = energy expenditure of activity.
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A Bland-Altman plot of the agreement between TEEactivpAL (mean=2859kcal/day,
SD=787, range=2129-5045) and TEEDLW (mean=2849kcal/day, SD=849,
range=2017-5309) demonstrated a mean difference of 9kcal/day (SD=411;
95%LOA=-796, 814) or absolute percentage error of 0.4% (Figure 10.5). No
obvious relationship was observed between TEEDLw and the difference in TEE
between the two methods as values were scattered evenly about the mean. In a
regression model, EEAActivPAL accounted for 85.1% of the variation in TEEdlw
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Figure 10.5 Bland-Altman plot of agreement between TEEacUvPal and
TEEdlw-
Y axis defined by calculation: TEEActivPAL - TEEDlw- Dotted lines represent 95%
limits of agreement (bias +/- 2SD). Black circles represent cancer patients whereas
white circles represent healthy controls.
DLW = doubly labelled water; TEE = total energy expenditure.
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10.6 Discussion
This study represents the first attempt to validate an activity-monitoring system in
patients with advanced cancer. It demonstrates that mean percentage errors in the
assessment of EE by the activPAL™ meter in healthy controls and advanced cancer
patients (with KPS 80-100) are low. However, to derive these small measurements
of mean error, an element of mathematical correction was required. For measured
EE variables, mean difference between the two methodologies (DLW and
activPAL™) was small: mean bias in TEE between activPAL™ and DLW was
only 9kcal/day, whereas the mean bias in EEA between the two methodologies was
an underestimation by activPAL™ of 18kcal/day. The results of the present study
show either similar or superior mean agreement between activPAL™ and DLW
compared with other studies of activity monitoring devices [714-717]. However, as
retrospective mathematical correction was required, further studies are required to
validate these measurements. Furthermore, despite small mean errors, within-
subject variability was high. For example, when considering EEA, the mean
measured EEADlw across the entire DLW study cohort was 1262kcal/day and yet
the 95%LOA between the two methodologies was approximately +/-700kcal/day i.e.
a potential variability of 55%. This high degree of variability would render the
conclusions of any intervention study using activPAL™-derived EEA as an
outcome measure very difficult to interpret. Sources of error that may have
introduced disagreement between methods in the current study would have included
under-report of steps during slow walking [712], Recently, it has been confirmed
that the activPAL™ meter is accurate in the registration of time spent in different
body postures and the number of sit-to-stand transfers, but is inaccurate at step
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count, in patients with advanced cancer (Guro Stene: personal communication from
a study carried out by a Norwegian group as a companion study to the present one).
These observations correspond with the body posture and transfer findings of other
validation studies of activPAL™ in healthy older persons [709], suggesting that
time in different body positions and numbers of transitions between positions are
reliable outcomes from the activity meter, even in frail persons. However, step
count in patients with advanced cancer demonstrated significant errors, particularly
in patients with lower KPS and slower gait speed. This is because slow gait speed
gives low acceleration amplitudes that may fail to be detected by the software
system as steps. Inspection of raw activPAL™ acceleration data in advanced cancer
patients has confirmed that steps registered by the monitor were left unrecognised
following software calculations. Similar high step count errors have also been
demonstrated in slow walkers (<0.8 m/sec) when using other activity-monitoring
systems [712, 718-720], and cumulatively, these observations suggests that, at the
present time, algorithms embedded in activity-monitoring softwares may not be
sophisticated enough to detect accurately step count in frail and slow walkers.
These same data also highlight the potential difficulties of validating PA outcome
measures in "mixed" populations. If step count might be altered by gait speed, it
could be argued that, in the future, validation studies should only be performed in
tightly grouped, homogenous cohorts of cancer patients. This argument might be
levelled at the present study, as, in a deliberate attempt to recruit individuals with a
wide range of EE, frail cancer patients and healthy controls were included within
the same study cohort.
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Although inaccuracy in step count is likely to have played a role in the widened
LOA observed within the present study, it is unlikely to be the sole reason, as there
were no obvious linear relationships between gold standard-derived measures of EE
(i.e. DLW-derived measures) and disagreement between methodologies. Another
potential source of variability may be differences in upper limb activity between
subjects. ActivPAL™ only records thigh activity and thus the relatively smaller
contributions of arm activity to TEE and EEA are not assessed. The non-linear
(power) relationship between EEA'met and EEA'dlw could therefore be explained
by a proportionally larger contribution of upper limb activity to EEA in fitter, more
active individuals. However, it is again worth noting that Bland-Altman plots did
not demonstrate any significant variations in bias by activPAL™ at extremes of
TEE and EEA.
Although cachectic cancer patients are known to exhibit higher REEs than healthy
controls, inter-subject variation in nutritional status or basal metabolic rate is
unlikely to explain observed differences in TEE or EEA between methodologies as,
in the present study, cancer patients and healthy controls did not differ significantly
with regards to weight, LBM, and measured REE. However, consistent with
previous studies [277], cancer patients did exhibit lower mean TEE and EEA.
The present study raises questions regarding the best way in which to utilise PA
outcome measures within the context of future intervention studies. Firstly, which
PA outcome measure would be superior for use? This study did not aim to compare
the validity of different outcomes derived from the meter. Thus, the type of PA
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measure that may be the most sensitive to change following anti-cancer/anti-
cachexia intervention is yet to be identified. Simple measures, such as step count,
may still represent superior outcomes for clinical trials, even in the face of
systematic under-reporting, compared with more complex, "combination"
outcomes, such as time spent upright or EEA. Future clinical trials may need to
assess a range of different outcomes from activity meters initially, in order to
stratify their relevant importance. Secondly, in which patients should the PA
outcome measure of choice be investigated? Recently, much interest has focused on
the concept of 'pre-cachexia' [25], and the fact that any systematic approach to the
treatment of cachexia requires early identification of patients at risk and institution
of prophylactic measures to attenuate the progression of disease, prior to the
development of significant weight loss. In the 'pre-cachectic' phase, patients are
more likely to be physically active than later in the disease trajectory, and thus the
accuracy of PA outcomes measured by activity-monitoring systems may be at their
highest.
In conclusion, activity meters are easy to use in the clinical setting, are time
efficient and cause minimal burden to patients. Furthermore, activity-monitoring
systems provide data on promising patient-focused outcomes for clinical trials and
the clinical management of patients with advanced cancer. ActivPAL™ can be used
to derive estimates of EE but there is considerable variability in the results, which
would be consistent, in part, with the described inaccuracy in step count in frail
patients. Further prospective EE validation studies are required. The role of
activity-monitoring systems should be supported in advanced cancer/cachexia
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patients, but particularly in patients with early cachexia receiving prophylactic
intervention to prevent further deterioration, as these more active patients might
have the highest accuracy of PA detection.
The present chapter has focused on the validation of an activity-monitoring system
with regards to the assessment of EE, arguably the most robust measure of global
PA. However, in the next chapter, all of the PA outcomes of the activPAL™ meter
are instead assessed in a group of advanced cancer patients undergoing palliative
chemotherapy, in an effort to detect how anti-cancer treatment and disease
longevity might impact on patient PA.
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Chapter 11 - Physical activity as an objective
measure of performance status and quality of life in
upper gastrointestinal cancer patients undergoing
palliative chemotherapy
11.1 Introduction
Depression, fatigue, nausea, anorexia, pain, disturbances in the sleep-wake cycle
and other symptoms may all affect cancer patients undergoing palliative
chemotherapy [721], Furthermore, certain chemotherapeutic agents are known to
worsen skeletal muscle depletion and thus exacerbate cancer cachexia. The result of
all these symptoms in advanced cancer patients is a number of adverse features,
including lower PS [8], impaired response to anti-cancer therapy [4], and,
ultimately, shortened survival [4].
In any future prophylactic management strategy for cancer cachexia, it is likely that
most patients will have been newly diagnosed with advanced disease. At this stage,
many patients will not yet have experienced significant weight loss, and may be
regarded as 'pre-cachectic' [25]. Such individuals are likely to be considered for
palliative chemotherapy. However, there are only limited objective data describing
in detail the functional consequences of advanced cancer, cachexia and palliative
chemotherapy. The data that do exist suggest that patients reduce their overall PA
in order to maintain energy equilibrium [277, 380], However, for cancer patients
living at home, 'non-exercise PA' (e.g. walking) is a significant component of daily
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PA, which plays an important role in social interaction and independent living. Any
reduction of non-exercise PA will thus impair independence and QoL.
In previous studies using the activPAL™ meter for one-off PA assessments of
advanced upper GI cancer patients undergoing palliative chemotherapy (n=20),
total energy expenditure was 8% lower, time spent upright was approximately two
hours/day less and step count was 43% lower compared with healthy, age-matched
controls [380], TEE (in METs) and step count correlated significantly with the
FACIT-F TOI (r=0.59, p<0.009) but not with the FAACT-TOI, EORTC QLQ-C30
Physical Functioning (PF), Fatigue or Global Health Status/QoF scores [380],
The aims of the present study were twofold. Firstly, to perform a longitudinal
analysis of objective PA in advanced upper GI cancer patients undergoing palliative
chemotherapy in order to investigate changes induced by treatment. Secondly, to
further investigate the relationship between PA, PS, mood and QoL in a larger
cohort of patient assessments.
360
11.2 Hypothesis
Objective measures of PA in advanced upper GI cancer patients are affected
deleteriously by palliative chemotherapy, and these changes are detectable using
the activPAL™ meter. PA measures correlate with PS, mood and QoL scores.
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11.3 Patients and healthy controls
Patients with advanced (stage IV) OGC (n=16) commencing on palliative
chemotherapy were recruited (see Methods Chapter 2.1, p. 167). Exclusion criteria
included physical handicap or severe co-morbidity/metastases that grossly impaired
mobility. At commencement of treatment, the intention was for each patient to
receive 6 cycles of chemotherapy. Patients wore the activPAL™ meter (see
Methods Chapter 2.10.1, p. 190) for 7 days at sequential time-points during
chemotherapy until either treatment was completed or the decision was taken by
oncology staff to discontinue treatment due to patient ill-health or deteriorating PS.
All time-point assessments were performed during periods whilst the patient was
living at home (i.e. not a hospital inpatient). Time-points were I) pre-
chemotherapy/after 1st cycle (i.e. at the beginning of intended chemotherapy); II)
after 2nd, 3rd or 4th cycles (i.e. during the middle of intended chemotherapy); and III)
after 5th or 6th cycle (i.e. at the end of intended chemotherapy). If the patient
completed 6 cycles of treatment and was able and willing to comply, a further time-
point was performed 2 months following chemotherapy completion (time-point IV).
At each time-point, nutritional assessment was performed (see Methods Chapter 2.2,
p. 168), and EORTC QLQ-C30, FAACT, FACIT-F and HADS questionnaires were
completed (see Methods Chapter 2.11, p. 196).
11.4 Statistical analysis
Due to the variability in validity of TEE and EEA between individual patients in
Chapter 10, EE has only been assessed using activPAL™-derived METs in the
present chapter (rather than attempt to convert METs to kcals). EEA has been
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chosen as the main EE output of activPAL™, as in this context, TEE simply equals
EEA + 30METs/day. EORTC QLQ-C30 data were reported and analysed using
linearised scores. Data are presented graphically using box plots. Mild outliers
(>1.5 times the IQR above the 3rd quartile/below the 1st quartile) are represented as
circles and extreme outliers (>3 times the IQR above the 3rd quartile/below the 1st
quartile) are presented as asterisks. Differences between multiple related groups
were determined by the Friedman test (FT), whereas differences between any 2
related groups were performed using the Wilcoxon signed-rank test (WT).
Differences between multiple independent groups were determined by the KWT,
whereas differences between any 2 independent groups were performed using the
MWT. All quoted p-values are two-sided asymptotic values except for MWT where
two-side exact p-values are reported. Correlation analysis was performed using
non-parametric Spearman's Rank Correlation Coefficient. When performing
correlation analysis, LBM was assessed as a percentage of total body weight (rather
than in kgs) in order to normalise LBM to body habitus. For observational analyses
of pooled data (e.g. correlation analyses), all data from all time-points (I-IV) were
included, but for longitudinal, time-series analyses, only data from time-points I to
III were included. Reverse time-series analysis was performed by considering each
patient's time-points in reverse order from the moment of cessation/completion of
treatment. Thus, the time-point closest to cessation/completion of treatment was
labelled time-point 1, the second time-point before the cessation/completion of
treatment was labelled time-point 2, and so on. In this way, the higher the





The demographics and chemotherapy data of the recruited patients (n=16) are
shown in Table 11.1. Five patients completed the full course of chemotherapy
whereas 11/16 patients discontinued treatment early (median 4.5 cycles, range 2-6).
Four patients performed the time-point I assessment only; 7 patients performed 2
sequential assessments; and 5 patients completed palliative chemotherapy and thus
performed at least 3 sequential assessments (3/5 of these latter patients completed a
further assessment at time-point IV). The total number of assessments was 36. A
consort diagram of the chemotherapy patients is shown in Figure 11.1. Median
percentage weight loss at time-point I was 8.3% (range 0.0-28.2).
11.5.2 Effect of palliative chemotherapy on physical activity
11.5.2.1 Longitudinal time-series analysis of individual patients
Patients demonstrated various PA responses following initiation of palliative
chemotherapy (Figures 11.2a-d). For example, when considering EEA, of those
patients who underwent sequential assessments at time-points I and II (n=12), 7
patients demonstrated deterioration in EEA, 4 patients demonstrated an elevation in
EEA and 1 patient remained static. Interestingly, of the 4 patients that demonstrated
an elevation in EEA, treatment was discontinued in 3 of them, and thus they did not




















Chemotherapy Completion (Yes: No) 5:11
Table 11.1 Demographics and chemotherapy regimens of the recruited
palliative chemotherapy patients (n=16).
C = cisplatin; E = epirubicin; F = 5-FU; M = mitomycin C; X = capecitabine.
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Pre-Chemo/lst Cycle 2nd~4th Cycle Sth/6th Cycle Post-Chemo
Figure 11.2C
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Figure 11.2D
Figure 11.2 Repeated assessments of PA measures of individual patients
during palliative chemotherapy. A) Time spent sitting/lying; B) Time spent
upright; C) Step count; D) EEA.
Patients demonstrated various PA responses following initiation of palliative
chemotherapy, including increased PA, decreased PA and no change.
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11.5.2.2 Longitudinal, related-samples, time-series analysis of patient
groups
In those patients who underwent sequential assessment at time-points I and II
(n=12), there were significant reductions in weight (median 72.5kg, range 50.6-
128.8 versus median 68.5kg, range 46.1-132.2; p=0.038), AMC (median 25.3cm,
range 17.8-32.0 versus median 23.8cm, range 18.1-28.7; p=0.034), and body fat
(median 19.6kg, range 14.2-46.3 versus median 15.9kg, range 10.0-46.1; p=0.008)
at time-point II compared with time-point I (WT for all comparisons), although
there was no significant difference in LBM. These changes in body composition
occurred despite the FAACT anorexia-cachexia syndrome (ACS) subscale score
actually improving (p=0.021, WT). There were no significant changes in either the
FAACT-TOI or FACIT-F TOI. Median PA measures also deteriorated between the
two time-points but these changes did not achieve statistical significance due to the
wide ranges of each measure (Figures 11.3a-d).
In those patients who underwent sequential assessments at time-points I, II and III
(n=5), similar deteriorations in median PA measures were observed across the time-
points, but again these changes did not achieve statistical significance (Figures
11.4a-d). In these patients, the FAACT Physical Well-Being (PWB) subscale score
decreased significantly across the time-points (p=0.034, FT), although there was no
change in the FAACT TOI or FACIT-F TOI. There were also no significant
changes in nutritional status, implying that those patients who complete
chemotherapy are those who do not develop severe cachexia. In contrast, those
patients who experience nutritional depletion discontinue treatment early.
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Pre-Chemo/1st Cycle 2nd4th Cycle
Figure 11.3C
Pre-Chemo/1st Cycle 2nd4th Cycle
Figure 11.3D
Figure 11.3 Box plots of different PA measures of patients undergoing
sequential assessments (time-points I and II) during chemotherapy (n=12). A)
Time spent sitting/lying; B) Time spent upright; C) Step count; D) EEA.



























Pre-Chemo/1 st Cycle 2nd-4th Cycle 5th/6th Cycle
Figure 11.4D
Figure 11.4 Box plots of different PA measures of patients undergoing
sequential assessments (time-points I, II and III) during chemotherapy (n=5).
A) Time spent sitting/lying; B) Time spent upright; C) Step count; D) EEA.
There was a non-significant trend (by FT) towards worsened PA as palliative
chemotherapy progressed. Asterisks represent extreme outliers.
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11.5.2.3 Relationship between PA and cessation/completion of
treatment
Baseline PA measures at time-point I did not correlate with the number of
chemotherapy cycles completed by each patient. Furthermore, baseline PA
measures did not differ significantly between patients who completed 6 cycles of
chemotherapy and patients who discontinued treatment early. In contrast, the
EORTC QLQ-C30 PF score at time-point I demonstrated a trend towards
correlation with chemotherapy cycle number (r=0.49, p=0.062), and the FAACT
Functional Well-Being (FWB) (p=0.007), FAC1T-F Fatigue (p=0.022), EORTC
QLQ-C30 Global Health Status/QoL (p=0.040) and PF (p=0.040) scores were
improved significantly in patients who completed chemotherapy compared with
those who did not. The FACIT-TOI at time-point I also demonstrated a trend
towards improvement in patients who completed chemotherapy (p=0.075).
Reverse time-series analysis demonstrated that median PA measures improved as
the time duration before cessation/completion of treatment lengthened (Figures
11.5a-d), but these changes did not achieve statistical significance when all time-
points (1,2 and 3) were considered. However, the FAACT PWB subscale score did
increase significantly as the time duration before cessation/completion of treatment
lengthened (p=0.024, KWT).
When time-points 1 and 3 were compared directly, time spent stepping increased
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Time-point
Figure 11.5D
Figure 11.5 Box plots of reverse time-series analysis of different PA
measures (n=16). A) Time spent sitting/lying; B) Time spent upright; C) Step
count; D) EEA.
Time-point 1 represents that closest to cessation/completion of chemotherapy.
Time-points 2 and 3 are of increasing time duration before cessation of treatment.
There was a non-significant trend (by KWT) towards improved PA as the time
duration before treatment cessation increased. Asterisks represent extreme outliers.
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spent upright (p=0.075), step count (p=0.091) and EEA (p=0.091) demonstrated
trends toward PA improvement. Furthermore, the EORTC QLQ-C30 Fatigue score
increased significantly between time-points 1 and 3 (p=0.033, MWT), and the
Global Elealth Status/QoL (p=0.066) and PF (p=0.066) scores demonstrated trends
toward increase.
11.5.3 Relationship between physical activity, nutritional status,
quality of life and mood
Time spent sitting or lying (r=-0.50, p=0.003), time spent standing (r=0.54,
p=0.001), time spent upright (r=0.50, p=0.003) and EEA (r=0.40, p=0.022)
correlated with the FACIT-F TOI. Only time spent standing (r=0.36, p=0.043)
correlated with the FAACT-TOI, despite the fact that time spent sitting or lying,
time spent standing, and time spent upright all correlated significantly with the
FAACT PWB (rvalues between 0.38-0.43; p<0.026) and Functional Well-Being
(FWB) (rvalues between 0.39-0.40; p<0.022) subscale scores, individual
components of the overall TOI. (EEA also correlated with the FWB subscale score
(r=0.36, p=0.034)). The lack of further correlations between PA measures and the
FAACT-TOI was due to the fact that PA measures did not correlate with the ACS
subscale score, the third component of the TOI (along with PWB and FWB).
However, despite the absence of an obvious relationship between PA measures and
the ACS subscale score, time spent sitting or lying (r=0.35, p=0.047), time spent
standing (r=-0.37, p=0.035), and time spent upright (r=-0.33, p=0.061) all
correlated or demonstrated a trend towards correlation with percentage weight loss.
LBM as a percentage of total body weight (rather than in kgs) correlated with time
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spent upright (r=0.35, p=0.041) and correlated inversely with time spent sitting or
lying (r=-0.35, p=0.041). LBM also correlated with time spent standing (r=0.33,
p=0.057) and time spent stepping (r=0.310, p=0.075).
Regarding EORTC QLQ-C30 scores, all PA measures, with the exception of step
cadence and up-down transition number, correlated with Global Health Status/QoL
score with r values between 0.38-0.43 (p<0.027), PF score with r values between
0.40-0.53 (p<0.007), and Fatigue score with r values between 0.40-0.53 (p<0.020).
When considering mood, only step count correlated inversely with the HADS-
Depression score (r=-0.34, p=0.044).
Percentage weight loss correlated inversely with the FAACT FWB (r=-0.47,
p=0.007), FAACT-TOI (r=-0.52, p=0.004), FACIT-F TOI (r=-0.38, p=0.040),
EORTC QFQ-C30 Global Health Status/QoL (r=-0.45, p=0.011), PF (r=-0.51,
p=0.003) and HADS-Depression (r=0.47, p=0.006), demonstrating the negative
impact that cachexia has on QoL and mood.
11.5.4 Relationship between physical activity and performance status
Excluding step cadence and up-down transitions, PA measures correlated with
WHO and KPS performance scores with r values between 0.34-0.48 (p<0.041). As
an example of the relationship observed between PA and PS, Figure 11.6 shows a
box-plot of step count across different scores of WHO PS. This figure demonstrates
the wide range and overlap of objective levels of PA that can be described by a


















Figure 11.6 Box plot of step count across different scores WHO performance
status scores (n=36 assessments in total).
Step count decreases as PS score increases (p=0.042, KW test). Results of MW
tests comparing individual groups are shown on the figure.
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median step count of 6046 steps/day (range 2293-8606); assessments with WHO
PS score 1 (n=21) had a median step count of 4390 steps/day (range 1007-7619);
assessments with WHO PS score 2 (n=2) had a median step count of 3985
steps/day (range 1588-6382); and assessments with WHO PS score 3 (n=3) had a
median step count of 1228 steps/day (range 919-2277) (p=0.042, KWT).
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11.6 Discussion
The present study describes a complex "journey" of PA taken by individual patients
with advanced upper GI cancer as they receive palliative chemotherapy. Individual
patients described worsened, improved or unchanged PA during treatment.
Furthermore, in some patients, PA measures fluctuated at different time-points
throughout treatment. However, the overall pattern (although largely statistically
non-significant) was one of deterioration in PA during palliative chemotherapy.
Similarly, when the data were analysed in reverse order from the point of cessation
of chemotherapy, a reduction in PA was noted near to the time of treatment
cessation. In particular, time spent stepping demonstrated a significant
improvement as time duration before chemotherapy cessation lengthened. Larger
longitudinal studies are required to confirm these findings and establish statistical
significance. Furthermore, additional data on disease response to chemotherapy
would help to tease out the separate impacts of chemotherapy and disease on PA.
Baseline FAACT FWB, FACIT-F Fatigue, EORTC QLQ-C30 Global Health
Status/QoL and PF scores were able to predict chemotherapy completion, whereas
PA measures were unable. It is not clear why this should be the case, but it may
simply be a reflection of the wide variation of habitual levels of PA seen at the
commencement of treatment. Surprisingly few data are available on the association
between baseline QoL and chemotherapy completion rates [722], although it has
been suggested that patients who have lower QoL scores may be less willing to
continue therapy [498]. Many previous QoL studies have targeted patients
undergoing follow-up after the cessation of therapy [513, 723], However, baseline
381
QOL has been shown previously to be capable of predicting patient survival. The
baseline EORTC QLQ-C30 PF scores predicted long-term survival in patients with
metastatic colorectal cancer [724] whereas, in newly diagnosed patients with
oesophageal cancer, an increase in the EORTC QLQ-C30 PF score of 10 points
corresponded to a 12% reduction in the likelihood of death [725]. Further studies
involving the pooling of various patient groups involved in activPAL™ studies are
underway in order to analyse the effect of PA on cancer patient survival.
With the exception of step cadence and up-down transitions, PA measures
correlated with EORTC QLQ-C30 Global Health Status/QoL, PF and Fatigue
scores. These observations are an advance beyond previous smaller studies that
could not demonstrate significant associations beyond PA and QoL [380]. Certain
PA measures, namely time spent sitting or lying, time spent standing, time spent
upright and EEA (but not step count), also correlated significantly with the FACIT-
F TOI score. These findings confirm that many PA measures can be used as
surrogate outcomes of QoL. The positive relationship observed between PA
measures and various QoL scores is encouraging. Different QoL questionnaire tools
are not indistinguishable and therefore cannot be assumed to be interchangeable
[502], However, if PA measures correlate with several different QoL tools, the
objective assessment of PA could be considered a superior and overall index of
QoL. Again, pooled studies of larger patient groups will characterise further
existent relationships between PA measures and QoL.
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Time spent standing correlated significantly with the FAACT-TOI score. The lack
of a relationship between other PA measures and the FAACT-TOI was largely
dependent on the fact that PA measures did not correlate with the FAACT ACS
subscale score. At first glance, this observation appears difficult to explain as
percentage weight loss correlated inversely with some PA measures and the ACS
subscale score (r=0.46, p=0.009). However, it prompts the suggestion that PA
measures do not adequately describe those symptoms identified by the ACS score.
Certainly, of the 12 questions that compose the ACS subscale score, 10/12 pertain
to patient appetite, early satiety, vomiting and general health, whereas only 2/12
questions relate to patient weight or body shape ("I am worried about my weight";
"I am concerned by how thin I look"). One might theorise that PA measures are
more likely to be influenced by objective changes in body composition (e.g. visible
reduction in weight) rather than subjective patient perceptions of decreased appetite.
Thus, the emphasis of the ACS score on nutritional intake rather than body
composition may be a contributory factor in the lack of association with PA
measures. This supposition is supported by evidence that weight loss is a larger
determinant (effect size 30%) than nutritional intake (effect size 20%) and
chemotherapy (effect size 10%) of EORTC QLQ-C30 PF scores [726]. Nutritional
intake was not formally assessed in the present study. However, percentage weight
loss was recorded, and it was shown that patients had lost a median of 8.3% weight
at baseline. Moreover, the institution of chemotherapy was associated with a further
loss of weight of approximately 3.7% (4.0kg). The observed weight loss will be one
mechanism that leads to the reduction of PA associated with chemotherapy,
presumably through a reduction in functional LBM. However, it is worth noting
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that, in the present study, BIA suggested that a large proportion of the lost body
compartment was fat rather than skeletal muscle. This finding may explain why the
observed reductions in PA associated with chemotherapy did not reach statistical
significance. Larger reductions in LBM may be required before it is reflected by a
significant impairment of patient PA. In the present study, LBM correlated with
some PA measures, and this observation would be consistent with the above
hypothesis.
Of all the PA measures, only step count correlated with depression scores. Further
studies are therefore required to ascertain the relationship between mood and PA in
advanced cancer. Interestingly, HADS-Depression scores also correlated
significantly with weight loss, which implies that either mechanisms that work
peripherally to produce weight loss also act centrally to cause depression (e.g. pro¬
inflammatory cytokines), or that undesirable changes in body composition affect
patient mood adversely.
The present study demonstrated that worsening PS was reflected in lower levels of
PA. However, it is apparent that subjective assessment of PS cannot be used to
describe activities in detail. Furthermore, PS does not take into account a patient's
objective, pre-morbid level of PA. Thus, two patients may have identical PS scores
but one could be an elite athlete whereas the other leads a sedentary lifestyle.
Therefore, PS scores offer a misleading impression of the actual level of PA or the
finite deterioration of PA that has been caused by disease or subsequent treatment.
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In the present study, patient assessments that had been assigned the same WHO PS
score varied by as much as 6000 steps/day, or more than 5 times the lowest step
count limit. The WHO scale differentiates PS scores of 2 and 3 on the basis of
whether or not someone is 'up and about' more than 50% of the waking time.
Assuming a waking time of 16 hours/day, not one assessment in the present study
exhibited a measure of waking time spent upright of >50% (median percentage
waking time spent upright 24.6%, range 4.0-43.0). If one considers the average day
of a healthy but sedentary individual (e.g. office worker), one can see that even
healthy individuals are unlikely to spend >50% of waking time upright, thus
highlighting the artificiality and subjectivity of PS.
PA measures show promise as outcomes for use in trials of anti-cancer and anti-
cachexia therapies, but their employment may now be timelier than ever. Recent
studies have focused on the use of exercise as an anti-cachexia therapy in advanced
cancer patients [727] [728] and PA measures would be the perfect outcomes to
assess its efficacy and compliance. Most studies to date have been of breast cancer
patients offered aerobic or resistance exercise programmes [418], Initial results
have been successful with median rates of uptake and completion of 63% and 87%,
respectively [418], A supervised high intensity exercise intervention in 269 cancer
patients undergoing chemotherapy resulted in improvements in fatigue, PF, aerobic
capacity (measured by maximal 02 consumption) and muscular strength, but not
global QoL [729]. In lymphoma patients, aerobic exercise training resulted in
improvement in PF, global QoL, fatigue, depression, cardiovascular fitness, and
LBM [422],
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In conclusion, palliative chemotherapy is likely to cause a deterioration in PA,
although larger studies are required to confirm these findings and establish the
predictive ability of PA measures on chemotherapy completion rates and survival.
PA measures correlate with QoL scores, including global QoL and PF. Lastly, PA
measures highlight the subjectivity and lack of detail offered by PS scores in
advanced cancer. The objective assessment of PA is now a relatively simple
procedure, and its use should be considered as a biomarker of skeletal muscle
function in the development of outcome measures in trial methodology of anti¬
cancer and anti-cachexia therapies.
This chapter represents the last of the Results section. In the next section, the
findings of the entire thesis are synthesised into a general discussion of the impact
of this thesis on cancer cachexia research.
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Part F - General Discussion, Bibliography
and Appendices
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Chapter 12 - General discussion
12.1 Summary of thesis findings and relevance to cancer
cachexia therapy
At the end of each of the nine Results chapters of this thesis, there is a detailed
discussion of the experimental findings. In this final Discussion, the work of the
thesis is amalgamated, limitations are discussed and the results are placed in
context. Furthermore, ongoing research studies based on the findings of this thesis
are described.
In the management of cancer cachexia, there is a pressing need for biomarkers that
are capable of recognising patients in the 'pre-cachectic' phase, prior to the
development of significant weight loss or muscle wasting, because early
multimodal intervention at this stage is more likely to be successful. These
biomarkers should either function as mediators themselves, or reflect the activity of
mediators, to identify both patients at risk and pharmacological targets. There is a
further need for biomarkers that allow the assessment of response to treatment in
key organs such as skeletal muscle. With these unmet clinical needs in mind, the
general aims of the present thesis were to:
1. Investigate tumour-derived mediators of cancer cachexia (including MIC-1,
a potential 'crossover' factor of both tumour and host derivation).
2. Investigate host-derived mediators of cancer cachexia.
3. Analyse metabolic/end-organ changes in skeletal muscle.
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4. Investigate biochemical biomarkers of skeletal muscle wasting.
5. Investigate clinical biomarkers of skeletal muscle function.
Figure 12.1 represents a schematic diagram of the way in which each chapter of the
present thesis has tackled a different component of cancer cachexia within the
context of the above general aims. Upper GI cancer patients were chosen as the
models for investigation in the clinical studies within this thesis as such patients are
known to experience high rates of cachexia [4].
In Chapters 3 and 4, dermcidin mRNA expression, as a proxy of PIF expression,
was analysed in human tumour tissue and immortalised cell lines. PIF is thought to
be a possible tumour-derived mediator of skeletal muscle wasting in cancer
cachexia, based on data derived predominantly from murine and in vitro models [17,
540]. However, controversy surrounds the existence of a potential human
homologue of PIF (for a detailed analysis of the unresolved biology of PIF see
Chapter 1.6.1, p.69). In particular, the mAb used to identify PIF has been reported
as non-specific, and capable of binding to other common proteins such as albumin
and Ig K-light chains [208]. Moreover, clinical studies using this mAb do not
associate PEF immunoreactivity specifically with malignancy, weight loss, muscle
catabolism [208, 209] or survival [183, 208]. Other difficulties arise when
considering that PIF appears to be transcribed from a gene (known as either DCD
or DSEP) that, depending on both the extent of transcription and post-
transcriptional/translational modification, may produce other functional proteins
[194, 195]. The unprocessed-110 amino acid protein product is known as dermcidin
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or HCAP, but this product incorporates several different sequence components,
including the 30-amino acid PIF-CP (Y-P30), the 47-amino acid antimicrobial
peptide found in human sweat (DCD-1), a 13-amino acid propeptide, and a 19-
amino acid signal peptide (see Figure 1.6, p.72). Due to the lack of a reliable and
sensitive method of PIF protein detection in human tissues/samples, dermcidin
mRNA expression was used as a proxy of PIF expression within the present thesis.
However, although dermcidin mRNA expression has been used previously as a
human homologue of PIF during investigations of human cancer tissue [197], at
present, there is no strong evidence that human PIF is indeed a downstream product
of dermcidin (through an unknown mechanism of post-trasncriptional/translational
processing), or that increased expression of dermcidin correlates with increased
expression of human PIF.
Using real-time PCR, dermcidin mRNA was expressed in 60% of pancreatic cancer
biopsies and 4% of OGC biopsies, but not in prostate cancer samples,
demonstrating the variable expression of this gene in different cancer types.
However, the finding that dermcidin was not expressed in primary prostate cancer
was discordant with that of a previous study by Wang et al [197]. These differences
may be due to either differing experimental techniques, including primer disparities
(note the difference in findings between the PIF and HCAP primers in Chapter 4)
or differences in the nature of the positive control. However, the low expression of
dermcidin mRNA in the majority of non-prostate cancer samples would support the
conclusion that dermcidin is unlikely to play a significant pro-cachectic role in
primary prostate cancer.
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Wang et al also identified dermcidin expression in metastatic prostate cancer
deposits [197], and thus it could be hypothesised that high levels of dermcidin
expression by tumour cells may only take place in the context of advanced
metastatic disease. However, although distant metastatic deposits were not included
in the present thesis, immortalised cell lines with a metastatic origin were analysed
(e.g. PC-3M, which was originally derived from liver metastases following
injection of human prostate adenocarcinoma cells into nude mice). Dermcidin
mRNA expression was absent in such cell lines using real-time PCR (PC-3M has a
CT value of 40). In fact, PC-3M cells required transfection with the
pcDNA3.1+DCD plasmid (during the generation of the positive control) to ensure
high expression levels of dermcidin mRNA (CT value of 23.1). Ultimately, the
question of dermcidin expression by metastatic deposits would be best answered by
a matched-pair comparison of expression levels between primary cancer tissue and
metastases in patients with advanced malignancy. However, currently, the findings
of the present thesis do not support or suggest increased dermcidin expression in
metastatic prostate cancer at least.
It is interesting that dermcidin mRNA was qualitatively detectable by RT-PCR in
several pancreatic and prostatic cell lines (including CFPAC, MIA-Pa-Ca-2, PC-3,
PC-3M, and DU145), but that quantitative expression by real-time PCR
demonstrated that the finite levels of expressed dermcidin mRNA were either low or
absent. This suggests that RT-PCR is capable of amplifying tiny amounts of
dermcidin mRNA sufficiently to allow detection by gel electrophoresis, despite the
fact that actual expressed levels of mRNA (and hence protein) may be insignificant
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clinically. (Four i.v. injections of 7-10|lg of murine PIF induced weight loss in mice,
even though some of the compound weight could be attributed to albumin bound to
PIF [185, 730], Moreover, murine PIF is reported as having high affinity for its
receptor [211]. However, the finite minimal concentration of a human homologue of
PIF that is required to have biological action in vivo is unknown). Thus, real-time
PCR may be more useful (than RT-PCR) in future studies as a true measure of
dermcidin mRNA activity.
Sequence analysis of the amplified dermcidin RT-PCR products derived from cell
lines did not detect any sequences that would increase the probability of N- or O-
glycosylation and thus increase the likelihood of a functional human PIF [203, 204],
The primers used for this analysis yielded variable results. PIF primers amplified
dermcidin cDNA from 8/10 cell lines, whereas HCAP primers amplified dermcidin
from only 6/10 cell lines and were not successful at permitting sequence
identification. Clearly, the choice of molecular analytical tool can affect the results
obtained when investigating such a controversial gene as DCD.
In summary, the failure of the present thesis to identify robust expression of
dermcidin in human cancer tissue and cell lines, in the context of no accurate
methodology to detect PIF protein, means that further investigation of a putative
human homologue of PIF remains difficult at this time. Large clinical studies of
dermcidin expression within patient tumour samples are unlikely to demonstrate
success of dermcidin as an early, sensitive biomarker of muscle wasting, as
expression is likely to be low or absent in many tumours. If undertaken, such studies
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should focus predominantly on cancer types where there is evidence (albeit small)
of regular dermcidin expression (e.g. pancreatic cancer). Initially, smaller studies
that utilise novel PIF protein detection methods (e.g. protein capture using the
putative PIF receptor) may be more useful to firstly confirm the presence of human
PIF, and then secondly, validate a sensitive measure of detection. Once done, these
studies could then be expanded within larger patient populations to assess the
usefulness of PIF as a biomarker of human cancer cachexia.
In Chapter 5, plasma MIC-1 was investigated within a cohort of patients with OGC
(n=293) as another potential tumour-derived mediator in the aetiology of cancer
cachexia [254]. Initially, MIC-1 had been selected for investigation as a potential
mediator derived from both tumour cells and TAMs i.e. a factor that crosses the
boundary between tumour-derived and circulating mediators. However, although
marcrophage-derived secretion of MIC-1 has not been analysed formally within the
context of cancer, previous data obtained from human, murine and in vitro studies of
prostate cancer has demonstrated that MIC-1 appears to be derived from tumour
cells [253, 254], Assuming that the same regulatory mechanisms of MIC-1
expression exist in OGC (the present thesis did not investigate the cellular source of
MIC-1), MIC-1 could also be considered a tumour-derived mediator within this
cancer type. Certainly, plasma MIC-1 concentrations were associated with tumour
site, stage and grade in OGC patients, supporting the hypothesis that OGC cancer
cells influence MIC-1 expression. However, plasma MIC-1 concentrations also
correlated independently with markers of systemic inflammation (namely CRP and
the mGPS), implying that MIC-1 acts as either an upstream inducer of the APPR or,
394
possibly, a downstream effector (although this latter hypothesis would require
reverse crosstalk between the liver and the tumour, a potential pathway that has not
yet been investigated in cancer cachexia). On linear regression, the effect size of
plasma MIC-1 on the variation observed in plasma CRP was only small (5.9%).
However, the association between plasma MIC-1 and CRP was highly significant,
implying that tumour cells are not necessarily the only source of circulating MIC-1
and that other inflammatory cells (e.g. monocytic PBMCs and macrophages) might
also secrete additional MIC-1. Thus, in future studies of factors that may induce the
APPR in cancer cachexia, MIC-1 would be a suitable candidate for investigation.
Co-culture experiments using PBMCs/macrophages, isolated human hepatocytes
and anti-MIC-1 antibodies may be useful to confirm both the cellular source of
MIC-1 secretion in cancer patients, and the end-organ effects of MIC-1. Figure 12.2
represents a diagram of the hypothesised role of MIC-1 in the aetiology of the
hepatic APPR in cancer cachexia.
Studies in mice with xenografted prostate tumours have suggested that the
mechanism underlying MIC-1-induced weight loss is anorexia caused by reduced
hypothalamic NPY expression and increased POMC expression [254]. However, in
patients with OGC, plasma MIC-1 concentrations did not correlate independently
with measures of nutritional status. Furthermore, plasma MIC-1 correlated only
weakly with diet score. Taken together, these observations imply that the central
modulation of appetite control observed in murine studies of MIC-1 may not hold
true in humans, particularly those with OGC. This assumption could be tested using







Figure 12.2 The hypothesised role of MIC-1 in the aetiology of the hepatic
acute phase protein response in cancer cachexia.
MIC-1 is secreted by tumour cells to initiate a small but significant induction of the
acute phase response, including a rise in plasma levels of CRP. At the present time,
it is unknown if TAMs are involved in the secretion of MIC-1, or if MIC-1 acts
directly on the liver or works indirectly through activation of PBMCs with further
release of other inflammatory intermediates such as IL-6. Dotted lines represent
possible, as yet uninvestigated, pathways.
CRP = C-reactive protein; IL-6 = interleukin 6; MIC-1 = macrophage inhibitory
cytokine-1; PBMC = peripheral blood mononuclear cell; TAM = tumour-associated
macrophage.
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of the brain following administration of exogenous MIC-1. As there was no
independent association between MIC-1 and nutritional status, and the effect size of
MIC-1 on CRP was small, it is perhaps not surprising also that plasma MIC-1 was
not an independent determinant of survival on multivariate analysis.
In summary, the present thesis has shown a potential role for MIC-1 in the induction
of the APPR in humans with cancer cachexia, but not nutritional depletion.
Therefore, it would appear unlikely that plasma MIC-1 concentration could function
as a sensitive, early biomarker of muscle wasting. In any future effort to establish
MIC-1 as a biomarker, a final consensus would need to be drawn regarding the true
normal range of plasma MIC-1, and whether or not this varies with age (as
suggested by the present thesis). At this present time, in the face of a lack of human
data linking MIC-1 to nutritional status, it would be difficult to justify randomised
controlled trials of targeted anti-MIC-1 therapies as a means of ameliorating cancer
cachexia.
In Chapter 6, the topic of focus changed from tumour-derived mediators to host-
derived circulating mediators. In particular, the potential role of neuroendocrine (sex
steroid) alterations in the aetiology of cancer cachexia was investigated. Sex steroid
abnormalities were hypothesised to be involved in cancer cachexia because of their
roles in normal muscle homeostasis [731]. In adult males, the maintenance of
muscle mass is controlled, in part, by testosterone acting through the AR and via
other indirect mechanisms (see Chapter 1.5.1.1, p.56), whereas, in elderly females,
post-menopausal loss of oestradiol is considered to be one of the main causes of
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age-related sarcopenia [611]. For the present study, a cohort of advanced pancreatic
cancer patients (n=167) was chosen as the model of investigation as pancreatic
cancer is associated with the most aggressive form of cachexia and its routine
treatment does not involve anti-androgen therapy (c.f. prostate cancer). In male
patients, hypogonadism (defined as a sub-normal level of cFT) was found in 73% of
male cancer patients. Futhermore, hypogonadism (defined as sub-normal levels of
either cFT or TT) was associated with worsened nutritional status, increased weight
loss, systemic inflammation, and shortened survival. The reasons for the high
prevalence of hypogonadism within male cancer patients is not known, but
hypothesised reasons include testicular suppression by pro-inflammatory cytokines,
and elevation in SHBG levels causing reduced levels of bioavailable testosterone
(SHBG itself may be an acute phase reactant in males with cancer as elevated serum
levels correlated with systemic inflammation [586]). Furthermore, one must
consider that hypogonadism in elderly males with cancer is also occurring on a
background rate of 20% [584] seen in otherwise 'healthy' males aged 60 to 80 years.
Perhaps one way in which to consider hypogonadism in the context of cancer
cachexia might be as a 'sick eugonadal syndrome' (analogous to the sick euthyroid
syndrome). In this way, the hypothalamic-pituitary-gonadal axis is not dysfunctional
or structurally abnormal but is responding to the presence of a non-gonadal illness
(i.e. cancer cachexia) in an aberrant fashion. The mechanism by which this sick
eugonadal syndrome links to worsened survival is unclear, however, as the limited
longevity of advanced pancreatic cancer patients would not support hypogonadism-
driven muscle wasting as the sole cause of death. Iatrogenic induction of
hypogonadism in males with prostate cancer only causes loss of LBM at a rate of
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2% per 6 months [600], and so it is unlikely that muscle effects alone would result
in demise. Rather, it is likely that hypogonadism acts as an overall frailty index that
reflects and incorporates several poor prognostic factors including, but not limited to,
the presence of tumour with systemic effects, ongoing muscle atrophy and the
presence of systemic inflammation.
Opioids inhibit the release of hypophyseal gonadotrophins and are thus an iatrogenic
cause of hypogonadotrophic hypogonadism [587]. In the present thesis, opioids
were also associated with worsened outcomes in male cancer patients. Within the
context of the present thesis, it was not possible to determine if this association was
the result of an opioid-induced anti-androgenic effect or a reflection of the fact that
opioids are often administered to patients with progressive advanced disease.
Previous studies have shown pain at diagnosis to be an independent poor prognostic
factor in pancreatic cancer [582], suggesting that the host inflammatory response
[613], pain-induced stress or the pattern of tumour invasion could also underlie any
detrimental response to opioids.
Clearly, the present thesis was only an association study and so cause and effect
does need to be establised by therapeutic intervention trials. However, taken
together, the results would support trials of androgen replacement (e.g. SARMs) as
an anti-cachexia agent in male cancer patients. To date, similar trials have been
carried out in HIV patients [107] and aged men [108], whereas Phase I and II
studies have been carried out in the cancer population [106]. Future trials could be
stargeted specifically to those male cancer patients who have documented
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hypogonadism. Such targeting of patients with documented hormonal abnormalities
might prevent a lack of positive findings, which has hampered previous trials of
hormonal therapies (e.g. flutamide [605], tamoxifen [607]) in patients with
pancreatic cancer. Additional study arms could be included that combine androgen
replacement with anti-inflammatory therapies, particularly as a recently published
study has suggested that hypogonadism and systemic inflammation can be
considered as additive, synergistic problems, which, if both present, place the
patient in a very poor prognostic group [732], In the present thesis, it has been
shown that hypogonadism and systemic inflammation are related intimately, and
thus it may not be possible to separate fully the two conditions (Figure 12.3
represents a proposed mechanism for the whole interaction between sex steroids,
systemic inflammation and opioid therapy). However, a synergistic approach to
treatment with combination anti-androgen/anti-inflammatory may be superior to
single therapy strategies. In any future trial, male patients receiving opioids should
also be considered as high risk of becoming hypogonadal, and, where possible,
alternative methods of analgesia (e.g. coeliac axis blockade) could be explored.
However, it is not ethical to withdraw opioids from a patient in significant pain if
there is no suitable analgesic alternative, and such a strategy should not be
supported.
Pancreas is a sex steroid-responsive tissue [601-603] and therefore pancreatic cancer
has been the subject of a number of experimental hormonal therapies. At first glance,
one might expect that previous trials of flutamide, an anti-androgen, should have
resulted in worsened survival of pancreatic cancer patients, rather than the lack
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of positive findings observed in some studies [605]. However, such trials have been
carried out in only small mixed populations of both men and women.
Although hypogonadism was the main finding in male patients with advanced
pancreatic cancer, relative 'hyperoestrogenism' was the chief observation in
females. Eighteen percent of elderly female pancreatic cancer patients exhibited
premenopausal serum concentrations of oestradiol. Furthermore, such
hyperoestrogenism was associated with systemic inflammation and worsened
survival, but not depleted nutritional status. Thus, although androgen replacement
in male patients might be a suitable strategy with which to improve nutritional
status and possibly survival, anti-oestrogen therapy in female patients might extend
survival without impact on nutritional or functional status. The mechanism
underlying the aetiology of hyperoestrogenism was hypothesised as cytokine-
induced stimulation of extragonadal aromatase activity, but the mechanism
underlying the deleterious effects of hyperoestrogenism remains unclear. At the
very least, hyperoestrogenism is a marker of systemic inflammation and therefore
one might expect it to correlate with shortened survival.
Female hyperoestrogenism was less prevalent than male hypogonadism (18% of
female patients versus 73% of male patients), and thus a targeted strategy of
hormonal manipulation might be even more important in female patients to avoid
negative findings. Previous trials of anti-oestrogen therapy (tamoxifen) in mixed
populations of men and women with pancreatic cancer have yielded variable results,
although several studies have shown an improvement in survival [608, 610],
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However, the relatively low prevalence of female hyperoestrogenism might imply
that the beneficial results of tamoxifen observed in all-comer trials must represent a
tumour effect rather than a body-wide effect of hormonal manipulation. In any
future trials, augmentation of hormonal therapies with anti-inflammatory agents
would appear to be as valid in female patients as in males.
One limitation of the current thesis is that serum hormone levels were only assessed
at a single time point. It would be interesting to observe the natural history of sex
steroid concentrations over the entire time course of a cancer patient's disease and
to correlate these concentrations with markers of the APPR and measures of
nutritional status. It is known that systemic inflammation fluctuates in severity with
time, and thus, it would be expected that sex steroid concentrations might mirror
such inflammatory variations. However, in the hypothesised 'sick eugonadal
syndrome' model, one would anticipate that, as the underlying disease progresses
and the severity of cachexia increases, abnormalities in the hypothalamic-pituitary-
gonadal axis might worsen. Derangement of the neuroendocrine axis system might
even represent a key mechanism in determining the mode of death in pancreatic
cancer, as low testosterone levels in males and high oestradiol levels in females
might confer increased susceptibility to cardiac arrhythmias [733]. A longitudinal,
observational study of sex steroid levels in cancer might also provide clues as to the
best timing of administration for hormonal therapies.
In summary, male hypogonadism would appear to represent a potential marker of
cachexia to be employed in future studies, whereas female hyperoestrogenism,
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although not necessarily a marker of depleted nutritional status, is also a marker of
poor patient prognosis. These results demonstrate sexual dimorphism between men
and women regarding the predominant hormonal patterns in advanced pancreatic
cancer. This opens the field to the possibility of other sex-specific alterations in
cancer cachexia. It has been known for several years that male patients with lung
cancer experience an eightfold faster rate of weight loss and shortened survival
compared with female patients matched for disease stage [734], Furthermore, in a
recent CT analysis of body composition, 61% of male patients with NSCLC were
classified as sarcopenic compared with only 31% of women [29]. Moreover, recent
reviews of the literature have suggested that sexual dimorphism influences the
regulation of muscle mass in response to ageing. In particular, younger women are
especially responsive to training compared with older women and men of all ages,
whereas postmenopausal women exhibit a greater anabolic resistance than older
men [735, 736], This sexual dimorphism may also extend to forms of cachexia
caused by chronic diseases other than cancer. For example, neutron activation
analysis of patients with liver cirrhosis demonstrated that protein depletion was
significantly more prevalent in men (63%) than in women (28%) [737]. Further
studies of other disease types are awaited.
Chapter 6 was the last to consider the role of mediators (be they tumour- or host-
derived) in the aetiology of cancer cachexia. In Chapters 7 and 8, metabolic
changes within skeletal muscle as a result of mediator action were investigated. In
Chapter 7, the prevalence of DGC deregulation within rectus abdominis samples
from a cohort of patients with OGC (n=27) was analysed. The DGC is a membrane-
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bound protein complex that connects the ECM with the intracellular cytoskeleton,
and protects skeletal muscle from contraction-induced injuries [317], Genetic
abnormalities in this complex are known to be the cause of certain types of
muscular dystrophy [631], but the possibility that acquired DGC abnormalities
might relate to cancer cachexia was explored within the present thesis. The
presence of DGC deregulation, incorporating reduced dystrophin expression,
hyperglycosylation of (3-DG and hyperglycosylation of P-SG, was found in 63% of
patient samples. Furthermore, in the same samples, reductions in DGC complex
association and actin-myosin complex association were also seen. DGC
deregulation was associated strongly with the presence of systemic inflammation,
suggesting that circulating pro-inflammatory cytokines may be the causative
mediators that induce sarcolemmal structural abnormalities. Furthermore, DGC
deregulation was associated with a trend towards worsened performance status,
implying that DGC deregulation could act successfully as a biomarker of muscle
function. (This idea would be consistent with the muscular weakness experienced
by patients with muscular dystrophy, who also exhibit DGC deregulation).
However, DGC deregulation was not associated significantly with weight loss. It is
unclear if this lack of relationship to nutritional status was due simply to the
relatively small number of muscle samples within the present thesis, as patients
with DGC deregulation did have a higher median weight loss than patients with
normal DGC (6.6% vs 0.2%, NS). Therefore, the question is still open as to
whether or not DGC deregulation is an upstream mechanism of intracellular protein
degradation within human skeletal muscle, or an end-organ effect (i.e. disruption of
membrane stability) in its own right. At present, murine studies have suggested that
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DGC deregulation might interact with the UPP (in an NF-KB-independent fashion)
to induce muscle wasting [321], but similar mechanistic studies are required in
humans to confirm this hypothesis.
The exact regulatory mechanisms underlying the reduced dystrophin expression
and the hyperglycosylation of other DGC members are also unknown. Interestingly,
in Western blots of patients with deregulated DGC, dystrophin expression appears
to be effectively absent. A similar absence can also be observed in patients with
muscular dystrophy [738], Yet, in the face of weakened but intact muscle function,
a complete absence of dystrophin might appear unlikely. The murine mAb reacts
strongly with the carboxy terminus (between amino acids 3669 and 3685) of human
dystrophin and shows no cross reactivity with mdx mouse tissue. Thus, it is unclear
if dytrophin has been truly lost or if the epitope recognised by the antibody has
been simply cleaved off.
Aberrant glycosylation of DGC members has been observed previously in specific
forms of muscular dystrophy (e.g. muscle eye brain disease and Fukuyama
congenital muscular dystrophy) [739]. However, these are predominantly
hypoglycosylation events of a-DG, as a result of mutations in certain
glycosyltransferase genes (protein O-mannosyl-transferase [POMT] 1; POMT2;
protein O-linked-mannose beta-l,2-N-acetylglucosaminyltransferase [POMGnT] 1;
fukutin; fukutin-related protein [FKRP]; and like-glycosyltransferase [LARGE])
[740], resulting in defective interaction with the ligand laminin [739]. It is easy to
understand how genetic mutations might cause protein hypoglycosylation, but it is
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less simple to explain an acquired cause of hyperglycosylation. One hypothesis is
that glycosyltransferase activity is increased as a response to circulating pro-
cachectic mediators. Thus, such enzymes may represent druggable targets in cancer
cachexia once identified. Interestingly, if the existence of a human homologue of
PIF is proven conclusively, one might theorise that cancer cachexia is a syndrome
of inappropriate hyperglycosylation, as a functional PIF would also require
assembly of an extensive carbohydrate shell.
On univariate survival analysis, DGC deregulation was associated with shortened
patient survival. In fact, only surgical patients who exhibited deregulated muscle
DGC died during the follow up period of assessment. However, larger patient
studies are required in order to eradicate any potential Type I errors and to allow
multivariate modelling to confirm if DGC deregulation is an independent predictor
of survival. A further question that can be answered by larger studies is the exact
'power' of the prognostic ability of DGC deregulation. In the current thesis, muscle
samples were extracted from patients undergoing surgical resection with curative
intent, and yet peri-operative DGC analysis appeared capable of predicting death in
the face of potentially curable disease. CRP is one of the few other analytes that has
demonstrated equivalent prognostic power in being able to predict post-operative
survival in patients with OGC [88] and colorectal cancer [741], At first glance, the
concept of a marker that can predict death in the face of curable disease (on pre¬
operative staging investigations) appears contradictory. However, it is known that
upper GI cancer has a high propensity for early recurrence even when
histopathological examination of the resected specimen suggests an RO resection
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[742], Pre/peri-operative elevated CRP and deregulated muscle DGC both imply a
tumour that, although localised anatomically, is having systemic effects. Thus, it
would not be surprising if these were the same patients who had sub-clinical
micrometastases. Larger clinical studies linking DGC status to pathological/nodal
status would be enlightening.
In summary, DGC deregulation can be found in patients with OGC, and it is likely
that in larger clinical studies it will be confirmed as a marker of both cachexia and
poor prognosis. Future studies might use ROC curves to assess the relationship
between DGC deregulation and varying clinical definitions of cachexia. As DGC
deregulation has already been proven conclusively (in the context of muscular
dystrophy) to result in muscle weakness and increased fatigue, DGC deregulation
might also represent a useful marker of patient functional status. This hypothesis is
supported by the present thesis that demonstrated a trend towards worsened KPS in
patients with deregulated DGC. If DGC deregulation were confirmed as a key
mechanism in cachexia and an independent predictor of survival, some treatments
being trialed for use in patients with muscular dystrophy would also be applicable
to the treatment of cancer cachexia. Examples of medications and strategies include
losartan (angiotensin II receptor anatagonist) [743], Protandim (anti-oxidant
nutritional supplement) [744], techniques of utrophin upregulation [745], and
pericyte stem cell replacement [746]. Doubt surrounds as to whether or not
dystrophin gene replacement therapy, arguably the most discussed potential
treatment for muscular dystrophy, would be beneficial (or ethically advisable) as, at
present, it is unknown if gene therapy-induced supra-physiological levels of
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dystrophin might be sufficient to overcome cachexia, or even if patients with cancer
cachexia also have underlying genetic defects of dystrophin. To date,
polymorphism studies of patients with cancer cachexia have not demonstrated any
sequence variants of significance within the dystrophin gene, although genome-
wide association studies are awaited.
Muscle mass is determined by the balance between protein synthesis and protein
degradation. Intracellular signalling mechanisms of either process may be key
targets for therapeutic intervention (see Figure 1.11, p. 101, and Figure 1.12, p. 102).
PKR is a serine/threonine specific protein kinase, which undergoes
autophosphorylation and activation, in the presence of interferon, in response to
viral attack [636] (see Figure 8.1). Activated PKR phosphorylates several protein
substrates including the a-subunit of eIF2 [637], resulting in inhibition of protein
synthesis in pre-clinical models [190]. Furthermore, phosphorylated PKR has been
shown to induce NF-xB-dependent protein degradation via the UPP in vitro [188,
190, 652]. In Chapter 8, increased phospho forms of PKR and eEF2a were detected
in rectus abdominis samples from weight-losing patients with OGC (n=15)
compared with healthy controls. Phospho PKR levels correlated with phospho
eIF2a levels, suggesting that PKR phosphorylation leads directly to eIF2a
phosphorylation. Moreover, phospho eIF2a levels correlated with myosin levels,
suggesting that PKR and eIF2a are intermediates in pathways leading to increased
protein degradation within skeletal muscle. Further studies to confirm mechanistic
links between PKR, NF-kB and the UPP have not yet been performed in human
muscle.
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Although the present study confirmed a clear alteration in phosphorylated mediator
levels between weight-losing cancer patients and controls, there did not appear to
be a correlation between the degree of weight loss and the level of mediator
phosphorylation. In studies using murine MAC 16 cachexia model, these changes
appeared to be progressive [652], Furthermore, studies of other intramuscular
mediators of protein degradation have shown that as weight loss increases, mediator
levels reach a maximum peak before falling again [360]. One reason for this
phenomenon is that depression of protein synthesis may become more influential
than induction of protein degradation at severe/refractory stages of cachexia [360].
These observational differences may simply reflect differences between murine
models and the human condition, but further studies incorporating larger numbers
of patients with extreme weight loss would help to confirm this.
The present thesis represents an association study and, as of yet, there are no data
regarding the upstream or downstream mediators of PKR phosphorylation. In
murine and in vitro models, PIF and angiotensin II have been proposed as the
upstream inducers [188, 190], However, at present, there is no strong evidence for a
role for either of these mediators in human cancer cachexia. It would make sense to
combine future studies of PKR phosphorylation with DGC deregulation as both
were investigated in the same tissue type (namely, rectus abdominis skeletal muscle
samples from OGC patients) within the present thesis. In this way, it would be
interesting to investigate if phosphorylation of PKR/eIF2a is an intermediate
downstream step of deregulated DGC-induced protein degradation. Comparative
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studies of trunk with limb muscle groups would offer information on differences
between weight-bearing and non-weight-bearing muscles.
In summary, phospho PKR and phospho eIF2a would both appear to have potential
as future biomarkers of skeletal muscle wasting, as elevated levels were even
observed in some patients who had not yet experienced weight loss. Phosphorylated
mediator levels might also represent an effective marker of patient response to anti-
cachexia therapeutic intervention. However, such levels might only be used in a
"yes/no" fashion, and may not predict accurately or correlate with the severity of
cachexia experienced. Inhibitors of PKR, such as the Ca2+ chelator 1,2-bis (o-
aminphenoxy) ethane-N,N,N',N'-tetraacetic acid tetra (acetoxymethyl) ester
(BAPTA/AM) [190], D-myo-inositol 1,2,6-triphosphate [747], HMB [413], and
potentially, insulin and IGF-1[748], may be prospective therapeutic agents for
cancer cachexia.
In Chapters 7 and 8, intramuscular metabolic changes induced by cancer cachexia
were analysed. However, in Chapter 9, the subject of focus was altered to the
investigation of the end-organ effects of skeletal muscle wasting. Specifically, MS
analysis of human urine was performed in order to identify candidate protein
biomarkers of cachexia, including breakdown products of skeletal muscle protein
degradation. (The proposed hypothesis underlying the existence of cachectic
biomarkers in human urine is shown in Figure 12.4). In particular, species of
myosin (including myosins 5C, 7A, heavy polypeptide 7, 9A, and 10) were









Figure 12.4 Proposed mechanism for the existence of biomarkers of skeletal
muscle wasting in cachectic human urine.
Myofibrillar proteins such as myosin are degraded by components of the ubiquitin
proteasome pathway. These smaller polypeptide fragments (representing
biomarkers) either leach out or are actively excreted by muscle cells through the
increasingly permeable sarcolemma. (Permeability is increased during cancer
cachexia through mechanisms including DGC deregulation). The polypeptides
enter the circulation and are filtered by the nephron to be excreted in urine from
whence they are detected. The exact size of the polypeptide biomarkers and the
mechanisms of ultrafiltration by the kidney require further elucidation.
NEPHRON
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(n=8; weight loss >10%) compared with weight-stable cancer patients (n=8) and
healthy controls (n=8), thus confirming the presence of myofibrillar degradation.
Despite the predominance of skeletal muscle wasting in cancer cachexia, the
present thesis represents the first identification of muscle breakdown products in
patient urine. Previous studies have focused simply on the detection of non-specific
proteinuria [659] or nitrogen excretion [658].
In the present thesis, the one conventional myosin detected specifically in cachectic
urine was MyHC 7/cardiac muscle/)) variant, a component of type I skeletal muscle
fibres and cardiac muscle [749]. However, in Chapter 7, it was described how
myofibrillar ATPase staining demonstrated selective atrophy of fast twitch type II
muscle fibres in the C-26 mouse model [321]. Furthermore, similar fibre type-
specific wasting is thought to occur during human cancer cachexia. Thus, the
proposal of type I fibre wasting might appear at odds with some previous studies.
However, other investigations have also demonstrated slight reductions in type I
MyHC within cachectic muscle [321] and switching of fibre type from I to Ha in
animal tumour models [691]. Chapter 7 also described how some changes of DGC
deregulation were not limited to type II fibres, and that a faint hyperglycosylated
form of (3-DG and limited reduction of dystrophin expression were detectable in
slow, oxidative, type I fibres also [321], Thus, although atrophy might occur
predominantly in type II fibres, some atrophy must also occur in type I fibres.
Taken together though, the data from this thesis demonstrate reduced intramuscular
myosin expression (Chapter 8) and actin-myosin complex association (Chapter 7)
within cachectic human muscle, and the presence of myosin within cachectic
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human urine (Chapter 9). These findings appear to confirm the presence of skeletal
muscle wasting, and also support the choice of myosin as a protein worthy of
investigation as a possible biomarker of cachexia. From the patient's perspective,
urinary analysis of myosin by MS would be preferential to muscle biopsy (in the
absence of resectional surgery).
Other potential biomarkers of cachexia detected in patient urine included bullous
pemphigoid antigen 1, chromosome 14 open reading frame 78, MIBP1, zinc finger
protein 106 homologue, nischarin, MACF1, MAP1B, and al-spectrin. Several of
these markers, particularly the latter three point to a disruption of basic cell
structure as a key process within cancer cachexia. Future observational studies of
human muscle samples should target these other potential biomarkers in order to
confirm intramuscular depletion in cachectic patients.
In Chapter 7, it was described how muscles from the C-26 mouse demonstrated free
uptake of EBD even though serum CK levels were only elevated moderately over
controls [321]. Furthermore, in the same chapter, sarcolemmal membrane
abnormalities (in the form of DGC deregulation) were confirmed in muscle samples
from patients with OGC. The detection of myosin and other structural proteins in
the urine of patients with the same disease, in the absence of plasma CK rise,
implies that membrane damage during cachexia is not sufficient to cause a
complete permeation of intracellular proteins. Rather these data point to a selective
loss of ultrastructure in the presence of mild membrane damage. Data from in vitro
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systems and the C-26 model, which show selective targeting of MyHC during
cancer cachexia [46], support this hypothesis.
In the present thesis, MS analysis was performed following tryptic digestion of
urinary protein. Database searching was then performed for whole proteins on a
probability basis. Thus, biomarker identification is dependent on statistical
probability, and therefore some of the listed cachectic biomarkers may be
inaccurate or redundant. Future proteomic studies that are capable of identifying
accurately the peptide fragments released by cachectic muscle will not only refine
the number and nature of the biomarkers, but also the size of the fragments. In this
way, conclusions may be drawn regarding whether such fragments simply leach out
of cachectic fibres or whether active transport mechanisms are involved, and how
the kidneys filter such fragments.
It is important to note that myoglobin was not detected in the urine of cachectic
cancer patients. If cancer cachexia in patients with OGC mirrored muscular
dystrophy exactly, one might not only expect a rise in plasma CK in some patients,
but also a rise in plasma and urinary myoglobin. However, previous studies have
shown that plasma levels of myoglobin are reduced by approximately 30% in
cachectic cancer patients compared with controls, and that plasma myoglobin
correlates with quadriceps cross-sectional area and the area fraction formed by type
I and Ha fibres [657]. Clearly, differences do exist in the mechanistic pathways of
muscle protein degradation and elimination between cancer cachexia and muscular
dystrophy.
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A human homologue of PIF was not identified in the cachectic patient urine using
the MS techniques employed in the current thesis. (Urine has been the predominant
patient sample used for the demonstration of apparent PIF immunoreactivity with
the PIF mAb [183]). However, interestingly, ZAG, the putative human LMF [220],
was detected in the urine of several of the cancer patients, both cachectic and
weight-stable. One could argue that this finding suggests that LMF production and
fat depletion occurs early in cachexia, whereas PIF production and muscle wasting
occurs later.
The ultimate aim of biomarker research is to identify individual markers or patterns
of markers that can be used either as inclusion criteria for clinical trials or can be
used to monitor response to therapy. Furthermore, the degradative pathways
involved in the early loss of myosin are a major area of current research in cancer
cachexia. In this preliminary proof-of-principle study, urinary myosin has shown
promise as a potential biomarker of skeletal muscle wasting. The next step should
seek to use a quantitative MS methodology (rather than the qualititative approach
used in the present thesis) in the context of a longitudinal study in order to measure
the changing fractions of urinary biomarkers over time, or pre- and post-
intervention. A different search strategy that employs identification of fragmented
peptide sequences rather than probability-based extrapolation of the original
progenitor molecule might also improve accuracy and reduce redundancy.
In cachexia intervention trials, the FDA has stated that measures of patient PF are
required alongside measures of body composition (e.g. LBM/skeletal muscle mass)
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[466], In Chapters 10 and 11, the subject of the present thesis moved away from the
analysis of molecular mediators and markers of muscle wasting, and focused on
muscle function and its potential as a clinical biomarker for cachexia studies.
Global muscle (and therefore patient) function was assessed using the activPAL™
meter, a lightweight accelerometer-based device worn on the patient thigh that
offers information on long-term, everyday PF within the home/outpatient
environment. ActivPAL™ offers a wide range of simultaneous outcome measures
(e.g. TEE, EEA, time spent sitting/lying, time spent standing, step count, step
cadence), each of which can be analysed during a single recording episode.
Furthermore, some of the simpler outcomes have been validated already in healthy
controls [708, 709]. The activPAL™ meter is user/patient friendly and
economically viable, thus offering significant advantages over the gold standard
methodology for assessing PA (i.e. DLW). The major outputs from the activPAL™
meter are estimates of TEE and EEA. These outcome measures are of importance in
cancer cachexia for several reasons. Firstly, although REE may be increased in
some wasted cancer patients, TEE may actually fall suggesting that they reduce
energy demand by decreasing PA, and hence EEA [277]. Secondly, and importantly,
it has been shown that objective measures of PA (PAL and EEA) can be improved
by anti-cachexia interventions (i.e. EPA) [277]. Lastly, as hypothesised in the
present thesis, there is emerging evidence that objective measures of PA correlate
with health-related QoL scores [380, 513], Thus, intervention-induced
improvements in patient PA should translate into improvements in QoL, which in
the context of advanced cancer patients with short life expectancy is a significant





Figure 12.5 The determinants of objective physical activity, and the
relationship with muscle function, muscle wasting and quality of life.
A patient's physical activity is influenced by a number of patient- and disease-
related factors. However, the objective assessment of physical activity will offer
information on that individual's muscle function, muscle wasting and quality of life.
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determinants of a patient's PA, and the relationship PA shares with muscle function,
muscle wasting and QoL.
In Chapter 10, a 2-week DLW protocol, in combination with indirect calorimetry,
was used to validate the EE output of the activPAL™ meter in a cohort of advanced
cancer patients (n=6) and healthy controls (n=9 assessments in 8 subjects). As
expected, when assessed by DLW, cancer patients exhibited lower mean TEE and
EEA compared with healthy subjects. Across the whole experimental group,
average measures of TEE and EEA were validated with only very small mean
absolute errors (0.4% and. 1.4%, respectively), although LOA were wide enough to
question the applicability of activPAL™-derived measures of EE in individual
patients (see Figure 10.4, p.351, and Figure 10.5, p.353). Further larger studies are
required to validate accurately the EE outputs of activPAL™.
TEE and EEA were chosen initially as the PA outcomes of choice, as they represent
global assessments of muscle function, incorporating all muscle activity. TEE also
incorporates REE, which may be increased during cancer cachexia [550], However,
EE outputs may not be the most sensitive measures of patient function. Simpler
measures of PF such as step count correlated well with EEA, and thus alternative
outcomes that are easier to assess by simpler devices (e.g. pedometers) may exist,
and may be superior in terms of sensitivity. However, the question remains why, if
EEA appears to be related intimately to step count, did activPAL™-derived
measures of EEA demonstrate high variability? Recent Norwegian data has
suggested that the validity of activPAL™-derived step count may vary according to
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walking speed (personal communication: Guro Stene), and that frailer, more
cachectic cancer patients demonstrate greater step count inaccuracy [712].
Assuming that PA meter validity may vary according to walking speed implies that
validation studies of outcome measures should only be carried out in the specific
patient population to which they will be applied, and that no studies of mixed
populations should occur. Thus, any validation data extracted from a certain patient
population cannot be transferred for use in another. This might be levelled as a
criticism against the present thesis, which used a mixed population of cancer
patients and healthy controls. However, despite the inherent difficulties, validation
studies remain of paramount importance in the development of accurate outcome
measures for trial use. As has been shown in the present thesis, assumptions that
underpin any device may be incorrect biologically when applied to a specific
population (e.g. the calorific value of 1 activPAL™-derived MET actually appeared
to be 0.84kcal/kg/hr within the present study cohort).
In summary, the activPAL™ meter can offer objective data on TEE and EEA in
patients with advanced cancer and healthy controls, although the variable validity
of this data precludes immediate use in clinical trials as a biomarker of muscle
function, pending further studies. Validation studies of other simpler activPAL™-
derived measures may offer more accurate, but possibly less informative outcomes
in the interim period.
In any future therapeutic strategy for cancer cachexia, it is likely that many of the
patients will also be receiving simultaneous palliative chemotherapy. Although
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such chemotherapy is often administered with the long-term aim of improving
patient PS, during the period of treatment, it is often associated with unwanted side
effects and a negative impact on QoL. Furthermore, some chemotherapeutic agents
are known to exacerbate skeletal muscle wasting [290], Therefore, any future
outcome measure for use in cachexia intervention trials must be applicable within
the context of palliative chemotherapy. In Chapter 11, activPAL™ was used to
perform sequential assessments of PA in a cohort of upper GI cancer patients
receiving palliative chemotherapy (n=16). Furthermore, QoL questionnaires were
completed to assess the relationship between PA and QoL. The present thesis
demonstrated an overall trend towards reduction in PA throughout chemotherapy
(although individual patients described a complex PA journey with some
demonstrating reduced, increased or unchanged PA). In general, results did not
achieve statistical significance, although time spent stepping did increase
significantly as the duration of time to cessation of treatment increased. It remains
an important finding in its own right, however, that activPAL™ was capable of
detecting demonstrable changes in the objective PA of individual patients in
response to treatment and over time.
Objective measures of PA, including time spent sitting or lying, time spent standing,
time spent upright and EEA correlated not only with subjective measures of PS and
questionnaire-derived measures of PWB and FWB, but also with EORTC QLQ-
C30 Global Health Status/QoL and mood (HADS-Depression score). This is a
contrast to previous studies that have not been able to confirm a relationship
between PA and global QoL. The present thesis helps to justify the use of objective
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PA as an outcome measure in future clinical trials of anti-cachexia therapies, and
supports the concept that intervention-induced improvement in PA will cause a
coincident improvement in QoL.
Although objective PA measures correlated significantly with subjective PS scores,
they highlighted the inherent inaccuracy and variability of PS. For example,
patients with WHO PS score 1 exhibited step counts of between 1007 and 7619
steps/day i.e. patients at the upper end of the WHO PS 1 category performed over 7
times the objective PA of patients at the lower end. Thus, it seems illogical that
such varying patients should be considered to have equivalent levels of PF. Clearly,
objective assessment of PA does hold some advantages over subjective scoring of
PS.
The present data also calls into question the ability of health-related QoL to model
accurately symptoms of cancer cachexia. PA measures correlated inversely with
percentage weight loss, an objective marker of altered body composition, and yet
they did not correlate with the FAACT ACS score. Furthermore, although patients
actually demonstrated significant reductions in weight, AMC and body fat
following initiation of chemotherapy, the ACS score was shown to improve in a
contradictory fashion. Thus, current self-reported scores of patient symptomatology
remain inferior to true measures of body composition during the diagnosis and
classification of cachexia.
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Importantly, time spent upright correlated with LBM as a percentage of total body
weight, thus demonstrating that PA and muscle mass are linked, and that reduced
PA should be a good surrogate marker of skeletal muscle wasting as well as
function. Morover, any intervention that increases muscle mass should improve PA,
and potentially, vice-versa. Ongoing studies comparing measures of muscle
strength/power and PA with MRI analysis of muscle volume are being perfomed to
investigate further the relationship between function and size.
One difficulty that has become apparent when analysing this sort of study is how to
factor in clinical events that occur within heterogenous populations of cancer
patients and that are bound to impact on patient PA (e.g. different types of cancer;
different types of chemotherapy regimen; chemotherapy side effects; blood
transfusion; oesophageal stenting). Preliminary trials using objective PA as an
outcome measure may need to specify patient homogeneity as much as possible
within inclusion criteria in order to mitigate any unwanted and confusing variability
in PA. Strict recording of both clinical events and tumour response to
chemotherapy will be required to tease apart the separate effects of disease,
chemotherapy and anti-cachexia intervention on patient PA.
In summary, objective measures of PA (derived using the activPAL™ meter) offer
data on global patient/muscle function during palliative chemotherapy, and
correlate significantly with both QoL and body composition. They also underline
the subjectivity and inaccuracies of both PS scores and some self-reported symptom
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scores. As markers of muscle function, PA measures should be considered as
outcomes in future trials of anti-cachexia interventions.
In the above section, the findings of the present thesis have been brought together,
and suggestions for future investigations have been made in order to answer some
of the remaining questions in cancer cachexia. However, in the next section, actual
funded research studies that have already been initiated are described briefly.
12.2 Ongoing research
The identification of markers for early intervention, data linking markers and
mediators with specific changes in skeletal muscle volume and function, and the
development of an effective multimodal treatment still represent clear unmet
clinical needs in cancer cachexia. Thus, two research programmes (funded by
CRUK and Wyeth, respectively) have been commenced, the specific aims of which
are to identify early markers of cachexia and relate these to longitudinal measures
of skeletal muscle volume and function. Building on the concept of 'pre-cachexia',
these studies will incorporate some of the experimental suggestions detailed above,
and are are based on the following hypotheses:
1. Cachexia is a progressive condition that begins prior to gross muscle wasting
and weight loss, and that this early phase can be identified from phenotypic
changes in blood, urine and skeletal muscle.
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2. There are early changes in skeletal muscle function (ahead of wasting), and
these changes can be related to biochemical markers of cachexia.
Upper GI cancer patients represent the investigative model of choice, and tissues
being studied include skeletal muscle, blood, urine, tumour and fat. The mediators,
mechanisms and biomarkers of skeletal muscle wasting and function that are being
employed in these newer studies are those with proven importance in the present
thesis:
• Sex steroids and gonadotropins
• DGC deregulation
• PKR/eIF2a phosphorylation and other mechanisms of reduced protein
synthesis and increased degradation
• Urinary biomarkers of muscle wasting, including myosin
• ActivPAL™-derived measures of PA, as markers of muscle function
12.3 Final conclusions
The present thesis has explored a number of different themes surrounding the
syndrome of cancer cachexia. The final conclusions of the thesis regarding
mediators, mechanisms and biomarkers of skeletal muscle wasting and function in
human cancer cachexia are:
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• A putative human homologue of PIF is yet to be proven as an important
factor in human cancer cachexia.
• MIC-1 does not appear to regulate significantly nutritional depletion or
skeletal muscle wasting in cancer cachexia.
• Sexually dimorphic alterations in patient gonadal status may influence
nutritional status and outcome in cancer cachexia.
• DGC deregulation and PKR/eIF2a activation play a role in skeletal muscle
wasting in cancer cachexia and represent novel therapeutic targets.
• Urinary biomarkers (e.g. myosin) of skeletal muscle wasting can be detected
in patients with cancer and should be developed further as potential
biomarkers of the cachexia syndrome.
• Objective PA as a marker of skeletal muscle function is a complex endpoint
that is influenced by numerous factors (including chemotherapy) but which
has inherent value within trial methodology.
Combined with findings from the published literature, extrapolation of these
conclusions to the hypothetical development of an ideal multimodal
intervention trial in cancer cachexia would suggest that any such trial might
include the following components:
• Experimental multimodal therapy
- nutritional support
- anti-inflammatories
- neuroendocrine modulation (e.g. androgen replacement therapy
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in men, oestradiol suppression in women)





- weight loss/reduced skeletal muscle mass
- systemic inflammation
- presence or raised levels ofurinary biomarkers (e.g. myosin)
• Outcome measures
- nutritional status
- objective assessment ofPA (as marker ofskeletal muscle function
and QoL)
- levels ofurinary biomarkers (e.g. myosin)
- survival
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Appendix I - Buffers
TAE X40
• Tris 193.6g
• Na acetate.3H20 108.9g
• diNaEDTA.2H20 15.2g
pH to 7.2 with acetic acid




• Boric acid 30g boric acid
1.6% agarose gel for PCR
• LE agarose 1.6g
• 1XTAE 100ml
Run in 1XTAE at 80 volts
6% acrylamide gel for PCR
• 40% acrylamide soln (29:1) (Sigma) 3ml
• dH20 12.8ml
• 5XTBE 4ml
• 10% AMPS 140pl
• TEMED 30pl
Run in 1XTBE at 200 volts
Low molecular weight markers
Reconstitute in 200pl loading buffer for markers (in fume hood)
Heat @ 95°C for 5mins
Aliquot-5pl
High molecular weight markers




Appendix II - Performance scores
Karnofsky performance score
• 100% - normal, no complaints, no signs of disease
• 90% - capable of normal activity, few symptoms or signs of disease
• 80% - normal activity with some difficulty, some symptoms or signs
• 70% - caring for self, not capable of normal activity or work
• 60% - requiring some help, can take care of most personal requirements
• 50% - requires help often, requires frequent medical care
• 40% - disabled, requires special care and help
• 30% - severely disabled, hospital admission indicated but no risk of death
• 20% - very ill, urgently requiring admission, requires supportive measures
or treatment
• 10% - moribund, rapidly progressive fatal disease processes
• 0% - death
World Health Organisation performance score
• 0 - asymptomatic (fully active, able to carry on all pre-illness activities
without restriction)
• 1 - symptomatic but completely ambulatory (restricted in physically
strenuous activity but ambulatory and able to carry out work of a light or
sedentary nature e.g. light housework, office work)
• 2 - symptomatic, <50% in bed during the day (ambulatory and capable of all
self care but unable to carry out any work activities. Up and about more than
50% of waking hours)
• 3 - symptomatic, >50% in bed, but not bedbound (capable of only limited
self-care, confined to bed or chair 50% or more of waking hours)
• 4 - bedbound (completely disabled, cannot carry on any self-care, totally
confined to bed or chair)
• 5 - death
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Appendix III - Questionnaires
1. European Organisation for Research and Treatment of Cancer QLQ-C30
(EORTC QLQ-C30)
2. Functional Assessment of Anorexia/Cachexia Therapy (FAACT)
3. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
4. Hospital Anxiety and Depression Scale (HADS)
485
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EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions yourself by
circling the number that best applies to you. There are no "right" or "wrong" answers. The information that you
provide will remain strictly confidential.
Please fill in your initials: I I I I I
Your birthdate (Day, Month, Year): I I I I I I I I I
10. Did you need to rest? 2 -3 , 4
11. Have you had trouble sleeping? 1 If 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked appetite? 1^3 4
14. Have you felt nauseated? 12 3 4
15. Have you vomited? 12 3 4
16. Have you been constipated? 12 3 4
Please go on to the next page
During the past week:
17. Have you had diarrhea?
18. Were you tired?
19. Did pain interfere with your daily activities?
20. Have you ha^difficulty in concentrating on things,
like reading a newspaper or watching television?
21. ^id you/eel tense?
22.s WffTyou worry?
23. Did yoi^el irritable?
24. Did you feel depressed?
25. Have you had difficulty raffieritheringjffngs?
26. Has your physical condition cy medical treatment
interfered with your family file?
27. Has your physical condition or medicj [treatment
interfered with your social activities?1
28. Has your physical condition or medical treatment
caused you financial difficulties?
For the following questions please ci























between 1 and 7 that
29. How would you rate your overall health during the past wi
1 2 3 4 5 6
Very poor
30. How would you rate your overall quality of life during the past week?
12 3 4 5 6 7
Very poor Excellent
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0
FAACT (Version 4)
Below is a list of statements that other people with your illness have said are important. Please circle
or mark one number per line to indicate your response as it applies to the past 7 days.
PHYSICAL WELL-BEING
Not A little Some- Quite Very
at all bit what a bit much
GS6
Qi
I have a lack of energy 0 12 3 4
I have nausea 0 1 2 3 4
Because of my physical condition, I have trouble
meeting the needs of my family 0 1 2 3 4
I have pain 0 12 3 4
I am bothered by side effects of treatment .....^1 0 12 3 4
I feel ill .......p 0 ' 1 2 3 4
I am forced to spend time in bed 0 12 3 4
SOCIAL/FAMILY WELL-BEING Not A little Some- Quite Very
at all bit what a bit much
I feel close to my friends .%. 0 12 3 4
I get emotional support from my family 0 12 3 4
I get supportfrom my friends 0 12 3 4
My family has accepted my illness 0 1 2 3 4
I am satisfied with family communication about my
illness 0 12 3 4
I feel close to my partner (or the person who is my main
support) 0 12 3 4
Regardless ofyour current level ofsexual activity, please
answer the following question. Ifyou prefer not to answer it,
please mark this box □ and go to the next section.
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FAACT (Version 4)
Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
EMOTIONAL WELL-BEING
I feel sad
I am satisfied with how I am coping with my illness
I am losing hope in the fight against my illness
I feel nervous
I worry about dying
I worry that my condition will get worse
y
FUNCTIONAL WELL-BEING
I am able to work (include work at home) 0
My work (include work at home) is fulfilling 0
I am able to enjoy life p .j 0
I have accepted my illness 0
Not A little Some- Quite Very







I am sleeping well.... 0
I am enjoying the things I usually do for fun 0





















A little Some- Quite Very
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FAACT (Version 4)
Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
ADDITIONAL CONCERNS Not A little Some- Quite Very









I have a good appetite 0
The amount I eat is sufficient to meet my needs 0
I am worried about my weight JM
Most food tastes unpleasant to me 0
I am concerned about how thin I look . v..... 0
My interest in food drops as soon as I try to eat...^, 0
■
1H|
I have difficulty eating rich or "heavy" foods 0
My family or friends are pressuring me to eat jS' 0
I have been vomiting , 0
When I eat, I seem to get full quickly 0
1 have pain in my stomach area 0
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FACIT-F (Version 4)
Below is a list of statements that other people with your illness have said are important. Please circle
or mark one number per line to indicate your response as it applies to the past 7 days.
PHYSICAL WELL-BEING
Not A little Some- Quite Very
at all bit what a bit much
Qi
I have a lack of energy 0 1 2 3 4
I have nausea 0 1 2 3 4
Because of my physical condition, I have trouble
meeting the needs of my family 0 1 2 3 4
I have pain 0 12 3 4
I am bothered by side effects of treatment 0 12 3 4
I feel ill . 0 12 3 4
I am forced to spend time in bed Jflk- 0 12 3 4
SOCIAL/FAMILY WELL-BEING Not A little Some- Quite Very
at all bit what a bit much
I feel close to my friends 0 12 3 4
I get emotional support from my family 0 1 2 3 4
I get support from my friends..... 0 12 3 4
My family has accepted my illness 0 1 2 3 4
I am satisfied with family communication about my
illness .f. 0 12 3 4
I feel close to my partner (or the person who is my main
support) 0 12 3 4
Regardless ofyour current level ofsexual activity, please
answer the following question. Ifyou prefer not to answer it,
please mark this box □ and go to the next section.






Please circle or mark one number per line to indicate your response as it applies to the past 7
days.
EMOTIONAL WELL-BEING Not A little Some- Quite Very
at all bit what a bit much
OEl I feel sad 0
I am satisfied with how I am coping with my illness 0
I am losing hope in the fight against my illness 0
I feel nervous J. 0
I worry about dying 0
I worry that my condition will get worse..
FUNCTIONAL WELL-BEING Not
at all
I am able to work (include work at home) .\ 0
My work (include work at home) is fulfilling 0
■
\ ■■■/
I am able to enjoy life p 0
I have accepted my illness 0
I am sleeping well 0
I am enjoying the things I usually do for fun 0















tie Some- Quite Very
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FACIT-F (Version 4)




I feel weak all over
I feel listless ("washed out")
I feel tired
I have trouble starting things because I am tired.
I have trouble finishing things because I am tired.
I have energy.
I am able to do my usual activities.
I need to sleep during the day
I am too tired to eat
I need help doing my usual activities.
Not A little Some- Quite Very
at all bit what a bit much
I am frustrated by being too tired to do the things I want
to do a
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Hospital Anxiety and Depression Scale (HADS)
Patients are asked to choose one response from the four given for each
interview. They should give an immediate response and be dissuaded
from thinking too long about their answers. The questions relating to
anxiety are marked "A", and to depression "D". The score for each answer
is given in the right column. Instruct the patient to answer how it currently
describes their feelings.
A 1 feel tense or 'wound up': 1
Most of the time 3
A lot of the time 2





I still enjoy the things I used
to enjoy:
Definitely as much 0
Not quite so much 1
Only a little 2
Hardly at all 3
A
I get a sort of frightened
feeling as if something awful
is about to happen:
!
Very definitely and quite
badly
3
Yes, but not too badly 2
A little, but it doesn't worry
me
1
Not at all 0
D
1 can laugh and see the funny
side of things:
As much as 1 always could 0
Not quite so much now 1
Definitely not so much now 2
Not at all 3
A Worrying thoughts go
through my mind:
A great deal of the time 3
A lot of the time 2




D 1 feel cheerful:
Not at all 3
Not often 2
Sometimes 1
Most of the time 0
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Not at all 3
D 1 feel as if 1 am slowed down:
Nearly all the time 3
Very often 2
Sometimes 1
Not at all 0
A
1 get a sort of frightened
feeling like 'butterflies' in
the stomach:
I





1 have lost interest in my
appearance: I
Definitely 3
1 don't take as much care as 1
should
2
1 may not take quite as much
care
1




1 feel restless as 1 have to be
on the move:
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0
D
1 look forward with
enjoyment to things:
As much as 1 ever did o
Rather less than 1 used to 1
Definitely less than 1 used to 2
Hardly at all 3
A
1 get sudden feelings of
panic:
|
Very often indeed 3
Quite often 2
Not very often 1 i
Not at all °
D
1 can enjoy a good book or




Very seldom 3 !
Scoring (add the As =
Anxiety. Add the Ds =
Depression). The norms
below will give you an idea of
the level of Anxiety and
Depression. |
0-7 = Normal
8-10 = Borderline abnormal I
11-21 = Abnormal
Reference:
Zigmond and Snaith (1983)
Appendix IV - Presentation of data from this thesis
Oral presentations
• Skipworth RJE, Stewart GD, Bhana M, Christie J, Cronshaw AD, Fearon
KCH, Ross JA. A mass spectrometric approach to the discovery of
protein biomarkers in the urine of patients with gastro-oesophageal
cancer and cachexia. Oral presentation at the Society ofAcademic and
Research Surgery Annual Conference, Birmingham, January 2008.
• Skipworth RJE, Deans DAC, Brown DA, Hunter M, Breit SN, Ross JA,
Fearon KCH. Plasma levels of macrophage inhibitory cytokine-1 in
patients with gastro-oesophageal cancer: association with systemic
inflammation. Oral presentation at the Society ofAcademic and Research
Surgery Annual Conference, Birmingham, January 2008.
• Skipworth RJE, Acharyya S, Guttridge DC, Fearon KCH. Deregulated
dystrophin glycoprotein complex: a novel marker of cachexia and
shortened survival in gastro-oesophageal cancer patients. Oral
presentation at the Royal College ofSurgeons ofEdinburgh/College of
Surgeons ofHong Kong Conjoint Scientific Congress, October 2006.
• Skipworth RJE, Moses AGW, Sturgeon CM, Seth J, Ross JA, Fearon KCH.
Sex, systemic inflammation and survival in advanced pancreatic cancer.
Oral presentation at the Society ofAcademic and Research Surgery Annual
Conference, Edinburgh, January 2006.
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• Skipworth RJE, Stene GB, Hendry PO, Dahele M, Small AC, Blum D,
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• Skipworth RJE, Hendry PO, Dahele M, Small AC, Preston T, Fearon KCH.
Criterion-based validation of accelerometer-derived energy
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• Ferriolli E, Skipworth RJE, Stenseth J, Dahele M, Wall L, Greig CA,
Fearon KCH. Association between quality of life and directly monitored
physical activity in patients with upper gastrointestinal cancer. Poster
presentation at the 5th Cachexia Conference, Barcelona, Spain, December
2009.
• Skipworth RJE, Stewart GD, Bhana M, Christie J, Cronshaw AD, Fearon
KCH, Ross JA. A mass spectrometric approach to the discovery of
protein biomarkers in the urine of patients with gastro-oesophageal
cancer and cachexia. Poster presentation at the 4th Cachexia Conference,
Tampa, USA, December 2007.
• Skipworth RJE, Deans DAC, Brown DA, Hunter M, Breit SN, Ross JA,
Fearon KCH. Plasma levels of macrophage inhibitory cytokine-1 in
patients with gastro-oesophageal cancer: association with systemic
inflammation. Poster presentation at the 4th Cachexia Conference, Tampa,
USA, December 2007.
• Skipworth RJE, Moses AGW, Sangster K, Sturgeon CM, Seth J, Yoss AC,
Fallon MT, Anderson RA, Ross JA, Fearon KCH. Interaction of gonadal
status with systemic inflammation and opioid use in determining
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presentation at the 4th Cachexia Conference, Tampa, USA, December 2007.
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• Acharyya S, Butchbach MER, Sahenk Z, Wang H, Saji M, Carathers M,
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Burghes AHM, Rafael-Fortney JA, Guttridge DC. Role of the dystrophin-
glycoprotein complex in the pathogenesis of cancer cachexia. Poster
presentation at the 3rd Cachexia Conference, Rome, Italy, December 2005.
Awarded Best Poster Prize.
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